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Alginate is an anionic polysaccharide comprised of β˗1,4˗linked D˗mannuronic acid 
(M) and L˗guluronic acid (G). The polymer is naturally harvested from seaweed and 
is widely exploited in various biotechnological and biomedical applications, due to 
the multitude of physicochemical characteristics it possesses, predominantly owed 
to the presence of charged C5˗carboxylic acid groups. Modification of the 
carboxylates would enable the development of alginate systems possessing novel 
physicochemical properties. 
Herein is presented for the first time the synthesis of C6˗hydroxamate and 
C6˗tetrazole D˗ManA building blocks. The optimised experimental protocols 
developed, delivered the building blocks in high yields and multi˗gram amounts. 
C6˗hydroxamate building blocks were evaluated for the chemical glycosylation of 
modified alginate oligosaccharides by employing an iterative approach, whereby the 
non˗reducing end was extended. Initial design of the strategy allowed access to the 
α˗ and β˗linked mixed˗system alginate disaccharides. The results derived from their 
evaluation emphasises the important contribution of both C6˗hydroxamate donor and 
acceptor reactivity. An additional objective presented was the chemical synthesis of 
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1. Alginate sources and chemical structure 
Alginate is a non˗repeating linear anionic polysaccharide consisting of variable 
proportions of β˗1,4˗linked D˗mannuronic acid (M) and its C5 epimer L˗guluronic acid 
(G) (Figure 1).1,2,3 Alginate was first extracted from brown algae (Phaeophyceae) in 
the 1880s, and it has been commercially available since the early 20th century. As a 
naturally occurring anionic and hydrophilic polysaccharide, alginate exhibits different 
viscosity and gel˗forming capacity, as the chain length of the polymer and ratio of M 
and G residues (block structure) depend on the source from which it is isolated. 
Alginate is one of the most abundant biosynthesised materials that has been 
extensively studied for the design and development of new biomaterials that can be 
used as stabilisers, viscosifiers and gelling agents in the food, beverage, paper and 
pharmaceutical industries.4,5,6,7 The wide range of alginate˗based biomaterial 
applications relies on its processability for the development of 3˗D scaffolding 
materials such as hydrogels, sponges, microspheres, microcapsules, fibres and 
foams.8 Modifying the chemical structure of alginate results in alternative 
physicochemical properties useful in the fields of biomedicine and biotechnology.7,8 
This emphasises the potential of modified alginate biopolymers in constructing novel 
materials for applications such as drug delivery or tissue engineering.8 
 
Figure 1: Chemical structure of alginate. 
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A large part of alginate polysaccharide research has focused on identifying and 
evaluating the impact of M and G molar fraction on the gelling, permeability, 
viscosifying and stabilising properties of the polysaccharide.6,9 The two uronic acids 
adopt different chair conformations (M: 4C1 and G: 1C4) in order to place the bulky 
carboxyl group in an energetically favoured equatorial position. Therefore, the 
glycosidic bonds at positions C1 and C4 will be equatorial in M and axial in G (Figure 
1).10 This conformational difference makes G˗blocks responsible for the specific 
divalent ion binding which consequently tunes the gelling properties of alginate.8,9 
The resultant interaction between two pairs of G˗blocks from a different polymer 
chain with a divalent cation induces the formation of an ‘egg˗box’˗like structure 
(Figure 2).11 
 
Figure 2: An indicative mechanism of ionic interaction between two interchain G˗blocks and a 
divalent cation (e.g. Ca2+, Mg2+, Fe2+, Ba2+, or Sr2+), forming an ‘egg˗box’˗like structure.1,8 
It has been proposed that M˗blocks and MG˗blocks function as elastic ‘hinges’ 
between the cross˗linked chains that lack the ability of binding divalent cations.1  The 
chelating properties of alginate signify its versatility as a biopolymer whereby 
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chemical modification of it can produce novel biomaterials with the capability to 
encapsulate and protect cationic drugs or therapeutically useful cells from the 
biological environment they are subjected to.8  
Alginate can additionally be produced by two genera of bacteria, 
Pseudomonas and Azotobacter.12 On the one hand, the soil dwelling A. vinelandii 
produces alginate with higher concentrations of G˗blocks, which in turn induce the 
formation of gels in the presence of divalent cations such as Ca2+. Gel formation 
constitutes an important feature that enhances the structural integrity of alginate 
produced by A. vinelandii.1,10,13 On the other hand, the opportunistic human pathogen 
P. aeruginosa synthesises acetylated alginate that lacks G˗blocks (homopolymeric 
fragments consisting of G monomers), leading to the formation of thick and highly 
structured biofilms (Figure 3).10,14,15 In this instance, alginate is considered a virulence 
factor, as it participates in the formation of persistent biofilms that protect the 
bacterium after infection of the lungs of cystic fibrosis (CF) patients.16  
 
Figure 3: Chemical structure of P. aeruginosa alginate comprising of β˗1,4˗linked M and its C5 
epimer, G. O˗acetylation may occur at the hydroxyl groups at the C2 and/or C3 positions of M. 
The extensive use of alginate in high˗value biotechnological and biomedical 
applications requires a steady supply of material with defined homogeneity in G/M 
composition and polymer lengths. Specifically, industrial alginate production reaches 
30,000 metric tons annually.17 Due to the abundance of algae in water bodies, a large 
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proportion of commercially available alginates is obtained from algal sources.17,18 
However, alginate extracted from seaweed suffer from problems with mechanical 
stability, heterogeneity in G/M composition and wide pore size distribution. Bacterial 
biosynthesis may provide alginate with more defined chemical structures and 
physical properties, however, due to the pathogenic nature of P. aeruginosa, any 
form of commercially available alginate is preferably produced by A. vinelandii or 
non˗pathogenic Pseudomonas spp.1 
A considerable amount of literature has been published focusing on alginate 
biosynthesis in P. aeruginosa, nevertheless, further understanding of the 
biosynthetic pathway is required, especially for the polymerisation, modification and 
secretion processes.1,2 The development of structure˗function tools to probe the 
various enzymatic pathways could shed light on the molecular mechanisms, thereby 
showing important information for the design of potential inhibitors. Considering both 
the advantageous material properties of alginate and its role as a virulence factor in 
P. aeruginosa, the research presented here divided its focus on the biomaterial 
aspect of alginate, as well as the biochemical aspect and specifically on the alginate 
biosynthetic pathway in P. aeruginosa. Following the introduction on alginate 
biosynthesis from the pathogen, the discussion on alginate derivatisation for the 
production of novel biomaterials, and the chemical synthesis of alginate oligomers, 
the design of synthetic tools is presented in Section 5. 
2. Alginate biosynthesis in P. aeruginosa 
Pseudomonas aeruginosa and Azotobacter vinelandii are the best˗characterised 
organisms that secrete alginate.19 Despite the fact that the two genera of bacteria 
utilise similar biosynthetic pathways to produce the heteropolymeric polysaccharide, 
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they require it for different biological functions.1,20 In brown algae and Azotobacter 
cysts, alginate serves as a cell wall constituent, whereas in Pseudomonas it 
contributes to the biofilm matrix.21 A large number of studies explain that the random 
structure of alginate stems from the fact that the enzymatic modification of M residues 
takes place at the polymer level. It has also been identified that the gram˗negative 
pathogen secretes at least two other exopolysaccharides, Psl and Pel.22 However, 
the biosynthetic pathway of alginate is the best characterised due to its direct 
involvement in acute and chronic pulmonary infections, especially in CF (Figure 
4).21,23 
Clinical isolates of P. aeruginosa obtained from CF patients display biofilms with high 
levels of alginate secretion (Figure 5).24,25 The genetic competence of P. aeruginosa 
to self˗encapsulate in differentiated three˗dimensional biofilm matrices constitutes a 
key adaptation strategy that augments its defense against hostile external conditions, 
such as antibiotic treatment, disinfectants, oxidative stresses, nutrient/oxygen 
restriction, metabolic waste accumulation, interspecies competition, and host immune 
response (phagocytosis).15,21,16,25 Particularly, in vitro experiments have 
demonstrated that biofilm properties such as viscoelasticity, bio˗volume, cell˗to˗cell 
interaction, cell aggregation, cell density, surface attachment, and architecture, are 




Figure 4: Overview of alginate biosynthesis in P. aeruginosa indicating the structures participating in 
each stage in the cytoplasm (blue). The polymerisation and acetylation processes take place in the 
inner membrane (IM) (green),acetylation, epimerisation, and degradation take place in the periplasm 
(orange), and secretion of mature alginate comes out from the outer membrane (OM) (red)  [Adapted 




Figure 5: Atomic Force Microscopy (AFM) image of the mucoid CF P. aeruginosa FRD1 strain, 
showing alginate as a dense gelatinous structure that surrounds the cells [Adapted from Franklin et al. 
(2011)].21 
Consequently, alginate polysaccharide is essential for the survival of P. aeruginosa 
during pathogenesis and antibiotic treatment, emphasising the need for an in˗depth 
understanding of alginate biosynthesis, as the information extracted from mechanistic 
pathways could aid in the design and development of inhibitors.16 In fact, it has been 
reported that these strains are resistant to almost all categories of widely used 
antibiotics, including cephalosporins, fluoroquinolones, amino glycosides and 
carbapenems.26 The ability of P. aeruginosa to switch from non˗mucoid strains to the 
alginate˗overproducing mucoid phenotype once it colonises the respiratory 
epithelium, is linked to the decline of pulmonary function and survival rate of 
individuals suffering from CF.19,15,27 
2.1. Alginate precursor synthesis 
The formation of the activated sugar nucleotide building block, guanosine 
diphosphate mannuronic acid (GDP˗D˗ManA), is an important process for the 
exopolysaccharide biosynthesis and consequently well˗characterised.1 The 
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precursor biosynthesis takes place in the cytosol, where a series of metabolic steps 
mediated by the enzymes AlgA, AlgC and AlgD deliver GDP˗ManA to the 
membrane˗bound multiprotein complex composed of the rest of the proteins encoded 
by the operon.14,15 To begin with, the bifunctional protein AlgA converts 
fructose˗6˗phosphate to mannose˗6˗phosphate by employing its phosphomannose 
isomerase (PMI) activity.28 Mannose˗6˗phosphate is then converted into 
mannose˗1˗phosphate by phosphomannomutase, AlgC.29 The third step requires the 
GDP˗mannose pyrophosphorylase (GMP) activity of AlgA responsible for the 
catalysis of activated mannose˗1˗phosphate to GDP˗mannose, using 
guanosine˗5'˗triphosphate (GTP).30 Interestingly, the GMP activity of AlgA favours the 
reverse reaction; however, the continuous and consecutive conversion of 
GDP˗mannose to GDP˗ManA by the activity of AlgD (GDP˗mannose˗dehydrogenase, 
GMD) shifts the reaction equilibrium towards the production of the desired 
sugar˗nucleotide.14,31 
The final step for the conversion of GDP˗mannose to GDP˗ManA is catalysed 
by GMD.32 The oxidation step by AlgD and the high intracellular concentrations of 
GDP˗mannose suggest that this final four˗electron transfer is underpinning to the 
overall alginate biosynthesis, as it supplies the alginate polymerization/secretion 
multiprotein complex with its precursor.14,31,33,34 GMD is a nicotinamide adenine 
dinucleotide (NAD+)˗dependent four˗electron˗transfer dehydrogenase.35 Snook et al. 
have determined the crystal structure of GMD in complex with its cofactor NAD(H) 





Figure 6: GMD active site structure and proposed mode of action. (a) Crystal structure of GMD active 
site with GDP˗ManA (gold), a conserved water molecule that contacts the pyrophosphate group. (b) 
Proposed step˗wise mechanism in a bi uni uni bi ping˗pong fashion. [Taken by Snook et al. (2003)].32 
Important mechanistic information was obtained from the crystal structure, as they 
categorised the multistep oxidation reaction into four steps: (1) oxidation of the C6 
hydroxyl to an aldehyde; (2) nucleophilic attack by a thiol group (Cys˗268) to form the 





release of GDP˗ManA by hydrolysis (Figure 6b). As a key regulatory enzyme in the 
alginate biosynthetic pathway, GMD has been conceived as a potential target to 
inhibit alginate secretion, thus making P. aeruginosa susceptible to antibiotic 
treatment.1 
2.2. Polymerisation of GDP˗D˗ManA 
To date, the polymerisation and translocation processes of alginate 
biosynthesis remain unclear. This uncertainty stems from the fact that no P. 
aeruginosa polymerase or polymerase complex has been purified for further detailed 
studies on function and structure determination.14 Nevertheless, one of the most 
significant findings in the alginate polymerisation process is the vital involvement of 
the inner membrane (IM) proteins, Alg8 and Alg44. In the light of experimental 
evidence from disruption mutagenesis studies, deletion mutations of alg8 and alg44 
resulted in the complete termination of alginate biosynthesis.19,36 The deletion of 
algG, algK, algX and algE resulted in the secretion of uronic acid oligomers generated 
by degradation of the alginate polymer caused by the catalytic activity of the 
periplasmic alginate lyase, AlgL.37,38,39 This observation suggests that AlgG, AlgK, 
AlgX and AlgE offer some degree of chemical modification that offers structural 
protection to alginate from AlgL, as they do not contribute directly to the 
polymerisation process.14,40,41 Furthermore, the mucoid phenotype of P. aeruginosa 
is maintained despite the deletion of algI, algJ, and algF. 21,42 
 Data from bioinformatic analysis have established that Alg8 is the best 
candidate for a polymerase.43 Homology studies classify Alg8 as a member of 
β˗glycosyltransferases of class II (GT˗2), a large family of glycosyltransferases that 
catalyse the transfer of an activated carbohydrate donor to a growing acceptor 
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carbohydrate chain.1 Considering that Alg8 shares structural similarity with other 
members of the transmembrane (TM) GT˗2 family, such as cellulose synthase 
(AcsAB) and chitin synthase (Ch1), it is predicted to possess at least five TM proteins 
and a large cytoplasmic GT domain.19,36 Remminghorst et al. demonstrated that 
Asp˗188/Asp˗190, Asp˗295/Asp˗296 and Lys˗297 of Alg8 were indispensable for in 
vivo polymerase activity, and therefore alginate production.3 The first pair of aspartic 
acids, Asp˗188/Asp˗190, is accommodated in the DXD motif which is believed to be 
involved in sugar˗nucleotide binding.44 The second pair, Asp˗295/Asp˗296 is detected 
in the cytoplasmic GT loop and it is suggested to play an acid˗base catalytic role. 
Site˗directed mutagenesis of the proposed conserved catalytic residues indicated 
loss of alginate production, validating the importance of the catalytic subunit.3 Further 
compelling evidence that highlights the significance of Alg8 in alginate polymerisation 
is the overproduction of alginate caused by the overexpression of Alg8, which finally 
led to a super mucoid phenotype.43 In fact, experimental support from in vitro 
polymerisation experiments conducted by Remminghorst and Rehm recommend 
Alg8 to be indispensable for alginate biosynthesis, as it amplified alginate secretion 
by a factor of 15 when a plasmid containing only the open reading frame (ORF) of 
alg8 (termed pBBR1MCS˗5:alg8) was exploited for restoring alginate production in 
the alg8 deletion mutant (termed PDO300Δalg8(pBBR1MCS˗5), as it subsequently 
converted it to a super mucoid mutant  (termed PDO300Δalg8(pBBR1MCS˗5:alg8)) 




Figure 7: P. aeruginosa biofilm formation in a continuous˗culture flow cell, analysed using a confocal 
laser scanning microscope(a,d) Control strain showing a mature and fully differentiated biofilm with 
well˗defined finger˗like microcolonies (b,e) alg8 deletion strain exhibiting a thinner biofilm with no 
apparent microcolonies (c,f) supermucoid strain showing the thickest biofilm [Adapted from Hay et al. 
(2009a)].43 
In addition to this, NMR analysis by using 14C labelled˗GDP˗D˗ManA as substrate 
indicated that additional alg8 gene copies influence alginate composition and 
architecture which finally affect properties such as solubility, morphology, and 
viscosity. The 1H NMR data that derived from the complementary mutant 
PDO300Δalg8(pBBR1MCS˗5:alg8) revealed an increase from 4.7% to 9.3% in the 
degree of 14C GPD˗D˗Man acetylation, whereas the same experiment suggested a 
significant decrease from 38% to 19% in the content of G residues.19 According to 
these results, Alg8 overexpression leads to higher level of alginate secretion, a larger 
degree of O˗acetylation and lower degree of epimerisation. Their results were 
consistent with a quantitative analysis provided by Hay et al., as their investigation 
showed that the thickest biofilm (90˗145 μm in height) was produced by the super 
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mucoid strain of P. aeruginosa (PDO300Δalg8(pBBR1MCS˗5:alg8)), containing high 
proportions of alginate (Figure 7c). Large quantities of alginate led to the development 
of exceptionally large microcolonies, verifying its crucial role in microcolony 
formation.43 Furthermore, Remminghorst and Rehm  have proven using enzymatic in 
vitro alginate synthesis with 14C GPD˗D˗ManA that alginate polymerase activity is 
localised in the cell envelope fraction (IM and outer membrane (OM) plus respective 
proteins), designating that the function of Alg8 strongly relies on the other proteins. 
This finding, along with the results from the above complementation studies create 
the following question; If an alginate multi˗protein biosynthetic complex is required for 
alginate production, why does the addition of alg8 gene copies amplify polymer 
production? Thus, Remminghorst and Rehm proposed Alg8 to be the bottleneck in 
alginate biosynthesis.19 
Prior to the work of Moradali et al., the specific role of Alg44 in alginate 
polymerisation was largely unknown. Alg44 was proposed to play an indirect but 
significant role in the polymerisation process.1 This conclusion was based on 
experimental evidence where deletion of alg44 led to a complete loss of alginate 
polymerisation, while its overexpression resulted in alginate overproduction.45,36 
Alg44 was suggested to function as a bridge between the IM protein Alg8 and the OM 
export protein AlgE, facilitating the transit, modification, and secretion of alginate.1,45 
Moradali et al. were the first to elucidate experimentally the direct protein˗protein 
interaction between Alg8 and Alg44, as well as the interaction between Alg44 and 
AlgK.15 Previously, Rehman et al. identified the interaction between Alg44, AlgX and 
AlgK, by observing reduced alginate production in algK and algX deletion mutants.2 
Their findings also confirmed the hypothesis of previous work supporting that Alg44 
is important for the structural integrity of the multiprotein alginate biosynthesis 
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machinery, Alg8˗Alg44˗AlgX˗AlgK˗AlgE (Figure 8).2,15,45 
 
Figure 8: Schematic overview of the protein˗protein interaction between Alg8˗Alg44, Alg44˗AlgK, 
and Alg44˗AlgX. 
2.3. Periplasmic translocation and modification of polymannuronate 
The post˗polymerisation modifications of the linear D˗mannuronate 
homopolymer define the functional properties of mature alginate.6,42,46 Once the 
exopolysaccharide is synthesised in the cytoplasm, it is translocated across the IM 
and undergoes three types of modification in the periplasm. One of the modifications 
is the O˗acetylation at the O2 and/or O3 positions of the M residues by the complex 
AlgI, AlgJ, AlgF, and AlgX (Figure 9).47 In general, high degrees of alginate acetylation 
increase water˗holding capacity, viscosity and pseudoplastic rheology of the biofilm 
and consequently the polymer acts as an impenetrable shield of protection for the 
bacterium.1,47,48 The glue˗like properties of O˗acetylated alginate are highly important 
for mucoid strains of P. aeruginosa, as they significantly impact biofilm architecture, 
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and therefore the cell aggregation at the early stages of surface colonisation, as well 
as the shape of macrocolonies.49   
A second modification is the C5 epimerisation of selected M residues to G by 
AlgG (Figure 9).50,51 Thus far, several studies have examined whether acetylation 
occurs prior to epimerisation, as studies revealed that acetylation of the M residues 
prevents the epimerisation to G residues by AlgG.13,46 In addition, O˗acetylation is 
suggested to prevent the third modification that might occur before alginate secretion, 
which is degradation by AlgL.52 
 
Figure 9:  Enzymatic modifications of alginate in the periplasm. M may be acetylated at C2 and/or C3 
positions by AlgX, AlgJ, AlgF, AlgI complex (red), epimerised to G by AlgG (blue), or degraded by AlgL 
in an unsaturated 4˗deoxy˗L˗erythro˗hex˗4˗enepyranosylouronate residue. 
Therefore, it is speculated that O˗acetylation occurs first, as it indirectly affects the 
degree of epimerisation, length of the exopolysaccharide, and therefore its molecular 
weight.1,14 In other words, the ability to control the first post˗polymerisation 
modification, which is alginate O˗acetylation, could allow some level of regulation over 
the magnitude of the subsequent modifications. Although P. aeruginosa does not 
produce alginate composed of G˗blocks, it is worth noting that their existence affects 
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the mechanical characteristics of the resulting polysaccharide.1 Specifically, the 
diaxial O˗glycosidic bond in G˗blocks leads to the formation of linkages with large 
hindered rotation, which enhance several gelling properties of alginate such as 
stiffness, swelling and porosity.1,9 
O˗acetylation of alginate is a complicated biological process of great 
significance for the survival and virulence of P. aeruginosa.25 Data from several 
sources have identified that this process demands the transportation of an 
acetyl˗donor into the periplasm by a membrane bound O˗acetyltransferase (MBOAT) 
and the transfer of the acetate onto the polymannuronate by a periplasmic 
O˗acetyltransferase.50,42,53,54 The four protein complex of P. aeruginosa is composed 
by a MBOAT protein (AlgI), two periplasmic O˗acetyltransferases (AlgJ, AlgX) and a 
protein of unknown function (AlgF).25,42,53,54 AlgF is not expected to possess a 
catalytic domain and given the current state of knowledge, its function can only be 
speculated. Moreover, it is currently uncertain why two O˗acetyltransferases are 
needed for alginate acetylation.25,50 It is hypothesised that AlgI catalyses the transfer 
of an acetate from an unknown cytoplasmic acetyl donor (possibly Coenzyme A or 
an acyl carrier protein) across the IM to AlgJ and/or AlgF in the periplasm.54 As 
opposed to AlgF and AlgX, AlgJ is associated with the IM through a TM domain, 
setting the enzyme closer to AlgI. In addition, AlgX can bind alginate in a 
length˗dependent manner, and catalyse its direct O˗acetylation after receiving the 
acetate or acetyl donor by AlgJ or AlgF.25 The fact that active site variants of AlgJ and 





Figure 10: Proposed catalytic mechanism of the acetyltransferase activity of AlgX [Adapted from 
Riley et al. (2013)].50 
Riley et al. proposed a mechanism of alginate O˗acetylation, based on their 
structural and functional analysis of P. aeruginosa AlgX crystal structure at 2.15 Å 
resolution (Figure 10). They suggested Ser˗269 to be both a nucleophile and one of 
the two proton donors in the oxyanion hole, and Gly˗296 residue to serve as the 
second proton donor which stabilises the negative charges of the tetrahedral acetyl 
oxyanion intermediate. The highly conserved His˗176 could act as a catalytic base 
accountable for the nucleophilic activity of Ser˗269, as it could deprotonate its 
hydroxyl group. The aspartic acid residue Asp˗174 present in the catalytic site is 
important for neutralising the charge developed on His˗176 during acylation.50 As 
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opposed to the majority of serine˗glycine˗N˗terminal hydrolases (SGNH) that possess 
a conserved asparagine residue responsible for the oxyanion hole stability, 
PaAlgX27˗474 has a tyrosine (Tyr˗328) residue instead. Specifically, a series of 
experiments replacing Tyr˗328 and Tyr˗275 with alanine led to a 40% and a 50% 
decrease of alginate O˗acetylation, respectively.25,50 These results emphasise the 
importance of these tyrosine residues to situate the polysaccharide chain correctly 
across the catalytic site.50 The annotated structures of both AlgJ and AlgX, as well as 
their phenotypic characterisation, have definitely provided crucial information 
regarding their role in the O˗acetylation of the alginate polysaccharide, as both 
enzymes are part of the SGNH hydrolase family and share the same amino acid 
residues required for O˗acetyl˗transferase activity.25,50 
As previously mentioned, Pseudomonas does not share the same need for 
G˗blocks in its alginate polymer with Azotobacter and brown algae.6 As opposed to 
Azotobacter vinelandii that encodes extracellular Ca2+˗dependent mannuronan C5 
epimerases (AlgE1˗7), Pseudomonas spp. produce only a single periplasmic 
Ca2+˗independent mannuronan C5 epimerase, AlgG.6,55 The periplasmic 
Ca2+˗independent alginate epimerases AlgG of both Pseudomonas spp. and 
Azotobacter vinelandii share ~60% sequence identity.56,57,58 The literature findings 
discussed above clarify that the correct balance between O˗acetylation and 
epimerisation processes plays a pivotal role in the pathogenesis of P. aeruginosa, as 
both modifications affect the material properties of mature alginate and subsequently, 
the structural integrity of the biofilm. 
Wolfram and co˗workers proposed an epimerase reaction mechanism based 
on the information obtained from solving the crystal structure of P. syringae AlgG at 
19 
 
2.1 Å resolution (Figure 11).59  
 
Figure 11: Proposed catalytic lyase (green) and P. syringae AlgG epimerase (blue) reaction 
mechanisms [Adapted from Wolfram et al. (2014)].55 
Firstly, they suggested that the negative charge of the carboxylate group on the uronic 
acid must be neutralised by the positive charge of Arg˗345. The proton on C5 position 
is then abstracted by His˗319 which acts as the base, forming an enolate group 
stabilised by resonance. According to the crystal structure of the active site, Wolfram 
et al. demonstrated that the hydrogen bond interaction between His˗319 and Asn˗320 
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is responsible for the former to facilitate the abstraction of the proton at C5, as their 
interaction reduces the pKa value of His˗319 leading to its deprotonation at the 
observed pH range (pH= 6˗7.5).55,56 In the epimerase reaction mechanism, the proton 
is added to the opposite side of the C5 of the pyranose ring by a water molecule, 
furnishing a G residue. In the case of the lyase reaction, a histidine or a lysine residue 
might be responsible for neutralising the negative charge of the uronic acid, while a 
tyrosine residue acts as the base. The lyase reaction mechanism utilises a similar 
mechanism, and the difference lies in the last step, where β˗elimination occurs after 
turning O4 it into a leaving group by protonation. The electron transfer from the 
carboxyl group leads to a double bond formation between C4 and C5 creating a new 
non˗reducing end after the cleavage of the O˗glycosidic bond.55 The catalytic acid in 
the lyase mechanism is the same tyrosine residue that acted as a base in the first 
step of proton abstraction.6,60 
As expected, point mutations of conserved amino acid residues in the cleft 
lead to the secretion of the exopolysaccharide lacking G residues.15,21 In comparison, 
algG deletion mutants result in the production of depolymerised alginate. These 
results connote that even though AlgG can be enzymatically inactive, its association 
with the other proteins in the multi˗protein machinery contributes to the protection of 
alginate from AlgL˗mediated degradation, as long as the 3˗D structure of the protein 
is maintained.21,39 This also proposes that the polymer can move through the 
biosynthetic machinery by interacting with the catalytic site of AlgG.21 The above 
conclusions were confirmed by Moradali et al. while trying to restore alginate 
production in AlgG˗negative mutants. Specifically, the addition of catalytically inactive 
variant AlgG(D324A) resulted in the highest alginate molecular mass (4.653 ± 1.1% 
kDa/ 22.876 uronic acid residues) compared to that of active AlgG, proposing that the 
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epimerisation event may restrict the acetylation process of alginate. The above 
experimental evidence also designated that as the molar fraction of G residues (FG) 
increases, the molecular mass of the resulting alginate decreases.15  
AlgG is responsible for converting 22˗44% of non˗acetylated M residues to G 
residues in P. aeruginosa.13,14,55 Based on the finding that the composition of alginate 
reached 75% of G content when D˗polymannuronate is incubated with AlgG, Schurks 
et al. and Jerga et al. suggested that strict regulation and/or competition between the 
modification processes might take place in vivo.61,62 This interpretation contrasts with 
that of Moradali et al., as they proposed that O˗acetylation and epimerisation are not 
competitive modification events, but linked.15 Moradali and his group utilised mutants 
with catalytically inactive variants of AlgX(S269A) and AlgG(D324A). Interestingly, 
the highest values of FG were obtained by the addition of active or inactive copies of 
AlgX (FG = 0.36), which supports that AlgX plays a crucial role in alginate 
epimerisation. Moreover, the addition of active or inactive copies of both AlgG and 
AlgX resulted in higher degree of alginate epimerisation. It is also of exceptional 
interest to note that additional copies of both AlgX and AlgG resulted in higher degree 
of O˗acetylation, as opposed to additional copies of AlgX alone. All of the above 
experimental evidence suggest that both AlgX and AlgG are fundamental for the 
fulfillment of both acetylation and epimerisation processes, indicating some form of 
auxiliary behaviour.15 Both modifications convert polymannuronate to mature alginate 
and as a result, it is protected from degradation by AlgL during transport across the 
periplasm.40 
Alginate lyases are produced by organisms that harness alginate as a carbon 
source. Although alginate˗producing bacteria synthesise alginate lyases as well, thus 
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far, none of them have been reported to utilise alginate as a carbon source.6 In P. 
aeruginosa, algL belongs to the gene cluster that encodes the enzymes required for 
alginate biosynthesis.6,63  In general, 7 Polysaccharide lyases (PL) families are  
currently  known, PL˗5, ˗6, ˗7, ˗14, ˗15, ˗17, ˗18 and their classification is based on 
the hydrophobic cluster of their primary structures.64 Homology modelling studies 
showed that P. aeruginosa AlgL is a member of PL˗5 family, and structurally similar 
to A1˗III of Sphingomonas spp.65 In terms of catalytic mode of action, there are 
endolytic and exolytic alginate lyases, where the former group degrades alginate into 
unsaturated di˗, tri˗ and tetra˗saccharides, and the latter can further cleave alginate 
polymer into monomers.66 Tipton et al. demonstrated that P. aeruginosa AlgL utilises 
endolytic catalysis, as confirmed by using 1H NMR spectroscopy together with mass 
spectrometry to characterise the degraded products.63  
P. aeruginosa AlgL is a periplasmic protein responsible for clearing 
mislocalised alginate polymer derived from non˗functional export complexes.40 The 
anionic polysaccharide attracts smaller cations, therefore its accumulation in the 
periplasm results in increased osmotic pressure which can subsequently cause lysis 
and cell death.40,67 Albrecht and Schiller suggested that the main consequence of 
algL deletion is the complete loss of alginate production, which they restored by the 
addition of the algL ORF.68 In other words, deletion of algL is lethal for P. aeruginosa, 
even though the enzyme is not part neither of the biosynthetic cluster or part of the 
secretion complex. 
2.4. Alginate secretion 
AlgK and AlgE are the proteins responsible for the translocation and secretion 
of mature alginate, respectively.69,70 Keiski et al. solved the crystal structure of AlgK 
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at 2.5 Å resolution and demonstrated that it is a lipoprotein attached to the inner leaflet 
of the OM via its lipid moiety. In addition, Keiski and co˗workers proved that AlgK is 
crucial for the production and secretion of high molecular weight alginate, and that it 
constitutes a major contributor to the proper localisation of the OM anion˗selective 
channel protein, AlgE.69 Their former conclusion indicates that AlgK functions as a 
scaffold that stabilises the alginate biosynthetic complex, while the latter suggests 
that the interaction between AlgK and AlgE leads to the formation of a new type of 
secretin, structurally distinct from any other bacterial secretion systems.21,69,71 
AlgE is an OM β˗barrel porin essential for the formation of highly specific anion 
channel through which mature alginate is secreted.72,73 The specificity of AlgE for 
alginate was assessed by electrophysiological analysis.74 The existence of a more 
electronegative potential impacted alginate secretion, indicating that AlgE forms an 
anion˗specific channel which facilitates the export of its substrate. Furthermore, algE 
deletion mutant exhibited a non˗mucoid phenotype, as it secreted degraded alginate 
in the form of free uronic acids. These experimental data highlight that AlgE is 
important for alginate translocation through the periplasm and across the OM.70 
According to all the aforementioned experimental data and conclusions regarding the 
alginate biosynthesis, chemical modification, translocation and secretion, a model of 




Figure 12: Proposed model of the alginate biosynthetic multiprotein machinery cluster based on the 
current state of knowledge established by recent studies. The protein˗protein interactions of 
Alg8˗Alg4415, Alg8˗AlgG2, Alg44˗AlgK15, Alg44˗AlgX2, AlgX˗AlgK75, AlgX˗MucD75, and AlgK˗AlgE2 are 
illustrated. This model denotes the positive regulation of alginate biosynthesis by c˗di˗GMP binding to 
Alg44, which in turn increases Alg8 catalytic activity through an unknown mechanism. The 
polymannuronate is then translocated across the periplasm where O˗acetylation and epimerisation 
occur successively. AlgL is also situated in the periplasm for degrading misguided polysaccharide 
oligomers. Alginate is finally secreted though AlgE leading to the formation of the bacterial biofilm 
[Adapted from Hay et al. (2013) and Rehman et al. (2013)].1,2 
3. Chemical modification of plant˗based alginate 
Chemical modification of alginate is applied as a strategy for the construction 
of materials with enhanced existing properties, such as improvement of ionic gel 
strength by additional covalent cross˗linking.17 In addition, chemical modification of 
alginate aims towards the production of materials exhibiting completely novel 
properties, for example, heparin˗like anticoagulant properties by sulfation.76 In other 
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words, controlled alginate derivatisation has proven to be advantageous for 
generating materials that exhibit inherent property enhancement or new property 
introduction.17 This highlights the increased potential to design novel alginate 
biomaterials, as different modifications on the polymer backbone may enable the 
tailoring of properties such as solubility, hydrophobicity and affinity for specific 
biomolecules or small molecules. 
Alginate modification strategies rely on the solubility, characterisation and 
reactivity of the polymer.17 In particular, the degree of alginate derivatisation, and 
consequently its substitution pattern, is dictated by the solvent system (aqueous, 
organic or mixed media) in which alginate dissolved. It is important to emphasise the 
sensitivity of alginates towards acidic, basic and reductive environments during 
derivatisation reactions, as the biopolymer can degrade rapidly causing drastic 
reduction of molecular weight and subsequent loss of functional performance.18 
Chemical modification of multiple alginate samples with a range of M/G ratios is often 
essential for in˗depth understanding of the substitution patterns.17,18 Regarding 
reactivity, the secondary –OH positions at C2/C3 or the –COOH at C6 can be 
modified selectively due to the reactivity difference between the two types of 
functional groups. The main techniques used to date for C2/C3 –OH modification are 
oxidation, sulfation, phosphorylation, acetylation, and coopolymerisation (Figure 
13).17,18,77 Chemical modification of the carboxyl groups include esterification, 
amidation and bis˗amidation (Ugi reaction) as part of multicomponent reactions.77 
The literature examples discussed below are focused on the derivatisation of the 
carboxylate group at the C6 position of M and G monomers, as it is relevant to the 




Figure 13: Examples of alginate hydroxyl group chemical modifications. Note that the degree of any 
of the depicted modifications is controlled by varying the concentration of the reagents used. 
Native alginate exhibits enhanced hydrophilicity at pH = 5 and above, due to 
the carboxylate ion on the polymer backbone.17 The alginate backbone can be readily 
transformed by esterification whereby alkyl groups can be attached in order to 
increase the hydrophobic nature of the polymer.77,78 Propene glycol esters of alginate 
(PGA) that can be obtained through coupling of alginate with propyleneoxide, were 
the first commercially valuable derivatives in food industry as a thickener and 
stabiliser for products of low pH or that contain calcium.79 Yang, Zhang, and Wen 
demonstrated that a water soluble amphiphilic cholesteryl ester of alginate obtained 
though coupling of the carboxylate and cholesterol with DCC and DMAP, can 
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self˗assemble into stable and compact nano˗aggregates in aqueous NaCl solution 
(Figure 14).80  
 
Figure 14: Synthesis of alginate derivative grafted with 3 cholesteryl groups per 100 uronic acid 
residues [Adapted from Yang et al. (2007)].80 
A study conducted by Broderick et al. showed that a butyl ester of alginate prepared 
from sodium alginate and BuOH in the presence of catalytic H2SO4, is capable of both 
hydrophilic and hydrophobic molecule encapsulation.81 An additional method of 
producing hydrophobically modified alginates is the conversion of the carboxylic acid 






Figure 15: (a) Four component Ugi reaction (b) Transmission electron microscope (TEM) image and 
dynamic light scattering (DLS) reveal that stable Ugi˗Alg self˗aggregated micelle with the average size 
of 162.3 nm [Adapted from H. Yan et al. (2016)].83 
The Ugi reaction is largerly applied in combinatorial chemistry involving the 
condensation of a ketone or aldehyde, an amine, an isocyanide and a carboxylic 
acid.77 A facile procedure was reported as follows: to stirred aqueous solution of 
acidified native alginate (pH = 3.6) is added consecutively formaldehyde, 
n˗octylamine and cyclohexyl isocyanide (Figure 15a)77,83. The linkage formed on the 
backbone of the polysaccharide was a bis˗amide, resulting in a hydrophobically 
modified alginate that could form stable self˗aggregated micelles in aqueous media 
with high thermal stability (Figure 15b).83 
An additional strategy followed for the carboxylate modification is amidation. 
The use of coupling agents such as EDC.HCl and NHS is commonly applied for the 





form amide linkages.18,77 By blending the amphiphilic alginate derivatives with 
polyvinyl alcohol (PVA) using an electrospinning method,  the resultant nanofibres 
were exploited as hydrophobic drug˗carriers.84  
 
Figure 16: Schematic representation of hydrophobically modified alginate stabilising sulindac in 
hydrophobic domain in aqueous media. [Adapted from Choudhary et al. (2018)].78 
Recent evidence suggests that hydrophobically modified alginate hydrogels with C8 
alkyl chains are promising candidates for the controlled delivery and release of 
hydrophobic drugs such as sulindac, as the amphiphilic modified polymer could 
stabilise the hydrophobic drug molecule in aqueous media (Figure 16).78 All of the 
above experimental evidence denotes that chemical transformation of the alginate 
carboxylic acid groups can impact significantly the overall physicochemical properties 
of the polysaccharide. 
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Alginate derivatives with high biomedical significance can be prepared by 
applying simple chemical modifications, however, the challenge relies on matching 
the chemical transformations with the required physical properties of the resulted 
biomaterial. It is noticeable that the main modification of the carboxylate backbone is 
hydrophobic, as a large proportion of the literature reported coupling with alkyl 
alcohols or amines.17,77 As described in the following section, modified alginate has 
a track record of safe clinical uses. The demonstrated biomedical utility of modified 
alginate emphasises the need for further chemical manipulation as a means to 
produce novel alginate˗based materials. 
3.1. Biomedical and biotechnological applications of modified/native 
alginate 
Alginate˗based biomaterials have proven to be of great significance in various 
human health applications such as drug delivery, wound healing, cartilage repair and 
bone regeneration.8,9 They constitute ideal scaffolding materials as they can be 
exploited as hydrogels, microspheres, porous scaffolds and fibres in a broad range 
of applications.8 Properties of alginate such as high mechanical and chemical 
stability, controllable swelling properties, minimal or negligible cytotoxicity, defined 
pore size and narrow size distribution, are the key elements that make the 
polysaccharide a promising tool for regenerative medicine and tissue engineering.85 
In addition, the higher molecular mass of alginate facilitates slower degradation rates, 
providing a lower number of reactive positions available for hydrolysis.8 Most 
importantly, as a naturally˗derived material, alginate has been regaining attention 




3.1.1. CF medicine 
The goal of a recent study was the investigation whether G˗rich alginate 
oligomers (OligoG CF˗5/20) could detach CF mucus by chelating Ca2+, which is 
important for normal mucin unfolding.86,87 The fact that the unfolding process of 
mucins secreted by the epithelial cells of CF patients is insufficient, they 
hypothesised that OligoG CF˗5/20 would lead to mucus detachment. Indeed, at 
1.5%, OligoG CF˗5/20 resulted in CF mucus detachment wheres M˗rich alginate 
oligomers failed to produce a similar effect.86 
3.1.2. Drug delivery vehicles 
Alginate˗based drug delivery carriers have attracted a lot of interest during the 
past decades, as they proved to successfully deliver small drugs, as well as 
biomacromolecules.88,89 The pH˗responsive properties of alginate˗based 
biomaterials profoundly influence degradation, mechanical and swelling properties, 
long term stability and in vitro performance, making them ideal delivery systems for 
cationic drugs and cells.4 The construction of alginate˗based microcapsules as 
drug˗delivery carriers aims to control the degradation properties of the biomaterial, in 
terms of calculating the number of encapsulation layers needed for preserving the 
stability of the drug at different pH values until they reach the targeting site.8 
Formulation of this kind of microcapsule can be achieved by combining different 
biopolymers or polymers, such as alginate, chitosan or polyethylene glycol (PEG).90 
An additional advantage of using alginate as an oral tablet formulation component is 
its ability to maintain gel formation at the acidic conditions of the stomach by forming 
an alginic acid gel. Raft˗forming formulations of alginate are also applied for treating 
heartburn and gastric reflux into the oesophagus, e.g. GavisconTM.91 
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3.1.3. Wound dressings 
Alginate˗based sponges, hydrogels and electrospun mats are applied as 
wound dressings, due to the advantageous characteristics they exhibit including 
hemostatic capability, good water absorptivity, optimal water vapour transmission 
rate, conformability, mild antiseptic properties, and gel˗forming ability when they 
absorb wound exudates.92 The antibacterial properties of alginate˗based materials 
are accompanied by nontoxicity and biodegradability which are important 
characteristics, considering that wounds constitute a favourable environment for 
microbial colonisation that often leads to infections that may in turn delay the healing 
process. 
The application of an alginate dressing at the wound surface creates a fibrous 
gel layer due to the ion exchange that occurs between the Ca2+ ions from alginate 
dressings and the Na+ ions that exist in the exudate (Figure 17). Additionally, the gel 
formation preserves the moisture on the wound which encourages cellular 
regeneration. The antimicrobial, as well as the moisturising properties of 
alginate˗based wound dressings accelerate the healing process, leading to better 
cosmetic repair.8 Interestingly, wound dressings composed by alginate are proposed 
to amplify wound healing through monocyte stimulation which results in increasing 
the levels of cytokines, for example interleukin˗6 (IL˗6) and tumour necrosis factor˗α 
(TNF˗α), which in turn induce pro˗inflammatory factors that lead to wound healing 
enhancement.93 Non˗woven wound dressings like KaltostatTM, SorbsanTM, SeasorbTM 





Figure 17: Ion exchange triggered by the presence of Na+ in the wound, releasing Ca2+ in the 
alginate˗based wound dressing. 
3.1.4. Regenerative medicine applications 
Alginate hydrogels are extensively used for addressing critical challenges 
encountered in tissue engineering applications. Alginate˗based bioinks are used in 
3˗D bioprinting due to their capability to form cell˗compatible hydrogels under 
physiological conditions.94,95,96 Viscosity and density constitute key material 
properties that make alginate suitable as a cell encapsulation material and as a matrix 
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scaffold to tune a specific 3˗D cell growth.7,95 In order to achieve a homogenous cell 
suspension throughout the whole printing process, it is essential the density of the 
biomaterial to be similar to that of the examined cell type, as this defines the desirable 
homogeneity of cell distribution in the bioink. Jia et al. investigated the viscosities of 
30 different biodegradable alginates combined with fluorescent˗labelled human 
adipose˗derived stem cells (hADSCs), and concluded that as the concentration of 
alginate in gelatin increased and degree of oxidation decreased, the density and 
viscosity of the bioink demonstrated an increasing trend (Figure 18).77 Nevertheless, 
the metabolic requirements of different cell types may demand oxidised alginate with 
alternative sets of viscosity and density, in order to permit the optimal diffusion of 
nutrients, as well as the homogenous distribution of cells.7 This example highlights 
the challenge of chemically modifying alginate for tuning its physicochemical 
properties for specific applications. 
 
Figure 18: Calcein˗stained hADSCs in the 5% ox.˗10% conc. (i.e., alginate with 5% oxidation and 10% 
w/w in Ca2+˗containing gelatin) (left) and 5% ox.˗2% conc. (right) material with and without successful 
cell suspension, respectively (scale bar= 500 μm) [Adapted from Jia et al.(2014)].7 
Chemical modification of alginate˗based bioinks is of great clinical significance 
for cartilage, bone and vascular regeneration.4,8.96 The application of injectable 
hydrogels, solid˗ and gel˗microspheres composed of alginate proved to be 
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advantageous for cartilage repair due the stiffness and strength that is formed almost 
instantly. In addition, the physical properties of an alginate hydrogel at a macroscopic 
level can be tuned according to the mechanical properties of the native cartilage 
tissue.97 As for bone regeneration, in situ osteogenesis is a beneficial strategy to 
pursue.8 To accomplish this, alginate is utilised as a bioink which is seeded with stem 
cells to produce an injectable scaffold that leads to bone tissue regeneration.98,99 To 
date, a number of studies demonstrated the effectiveness of using injectable 
alginate˗based bioink scaffolds for inducing osteogenesis.100,101,102 Apart from 
osteogenic properties, alginate also exhibits angiogenic properties that aid in the 
design of scaffolds applicable for vascular regeneration.4,8 Based on the above tissue 
repair and regeneration examples, it is clear that alginate is a promising substrate 
material for the successful construction of biopolymers useful for a wide range of 
biomedical applications. 
4. Chemical synthesis of alginate  
4.1. Concepts in oligosaccharide synthesis 
Synthetic carbohydrate chemistry approaches have been developed for the 
chemical production of complex carbohydrates of biological, medicinal and 
biomaterial significance. The plethora of biological functions that carbohydrates and 
glycoconjugates perform stems from their structural diversity. Polysaccharides owe 
their complexity to the large variety of monosachharide building blocks from which 
they can be accessed. Any difference in stereo˗ and regio˗chemical aspects of the 
glycosidic linkages, may result in alternative polysaccharide structures with a great 
variety of properties and functions.103,104 In particular, the stereoselective formation 
of a glycosidic linkage depends on the α˗ and β˗ geometric isomers that exist. 
36 
 
Regioselectivity is based on the possible reaction of the five hydroxyl groups in the 
glycosyl acceptor with the anomeric position of the glycosyl donor (Figure 19).  
Clearly, the aforementioned make the assembly of oligo˗ and polysaccharides 
significantly more complicated compared to the synthesis of other natural polymers. 
The vast majority of polysaccharides derive primarily from bacteria and fungi, and 
are characterised by well˗defined structures with specific types of glycosidic linkages. 
 
Figure 19: Concepts in glycosylation. Stereoselectivity refers to the possible formation of two isomers 
of a mannose dimer. Regioselectivity depends on the position of the hydroxyl group that participates 
in the formation of the glycosidic linkage. 
To date, a great obstacle in glycochemistry and glycomedicine is the synthesis of 
structurally well˗defined and pure carbohydrates and their glycoconjugates. The 





both stereo˗ and regiochemistry, therefore it requires the design of appropriate and 
efficient glycosylation and protecting group strategies. 
Chemical glycosylation may appear as an extremely simple concept, however, 
the complications in this synthetic process are manifold, often leading to low yields 
and/or mixture of anomers. The difficulty of controlling the stereochemical outcome 
of a glycosylation reaction relies on correlating factors, such as the potency of the 
anomeric leaving group, the activation conditions, the reaction solvent, the 
temperature, the identity of the glycosyl donor and acceptor, and most importantly, 
the protecting groups of both glycosylating agents. Stereocontrolled synthesis of both 
α˗ and β˗ or 1,2˗trans and 1,2˗cis glycosides is important, as they usually exist in a 
variety of naturally occurring polysaccharides.  
Glycosidic bond formation involves the displacement of a leaving group at the 
anomeric position of the glycosyl donor by a free hydroxyl group of the glycosyl 
acceptor, in the presence of a promoter or an activator (Figure 20). Upon activation, 
the loss of the anomeric leaving group produces a glycosyl cation which is a 
stabilised oxocarbenium ion. The formed cation at the anomeric carbon is stabilised 
by electron donation from a lone pair of ring oxygen (O5). The hydroxyl group of a 
suitably protected acceptor acts as the nucleophile in this reaction, attacking either 
from the top or bottom face of the flattened oxocarbenium intermediate. Thus, the 
reactions proceed via an SN1 mechanism which may lead to the formation of the 
1,2˗cis or the 1,2˗trans glycoside, posing a challenge in stereoselectivity. Note that 
in the manno˗series glycosylation reactions, 1,2˗trans linkages are favoured by the 
anomeric effect (Figure 20a). The employment of an ester protecting group at the 
C2˗position of the donor can yield almost exclusively 1,2˗trans glycosidic linkages, 
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as in this case, a bicyclic acyloxonium ion is the major intermediate. Considering that 
the top face of the mannose analogue is blocked during the bicyclic acyloxonium ion 
formation, the nucleophilic attack by the hydroxyl group of the acceptor would take 
place at the bottom α˗face of the ring (Figure 20b). In some cases, orthoester 
formation or 1,2˗cis glycosides may additionally be observed, depending on the 
reactivity and types of the acceptors used.105 
 
Figure 20:  General mechanistic outline of chemical glycosylation. (a) Glycosylation mechanism when 
a non˗participating group is placed at C2, where the anomeric effect dictates the formation of a 
1,2˗trans linkage in mannose derivatives (b) An ester protecting group at C2 promotes the nucleophilic 
attack of the glycosyl acceptor at the bottom face of the mannopyranoside. 
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In general, the four types of glycosidic linkages based on C1 and C2 
geometries are 1,2˗trans˗β, 1,2˗trans˗α, 1,2˗cis˗β and 1,2˗cis˗α (Figure 21). As 
depicted in Figure 20, the synthesis of 1,2˗trans saccharides can be succeeded with 
the use of neighbouring group participation (NGP) on the C2˗position of the glycosyl 
donor, while 1,2˗cis glycosides have proven to be synthetic more challenging for 
carbohydrate chemists.106 
 
Figure 21: Four types of glycosidic linkages based on C1 and C2 geometries. 
Even though a large number of examples in the literature demonstrate 
excellent 1,2˗cis stereoselectivity, none of them provides a fully comprehensive 
method, especially for producing 1,2˗cis˗β˗glycosidic linkages.106,107 In addition to the 
non˗availability of NGP, the reasons behind the synthetic challenge for the 
construction 1,4˗β˗linkage are both steric and electronic. The steric factor is based 
on the repulsive interactions between the nucleophile approaching from the top face 
of the ring and the axial C2 substituent, while the electronic relies on the the anomeric 
effect, which would favour α˗1,4˗linkages. The anomeric effect describes the 
preference of electronegative substituents at the anomeric carbon to adopt an axial 
orientation (α˗anomer) rather than an equatorial (β˗anomer) (Figure 22).108,109 The 
theory of hyperconjugation is the most widely accepted explanation, whereby the 
tendency to adopt an axial orientation is a result of electron delocalisation from the 
ring oxygen (O5) lone pair to the anomeric C1˗X antibonding orbital (nσ*), also 
known as the endo˗anomeric effect. Due to orbital misalignment, the β˗anomer 
1,2˗trans˗α 1,2˗cis˗β 1,2˗cis˗α 1,2˗trans˗β 
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cannot be stabilised by the endo˗anomeric effect, therefore the equatorial orientation 
is less favoured.110 Evidence of a shortened and consequently strengthened C1˗O5 
bond accompanied by a longer and weakened C1˗X bond in compounds supported 
this theory of hyperconjugation.111  
 
 
Figure 22: Schematic representation of the endo˗ and exo˗anomeric effect based on the 
hyperconjugation theory. Stabilisation of the α˗anomer by the overlap of the n (O5) and σ* (C1˗X) 
syn˗periplanar orbitals (top left) and by the overlap of the n (O1) and σ* (C1˗O5) syn˗periplanar orbitals 
(bottom left). The endo˗ anomeric effect is not observed with the β˗anomer, therefore no stabilisation 
can occur (top right). The β˗anomer can only be stabilised by the exo˗anomeric effect.108,109,112 
Furthermore, the existence of an anomeric exocyclic alkoxy –OR gives rise to an 
additional anomeric effect known as the exo˗anomeric effect, whereby the aglycon 
dictates the conformation.112 In particular, the anti˗periplanar arrangement of a 
molecular orbital (n) on O1 and an unoccupied σ* molecular orbital along the C1˗O5 
bond stabilises both α˗ and β˗anomeric configuration, as depicted in Figure 22. The 
α˗anomer is stabilised by both endo˗ and exo˗anomeric effects, whereas the 
β˗anomer can only be stabilised by the exo˗anomeric effect. 
The so˗called Δ2 effect constitutes a stereo˗electronic factor that also favours 



















The Δ2 effect was first proposed by Reeves as part of his pioneering work on the 
shape of the pyranose ring conformation. It describes the occurring destabilisation of 
the pyranose ring conformation due to the repulsion between the three indicated 
oxygens in the β˗anomer. Notably, this repulsion takes place when the hydroxyl 
group attached to C2 is axial and bisects the torsional angle between the C1˗O5 and 
C1˗O1 (Figure 23b).113  
 
Figure 23: The Δ2 effect. Newman projection represents view C2C1 axis [Adapted from Reeves 
(1950)].113 
In addition, the Woerpel model described that nucleophilic attack of the glycosyl 
cations formed during an SN1 mechanism occurs along a pseudoaxial trajectory to 
maximise the overlap between the nucleophile HOMO and oxoxarbenium ion 
LUMO.115 For a 4H3 glycosyl cation, a bottom face attack leads to a more favourable 
chair˗transition state furnishing α˗linked products (Figure 24).115,116 Axial attack from 
the top face of the 4H3 half˗chair conformation results in the higher˗energy twist/skew 





Figure 24: Mechanisms of SN1˗type glycosylations leading to α˗configurations [Adapted from 
Woerpel et al. (2003)].116 
A large number of efforts have been made for the development of an efficient 
methodology to overcome these hurdles. These include direct β˗mannosylation by 
employing mannosyl halide glycosyl donors with silver salts,117–120 inversion of the 
C2 configuration of β˗glucosides via a sequence of deprotection, oxidation and 
reduction reactions,121–126 intramolecular aglycone delivery (IAD),126–128 anomeric 
O˗alkylations,129–131 application of mannosyl donor protecting groups such as, 
4,6˗O˗benzylidene,132–137 4,6˗O˗arylboronate138 or 4,6˗O˗silylene,139 
hydrogen˗mediated aglycone delivery (HAD),140, application of boronic ester catalyst 
that derived from the glycosyl acceptor with 1,2˗anhydromannosyl donors,141,142 and 
use of 2,6˗107 or 3,6˗lactones on mannosyl donors143. -corrected punctuation 
Chemical glycosylation reactions often follow an SN1 mechanistic pathway which 
involves the loss of the anomeric leaving group as the first step. Therefore, one could 
suggest that the orientation of this leaving group is irrelevant. However, depending 
on the activation conditions, chemical glycosylations may proceed via a mixture of 
SN1 and SN2 mechanism, where the latter stereospecifically results in the inversion 






Figure 25: Schematic representation of the possible SN1˗like and SN2˗like glycosylation mechanisms 
deriving from covalent adducts and oxocarbenium ion counter ion˗pairs [Adapted from Codée et al. 
(2017)].144 
Notably, SN2  leaving groups that have been proven to provide mostly 1,2˗cis 
stereoselectivity are β˗glycosyl halides that derive from their respective α˗glycosyl 
halides with bromonium ions,145 or from α˗thioglycosides in the presence of 
bromine,146 glycosyl thiocyanates,147 and anomeric mannosyl triflates generated in 
situ from thioglycosides or sulfoxides for β˗mannosylation.148,149 
A large and growing body of literature focused on identifying and evaluating 
the role of protecting groups of the donor in β˗mannosylation, as the ring substituents 
play a decisive role on its reactivity.150 Paulsen and co˗workers were the first to 
observe that EWG on carbohydrates slow down the production of oxocarbenium ion, 
α˗covalent adduct 














as they destabilise the formation of partial positive charge at the anomeric centre. As 
a result, the rate of hydrolysis and/or glycosylation is retarded.151 This observation 
was formulated as the ‘armed˗disarmed’ concept by Fraser˗Reid and co˗workers 
based on their observation where benzylated glycosyl donors (armed) were activated 
and coupled to acetylated glycosyl donors (disarmed).152,153 They suggested that this 
phenomenon is supported by the instability of the positively charged intermediate 
which stems from the presence of adjacent electron˗withdrawing groups on the 
glycosyl donor.153 Moreover, the research groups of Wong154–157 and Ley158 have 
examined the reactivity of diversely substituted thioglycosyl donors, and concluded 
that the nature of the mono˗ or oligo˗saccharide, as well as the location of the 
substituents on the sugar ring, have a specific influence on the conversion rate of the 
glycosylation. For example, computational calculations of the relative reactivity 
values (RRV’s) of a specific thiogalactoside with different protection and functional 
groups at the C2˗position, were quantified as –N3 > ˗O(CIAc) > ˗NPhth > ˗OBz> 
˗OBn.155 Most importantly, the ‘armed˗disarmed’ concept is widely applied in 
chemoselective glycosylation strategies, where the electronic effects of the glycosyl 
donor and acceptor protecting groups are exploited for enabling orthogonal 




Figure 26: Schematic representation of chemoselective glycosylation strategy, employing the 
‘armed˗disarmed’ concept [Adapted from Codée et al. (2005)].159 
In˗depth understanding of the aforementioned fundamental concepts of 
oligosaccharide synthesis has improved the development of solution˗phase synthetic 
protocols and subsequently provided access to pure and complex oligosaccharides. 
Considerable effort is still needed for the synthesis of carbohydrate sequences, as 
stereoselectivity, reactivity and overall structural complexity require the design of a 
series of methodologies which involve various protecting group manipulations and 
long synthetic routes. 
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4.2. Mannuronic acid building blocks in oligosaccharide synthesis 
The synthesis of alginate oligosaccharides is highly demanding, not only 
because of the 1,2˗cis configuration it possesses, but also because of the carboxylic 
acid group at the C5 position of the carbohydrate core of both M and G monomers.150 
Generally, the construction of mixed˗sequence alginate oligosaccharides can be 
succeeded by the use of M and G as monomeric or GM or MG as dimeric synthons 
in a pre˗glycosylation or post˗glycosylation oxidation approach.160 In order to 
minimise functional˗group alteration at a late stage of the oligosaccharide synthesis, 
a number of studies focused on investigating the reactivity of various mannuronate 
donors and acceptors. 150,144,161 Uronic acids are regarded to be among the most 
unreactive glycosyl pyranoside donors, as the electron withdrawing character of the 
carboxylate group at C5 is considered to have a ‘disarming’ effect responsible for 
retarding the formation of positive charge at the anomeric position, and therefore, 
slowing down the rate of the glycosylation.150,162  
4.2.1. Effect of glycosyl donor in alginate oligosaccharide synthesis 
Codée and co˗workers have provided experimental evidence of high 
β˗stereoselectivity by using 2˗azido˗mannuronate ester as a glycosyl donor.163 Their 
choice of this donor relies on its tendency to partake in SN2˗type reactions due to the 
electron˗withdrawing effect of the C2 azide that stabilises the anomeric triflate as the 
reactive intermediate. They explained that the application of Ph2SO/Tf2O on 
α˗thiophenol mannuronic acid 1, leads to the preferential formation of the axial 
anomeric triflate 3, which also exists as an oxacarbenium ion intermediate with a 3H4 




Figure 27: β˗directing effect of the glycosyl C5˗carboxylate in 3H4˗oxacarbenium ion intermediate 
[Adapted from Codée et al. (2009)].164 
The α˗triflate intermediate 3 follows SN2˗like displacement providing the β˗linked 
product, while the oxocarbenium intermediate proceeds through SN1˗like pathway 
allowing the nucleophilic attack of the acceptor from the β˗face. In addition, they 
suggested that substituents at C3 and C4 prefer to occupy pseudoaxial postions, as 
in this way they exhibit less disarming effect, whereas the C2 substituent occupies a 
pseudoequatorial position on the mannosyl half˗chair.115,165–167 Most importantly, 
they suggested that the C5 carboxylic acid ester group displays strong preference 
for a pseudoaxial position due to  the through˗space interaction between its 







Based on the latter line of recommendation, Codée et al. also demonstrated 
experimentally that the C5 carboxylate ester reacts in a highly 1,5˗cis selective 
fashion, depending on the steric demands of the nucleophile.164 Moreover, by 
employing carboxylbenzyl and N˗PTFA glycosyl donors that led to the formation of 
β˗mannosidic linkage, showed that the stereoselectivity of these mannosylations 
does not depend on the type of donor or pre˗activation conditions. Their work on the 
remote stereodirecting effect of the C5˗carboxylate ester highlighted the importance 
of the 3H4 half˗chair in the formation of β˗mannosidic linkage.164 
Walvoort et al. tested and compared the activation and glycosylation behaviour of 
α˗thio˗mannuronic acid donors and their non˗C6 oxidised counterparts 
demonstrating that not only α˗thio˗mannuronic acid donors can provide high 
β˗stereoselectivity in mannosidic linkage formation, but they also exhibited 
considerably high reactivity.150 Their experiments showed that α˗thio˗mannuronic 
acid 13 is 30 times less reactive than the α˗configured 4,6˗O˗acetylated and 
4,6˗O˗benzylidene analogues, due to the presence of the C5 carboxylic acid ester. 
Interestingly, the respective β˗thio˗mannuronic acid donor 7 indicated higher 
reactivity than the β˗configured 4,6˗acetylated and 4,6˗benzylidene analogues, which 
again signifies the effect of the formed 3H4˗oxacarbrenium ion intermediate 5 (Figure 
28). As opposed to β˗thio˗mannuronic acid 7, the α˗thio˗mannuronic acid donor 13 
leads primarily to the formation of the more unstable 4H3˗oxacarbenium ion 12, where 
the substituents are positioned in unfavourable orientations. Nevertheless, both α˗ 
and β˗mannuronates reacted in a stereoselective manner to provide β˗mannosidic 
linkages, which is strongly based on the relatively favourable 3H4˗oxacarbrenium ion 
intermediate.150 In other words, the incorporation of a C5˗carboxylate ester on the 
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mannopyranosyl building blocks is valuable, making them highly β˗selective 
glycosylating agents for the construction of alginate oligomers. 
 
Figure 28: Proposed mechanism for the formation of β˗mannosidic linkage from α˗ and 
β˗mannuronic acid donors [Adapted from Walvoort et al. (2011)].150 
Codée and co˗workers reported the construction of D˗ManA alginate 
oligomers by automated solid phase synthesis incorporating up to twelve 1,2˗cis 
mannosidic linkages.169 The stereoselective formation of β˗mannosidic linkages was 
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carried out successfully by the application of a second˗generation automated 
oligosaccharide synthesiser. Merrifield resin functionalised with a butanediol linker 
was used, which can be selectively cleaved through cross metathesis with 
ethylene.170 They chose to use N˗PTFA donors prepared from their respective 
thioglycoside donors. N˗PTFA donors can be activated by catalytic amounts of Lewis 
or Brønsted acid, as opposed to thioglycoside donors that prohibit the application of 
soft electrophiles for activation which was not compatible with the nature of the 
linker.171 They demonstrated that solid˗phase synthesis offers the capability to 
construct oligosaccharides of a length initially considered difficult to synthesise in 
solution. Their methodology produced multi˗milligram quantities of the 
dodecasaccharides that enabled their full characterisation, and their use in biological 
experiments.169 
To date, Pan et al. reported the first solution˗phase synthesis of a 
β˗mannuronic acid alginate hexadecasaccharide introducing the longest synthetic 
polymannuronate (Figure 29).172 Their approach was based on the orthogonal and 
consecutive activation of thioglycosides and glycosyl N˗phenyl trifluoroacetimidates 
in a [2+2], [4+4] and [8+8] coupling. The use TfOH was preferred over TMSOTf or 
TBDMSOTf, due to the higher yields and slight increase in β˗selectivity. Their highly 
convergent strategy exhibited satisfactory coupling efficiency by consuming only 1.5 
equiv. of N˗PTFA donors, as opposed to the 5.0 equiv. of donor used in the 




Figure 29: Synthesis of the β˗mannuronic acid alginate hexadecasaccharide 17 by coupling 
octamannuronate N˗phenyl trifluoroacetimidate donor 14 and the octamannuronate acceptor 15 
[Adapted from Pan et al. (2019)].172 
4.2.2. Effect of glycosyl acceptor in alginate oligosaccharide synthesis 
Previous studies concluded that the reactivity of an acceptor is inversely 
correlated with the stereoselectivity, as the most reactive alcohols provide the lowest 
α/β˗ratios.173 It is well established that stronger nucleophiles proceed through faster 
reactions which are consequently more difficult to direct in terms of the 
stereochemical outcome.105 Thus far, several studies have reported that acylated 
(disarmed) acceptors are less reactive compared to the corresponding benzylated 
β/α = 12/1 
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(armed) acceptors, because of the ester electron˗withdrawing effect that reduces the 
electron density of the adjacent hydroxyl group, and therefore its nucleophilicity.174–
176 Instalment of such electron˗withdrawing groups is used for controlling 
glycosylation reactions, as in this way stereoselectivity may be improved. 
An example depicting the reactivity of mannuronate acceptors was showed by 
Zhang et al. in their work where the total synthesis of alginate oligosaccharides 
containing both M and G residues was performed.177 In particular, by utilising a G 
acceptor and a M donor they managed to assemble a set of GM, GMG, GMGM, 
GMGMG, GMGMGM, GMGMGMG, and GMGGMG alginates in a fully 
β˗stereoselective manner. They explained that the use of GM as a glycosyl acceptor 
provided low glycosylation yields due to the poor nucleophilicity of G C4˗OH.166,178,179 
Furthermore, their studies provided further insight in the construction of alginate 
oligosaccharides, as they confirmed that the nature of the reducing˗end anomeric 
centre, in terms of conformational flexibility, exhibits a tremendous effect on the 
efficiency and effectiveness with which the disaccharide building blocks were 
merged. This suggestion derived from a series of glycosylation experiments they 
conducted for the assembly of four monomers and more, by using glycosyl GM 
acceptors with different anomeric functionality. NMR analysis established that GM 
acceptor 20 bearing the β˗azidopropanol anomeric group occupies a normal 4C1 
conformation, whereas GM acceptor with α˗thiocresol anomeric group exists as an 
equilibrium of a 4C1 (18) and 1C4 (19) conformation (Figure 30). More importantly, the 
equilibrium exhibits strong preference towards the 1C4 conformation which is a more 
reactive conformation that makes C4˗OH more accessible for the incoming donor. 
The conformational flexibility of the GM acceptor bearing the α˗thiocresol anomeric 
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group arises from the presence of the C5˗carboxylate group and the α˗anomeric 
configuration, and both are required for producing the desirable 1C4 conformation.177 
 
Figure 30: GM acceptors bearing α˗thiocresol and β˗azidopropanol in their chair conformation 
[Adapted from Codée et al. (2015)].177 
Preliminary investigation on the relationship between mannuronic acid donors 
and acceptor reactivity by Codée et al. demonstrated that they provide β˗selective 
condensations with all acceptors explored, except with the very unreactive 
O˗nucleophile hexafluoro˗iso˗propanol that gave both anomers at a 1:1 ratio.144 The 
use of partially fluorinated ethanols as a “toolset” to determine the effect of acceptor 
nucleophilicity on the stereochemical outcome of a glycosylation showed that SN1 
character is dominant when the acceptor nucleophilicity is decreased (Figure 31). As 
previously discussed, 3H4 half˗chair oxocarbenium ion 5 is the most stable conformer 
that tends to be attacked from the top face to give β˗linked products 23. Based on 
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their results, they concluded that for less reactive O˗nucleophiles, the higher energy 
4H3 half chair transition state 12 becomes equally favourable with the more stable 
3H4 half chair conformation 5, leading to the formation of α˗O˗mannuronic acids 24. 
Most secondary carbohydrate acceptors are weak nucleophiles, therefore they react 
with donors that exhibit more carbocation character. 
 
Figure 31:  Conformations and intermediate transitions states to account for the selectivity in 
glycosylations of mannuronic acid donors [Adapted from Codée et al. (2017)].144 
A more recent study by the same group explored the reactivity of uronic acid 
acceptors and their non˗C6 oxidised counterparts by employing two conformationally 
locked thioglycoside donors, 4,6˗O˗benzylidene protected glucose 25 and 
glucosazide 26 (Figure 32).180  




Figure 32: Glycosylation stereoselectivities of model donors 25 and 26 with mannuronic acid 
acceptors 27˗29 [Adapted from Codée et al. (2018)].180 
Again pre˗activation conditions were applied for the formation of α˗triflate donors, 
with donor 26 giving a more stable intermediate as a result of the 
electron˗withdrawing effect of C2 azide. Consequently, donor 26 exhibited high 
β˗stereoselectivity by participating in SN2˗type reactions. They demonstrated that the 
anomeric centre configuration does not influence the reactivity of C4˗OH acceptors, 
as the employment of α and β˗methyl uronic acid acceptors 27 and 28 gave the same 
α/β ratios with donors 25 and 26. Although the protecting groups at C2 position 
showed no effect on the glycosylation stereoselectivity, the nature of the protecting 
group at C3 position had an apparent effect. In particular, the exchange of C3˗Bn 
with C3˗Bz functionality in uronic acid acceptor 27, 29 gave significantly higher α/β 
ratios with both donors 25 and 26 (>20/1).  
α:β (yield) α:β (yield) α:β (yield) 
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Previous research on native alginate synthesis enriched the current state of 
knowledge with significant information regarding methodology and mechanistic 
interpretation. This thesis focused mainly on the application of established synthetic 
methodology for native alginate oligosaccharides in the attempted construction of 
structurally˗defined modified alginate oligosaccharides. As summarised in Section 
3.1, alginate is of high significance in various applications, and thus far, 
hydrophobically˗modified alginate is the major biomaterial exploited. 
5. Concepts underpinning the work described in this thesis 
5.1. C6˗modified alginate oligosaccharide synthesis 
As discussed throughout Section 3, alginate exhibits material properties that 
can be tailored to become beneficial for high˗value medical applications. The 
examples described on C6˗carboxylate modification focuse mainly on the production 
of hydrophobically modified alginate. The work presented here targets the design 
and synthesis of C6˗bioisosteric D˗ManA building blocks which could then be 
assembled for the synthesis of structurally defined modified alginate 
oligosaccharides. The carboxylic acid group bioisosteres selected for this purpose 
were hydroxamic acid and tetrazole (Figure 33). This novel strategy of alginate 
derivatisation would generate designer alginates possessing improved or new 
material properties, such as new ion chelating properties. In addition to the 
biomaterial aspect, the mimetic alginate oligosaccharides could be exploited as 




Figure 33: Generic representation of designer alginate oligosaccharides from mimetic 
monosaccharide building blocks of D˗ManA (P = protecting group). 
5.1.1. Hydroxamic acid 
Focusing on the selection of carboxylic acid bioisosteres, hydroxamic acid 
was chosen based on its coordination properties that have proven advantageous in 
biological areas including medicine, pharmacology and different agricultural fields.181 
In the context of an anionic oligosaccharide synthesis, the physicochemical 
parameters to consider are acidity, lipophilicity and permeability.182 Even though 
hydroxamic acids are less acidic than carboxylic acids, exhibiting pKa values in the 
range of ~8˗9, they have been successfully employed in drug design as carboxylic 
acid bioisosteres.183,184 In addition, replacement of carboxylic acids with hydroxamic 
acids results in compounds with increased lipophilicity, leading to favourable activity 
profiles in cellular assays, in terms of permeability, absorption and distribution.185 
Hydroxamic acid derivatives are also often utilised for the analysis of trivalent 
elements such as Fe(III).186 Extensive research has focused on the ability of 
hydroxamic acids to inhibit certain metalloenzymes that contain Fe(III) and 
Zn(II).187,188 Complexes of hydroxamate species with other metal ions such as Co(II), 
Co(III), Ni(II), Cu(II) and V(IV) have also been investigated, indicating the variety of 
coordination complexes that can be formed.189 The vast majority of the metal 
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complexation of simple primary hydroxamic acid ligands occurs by deprotonation of 
the NH–OH which leads to coordination of the metal ion to the carbonylic oxygen and 
the deprotonated oxygen NH–O˗, giving the hydroamato (1˗) species 30 (Figure 34a). 
A second metal˗induced deprotonation can also take place, producing the 
hydroximato (2˗) type of ligand 31 (Figure 34b).189 
 
Figure 34: (a) Metal ion [O,O] coordination by a gereric hydroamato (1˗) derivative 30 (b) metal 
induced deprotonation leading to metal ion [O,O] coordination by a generic hydroximato (2˗) type of 
species 31.189 
To consider an example, hydroxamic acid was employed as a C6 functional 
group in octyl D˗glucosides in an attempt to produce biodegradable surfactants with 
good chelating properties for the removal of contaminant metals in wastewater.190 By 
performing flotation experiments using Fe(III) solutions as a model contaminant 
metal, Ferlin et al. demonstrated that hydroxamic acid derivatives exhibit better iron 
extraction than their respective carboxylic acid derivatives. The ability of compounds 
containing hydroxamic acid groups to coordinate Fe(III) has categorised them in a 
highly diverse group of compounds called siderophores.191,192 The chelating 
properties of hydroxamate make it an interesting carboxylic acid bioisostere for 




Focusing on tetrazole as a bioisostere, 5˗Substituted tetrazoles (5˗STs) are 
frequently referred to as tetrazolic acids and exist as a nearly 1/1 ratio of 1H˗ and 
2H˗tautomers. In addition, tetrazolic acids are often described as imidoyl azides 
(Figure 35a).183  
 
 
Figure 35: Tetrazolic acids are carboxylic acid bioisosters (a) Tautomers of 5˗substituted 
tetrazoles.193 (b) Skeleton and surface models of 5˗methyltetrazole and acetic acid anions [Adapted 
from Hamada and Kiso (2012)].194 
Lassalas et al. showed that a tetrazole surrogate moiety exhibits stronger hydrogen 
bond interactions than the respective carboxylic acid group, and their findings are 
consistent with previous studies.182,195 The enhanced hydrogen bonding capability of 








as it is apparent that the hydrogen bonding region in tetrazole (magenta on the 
surface model) is greater than in carboxylate (Figure 35b).183 
Under physiological conditions (pH = 7.4), carboxylic acids are partially 
dissociated (pKa ~ 4). The resulting delocalisation of the negative charge between 
the two oxygen atoms of the carboxylate anion provide two hydrophobic regions 
(green on the surface model) that contain a π˗orbital above and below the plane of 
the anion.194 Therefore, the tetrazole ring can be applied as non˗classical carboxylic 
acid bioisostere, which appears to be more effective as a surrogate moiety than a 
carboxamide group. The term non˗classical isostere refers to the fact that tetrazole, 
as an aromatic heterocycle, differs in size and number of atoms from the carboxylic 
acid group.194,193 According to the surface model in Figure 35b, the hydrophobic 
region of tetrazoles is larger, therefore they are more lipophilic compared to 
carboxylate anions and potentially more permeable.182 The free N˗H bond of 
tetrazoles makes them acidic molecules, hence, they are also ionised at 
physiological conditions, exhibiting a planar structure.194 Moreover, the delocalisation 
of the negative charge around the tetrazole ring is distributed over a larger molecular 
surface area, which can lead to a more favourable interaction with the targeting site, 
or it may complicate it. 183,193 Acidic compounds often exhibit low permeability and 
bioavailability, nevertheless, computational studies calculating the aqueous acidity of 
tetrazole suggested that it is the most preferred carboxylic acid bioisostere  due to 
its in vivo stability.196 Similarly to the hydroxamic acid group, tetrazole constitutes a 




5.2. C6 and C5˗modified alginate precursor building blocks 
Sugar˗nucleotides play a crucial role as precursors or intermediates in 
carbohydrate metabolism and glycoconjugate biosynthesis.197 A large and growing 
body of literature focuses on the development of structural analogues of 
sugar˗nucleotides which can be employed as substrates for enzymatic reactions in 
carbohydrate synthesis, as enzyme inhibitors, or as innovative tools for assay 
development and for the study of glycoconjugate biosynthesis.198,199 The importance 
for accessing both natural and non˗natural sugar˗nucleotides is emphasised from the 
numerous studies focusing on their efficient preparation for subsequent investigation 
of biological pathways in both mammalian and bacterial cells.197,198,200,201  
 
Figure 36: Generic representation of C6˗modified and C5˗substituted GDP˗D˗ManA analogues from 
respective 1˗phosphates (P = protecting group). 
A secondary aim of this thesis is the synthesis of C6˗bioisosteric D˗ManA 
1˗phosphates and subsequent production of their sugar˗nucleotides (Figure 36). 
Similar to the strategy discussed in Section 5.1, the targeted structures designed 
incorporate C6˗hydroxamic acid and C6˗tetrazole moieties. C6˗bioisosteric D˗ManA 
1˗phosphates can be used as structure˗function tools to further study of AlgA, while 
their respective sugar˗nucleotides can investigate AlgD, as both enzymes are 
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crucially involved in alginate precursor (GDP˗D˗ManA) biosynthesis. In addition, 
C6˗modified GDP˗D˗ManA analogues could be employed to modulate the 
biosynthesis of alginate in P. aeruginosa for biotechnological, as well as therapeutic 
applications.  
An additional research aim presented here focuses on the design and 
synthesis of C5˗Me modified alginate building blocks, as a means to probe 
epimerase AlgG and lyase AlgL (Figure 36). As previously discussed, the mode of 
action of both enzymes strongly relies on the H5 abstraction for completing their 
mechanistic function, therefore the replacement of C5˗proton with a C5˗Me group 
could potentially block this preliminary deprotonation. In other words, C5˗Me˗ManA 
could be incorporated in the biosynthesised polymannuronate and consequently 
affect alginate modification and/or production. 
6. Synthesis of native and C6˗modified mannuronate building blocks 
The synthetic approach undertaken initially for the synthesis of structurally 
defined C6˗modified alginate oligosaccharides was based on a pre˗glycosylation 
oxidation route, as Codée et al. clearly demonstrated that the stereodirecting effect 
of the electron˗withdrawing C5˗carboxylic ester is the major contributor in the 
formation of β˗linkages with mannuronate donors.166,164 Therefore, the objective was 
to incorporate the hydroxamate and tetrazole functionality at an early stage, to enable 
the assembly of modified alginate oligomers in a fashion similar to that seen for the 




Figure 37: C6˗modified mannuronate monosaccharide toolset for accessing designer alginate 
oligosaccharides and sugar˗1˗phosphates (P = protecting group, e.g. Ac, Lev, TBDMS, PMB, X = 
SPh, OCH2CH2CH2N3, OCH2CH2CH2N(H)Cbz). 
C6˗modified thioglycosides 32 and 33 were designed as suitable mimetic 
glycosyl donors for the oligosaccharide assembly. Thioglycosides are extensively 
used in oligosaccharide synthesis due to the stability of the anomeric thio function 
under a wide range of conditions applied during protecting group manipulations. 
Moreover, the thioether anomeric functionality can be activated using varied types of 
glycosylation conditions, as the soft sulfur atom can selectively react with soft 
electrophiles. These characteristics emphasise the versatility of thioglycosides, 
making the thio˗functionality (e.g. thiophenol) a suitable anomeric protective group 
and an efficient leaving group. Considering that alginate is composed of 
β˗1,4˗linkages, the  protecting group at C4 position of 32 and 33 was orthogonal to 
the rest of the protecting groups, allowing selective deprotection for iterative 
glycosylation reactions. Access to thioglycosides 32 and 33 was also used as 
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precursors useful in the synthesis of respective glycosyl acceptors and 1˗phosphates 
34 and 35 (Figure 37). 
The following sections are divided as follows: synthesis of native and 
C6˗modified thioglycoside series, conversion to their respective sugar˗1˗phosphates, 
alginate disaccharide synthesis using native mannuronate and C6˗hydroxamate 
building blocks, synthesis of conjugable C6˗modified mannuronates and future work 
and directions. 
6.1. Mannuronate donor and acceptor synthesis 
The route towards the synthesis of D˗ManA building block 42 was completed 
following established literature procedures (Scheme 1).202,203,204,205 Uronic acid 42, 
reported by Codée and collaborators for automated alginate oligosaccharide 
synthesis169, was an important intermediate for the synthesis of both a native and a 
hydroxamate precursor series. 
 
Scheme 1:  Synthesis of D˗ManA derivative 42 (i) Ac2O, H2SO4, RT, 1 h., 91% (ii) PhSH, BF3.Et2O, 
CH2Cl2, RT, 48 h, 75% (iii) Na(s), MeOH, RT, 2 h, 94% (iv) PhCH(OMe)2, HBF4.Et2O, DMF, RT, 24 h, 
67% (v) NaH, BnBr, DMF, RT, 24 h, 74% (vi) p˗TsOH.H2O, MeOH, 80 °C, 2 h, 72% (vii) TEMPO, 




Peracetylation of α/β˗D˗mannose furnished 36 as α˗ and β˗anomers in a 4/1 
ratio, as determined by 1H NMR and NOESY spectra. Equatorial H1 (6.09 ppm, d, 
3JH1˗H2 = 1.9 Hz) was expected to resonate downfield to the axial H1 (5.88 ppm, d, 
3JH1˗H2 = 1.1 Hz), and the obtained NOESY spectrum confirmed through space 
correlation of the axial H1 (β˗anomer) with the axial H3 (5.15 ppm, dd, 3JH3˗H4, H3˗H2 = 
10.0, 3.2 Hz). Thioglycoside 37 was obtained in 75% yield through reaction of 36 with 
thiophenol and BF3.Et2O. Following thioglycosidation, the acetyl groups were 
removed by treatment with NaOMe, produced in situ by dissolving Na(s) in MeOH to 
give tetraol 38. 4,6˗O˗benzylidene protection of 38 produced the trans˗fused ring 
system 39 in 67% yield, using benzaldehyde dimethyl acetal under protic catalysis. 
Initial attempts towards the synthesis of 40 with NaH and BnBr led to a 74% 
yield of the desired product. A monobenzylated product was also isolated (15 mg, 
4.3%), however, NMR data (COSY, HSQC, HMBC, and NOESY) were inconclusive. 
H2 and H3 were merged in the 1H NMR spectrum, as well as H1 and the 
benzylidene˗CH. C2 and C4 were also merged in the HMBC spectrum, making 
assignment difficult. The 1H NMR spectrum obtained for 43 matched the literature 
values for a C2˗benzylated compound, however, X˗Ray crystallographic data were 
produced to further confirm the assignement.206 As such, 8 mg of 43 was dissolved 
in 0.5 mL of CH2Cl2:hexane (1/1) to successfully produce a crystal sample by slow 
evaporation at room temperature. Crystal formation was completed after 16 h and 
the crystallographic data obtained verified that C2 position was benzylated, 
suggesting a relative order of reactivity for the bis˗benzylation of 39 (Figure 38). 
These results can be attributed to the higher acidity of C2˗OH, as previously 






Figure 38: Crystal structure of 43 indicating the benzyl group ac C2. 
Deprotection of 40 was completed by cleavage of the benzylidene group 
evaluating two alternative sets of acidic conditions. The first conditions used p˗TsOH 
whereas the second used 60% aq. AcOH. The former conditions were more efficient, 
providing higher yields of 41 (72%). Heating to reflux with 60% aq. AcOH at 120 °C 
for 6 h gave only 31% of 41 and the starting material recovery was 24%. Moreover, 
the use of the latter conditions gave additional by˗product 44 in 13% yield (Scheme 
2a). The 1H NMR data for this by˗product were in a good agreement with literature 
values.208 In situ generation of acylium ion 48 from AcOH through carbocation 45 
formation and a series of proton transfers (46, 47) accounts for the formation of 44 
(Scheme 2b). The mechanism could also proceed through common ester forming 
mechanism in acidic conditions.  
 




Repeated large scale synthesis of 41 starting from ~ 80 g of D˗mannose was 
achieved for acquiring satisfactory amounts (~ 30 g) of 41, giving a 15% overall yield. 
BAIB and catalytic TEMPO were next employed for a regio˗ and 
chemoselective oxidation of 41 to 42, as these reagents do not readily promote the 
oxidation of an anomeric thiohemiacetal, or oxidation of a secondary alcohol.209 The 
oxidising species generated in situ from the reaction of TEMPO and BAIB is the 
N˗oxoammonium intermediate 49, and depending on the reaction medium 
(anhydrous or aqueous) the oxidation can be tuned by stopping at the aldehyde 52 
or carboxylic acid 42 stage (Scheme 3).  
 
Scheme 3:  Postulated oxidation mechanism of 42 using TEMPO/BAIB in aqueous medium 
[Adapted from Parlanti et al. (1997)].210 
More specifically, the presence of water hydrates the aldehyde to give 53, allowing 
the oxidation towards the carboxylic acid by repeat of the same catalytic steps, 
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proceeding via intermediate 50.210 Finally, the formed hydroxylamine 51 is oxidised 
to TEMPO by BAIB, thus completing the catalytic cycle. 
With amount of 42 in hand, literature procedures were followed for the 
construction of native D˗ManA building blocks 54, 55, and 56 (Scheme 4).211 A 
C4˗OTBDMS protected donor was accessed by the use of TBDMSOTf, imidazole 
and DMAP in DMF. The reason behind the synthesis of 3 differentially C4˗protected 
mannuronate donors was to examine the deprotection protocols applied in terms of 
yield and influence on the existing linkages (Section 8.1.). Mannuronate donor 55 
was subsequently used with Ph2SO/Tf2O and TTBP in CH2Cl2, to furnish 58 in 67% 
yield, which was then refluxed in acetone with NaN3 for 48 h to give 59 in 97% yield. 
13C NMR confirmed the installation of an azide functionality, as the resonance of the 
α˗carbon to N3 shifted downfield from 30.4 ppm to 48.3 ppm.  
 
Scheme 4: Synthesis of the native donors and acceptor (i) MeI, K2CO3, DMF RT, 24 h, 77% (ii) 
TBDMSOTf, imidazole, DMAP, DMF, RT, 16 h, 96% (iii) Ph2SO, TTBP, Tf2O, 3˗bromopropanol, 




Finally, basic transesterification of the C4˗OAc under Zemplén conditions, gave the 
reducing end mannuronate acceptor 60 in 87% yield. A coupled HSQC spectrum 
confirmed the expected β˗configuration (1JC˗H = 156 Hz) of 60. It is worth noting here 
that HSQC experiments obtained without 13C decoupling enable the assignment of 
the anomeric configuration by providing one-bond CH coupling constants (1JC-H) 
exhibiting a 10 to 20 Hz difference. An empirical rule is that 1JC1-H1 = 170 Hz indicates 
an equatorial proton at C1 (e.g., α-D-glucose), while 1JC1-H1 = 160 Hz indicates an 
axial proton.212 
The selection to install the 3˗azidopropanol functionality on the native and 
modified reducing end glycosides was based on its dual advantage of differentiating 
the anomeric configuration with the thioglycoside donors (Sections 8.1. and 8.2.) and 
enabling further elaboration of the azide moiety for future conjugation studies, as it 
has been successfully employed for many applications in carbohydrate chemistry 
(Section 9.1.).213 
6.2. 6˗C˗hydroxamate donor and acceptor synthesis 
A hydroxamate functionality was installed by coupling O˗benzylhydroxylamine 
with 42 using PyBOP in the presence of hindered base DIPEA (Scheme 5a). 
C6˗hydroxamate scaffold 61 was delivered in 81% yield and 13C NMR data confirmed 
the coupling by showing an upfield shift of the carbonyl carbon peak from 172.9 ppm 
in mannuronic acid 42 to 168.4 ppm in 61. The next step towards donor 62 was the 
chemoselective protection of C4˗OH with an acetate group. Initial attempts using 1.2 
and 1.7 equivalents of Ac2O gave 62, 63 and a significant amount of starting material. 
The reaction was completed successfully when 2.2 equivalents of Ac2O were used 
leading to 62 in 68% yield, as well as acylation of the hydroxamate nitrogen (63, 
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20%). An increased nucleophilicity of the nitrogen in the hydroxamate group caused 
by the α˗effect could account for the N˗acylation (Scheme 5b). 
Analogous linker installation conditions with native donor 55 were attempted 
to access C6 hydroxamate glycosyl acceptor 66 from donor 62 (Scheme 6a). Upon 
activation of the α˗thiophenyl group and addition of 3˗bromopropanol, TLC analysis 
suggested conversion to a material with an unexpected higher Rf. 
 
Scheme 5: (a) Initial synthetic route towards C6˗hydroxamate donor 62 (i) O˗benzylhydroxylamine, 
PyBOP, DIPEA, CH2Cl2, RT, 3 h, 90% (ii) Ac2O, pyridine, CH2Cl2, RT, 24 h, 62: 68%, 63: 20%. (b) 
depiction of α˗effect: the resulting π˗orbital splitting by the alpha atom (O) increases the energy of the 
HOMO, requiring less energy for the electron transfer from the ‘alpha’ nucleophile (N) HOMO to the 
C=O LUMO of Ac2O. 
NMR data showed that the 3˗bromopropyl unit was not installed and instead the 
nitrogen of the hydroxamate group had acted as a nucleophile creating a bridge from 
C5 to C1, giving 64 in a 62% yield. 1H NMR analysis suggested 64 to be in 1C4 
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conformation, due to the small 3J value observed for the apparent triplet peak 
corresponding to H4 (5.06 ppm, app. br. t, 3JH4˗H3, H4˗H5 = 1.9 Hz). The reaction 
presumably proceeded via an intramolecular nucleophilic substitution producing 64 
as the sole product. An N˗C1 bond formation was confirmed by HMBC, where the 
anomeric proton (H1: 5.80 ppm, app. t, 3JH1˗H2, H1˗H3 = 1.2 Hz) showed correlation to 
the carbonyl carbon of the hydroxamate (C(O)NOBn: 150.4 ppm) (Scheme 6b). 
 
 
Scheme 6: (a) Attempted synthesis of 65 using donor 62 with Ph2SO, TTBP, Tf2O, 3˗bromopropanol, 
CH2Cl2, ˗60 °C to ˗90 °C, 1 h gave 64 at 62% yield (b) HMBC data confirming the connection of  





δH1: 5.80 ppm 
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Based on these results, 63 was next employed as the scaffold to attach the 
linker at the anomeric position using the same glycosylation conditions. 
Unfortunately, the acetyl protecting group on the hydroxamate nitrogen was 
hydrolysed, giving 62 as the product of the reaction. Considering the observed 
instability of an N˗Ac protecting group during these glycosylations, a benzyl group 
was introduced instead. 
Accordingly, N˗benzylation of 62 with BnBr and K2CO3, afforded 67 in 42% 
yield (Scheme 7a).214 The reaction was monitored by TLC every hour (for 6 h), which 
showed formation of a decomposed material (with a lower Rf) and was responsible 
for the low yield of 67.The yield of the reaction remained the same even after 24 h at 
room temperature. The alternative route designed as a means to improve the overall 
yield of 67, started with N˗benzylation of 61, giving 68 in varying yields (45% ˗ 64%) 
(Scheme 7b). The low yield spectrum reported was again due to the formation of the 
unidentified decomposed material, as determined by TLC and NMR analysis. 
Acetylation or levulinoyl protection of 68 gave 67 or 69 in 87% and 91% yield, 
respectively. 
 
Scheme 7: Synthetic pathways towards C6˗hydroxamate glycosyl donors 67 and 69 (a) (i) K2CO3, 
BnBr, DMF, RT, 15 h, 42% (b) (ii) K2CO3, BnBr, DMF, RT, 15 h, 45% ˗ 64% (iii) Ac2O, pyridine, CH2Cl2, 
RT, 24 h, 87% (iv) Lev2O, pyridine, CH2Cl2, RT, 24 h, 91%. 
73 
 
An alternative approach was taken to optimise the yield of the synthetic 
pathway towards 67 and 69, evaluating a direct coupling of N,O˗dibenzyl 
hydroxylamine 71 with uronic acid 42 (Scheme 8). This route required a synthesis of 
71 from tert˗butyl˗N˗(benzyloxy)carbamate 70, which was then used for coupling with 
42.215 Reagent 71 was successfully synthesised by N˗benzylation of 70 followed by 
treatment with TFA for N˗Boc cleavage (Scheme 8a). 
 
Scheme 8: Proposed synthetic route towards 68 via coupling of 42 with 71 (i) NaH, BnBr, DMF, RT, 
3 h (ii) 3% TFA in CH2Cl2, 24 h, RT, 62% (2 steps) (vi) 71, PyBOP, DIPEA, CH2Cl2, 0 °C, 40 min, gave 
C4˗C5 elimination product 72 in 38% yield. 
In a first attempt to directly synthesise 68 from 42, two equivalents of 71 were 
used which delivered an unwanted C4˗C5 elimination product 72, in 38% yield 
(Scheme 8b). 1H NMR data of 72 showed a doublet at 5.62 ppm corresponding to 
vinylic H4 (3JH4˗H3 = 5.4 Hz), and confirming the absence of H5. This observation 
suggested an increased basicity of 71 compared to the O˗benzylhydroxylamine 
(used for the synthesis of 61). In light of this result, the reaction was repeated by 
stirring 42 with PyBOP and DIPEA at 0 °C, followed by a dropwise addition of 71 (1.3 
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equiv.). The major product obtained after 40 min. at 0 °C was again 72, and NMR 
data showed no evidence of the desired product 68. These results imply that the 
basicity of 71 outweighed its nucleophilicity for this reaction and prevented a 
streamlined access to 68 (and ultimately 67 or 69) from 42. Therefore, the route 
reported in Scheme 7b was applied for the synthesis of building blocks 67 and 69. 
C6˗hydroxamate donors 67 and 69 were synthesised on a multigram scale and were 
subsequently employed as donors in synthesis of acceptor 78. 
 
Scheme 9: 3˗bromopropyl linker instalment at the anomeric position of 67 and 69 (i) Ph2SO, TTBP, 
Tf2O, 3˗bromopropanol, CH2Cl2, ˗60 °C to ˗80 °C, 1 h, 73: 89%, 74: 78%. 
Table 1: Glycosylation conditions attempted for the synthesis of 73 from 67 












Observation by TLC 
analysis 
1 NIS (1.5) 
TMSOTf (2.0)c 
1.5 0.05 24 h /RT Slow conversion (17% 
isolated yield) 
2 NIS (1.5) 
TMSOTf (2.0)c 
4.0 0.08 24 h /RT       
24 h /35 °C 
Slow conversion (not 
isolated) 
3 NIS (1.5) 
AgOTf (0.5) 
1.5 0.06 45 min. /0 °C 




4 NIS (1.5)  
TfOH (1.0) c 
2.0 0.07 1 h /0 °C         
2 h /RT 
Slow conversion (not 
isolated) 
5 NBS (1.5) 
TMSOTf (0.5) 
1.5 0.05 45 min. /0 °C 




Pre˗activation using NIS and equimolar TMSOTf 
6 NIS (1.5) 
TMSOTf (2.5) 
4.0 0.06 1 h /RT           




a 67, 3˗bromopropanol and NIS (1.5 equiv.) were stirred at ˗10 °C before the addition of Lewis acid. 
b The solvent used in all attempts was CH2Cl2. 
c Started from 0.5 equiv. and increased over the given time to the equivalents indicated in the brackets. 
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Similarly to the synthesis of native acceptor 60, the route towards 
C6˗hydroxamate acceptor 78 required the attachment of a 3˗bromopropyl group at 
the anomeric centre of 67 and 69 (Scheme 9). Multiple reaction conditions were 
attempted for this transformation and are summarised in Table 1.  
All of the glycosylation reactions started with 0.5 equivalents of the indicated 
Lewis acid, and increased up to 2.0 equivalents within the denoted reaction time. 
Significant drawbacks of the glycosylation using NIS/TMSOTf (2.0 equiv.) were the 
slow conversion of 67 and low yield (17%) of 73, even after stirring for 24 hours at 
room temperature (Entry 1). Coupled HSQC data obtained for 73 suggested a 
β˗anomeric configuration, with a value similar to the one obtained for the native 
acceptor (1JC1˗H1 = 152 Hz). The same glycosylation conditions were applied with 
increased amounts of the linker 3˗bromopropanol (4.0 equiv.) for 24 hours at room 
temperature and then 24 h at 35 °C (Entry 2). Again, incomplete conversion was 
observed by TLC analysis. Changing the Lewis acid to AgOTf (0.5 equiv.) showed 
the formation of 73 by TLC analysis after 45 min. at 0 °C, alongside a significant 
amount of starting material 67. The reaction was left to warm to room temperature 
and TLC analysis after 15 min. indicated the formation of an inseparable mixture 
(Entry 3). NMR data showed no evidence of 73. 
NIS and TfOH (1.0 equiv.) were evaluated next as an alternative promoter 
system, and gave a result similar to that seen with NIS/TMSOTf activation (Entry 4). 
NBS and TMSOTf (0.5 equiv.) were attempted next, where TLC analysis of the 
reaction indicated incomplete conversion after 45 min. at 0 °C. The reaction mixture 
was left stirring for an additional 45 min. at room temperature, which gave a 
complicated mixture by TLC whereby 73 was not indicated (Entry 5). Interestingly, 
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TLC analysis suggested the formation a new spot with lower Rf compared to that of 
73 and NMR data unexpectedly confirmed the material as 75 (11% yield), a product 
where the N˗Bn and O˗Bn groups were hydrolysed and 3˗bromopropanol was 
glycosylated at the anomeric position (Scheme 10). HMBC data indicated C1 (99.2 
ppm) correlating through bond with the linker protons OCH2CH2CH2Br (3.82 ppm and 
3.55 ppm) and also confirmed that the remaining 2 Bn groups (benzylic protons: 4.83 
ppm, 4.64 ppm and 4.61 ppm) were attached to C2 (74.7 ppm) and C3 (76.5 ppm), 
respectively. Coupled HSQC spectrum showed the formation of an α˗linkage (1JC1˗H1 
= 172 Hz). Taken together, these observations suggested that glycosylation of 
3˗bromopropanol occurred prior to hydroxamate debenzylation. 
 
Scheme 10: Attempted synthesis of 73 from 67 with NBS/TMSOTf (Entry 5), gave 75 in 11% yield. 
Entries 1˗5 in Table 1 are categorised as pre˗mixing donor and acceptor 
methodologies, where the promoter system was added to a stirring mixture 
containing both the glycosyl donor and acceptor. Pre˗activation conditions were also 
investigated for the synthesis of 73, whereby an equimolar amount of TMSOTf was 
added for the activation of 67 with NIS, in the absence of 3˗bromopropanol linker 
(Entry 6). A mixture of 67 and NIS in CH2Cl2 was cooled to ˗40 °C before TMSOTf 
(2.5 equiv.) was added. The reaction mixture was allowed to warm to ˗30 °C (15 min.) 
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whereupon 3˗bromopropanol (4.0 equiv.) was added dropwise. The mixture was next 
allowed to warm to room temperature over 1 h with TLC analysis this time indicating 
the presence of 67. The mixture was stirred for an additional 1 h which produced a 
complicated mixture not containing 73. Finally, the original pre˗activation conditions 
with Ph2SO/Tf2O and TTBP in CH2Cl2 that were used for the synthesis of 58, were 
applied for a synthesis of 73. These conditions were successful, delivering the 
desired product in 89% yield and with a β˗configuration (1JC1˗H1 =156 Hz). The same 
conditions were applied to donor 69, which led to the formation of β˗linked 
monosaccharide 74 in 78% yield. 
Refluxing 73 with NaN3 in acetone for 48 h gave 76 in 76% yield (Scheme 11). 
The conditions were optimised by warming a solution of 74, NaN3 and TBAI in DMF 
to give 77 (73%) in a shorter amount of time (24 h). C4˗OH of 76 was released using 
NaOMe, giving 78 in 76% yield. C4˗OH deprotection of 77 with H2N˗NH2.AcOH in 
pyridine/AcOH (4/1, v/v) gave 78 in 92% yield. 
 
Scheme 11: Final steps towards the synthesis of hydroxamate mannosyl acceptor 78 (i) NaN3, 
acetone, 55 °C, 48 h, 76: 76% (ii) NaN3, TBAI, DMF, 65 °C, 77: 73% (iii) Na(s), MeOH, RT, 24 h, 76% 
(iv) H2N˗NH2.AcOH, pyridine/AcOH (4/1, v/v), RT, 30 min, 92%. 
The synthetic methodologies developed for the production of C6˗hydroxamate 
building blocks 67, 69 and 78 proved to be efficient, providing them in satisfactory 
yields for subsequent manipulation (i.e. anomeric phosphorylation (Section 7.1) and 
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oligosaccharide synthesis (Section 8)). Although multiple glycosylation conditions 
were attempted for instalment of the 3˗bromopropanol linker on thioglycosides 67 
and 69, preactivation protocol using Ph2SO/Tf2O and TTBP in CH2Cl2 furnished 73 
and 74 in 89% and 78% yield respectively. Successful synthesis of acceptor 78 
integrated the toolset of hydroxamate building blocks required for oligosaccharide 
assembly (Section 8). 
6.3. 6˗C˗tetrazole precursors synthesis 
A number of synthetic methodologies have been developed for the 
preparation of tetrazole rings. The main synthetic routes towards their synthesis are 
based on cyclisation reactions using NaN3.216 Herein, tetrazole ring synthesis at C6 
of mannuronic acid derivatives is attempted in two ways; firstly from a 
C6˗cyanoalkylamide, followed by a dipolar cycloaddition with NaN3 and elimination 
of acrylonitrile, and secondly from a C6˗nitrile (Schemes 12 and 13). 
 
Scheme 12: Synthetic route from 42  towards C6˗tetrazole derivative 82 (i) PyBOP, DIPEA, CH2Cl2, 
3˗aminopropionitrile, 0 °C, 40 min, 79: 47%, 83: 44% (ii)TBDMSOTf, imidazole, DMAP, DMF, RT, 24 
h, 80% (iii) PPh3, DIAD, TMSN3, MeCN, 80 °C, 48 h (iv) PPh3, DIAD, TMSN3, MeCN, 80 °C, 48 h. 
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A first route followed towards C6˗tetrazole derivative 82 involved coupling of 
3˗aminopropionitrile to 42, TBDMS˗protection of the free C4˗OH, and Mitsunobu˗type 
reaction conditions, along with TMSN3 to effect tetrazole formation (Scheme 12). The 
conditions evaluated for the first step included stirring 42 with PyBOP, DIPEA and 
EDC.HCl for 5 min. in CH2Cl2, before 3˗aminopropionitrile was added.182 The reaction 
was left stirring for 1.5 h at room temperature, resulting in the formation of C4˗C5 
elimination compound 83 (35%) as the major product and desired 79 (7%) as the 
minor. In an attempt to optimise conditions for the formation of 79, 
3˗aminopropionitrile was added to a stirred mixture of 79, PyBOP and DIPEA in 
CH2Cl2 at 0 °C, maintaining this temperature for 40 min. The yield was improved, 
affording 79 in 47% and 83 in 44% yield, respectively. Silyl protection of C4˗OH in 79 
was successful by applying the same conditions used to convert 54 to 57 
(TBDMSOTf, imidazole and DMAP), furnishing 80 in 80% yield. Attempts to convert 
80 to a propanenitrile˗protected tetrazole by applying Mitsunobu protocol with PPh3, 
DIAD and TMSN3 was unsuccessful.182 TLC analysis and NMR data obtained 
indicated no conversion of the starting material 80, even after stirring at 80 °C in 
MeCN for 41 hours. NMR data obtained also corroborated this. 
A second route commenced with selective benzoylation of the primary alcohol 
in 41, giving 84 in 90% yield (Scheme 13). The next step was orthogonally protecting 
C4˗OH of 84 with a TBDMS group, giving 85 in 78% yield. Treatment of 85 with 
NaOMe yielded 86 in 90%, which was subsequently subjected to oxidation conditions 
with DMSO, SO3.pyridine and Et3N to deliver aldehyde 87 in 98% crude yield. From 
aldehyde 87, oxime 88 was synthesised effectively as a mixture of its trans and cis 
(6.7/1) isomers in 70% yield. Subsequent dehydration of 88 using POCl3 gave 89 
(22% yield) and 90 (26% yield). The acidic reaction mixture led to the 
80 
 
TBDMS˗deprotection of C4˗OH of 89, which was retrieved by stirring 90 with 
TBDMSOTf, imidazole and DMAP in DMF (87% yield). 
C6˗nitrile 89 was successfully converted into C6˗tetrazole 82 in 51% yield 
using TMSN3 and catalytic amounts of Bu2SnO.13C NMR data collected from the 
isolated material showed the presence of a new quaternary carbon (Cq tetrazole) 
peak at 155.8 ppm and disappearance of the nitrile carbon (C≡N) peak at 117.0 ppm, 
confirming the conversion of C6˗nitrile to C6˗tetrazole. HRMS data supported the 
synthesis of 82, with the major ion observed at m/z 605.2628 (C32H41N4O4SSi 
requires (M+H)+,605.2618). 
 
Scheme 13: Synthetic route from 41 towards C6˗tetrazole derivative 82 (i) BzCl, DMAP, pyridine, 
CH2Cl2, RT, 24 h, 90% (ii) TBDMSOTf, imidazole, DMAP, DMF, RT, 24 h, 78% (iii) Na(s), MeOH, RT, 
16 h, 90% (iv) DMSO, SO3.pyridine, Et3N, RT, 1h, 98% (v) H2NOH.HCl, Na2CO3, THF, 0 °C to RT, 24 
h, 70%, cis/trans = 9%/61% (vi) POCl3, MeCN, RT to 65 °C, 3 h, 89: 22%, 90: 26% (vii) TBDMSOTf, 
imidazole, DMAP, DMF, RT, 24 h, 87% (viii) TMSN3, Bu2SnO, toluene, reflux at 120 °C, 16 h, 51%. 
Furthermore, 1H NMR analysis indicated a doublet peak at 5.64 ppm for H5 which 
was further downfield compared to the chemical shifts of H5 proton peaks (4.54 – 
4.56 ppm) observed previously for the mannuronate and hydroxamate series. The 
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coupling constant calculated for H5 was JH5˗H4 = 8.9 Hz, designating a 4C1 pyranose 
conformation for 82.  
 
Scheme 14: Proposed mechanism for the synthesis of 82 between nitrile 89 and TMSN3 in the 
presence of Bu2SnO. 
The reaction proceeded via intermediates 92 and 93 which occurred from the 
bond formation between the nitrile nitrogen in 89 and the generated 
dibutyl(trimethylsilyloxy)tin azide complex 91 (Scheme 14). The generated catalyst 
91 activates the nitrile carbon for the attack of the azide group in 92 giving the 
open˗chain intermediate 93, which subsequently cyclises to the 
1˗[dibutyl(trimethylsilyloxy)stannyl]˗5˗substituted tetrazole 94. The catalytic complex 
91 is then regenerated through a SN2 reaction between 94 and TMSN3 via transition 
state 95, where the produced N˗(trimethylsilyl) tetrazole product 96 is hydrolysed into 
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82 during the acidic workup.217 The proposed mechanism by Cantillo et al. 
contradicts the one first suggested by Wittenberger et al., as the latter recommended 
the regeneration of Bu2SnO instead of 91.218,219 
In order to reduce reaction times and improve the yields of the three latter 
synthetic steps towards 82, a different protocol was performed on C6˗aldehyde 87. 
A one˗pot three component strategy of 5˗substituted 1H˗tetrazole has recently been 
reported, claiming that various aromatic aldehydes in a reaction mixture with 
H2NOH.HCl, NaN3 and a catalytic amount of [(NH4)4Ce(SO4)4.2H2O] can be 
converted to 1H˗tetrazole derivatives in shorter reaction times and in good to 
moderate yields.220 Initial attempts showed a considerably slow reaction time (45 °C 
to 125 °C over 50 h), as TLC analysis indicated C6˗nitrile formation after 20 h and 
was completed in 36 h. The reaction was left stirring for additional 14 h at 125 °C; 
however, the desired C6˗tetrazole analogue 82 was not isolated due to 
decomposition of the reaction. A second attempt starting at a higher temperature 
(100 °C) exhibited again a slow reaction time, giving C6˗oxime 88 and C6˗nitrile 89 
in 35% and 14% yields respectively over 40 h. The long reaction times as well as the 
low yields obtained from this set of conditions proved this strategy to be ineffective; 
therefore the original route depicted in Scheme 13 was followed for the successful 
synthesis of 82. 
The next step towards the synthesis of a fully protected C6˗tetrazole glycosyl 
donor was the nitrogen protection of the tetrazole group. C6˗tetrazole scaffold 82, as 
a 5˗ST, exists as two tautomers: 1H˗ (97) and 2H˗ (98) respectively (Scheme 15). 
The acidity of such systems relies on their ability to delocalise negative charge after 
deprotonation, such as in system 99, making their subsequent substitution poorly 
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regioselective. As a result, alkylation, arylation and acylation of a tetrazolate anion, 
leads to a mixture of 1˗ and 2˗substituted tetrazole isomers in various ratios.217 
Ostrovskii et al. suggested that the first rate˗limiting step of a substitution reaction 
involves a bimolecular process that aids in the formation of an unstable intermediate 
100, followed by a second step where the isomers 101 and 102 are formed. The 
properties of the reaction intermediate 100 are influenced by the stereochemical 
properties of the C5˗substituent, reactivity of the electrophile used, and the reaction 
medium.221 
 
Scheme 15: 1H˗ and 2H˗ tautomers of 5˗STs and the bimolecular mechanism that tetrazolate anion 
undergoes during electrophilic substitution, giving the two isomers [Adapted from Roh et al. (2012)].217 
A first attempt to protect the tetrazole group involved the reaction of 82 with 
PMBCl in DMF, having K2CO3 as a base and KI for nucleophilic catalysis. Two 
isomers 103 and 104 were produced in a ratio of N1/N2 = 1.1/1 (Scheme 16). 
 
Scheme 16: The two isomers 103 and 104, obtained by paramethoxybenzylation of C6˗tetrazole 82 





HMBC spectra of 103 and 104 were obtained to clarify the position of the PMB 
group on the tetrazole ring in each case. The HMBC spectrum of 103 showed 
correlation of tetrazole Cq (152.0 ppm) with the benzylic protons of the PMB group 
(5.66 ppm, d, 2J = 15.0 Hz and 5.63 ppm, d, 2J = 15.0 Hz), H4 (4.59 ppm, app. t, 
3JH4˗H3, H4˗H5 = 9.4 Hz) and H5 (5.68 ppm, d, 3JH5˗H4 = 9.4 Hz) (Figure 39). The HMBC 
spectrum of 104 indicated no correlation between tetrazole Cq (164.4 ppm) and the 




Figure 39: HMBC spectrum of 103 confirming its structure as the N1˗isomer. 
It has been suggested that the use of 5˗STs as ammonium salts in substitution 
reactions may lead to a more regioselective outcome.217 In particular, in aprotic 
solvents these salts exist as hydrogen˗bonded complexes possessing lower 
aromaticities compared to their tetrazolate anion counterparts such as 99 (Scheme 
δC=N: 
150.4 ppm 
δH5: 5.68 ppm 
δCH2˗PMB: 5.66 and 5.63 ppm 
δH4: 4.59 ppm 
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17).222 It was proposed that the hydrogen˗bonded N1 would direct the electrophilic 
substitution to the double bond between N2 and N3 of the tetrazole ring (not to the 
plane of the tetrazole as in the case of the tetrazolate anion 99), giving 
2,5˗disubstituted tetrazoles. Steric hindrance at the N1 was an additional argument 
supporting this hypothesis.223 Evidence suggest that both triethylammonium and 
sodium salts of 5˗STs gave only 2,5˗disubstituted tetrazoles, which proved that the 
steric aspect is the major driving force of regioselectivity.224 
 
Scheme 17: Suggested electrophilic attack to an ammonium salt of a 5˗ST [Adapted from Roh et al. 
(2012)].217 
In order to try and improve the N1/N2 ratio an approach detailed by Ostrovskii 
et al. was adopted here by firstly converting 82 to its respective triethylammonium 
salt 105. The reason behind this strategy was to increase or decrease the N1/N2 ratio, 
as this would lead to better separation and consequently higher regioisomeric purity 
of 103 and 104. The plan here was to use the N1˗isomer for the sugar 1˗phosphate 
route and the N2˗isomer as a donor for the oligosaccharide synthesis. Subjection of 
a N1/N2 mixture of donors 103 and 104 (or 106 and 107) to glycosylation conditions 
for disaccharide synthesis would be problematic considering that each regioisomer 
would give an anomeric mixture of disaccharides (or/and hydrolysed materials), 
generating a complex mixture of products. However, reaction of 105 with BnBr in 
DMF gave the two isomers 106 and 107 in comparable amounts (N1/N2 = 1/1.2) in 
low a low yield (31%) (Scheme 18). TLC analysis showed consumption of 105 and 
86 
 
formation of a complicated mixture that was not separated. Higher yields (98%) were 
obtained by subjecting 105 to reaction with PMBCl in DMF, producing regioisomers 
103 and 104 in similar amounts (N1/N2 = 1/1.1). Column chromatography separation 
of 103 and 104 was challenging, giving the pure regioisomers in low quantities. 
 
Scheme 18: Attempted alkylation of the tetrazole triethylammonium salt 82 (i) Et3N, CH2Cl2, RT, 1 h, 
94% (ii) BnBr, DMF, RT, 1 h, 31% (iii) PMBCl, DMF, RT, 24 h, 98%. 
The strategies discussed above (starting from 82 or its triethylammonium salt 
105) led to similar N1/N2 ratios (with both Bn and PMB groups), therefore a new 
synthetic route was revised for the production of C6˗tetrazole thioglycosides that 
were exploited as scaffolds for the synthesis of C6˗tetrazole 1˗phosphate building 
block 35 (Section 7.2.) and 3˗aminopropyl C6˗tetrazole conjugable monosaccharide 
174 (Section 9.3.). 
The synthetic protocol followed towards 103 and 104 was repeated starting 
from precursor 108 that was not chemoselectively protected with a TBDMS group, 
as a means to improve overall yield (Scheme 19). In addition, global deprotection to 
give the final C6˗tetrazole 1˗phosphate 35 and 3˗aminopropyl monosaccharide 174 
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made an orthogonal protection unnecessary. Repeat of the Parikh˗Doering oxidation 
afforded aldehyde 109 in 96% crude yield which was converted to oxime 110 as a 
mixture of cis and trans (1/7) isomers in 89% yield. Subsequent dehydration of 110 
using POCl3 gave 111 in 59%, which was then converted into C6˗tetrazole 112 in 
55% by using TMSN3 and catalytic Bu2SnO. Tetrazole 112 was finally stirred with 
PMBCl, K2CO3 and KI in DMF, to give the two isomers 113 and 114 in a ratio of N1/N2 
= 1/1. Their structure was confirmed by HMBC data analysis, as previously 
illustrated. 
 
Scheme 19: (i) DMSO, SO3.pyridine, Et3N, RT, 1h, 96% (ii) H2NOH.HCl, Na2CO3, THF, 0 °C to RT, 
24 h, 89%, cis/trans = 11%/78% (ii) POCl3, MeCN, RT to 65 °C, 3 h, 59% (iv) TMSN3, Bu2SnO, toluene, 
RT to 120 °C, 16 h, 55% (v) PMBCl, K2CO3, DMF, RT, 16 h, 76%. 
The steps required for completing the route depicted in Scheme 19 were 
significantly decreased compared to the one in Scheme 13 (9 steps reduced to 5), 
due to the protecting group manipulation that was required for the latter. Moreover, 
the overall yield was increased from 9% to 21%, making it a more facile and 




Thioglycosides 113 and 114 were additionally used as scaffolds for the 
instalment of an anomeric linker, allowing the synthesis of conjugable C6˗tetrazole 
mannuronate 174 which is discussed in further detail in Section 9.3. A 1/1 mixture of 
113 and 114 was subjected to glycosylation conditions with NIS/AgOTf and 
3˗(benzyloxycarbonylamino)˗1˗propanol for 3 h, giving N2˗PMB tetrazole 115 as an 
anomeric mixture α/β = 1/1 (Scheme 20). Hydrolysed product (18% recovery) 
overlapped with 115 on the TLC plate therefore subsequent acetylation of the crude 
material facilitated purification, furnishing 115 in 34% yield. N1˗PMB tetrazole 
thioglycoside 113 (20% recovery) demonstrated reduced reactivity during these 
conditions, contributing further to the low yield of the reaction. 
 
Scheme 20: Synthesis of 3˗(benzyloxycarbonylamino) propyl (2,3,4˗tri˗O˗benzyl˗6˗C˗(2˗para 
˗methoxybenzyl˗tetrazol˗5˗yl)˗α/β˗D˗mannopyranoside 115 (i) NIS, AgOTf, CH2Cl2, ˗30 °C to ˗10 °C, 
3 h, 34%. 
The strategy designed for the synthesis of C6˗tetrazole thioglycosides was 
more challenging compared to C6˗hydroxamate thioglycosides, as production of the 
2 regioisomers (103, 104) in equal amounts was unavoidable. Nevertheless, the 
route for the production of 113 and 114 was more viable, providing sufficient amount 
of material. The toolset of modified thioglycosides was ready to be utilised in the 
following sections. 
α/β= 1/1  
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6.4. 5˗C˗methyl˗α/β˗D˗mannopyranoside peracetate 
The first route designed for the synthesis of a C5˗methylated building block 
was based on the observations of C4˗C5 elimination of mannuronates 55 and 59 
under basic conditions (Zemplén deacetylation conditions with pH ≥ 11). In particular, 
55 was used as a scaffold in an experimental procedure where LDA was added as 
base for the generation of enolate 116 via an E1cB pathway, and MeI was employed 
as a suitable electrophile for subsequent C5˗methylation (Scheme 21). 
 
Scheme 21: Attempted C5˗alkylation of 55 using LDA and MeI for a proof of concept synthesis of C5 
methylated analogue 117. The reaction proceeded via an E1cB elimination pathway, giving 118 in 
61% and 67% yield. 
More specifically, the intermediate enolate ion 116 was expected to react through 
carbon with MeI, as the reaction is dominated by orbital interactions when alkyl 
halides are used as electrophiles. The designed protocol started with a stirred 
solution of 55 in THF (0.2 M) being cooled to ˗70 °C, whereby a 1 M solution of LDA 
(1.2 equiv.) in THF/hexane was added dropwise. The reaction mixture was kept 
between ˗80 °C and ˗70 °C for 15 min. before MeI (1.5 equiv.) was added dropwise, 




was not isolated, and only elimination product 118 was identified (61% yield), 
suggesting that elimination occurred in preference to α˗substitution. A second 
attempt using an inverse addition, i.e. the addition of LDA (1.2 equiv.) to a stirring 
solution of 55 and MeI (1.5 equiv.) in THF (0.2 M) at ˗80 °C to ˗70 °C gave similar 
results, as 118 was isolated in 67% yield. 
An entirely different approach was thus taken, based on previous work of 
Davis et al.225 By following their developed methodology, 5˗C˗Me˗D˗mannose 119 
was produced by a colleague in the group and its synthesis is therefore not described 
here. NMR data of 119 indicated an α/β = 1/2.8 ratio with coupling constants 3JH1˗H2 
= 2.4 Hz for H1α and 3JH1˗H2 = 1.3 Hz for H1β. Further information was obtained by 
coupled HSQC data analysis, where the calculated coupling constants for the 
α˗anomer (C1: 94.7 ppm) and the β˗anomer (C1: 89.3 ppm) were 1JC1˗H1 = 172 Hz 
and 1JC1˗H1 = 164 Hz, respectively. The fact that the β˗anomer of 119 dominates at 
equilibrium in aqueous solution emphasises the steric effect caused by the Me group 
at the C5 position, making a heavily solvated axial hydroxyl group (α˗anomer) less 
favourable. 
With 119 in hand, peracetylation was performed with Ac2O and catalytic 
H2SO4. The reaction gave the expected mixture of products (120: 40%, 121: 43%, 
122: 5%, and 123: 12%) in 62% overall yield (Scheme 22). Column chromatography 
provided a mixture of peracetylated products (120: 43%, 121: 45%, 123: 10%). 
Coupled HSQC data of the crude material were obtained to verify the reported 
anomeric ratio, showing 120 (C1: 91.1 ppm) with a coupling constant 1JC1˗H1 = 176 




Scheme 22: Peracetylation of 5˗C˗methyl mannose 119 (i) Ac2O, H2SO4, RT, 45 min, 62%. 
In order to support the above assignment, coupled HSQC data of peracetylated 
D˗mannopyranoside 36 were collected, exhibiting coupling constants 1JC1˗H1 = 180 
Hz (6.09 ppm) for the α˗anomer, and 1JC1˗H1 = 164 Hz (5.88 ppm) for the β˗anomer, 
similar to those calculated for 120 and 121. Considering that Ac2O/ cat. H2SO4 
procedure furnished 36 in an α/β = 4/1 and 120/121 in an α/β = 1/1.1 ratio, it is clear 
that the C5˗Me group in 120 and 121 influences their equilibration under acidic 
catalysis. More specifically, the acid˗catalysed equilibration that occurs under these 
conditions provided predominantly the α˗product of 36, as dictated by the anomeric 
effect. However, in the case of 5˗C˗Me pentaacetates, the equilibration gave a ratio 
with a slight preference for β˗product 121 which again highlights the steric effect of 
the C5˗Me group on the final anomeric configuration. 5˗C˗Me peracetylated products 
120, 121 and 123 were key intermediates in the synthesis of their respective sugar 
1˗phosphates, which is further discussed in Section 7.3. 
7. Synthesis of C6˗modified mannuronate 1˗phosphate building blocks 
7.1. Synthesis of 6˗C˗hydroxamic acid (α˗D˗mannopyrannoside) 
1˗phosphate 34 
The route designed for the synthesis of C6˗hydroxamic acid 1˗phosphate 34 
started by introducing DBP stereoselectively at the anomeric centre of 69 using 
NIS/AgOTf as a promoter system, giving 124 in 55% yield (Scheme 23). 
92 
 
The expected α˗stereochemistry of 124 was confirmed, as coupled HSQC 
data showed a coupling constant of 1JC1˗H1 = 180 Hz (C1: 96.0 ppm). Subsequent 
C4˗OH deprotection of 124 with H2N˗NH2.AcOH delivered 125 (72% yield), which 
was then subjected to hydrogenolysis conditions for global deprotection. 
 
Scheme 23: Route for the synthesis of C6˗hydroxamic acid 1˗phosphate 34 from 69. (i) NIS, AgOTf, 
DBP, CH2Cl2, ˗30 °C to ˗10 °C, 2.5 h, 55% (ii) H2N˗NH2.AcOH, pyridine/AcOH (4/1, v/v), RT, 1 h, 72% 
(iii) H2(g), Pd/C (10%), Pd(OH)2/C (20%), 5% aq. NaHCO3, EtOH/THF (1.5/1, v/v), RT, 32 h, 89% (iv) 
H2(g), Pd/C (10%), Pd(OH)2/C (20%), 5% aq. NaHCO3, EtOH/THF (1.5/1, v/v), RT, 5 h, 67%. 
A first attempt to cleave all Bn groups in 125 under hydrogenolysis conditions with 
1.2 equiv. (0.2 equiv. per Bn group) of Pd/C and 1.2 equiv. Pd(OH)2/C in EtOH/THF 
(1.5/1, v/v, 0.05 M) and 2.0 equiv. of 5% aq. NaHCO3 gave C6˗amide 1˗phosphate 
126 after 32 h. ESI˗MS analysis confirmed the structure of 126, as the major ion was 
found at m/z 272.0178 (C6H11NO9P, 126 requires (M˗H)˗ 272.0177). 13C and 31P NMR 
spectra collected for 126 showed the carbonyl carbon peak of the amide moiety at 
174.7 ppm and a phosphorous peak at 1.89 ppm, respectively. To avoid this 
unwanted reductive cleavage of the OBn group from the hydroxamate, a second 
attempt was performed using 0.3 equiv. (0.05 equiv. per Bn group) of Pd/C and 0.3 
equiv. of Pd(OH)2/C. The reaction was monitored by TLC analysis, and suggested 
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completion after 5 h. NMR data of the product were different compared to that of 126. 
A weak carbonyl carbon peak of the hydroxamic acid appeared at 167.5 ppm while 
the phosphorous peak indicated a chemical shift of 1.91 ppm. The difference 
between the 31P NMR spectra of 34 and 126 was not strikingly evident, exhibiting 
small chemical shift difference. HRMS data gratifyingly confirmed the mass of 34, 
with the major ion observed at m/z 288.0127 (C6H11NO10P, 34 requires (M˗H)˗ 
288.0126).  
7.2. Synthesis of 6˗C˗tetrazole (α˗D˗mannopyrannoside) 1˗phosphate 35 
C6˗tetrazole thioglycoside 103 was used to attempt an anomeric 
phosphorylation with DBP and NIS/AgOTf conditions, giving 127 in a low yield (16%). 
The use of AcCl in MeOH for cleavage of the C4˗OTBDMS led to decomposition of 
the reaction, thus this method was abandoned (Scheme 24). 
 
Scheme 24: Towards the synthesis of protected C6˗tetrazole 1˗phosphate 128 (i) NIS, AgOTf, DBP, 
CH2Cl2, ˗30 °C to ˗10 °C, 3.5 h, 16% (ii) AcCl, MeOH, 0 °C to RT, 16 h. 
The next attempt for installing the anomeric phosphate employed both 113 
and 114 as starting materials, as cleavage of the PMB group at the final step would 
result in a single C6˗tetrazole 1˗phosphate compound. Accordingly, a NIS/AgOTf 
protocol was applied for the glycosylation of DBP, furnishing 129 and 130 in 72% 
yield (Scheme 25). The N1/N2 ratio of thioglycosides 113 and 114 was 1/1, as well 
as the ratio of 1˗phosphates 129 and 130 obtained, indicating that 113 and 114 
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exhibited the same reactivity for the anomeric phosphorylation. These results were 
contradictory to those discussed in Section 6.3., where glycosylation of 
3˗(benzyloxycarbonylamino)˗1˗propanol under the same conditions gave only 
N2˗PMB product 115. Hydrogenolysis conditions of 129 and 130 with 0.6 equiv. of 
Pd/C (0.1 equiv. per Bn group) and 0.6 equiv. of Pd(OH)2/C gave desired compound 
35 in 72% yield after 24 h. 13C NMR of 35 showed a weak peak at 160.8 ppm for Cq 
tetrazole while the phosphorous peak appeared at ˗2.15 ppm on 31P NMR spectrum. 
HRMS data confirmed the mass of 35, as the major ion was identified at m/z 
297.0236 (C6H10N4O8P, 35 requires (M˗H)˗, 297.0233). 
 
Scheme 25: Designed route towards the synthesis of C6˗tetrazole 1˗phosphate 35 starting from 113 
and 114 (i) NIS, AgOTf, DBP, CH2Cl2, ˗30 °C to ˗10 °C, 3.5 h, 72% (ii) H2(g), Pd/C (10%), Pd(OH)2/C 
(20%), 5% aq. NaHCO3, EtOH/THF (1.5/1, v/v), RT, 24 h, 72%. 
As part of a program in our group that focuses on the chemoenzymaric 
synthesis of alginate sugar nucleotide building blocks, C6˗bioisosteric 1˗phosphates 
34, 126 and 35 were used as substrates of GMP to deliver a toolbox of C6˗modified 
GDP˗ManAs. An additional objective of this program is the design and development 
of GMD inhibitors and/or structure˗function tools, therefore the enzymatically 
synthesised C6˗modified sugar nucleotide analogues could be tested. 
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7.3. Synthesis of 5˗C˗methyl˗α/β˗D˗mannopyranose 1˗phosphate 120 
A mixture of peracetylated products (120: 43%, 121: 45%, 123: 10%) was 
subjected to MacDonald reaction conditions226furnishing their respective sugar 
1˗phosphates 131 (56%), 132 (23%) and 133 (21%) in 19% overall yield (Scheme 
26). 
 
Scheme 26: Synthesis of 1˗phosphates 131, 132 and 133 (ii) H3PO4(s), 60 °C, 2 h and then THF, 1 
M LiOH(aq.), 0 °C to RT, 72 h, 19%. 
1H NMR data showed chemical shifts at 5.27 ppm (dd, 3JH1˗31P, H1˗H2 = 9.1, 2.2 
Hz) for H1α and 5.19 ppm (dd, 3JH1˗31P, H1˗H2 = 8.6, 1.1 Hz) for H1β with a 2/1 preference 
for formation of the α˗1˗phosphate (Figure 40). Coupled HSQC data verified the 
assignments, as the α˗anomer 131 (C1: 95.8 ppm) exhibited a coupling constant of 
1JC1˗H1 = 172 Hz, while the β˗anomer 132 (C1: 89.3 ppm) showed 1JC1˗H1 = 168 Hz. 
In addition, 31P NMR spectrum showed 2 distinct peaks at 1.85 ppm (α˗anomer 131) 




Figure 40: 1H NMR data of 131 and 132. α˗pyranoside 131: 5.27 ppm with coupling constant of 3JH1˗H2, 
H1˗31P = 2.2, 9.1 Hz (indicated on figure), and β˗pyranoside 132: 5.19 ppm (3JH1˗H2, H1˗31P = 1.1, 8.6 Hz). 
MacDonald phosphorylation of an anomeric mixture of D˗mannose 
pentaacetate 36 conducted by Beswick et al. furnished exclusively 
α˗D˗mannose˗1˗phosphate.227 As previously discussed in Section 6.4., it is clear that 
the C5˗Me group sterically affects the outcome of the reaction, introducing a 
competing pathway for formation of the β˗1˗phosphate. In addition, MacDonald 
phosphorylation on substrates 120 and 121 with an α/β = 1/2 (obtained from 
Ac2O/pyridine) performed by a colleague in the group, delivered 1˗phosphates 131 
and 132 in a similar ratio (α/β = 2/1), denoting that the anomeric mixture ratio used 
as starting material does not influence the anomeric composition of 1˗phosphates 
131 and 132. Future work involving 131 will be similar to that described for 34, 126 
and 35, and is further outlined in Section 10.2. 
3JH1˗31P = 9.1 Hz  
3JH1˗H2 = 2.1 Hz  
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8. Synthesis of C6˗modified alginate disaccharides 
Following their successful preparation, both native and C6˗modified 
monosaccharides (donors and acceptors) were utilised for the production of modified 
alginate disaccharide building blocks. As discussed in Section 6, the initial route 
designed was based on a pre˗glycosylation oxidation approach, as this was 
considered to promote β˗linkage formation through a similar pathway to that 
demonstrated by C5˗carboxylate donors.166,150 Their construction proceeded on an 
iterative basis, by extending from the non˗reducing end of acceptors 60 and 78. 
Consequently, after non˗reducing end O4˗position deprotection, the newly formed 
sachharide would act as the new acceptor in a subsequent glycosylation step with a 
new donor. 
8.1. Synthesis of native D˗ManA – D˗ManA disaccharide 136 
For D˗ManA – D˗ManA disaccharide synthesis, a mixture of donor 55, acceptor 
60 and NIS in CH2Cl2 was cooled to ˗60 °C and a catalytic amount of TMSOTf was 
added to afford β˗linked disaccharide 134 in 56% yield. The β˗linkage was 
determined through coupled HSQC with coupling constant values 1JC1’˗H1’ = 155 Hz 
and 1JC1˗H1 = 156 Hz. (Scheme 26). Codée et al. proposed that this NIS/TMSOTf 
mediated glycosylation event proceeds solely via an SN1 pathway, where the 
displacement of the initially formed iodosulfonium species takes place, giving the 
desired β˗stereoselectivity. This was demonstrated by pre˗activation of donor 55 with 
NIS and equimolar amount of TMSOTf. They confirmed by TLC analysis that no 
complete activation of the donor was achieved; however, the addition of the acceptor 
afforded the same β˗disaccharide in high yields. These observations imply that the 
NIS/TMSOTf glycosylation mechanistic pathway does not proceed through an 
α˗triflate intermediate, but only through the 3H4˗oxocarbenium ion intermediate.211 
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This highlights the capacity of C5 carboxylate esters to form β˗mannosidic linkages 
independently of their anomeric configuration, as this was additionally confirmed by 
the use of both α˗ and β˗mannuronate thioglycosides as glycosyl donors.150 
 
Scheme 26: Attempted synthesis of  native system 136 (i) NIS, TMSOTf, CH2Cl2, ˗60 °C to RT, 30 
min, 56% (ii) Na(s), MeOH, RT, 2 h, 32%. 
Native disaccharide 134 was subsequently subjected to Zemplén 
deacetylation conditions at room temperature to unexpectedly furnish disaccharide 
acceptor 135 (Scheme 26). The reaction was left stirring at room temperature for 2 h 
(pH ~ 9˗10) and was quenched with ion exchange Amberlite 120 (H+) resin (pH ~ 
5˗6). TLC analysis showed starting material 134 and the slow formation of a lower Rf 
spot. The NMR data collected for this material were not consistent with the 
literature,211 whereby H1’ was found at 5.43 ppm instead of 4.73 ppm. Moreover, 
coupled HSQC showed coupling constants 1JC1’˗H1’ = 176 Hz and 1JC1˗H1 = 156 Hz 





Figure 41: NMR data of α˗linked disaccharide 135 (a) Coupled HSQC showing C1: 102.0 ppm with 
1JC1˗H1 = 156 Hz and C1’: 99.8 with 1JC1’˗H1’ = 176 Hz (b) nOe spectrum of 135, verifying an α˗linked 
product. 
These data suggested that the applied conditions had liberated C4˗OH (2.95 ppm, 
br. s) but also altered the anomeric integrity at the non˗reducing glycosidic linkage. 
(b) 
(a) 
δH1’: 5.42 ppm 
δH1: 4.43 ppm 
δC1’: 99.8 ppm 
δC1: 102.0 ppm 
δH1’: 5.42 ppm 
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ESI˗MS analysis found the sodium adduct of 135 at m/z 864.3343 which matched 
the reported literature (C45H51N3O13, 135 requires (M+Na)+ 864.3320).211 To examine 
whether the applied NaOMe conditions caused epimerisation at the non˗reducing 
end linkage, the NMR data of 135 were compared to that of the disaccharide 
containing L˗guluronic acid as the reducing end monomer, which was found in the 
literature (H1’Gul : 5.24 ppm).177 The NMR analysis here did not match, excluding 
possible epimerisation. The next step taken towards confirming the stereochemistry 
of the non˗reducing end linkage was the implementation of nOe experiments, where 
the anomeric proton of the non˗reducing end mannuronate H1’ (5.42 ppm, s) was 
irradiated (Figure 41b). The nOe data collected for 135 confirmed the change of the 
disaccharide linkage from β to α, as H1’ showed transfer to H4 (4.45 ppm, app. t, 
3JH4˗H3, H4˗H5 = 9.3 Hz) and H2’ (3.65 ppm˗hidden under multiplet with H3’) and none to 
H5’ (4.01 ppm, d, 3JH5’˗H4’ = 9.7 Hz).  
To evaluate whether the anomerisation process had taken place during the 
basic conditions of the reaction or during stirring with Amberlite 120 (H+) resin, a 
repeat was performed, terminating the reaction at 1 h with H+ resin. 1H and 13C NMR 
spectra clearly indicated a mixture of α˗ and β˗linked products with a ratio of 1/4.9 
respectively. The same mixture was then stirred overnight with Amberlite 120 (H+) 
resin in MeOH and the 13C NMR spectrum obtained showed no further change 
(Figure 42). The information gathered suggested that the anomerisation process was 
underway during the basic deacetylation conditions (pH ~ 9˗10) and was terminated 
with the addition of the acidic resin (pH ~ 5˗6). It is unclear how this occurred; one 
explanation could be that an E1cB elimination from the reducing end uronate, 
mutarotation of the released hemiacetal to the α˗anomer which is subsequently 
re˗added to the bottom face of the elimination product, delivering 135 from 134. The 
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data obtained also suggest that this happened after C4˗OAc hydrolysis. Repeated 
attempt to hydrolyse the acetate group with NH3 and Et3N in MeOH at room 
temperature and 35 °C were unsuccessful, and only 134 was recovered. 
 
Figure 42: (a) 13C NMR data taken after 1h of stirring 134 with NaOMe in MeOH (the reaction was 
quenched with Amberlite 120 (H+) resin (b) 13C NMR data taken after stirring the mixture with Amberlite 
120 (H+) resin in MeOH O/N. The NMR spectra show no difference, suggesting that the anomerisation 
is not acid˗assisted. 
By employing the same conditions used for the synthesis of 134, donor 57 and 
acceptor 60 delivered β˗linked disaccharide 137 as the sole product in 61% yield 
(Scheme 27). Subsequent removal of the TBDMS group with AcCl in MeOH gave 
136 in 32% yield, and in this case, the NMR data obtained were in a good agreement 
with the literature, giving coupling constants values 1JC1˗H1 = 156 Hz (C1’: 102.5 ppm) 
and 1JC1’˗H1’ = 156 Hz (C1: 101.8 ppm).211  
(a) 
(b) 




β˗linked native disaccharide 137 





Scheme 27: Synthesis of native β˗disaccharide 136 (a) (i) NIS, TMSOTf, CH2Cl2, ˗10 °C to RT, 30 
min, 61% (ii) AcCl, MeOH, 0 °C to RT, 16 h, 32%. 
nOe data of 136 were obtained to further verify its β˗linkage, as well as to 
compare it with that of 135 (Figure 43). The spectrum clearly showed transfer from 
H5’ (3.59 ppm, d, 3JH5’˗H4’ = 9.6 Hz) to H1’ (4.72 ppm, s) and H3’ (3.32 ppm, dd, 3JH3˗H4, 
H3˗H2 = 9.5, 2.8 Hz), and not H4 (4.45 ppm, app. t, 3JH4˗H3, H4˗H5 = 8.6 Hz), suggesting 
the existence of a β˗linkage. The low yield of 136 owed to the formation of a highly 
polar material which was not isolated. 
 
Figure 43: nOe spectrum of 136, verifying a β˗linked product. 
(b) 
δH3’: 3.32 ppm 
δH5’: 3.59 ppm 
δH1’: 4.72 ppm 





8.2. Synthesis of C6˗hydroxamate D˗ManA – D˗ManA 140 
Synthesis of a mixed disaccharide system was first attempted by coupling 
N˗acyl hydroxamate donor 63 and native acceptor 60 with the same promoter system 
(NIS/TMSOTf) employed for the synthesis of 134. TLC analysis of the reaction 
suggested the formation of a complicated mixture after 1 h. Disaccharide 138 was 
isolated as a single diastereoisomer in 54% yield (Scheme 28). Similar to the 
glycosidation of 63 to 3˗bromopropanol, 1H and 13C NMR data suggested N˗Ac 
cleavage of 63 had occurred, which minimised the overall yield. Interestingly, 
O˗benzyl (4˗O˗acetyl˗2,3˗di˗O˗benzyl˗ bicyclo [3.2.1˗O]) hydroxamate 64 was not 
isolated as one of the by˗products of the reaction, suggesting that the N˗Ac hydrolysis 
might have occurred after the glycosylation between 63 and 60. Mass spectrum 
analysis contradicted with the structure extracted from the NMR data, as COSY, 
HSQC and HMBC data suggest the structure of 138 to be as depicted in Scheme 28. 
 
Scheme 28: Synthesis of mixed sequence disaccharide 138 (i) NIS, TMSOTf, CH2Cl2, ˗60 °C, 1 h, 
54%. 
The coupled HSQC spectrum showed coupling constant of 1JC1’˗H1’ = 165 Hz 
(C1’: 100.6 ppm), and an expected coupling constant of 1JC1˗H1 = 154 Hz (C1: 102.1 
ppm).  To confirm the configuration of the newly formed glycosidic bond of 138, nOe 
104 
 
experiments were conducted by irradiating the non˗reducing end proton, H5’ (3.92 
ppm, d, 3JH5’˗H4’ = 9.9 Hz). The data obtained determined the formation of a β˗linkage, 
as H5’ showed transfer to H1’ (4.71 ppm, s) and H3’ (3.52 ppm, dd, 3JH3’˗H4’, H3’˗H2’ = 
9.7, 2.8 Hz) indicating an axial position of the H1’ and consequently β˗stereochemistry 
of the non˗reducing end linkage (Figure 44). 
 
Figure 44: nOe spectrum of 138, verifying a β˗linked product. 
A second mixed disaccharide was synthesised using native mannuronate 
acceptor 60 and N˗Bn hydroxamate donors 67 and 69 (Scheme 29). Thioglycosides 
67 and 69 were considered to be more robust during the glycosylation conditions 
with NIS and TMSOTf, as opposed to N˗Ac counterpart 63. Similar to the synthesis 
of 138, TLC analysis indicated the formation of a complicated for 138 mixture over 
30 min. at 0 °C. Purification by silica gel flash column chromatography gave 139 in 
extremely low yield (12%) with an anomeric ratio α/β = 9/1. Coupled HSQC indicated 
δH3’: 3.52 ppm 
δH5’: 3.92 ppm 
δH1’: 4.71 ppm 
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α˗stereochemistry for the non˗reducing end linkage, with 1JC1’˗H1’ = 176 Hz (C1’: 99.4 
ppm). 
 
Scheme 29: Synthesis of mixed disaccharide 140  (i) NIS, TMSOTf, CH2Cl2, 0 °C, 30 min, 12% (ii) 
Na(s), MeOH, RT, 16 h, 54% (iii) NIS, TMSOTf, CH2Cl2, ˗40 °C to ˗10 °C, 6.5 h, 30%  (iv) 
H2N˗NH2.AcOH, pyridine/AcOH (4/1, v/v), RT, 30 min, 76%. 
In order to improve the yield, the NIS/TMSOTf promoter system was repeated 
using substrates 69 and 60 at lower temperatures and for prolonged period of time 
(1 h at ˗40 °C, 2 h at ˗25 °C, 3 h at ˗20 °C and 30 min. at ˗10 °C). The yield for this 
glycosylation was slightly improved but not optimised, as TLC analysis again denoted 
the formation of a complicated mixture, giving 141 in 30% yield (with 14% recovery 
of acceptor 60) and in the same anomeric ratio as before (α/β = 9/1). The α˗linkage 
of 141 was again confirmed via coupled HSQC, with 1JC1’˗H1’ = 176 Hz (C1’: 99.4 
ppm), the same value observed for 139. Promoter system Ph2SO/Tf2O (30 min. from 
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˗80 to ˗30 °C) was additionally evaluated for improving the reaction yield, using 69 
as the donor. Unfortunately, the yield acquired was similar to that obtained previously 
(34%), as well as the anomeric configuration (α/β = 9/1). 
Mixed disaccharide 140 was successfully delivered by C4˗OH deprotection of 
139 with NaOMe (54% yield) and deprotection of the levulinoyl group in 141 with 
H2N˗NH2.AcOH (76% yield). To further examine the stereochemistry of 140, a 
coupled HSQC spectrum was obtained showing 1JC1’˗H1’ = 176 Hz for the 
non˗reducing end (C1’: 99.4 ppm), and 1JC1˗H1 = 156 Hz for the reducing end linkage 
(C1: 101.9 ppm). The nOe spectrum acquired by irradiating H5’ (3.98 ppm, d, 3JH5’˗H4’ 
= 9.6 Hz) indicated strong transfer only to H3’ (3.66 ppm, dd, 3JH3’˗H4’, H3’˗H2’ = 9.6, 2.3 
Hz) (Figure 45). The absence of a transfer signal from H5’ to H1’ implied the equatorial 
configuration of H1’. 
 
Figure 45: nOe spectrum of 140, verifying an α˗linked product. 
δOCH2CH2CH2N3: 3.53 ppm 
δCO2CH3:     
3.58 ppm 
δH5’: 3.98 ppm 
δOCH2CH2CH2N3: 4.06˗4.00 ppm 
δH3’: 3.66 ppm 





8.3. Synthesis of D˗ManA – C6˗hydroxamate D˗ManA disaccharide 143 and 
C6˗hydroxamate D˗ManA – D˗ManA – C6˗hydroxamate D˗ManA trisaccharide 
144 
The inverse sequence disaccharide was next synthesised by employing 
hydroxamate acceptor 78 and native donor 56 (Scheme 30). The promoter system 
applied was NIS/TMSOTf, starting from ˗40 °C. The reaction was monitored and 
upon complete consumption of the acceptor, was quenched within 45 min. 
Disaccharide 142 was obtained as a single diastereoisomer (1JC1’˗H1’ = 156 Hz, C1’: 
102.3 ppm, 1JC1˗H1 = 156 Hz, C1: 101.8 ppm) in 55% yield. The stereochemical 
outcome was in agreement with the studies conducted by Codée et al. regarding the 
reactivity of  mannuronic acid donors.150,144 Donor 56 was recovered (30%), which 
explained the reduced yield of the reaction.  
 
Scheme 30: Synthesis of mimetic of trisaccharide 144 (i) NIS, TMSOTf, CH2Cl2, ˗40 °C to 0 °C, 45 
min, 55%  (ii) H2N˗NH2.AcOH, pyridine/AcOH (4/1, v/v), RT, 30 min, 81% (iii) Ph2SO, TTBP, Tf2O, 69, 
CH2Cl2, ˗60 °C to ˗90 °C, 1 h, 14%. 
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C4˗OH liberation using H2N˗NH2.AcOH furnished disaccharide acceptor 143 in 81% 
yield, which was successfully glycosylated under Ph2SO/Tf2O mediated conditions 
with hydroxamate donor 69, giving trisaccharide 144 in 14% yield. (Scheme 30). 
ESI˗MS analysis found the ammonium adduct of 144 at m/z 1689.7330 
(C97H105N6O21, 144 requires (M+NH4)+ 1689.7327). Coupled HSQC data obtained for 
144 were inconclusive, as the anomeric peaks in the 13C NMR spectrum were in 
close proximity, making it difficult to calculate the one˗bond coupling constant 
(1JC1’’˗H1’’) for the newly formed linkage. Considering the fact that donor 69 afforded 
α˗linked disaccharide 141 when condensed with native acceptor 60, the coupling of 
69 with disaccharide 143 is proposed to be a trans˗glycosylation. The poor yield of 
trisaccharide 144 implies a dismissal for the construction of multiple 1,4˗linkages. 
8.4. Synthesis of C6˗hydroxamate D˗ManA – C6˗hydroxamate D˗ManA 
disaccharides 145 and 146 
The synthesis of a C6˗hydroxamate disaccharide system was attempted by 
using N˗Bn hydroxamate donors 67 or 69 and N˗Bn hydroxamate acceptor 78. 
Different thioglycoside activation protocols were evaluated for the reaction of 67 or 
69 with 78, as outlined in Scheme 31, and the results are summarised in Table 2. 
 




a The equiv. used were 1.3 equiv. of Ph2SO, 1.3 equiv. of Tf2O and 2.5 equiv. of TTBP. The results 
discussed derived from reaction of 69 with 78. The observations when 67 was used as a donor were 
similar to that of 69. 
b The initial reaction temperature in all entries was ˗80°C (donor and promoter stirred for 5˗10 min), 
except from entry 6 where the reaction started at ˗40°C. 
c HRMS samples of the reaction mixtures were submitted. No trace of the desired products was 
detected in the reported entries. 
d The equiv. used were 1.3 equiv. of BSP, 1.3 equiv. of Tf2O and 2.5 equiv. of TTBP. 
e  Preparation: A 1 M solution of the reagent was made by adding Tf2O (168 µL, 1 mmol) to a solution 
of Me2S2 (100 µL, 1.1 mmol) in dry CH2Cl2 (750 µL) at 0°C and stirring the mixture for 30 min. at the 
same temperature before use. 1.5 equiv. of the promoter were added to the reaction 0.8 equiv. of 
DTBMP were used as a base in the glycosylation reaction. 
Considering that the pre˗activation conditions with Ph2SO/Tf2O and TTBP 
gave high yields for the synthesis of 73 and 74 the same conditions were applied for 
the synthesis of 145 and 146. Donor 69 was stirred for 5 min. with Ph2SO/Tf2O and 
TTBP at ˗60°C before cooling down to ˗80 °C. At that temperature, acceptor 78 
Table 2: Glycosylation conditions attempted for the synthesis of 145 and 146 
          Pre˗activation using Ph2SO/Tf2Oa 






temperatureb   
(°C) 
Observations from TLC analysis and 
NMR datac 









20 min. / ˗20 °C 
Complicated mixture, NMR showed 
hydrolysed donor (28%), unreacted 
acceptor (60%) and decomposed 
material with low Rf value 
3 1.1 0.05 15 min. / ˗40 °C Similar results with entry 2 
Pre˗activation using BSP/Tf2Od 
4 1.1 0.05 45 min. / ˗40 °C Baseline spot and recovery of donor 
(77%) 
Pre˗mixing glycosylation using Me2S2/Tf2Oe 
5 1.1 0.07 20 min. / ˗55 °C Decomposition, recovered donor 
(23%) and acceptor (12%) 
Inverse glycosylation using NIS/TMSOTf 
6 1.1 0.05 3.5 h / ˗20 °C Complicated mixture, recovered 
acceptor (49%) and decomposed 
baseline material 
Standard glycosylation using NIS/TMSOTf 
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1.1 0.07 3.5 h / ˗20 °C Donor hydrolysis (63%) and 
recovered acceptor (76%) 
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dissolved in CH2Cl2 was added dropwise, and the reaction was stirred for 30 min., 
allowing the mixture to warm up to ˗10 °C (Entry 1). TLC analysis showed the 
presence of a decomposed material close to the baseline which was not isolated. 
Donor 69 and acceptor 78 were used again under the same glycosylation conditions, 
but the reaction mixture was only allowed to warm up to ˗20 °C and stirred for 20 min. 
TLC analysis showed a complicated mixture, and NMR data revealed that the main 
components was hydrolysed donor (28%), unreacted acceptor (60%) and the same 
decomposed material with low Rf value (Entry 2). The same results were obtained 
when the reaction mixture was allowed to warm to ˗40 °C and left stirring for 15 min. 
(Entry 3). The BSP/Tf2O protocol was next applied, as it was also reported to promote 
the highly stereoselective formation of β˗mannuronate linkages.228,161 Similarly to the 
procedure applied with Ph2SO/Tf2O, donor 69 was stirred for 5 min. with BSP/Tf2O 
and TTBP at ˗60 °C before cooling down to ˗80 °C and adding acceptor 78. The 
reaction was warmed up to ˗40 °C and stirred for 45 min, whereby TLC analysis 
suggested decomposition of the mixture, baseline material formation and unreacted 
donor thioglycoside was recovered (77%) (Entry 4). 
Me2S2˗Tf2O was employed as an alternative organosulfur activating promoter 
system. Fügedi et al. demonstrated that by analogy with the preparation of DMTST, 
Me2S2 can react with Tf2O to give a more electrophilic product, as one of the methyl 
groups will be replaced by a strongly electron˗withdrawing trifluoromethanesulfonyl 
group.229 They demonstrated that the use of Me2S2˗Tf2O reagent can activate 
thioglycosides at low temperatures with the glycosylation reaction completed within 
a short time. TLC analysis for using these conditions suggested decomposition of the 
mixture and purification by column chromatography recovered donor 69 (23%) and 
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acceptor 78 (12%) (Entry 5). NMR spectra obtained from other isolated materials 
showed no evidence of 145, and remain unresolved. 
Inverse glycosylation conditions with promoter system NIS/TMSOTf were also 
applied to substrates 69 and 78. The reaction started at ˗40 °C and was monitored 
while the temperature increased up to ˗10 °C over 3.5 h. TLC analysis again showed 
the production of a complicated mixture, indicating consumption of donor 69. NMR 
data obtained after purification revealed the presence of the remaining acceptor 78 
(49%) and an unidentified material with low Rf that was observed in the previous 
entries (Entry 6). A final attempt for the synthesis of 146 with standard pre˗mixing 
glycosylation conditions using NIS/TMSOTf was unsuccessful, as TLC analysis 
showed that the hydroxamate acceptor 78 was not consumed and donor 69 slowly 
hydrolysed (Entry 7). NMR data confirmed the presence of hydrolysed donor 69 
(63%) and recovered acceptor 78 (76%). 
The results derived from the aforementioned experiments using 
C6˗hydroxamate donors 67, 69 and acceptor 78 indicate that the application of 
various thioglycoside activation protocols failed to deliver desired disaccharides 145 
and 146. The main components isolated from the complicated reaction mixtures were 
hydrolysed donor, unreacted acceptor and a highly polar material. 1H and 13C NMR 
spectra of this material were complex, however, they showed presence of a Lev 
group, 4 Bn groups and a carbonyl carbon at 148.8 ppm, suggesting an alteration/ 
decomposition of donor 69. This baseline material was not observed when 67 and 
69 were glycosylated to native acceptor 60 or when C6˗hydroxamate acceptor 78 
was glycosylated to native donor 56, implying that there is a delicate balance of 
reactivity contributed from both C6˗hydroxamate donors and acceptor. To further 
112 
 
investigate and identify successful conditions for the synthesis of 145 and 146, new 
methodologies were examined using different types of C6˗hydroxamate donors.  
Based on the results and observations exhibited in Table 3, a different type of 
donor was used for the next attempt to synthesise 145 and/or 146. An N˗PTFA donor 
was selected, as it has been reported to be advantageous for the synthesis of 
β˗mannuronates.164,135 An additional advantage of N˗PTFA donors derives from their 
low tendency to undergo side reactions during glycosylations, as opposed to TCA 
donors where an N˗glycoside by˗product can be formed.230 Donor 148 was prepared 
from hemiacetal 147 by treating the latter with PTFA.Cl in the presence of a 
stoichiometric amount of K2CO3 in a water/acetone solvent mixture (Scheme 32).169 
The applied conditions gave 148 which was used directly after for glycosylation with 
78. 
 
Scheme 32: Attempted synthesis of disaccharide 145 from N˗PTFA donor 148 and acceptor 78 (i) 
NIS, AgOTf, CH2Cl2/H2O (10/1, v/v), 0 °C, 4 h, 78% (ii) N˗PTFA.Cl, K2CO3, acetone/H2O (20/1, v/v), 0 
°C to RT, 20 h, 66% (iii) TBDMSOTf, CH2Cl2, ˗78 °C, 24 h, 16%. 
The activator used for the attempted synthesis of 145 was TBDMSOTf, which 
was previously used for the activation of D˗ManA N˗PTFA donor.231 Unfortunately, 
the glycosylation reaction was unsuccessful giving an anomeric mixture (α/β = 1/1) 
(α/β = 9/1) 
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of by˗product 149 (16%), along with the unreacted acceptor 78 (87%).  No hydrolysed 
donor was recovered; however, the results obtained can be attributed to the 
presence of moisture. The same conditions were tested again with a fresh bottle of 
promoter TBDMSOTf, giving similar results after stirring the reaction from ˗78 °C to 
˗30 °C for 24 h. In order to avoid the formation of 149, TMSOTf was used (from ˗78 
°C to ˗30 °C, 24 h), whereby TLC and NMR analysis showed the major components 
of the reaction mixture to be unreacted acceptor 78 (58%) and hydrolysed donor 
(20%). NMR data obtained after flash column purification of the mixture showed no 
evidence of desired disaccharide 145. 
A subsequent strategy designed for the condensation of two C6˗hydroxamate 
building blocks required the conversion of 147 to the corresponding glycosyl bromide 
150 (Scheme 33). Based on the mechanistic study of the Koenigs−Knorr reaction of 
2,3,4,6˗tetra˗O˗acetyl˗α˗D˗glucopyranosyl bromide, Wulff and Rӧhle suggested that 
1,2˗trans glycosyl bromides are more favourable for the preparation of 1,2˗cis 
glycosides, as a result of a putative associative transition state (Figure 46).232 
Specifically, they proposed that in the presence of non˗polar solvents, insoluble silver 
salts promote an SN2˗type transition state which can yield higher amounts of cis 
glycosides. Their recommendation was also based on the fact that the reaction rate 
depended on the concentration of both donor and acceptor. The design of this route 
was based on Westman’s approach to condensate iduronic acid bromide with an 





Figure 46: Kinetically˗derived associative transition state for the reaction of 
2,3,4,6˗tetra˗O˗acetyl˗α˗D˗glucopyranosyl bromide with alcohols and an insoluble silver salt in diethyl 
ether [Adapted from Wulff and Rӧhle (1974)].232 
Glycosyl acetate 150 was synthesised in 90% yield from 147 with 
Ac2O/pyridine (Scheme 33). NMR analysis of the material isolated indicated only the 
α˗anomer of 150, with H1 at 6.18 ppm (d, 3JH1˗H2 = 2.2 Hz), while coupled HSQC 
spectrum showed a coupling constant of 1JC1˗H1 = 176 Hz. Following a protocol by 
Jakeman et al.234 for installing the bromo substituent at the anomeric centre of 150 
with PBr3 and H2O did not furnish 151. TLC analysis after 40 min. showed 
consumption of starting material 150 and the formation of two lower Rf spots. NMR 
of the reaction suggested a mixture of compounds that did not include the desired 
glycosyl bromide, as the 13C NMR of the major product showed no significant change 
at the anomeric centre (150: 91.6 ppm, 152: 91.0 ppm). 1H and HMBC analysis 
confirmed the cleavage of a Bn group from the hydroxamate (explaining the 
difference in Rf), and the existence of the anomeric OAc group. Moreover, 152 was 
isolated as an anomeric mixture (α/β = 5.6/1), and the 3J values of both anomers 
suggested a 1C4 ring conformation. HRMS data confirmed the proposed structure of 
152, as the protonated species was found at m/z 620.2498 (C34H38NO10, 152 
requires (M+H)+ 620.2496). N˗Bn hydrolysis was previously observed during 
glycosidation of 67 with 3˗bromopropanol using NBS/TMSOTf (Table 1, Entry 5), 
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indicating that C6˗hydroxamate donors are susceptible to N˗hydrolysis when 
exposed to highly acidic conditions. 
 
Scheme 33: Designed route towards mimetic disaccharide 145 (a) (i) Ac2O, pyridine, CH2Cl2, RT, 24 
h, 89% (ii) PBr3/H2O, CH2Cl2, 0 °C, 40 min, 95%. 
8.5. Discussion of possible mechanistic pathways involving 
C6˗hydroxamate donors 67, 69 and acceptor 78 
It is important to note that the glycosylation of hydroxamate donors 67, 69 and 
acceptor 78 with the respective native acceptor 60 and donor 56 was successful, as 
desired disaccharides 140 and 143 were obtained (Sections 8.2. and 8.3.). In 
general, mannuronic acid donors are regarded to be among the most unreactive 
donors due to their electron˗withdrawing C6 oxidised moiety.150,160 However, in a 
later study Codée et al. showed that they owe their high reactivity and β˗selectivity 
to the formation of the relatively favourable 3H4˗oxacarbenium ion˗like intermediate, 
and based on their observations, the synthesis of both mixed and fully C6˗modified 
disaccharides was designed based on a pre˗glycosylation oxidation route.150 The 
yield observed from the synthesis of mixed disaccharide 142 (55%) showed that 
(α/β = 5.6/1) 
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hydroxamate acceptor 78 displayed similar nucleophilicity with is native counterpart, 
as the yield obtained was similar with the one for the synthesis of 134 (56%). Taking 
into consideration the yields for the synthesis of 139 (12%), 141 (30%) and 144 (14%) 
hydroxamate donors 67 and 69 exhibited reduced reactivity during glycosylation 
reactions with mannuronate acceptor 60 and disaccharide acceptor 143. As 
previously mentioned, the reason behind the failed attempts to synthesise 
C6˗hydroxamate disaccharides 145 and 146 could be attributed to the relatively poor 
reactivity of both hydroxamate donors 67, 69 and acceptor 78 demonstrated under 
various glycosylation protocols. 
 
Scheme 34: Synthesis of disaccharide 154 for stereochemistry investigation (i) Ph2SO, TTBP, Tf2O, 
153, CH2Cl2, ˗78 °C to ˗20 °C, 2 h, 27%. 
To further investigate the reactivity of the designed hydroxamate donors, 153 
bearing a free C6˗OH was used as a monosaccharide acceptor in a glycosylation 
reaction with hydroxamate donor 69. A preactivation protocol with Ph2SO/Tf2O and 
TTBP furnished β˗linked disaccharide 154 (1JC1’˗H1’ = 156 Hz, C1’: 102.2 ppm) in 27% 
yield (Scheme 34). The yield obtained for 154 was similar to that of 141 (30%), 
implying that the conversion percentage observed for glycosylation reactions 
involving donor 69 with other monosaccharides (60, 153) is mainly influenced by the 
low reactivity of 69. However, the stereochemical outcome was different when the 2 
acceptors (60, 153) were used (α˗linkage for 141 and β˗linkage for 154), suggesting 
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that their reactivity (and steric hindrance) may contribute at a higher degree to the 
stereochemistry of the glycosidic linkage. 
Given the mechanistic explanation provided by Codée et al. (Figures 27 and 
31), herein a similar mechanistic pathway was proposed based on the results and 
observations from the glycosylation reactions discussed earlier in this section (Figure 
47). Preactivation of donors 67 and 69 could give their respective α˗triflate 
intermediates 156 that undergo a fast β˗face (SN2˗like) attack when a strong 
O˗nucleophile is present as an acceptor (e.g. primary alcohol, 3˗bromopropanol and 
O˗glycoside 153) to give products 159 (Figure 47a). In the presence of weak 
O˗nucleophiles (e.g. mannuronate acceptor 60 and disaccharide acceptor 143), 
solvent˗separated ion pair 157 becomes more favourable, as it exhibits more 
carbocation character than 156. Following a SN1˗like pathway, intermediate 157 
leads to the formation of α˗linked products 158. A more detailed explanation of the 
SN1˗like pathway included intermediate transition states 160, 161 and 162 (Figure 
47b). Half˗chair oxocarbenium ions 160 and 161 are attacked from the α˗bottom face, 
as in both cases the top face is hindered by C6˗hydroxamate, leading to α˗linked 
products 158a and 158b. 4H3 half˗chair oxocarbenium ion 160 was considered to be 
more favourable compared to 3H4 half˗chair oxocarbenium ion 161 because of the 
steric interactions between C3˗OBn and N,O˗dibenzyl functionality present in the 
latter intermediate. An alternative pathway could also exist via intermediate 162, 
leading to the production of α˗glycosides by bottom face attack. Cyclised 
intermediate 162 was proposed based on the production of by˗product 64 that was 




Figure 47: Possible mechanistic pathways involving putative transition states and conformations 
showing dominantly the α˗directing effect of hydroxamate donors. SN1 character increases with 
decreased acceptor nucleophilicity, leading to α˗linked products. 
Given the considerably low yielding glycosylation reactions and the production 
of α˗linked disaccharides (instead of desired linked products) discussed above, a 
subsequent synthetic methodology was designed based on a late stage oxidation 
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approach. This strategy was considered to be more beneficial in terms of delivering 
the products in higher yields compared to the use of C6˗oxidised donors 67, 69. The 
challenge of the following approach laid in developing a methodology that could 
provide β˗linked disaccharide building blocks which could then be elongated with 
high β˗stereoselectivity. An additional challenging point was the ability to easily 
modify the obtained oligosaccharide at a later stage. Preliminary experimental data 
are discussed in Section 8.6. and the strategy is further elaborated is Section 10.1. 
8.6. Synthesis of modified alginate oligosaccharides involving a late stage 
C6˗modification 
8.6.1. β˗mannosylation approach 
The following strategy was constructed based on the advantages offered by 
Crich’s 4,6˗benzylidene˗mannopyranoside sulfoxide donor 163 and Codée’s uronate 
thio˗mannopyranoside building block 54 to provide high β˗selectivities (Scheme 
35).148,235,161 In particular, disaccharide building block 164 was synthesised and 
further manipulated into producing disaccharide thioglycoside acceptor 166 and 
sulfoxide donor 167. 
Sulfoxide donor 163 was furnished as a single diastereoisomer in 73% yield 
with the use of oxidant m˗CPBA in CH2Cl2 at ˗78 °C to ˗30 °C (Scheme 35).236 
Preactivation of 163 with Tf2O in the presence of TTBP in CH2Cl2 at ˗78 °C and 
subsequent dropwise addition of 54 dissolved in CH2Cl2, furnished 164 as a β˗linked 
disaccharide in 75% yield (1JC1’˗H1’ = 156 Hz, C1’: 101.1 ppm). This material was then 
exploited in producing thioglycoside disaccharide acceptor 166 (with acetal 
hydrolysis and selective protection of primary alcohol with a benzoyl group), and 




Scheme 35: Synthesis of disaccharide acceptor 166 and donor 167 (i) m˗CPBA, CH2Cl2, ˗78 °C to 
˗30 °C, 3 h, 73% (ii) TTBP, Tf2O, 54, CH2Cl2, ˗80 °C, 30 min, 75% (iii) p˗TsOH.H2O, MeOH, 85 °C, 2 
h, 69% (iv) BzCl, DMAP, pyridine, CH2Cl2, RT, 18 h, 76% (v) m˗CPBA, CH2Cl2, ˗78 °C to ˗40 °C, 2 h, 
66%. 
Sulfoxide 167 was isolated as a mixture of two diastereoisomers (3/1), as indicated 
by NMR data analysis. 1H NMR data of 166 and 167 suggested that the reducing end 
in both disaccharides adopted a 1C4 conformation. This is based on the coupling 
constants of the anomeric protons, exhibiting values equal to 3JH1˗H2 = 9.1 Hz (H1: 
5.79 ppm) for 166 and 3JH1˗H2 = 10.1 Hz (H1: 5.05 ppm) for 167, implying an axial 
relationship with neighbouring H2. 
Unfortunately, the glycosylation between 166 and 167 was fruitless, as 
tetrasaccharide 168 was not detected by NMR (Scheme 36). TLC analysis 30 min. 
after the addition of acceptor 167 showed decomposition of 167 and the presence of 
unreacted 166. Flash column purification of the mixture did not isolate the hydrolysis 
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product of 167, and only acceptor 166 (64%) was recovered. This late˗stage 
modification strategy is further outlined in Section 10.1.1., as it could be a more viable 
approach for the production of a modified alginate oligosaccharide. 
 
Scheme 36: Attempted synthesis of tetrasaccharide 168 for assembly of longer alginate 
oligosaccharide using a post˗glycosylation modification approach (vi) Ph2SO, TTBP, Tf2O, 166, 
CH2Cl2, ˗80 °C to ˗30 °C, 1 h. 
8.6.2. Synthesis of disaccharide 170 as a building block for the solid phase 
synthesis of modified alginate oligosaccharides 
The next strategy was designed for the synthesis of a disaccharide building 
block for the construction of modified alginate oligosaccharides on solid phase. The 
past decade has seen dramatic developments in the area of solid phase˗supported 
oligosaccharide synthesis.237 The increasing interest in polymer˗supported synthesis 
relies on the fact that it permits synthesis without the necessity of purifying and 






Scheme 37: Synthesis of building block 170 that could be used for the construction of longer 
C6˗modified alginate sequences in solid˗phase synthesiser (i) TEMPO, BAIB, CH2Cl2/H2O (2/1, v/v), 
RT, 1 h, 70% (ii) BnBr, K2CO3, DMF, RT, 24 h, 93%. 
As presented in Section 4.2., Codée and co˗workers developed a 
methodology involving the conversion of thioglycoside donors to N˗PTFA donors 
which were efficiently assembled with catalytic amounts of TfOH to construct alginate 
oligomers.169 The first step taken towards this approach was the design and 
synthesis of disaccharide 170 (Scheme 37). C6˗oxidation of the non˗reducing end of 
165 under TEMPO/BAIB conditions gave 169 in 70%. 13C NMR data of 169 showed 
the presence of a new carbonyl carbon peak at 171.0 ppm, corresponding to the new 
carboxylic acid group. C6˗esterification using BnBr and K2CO3 afforded 170 in 93% 
yield. NMR and HRMS analysis of 170 confirmed its structure (Found ammonium 
adduct at m/z 944.3685, C54H58NO12S 170 requires (M+NH4)+ 944.3680). The future 
work envisaged for 170 is further explained is Section 10.1.2. 
9. Synthesis of conjugable 3˗aminopropyl˗D˗ManA and 3˗aminopropyl 
C6˗modified D˗ManA monosaccharides 
Polymer modification via carbohydrate conjugation has attracted tremendous 
interest over past few decades due to their degradation properties in vivo, as well as 
inherent tunability and chirality. In particular, such biopolymers are ideal for delivery 
systems, owing to their inherent biocompatibility, biodegradability, and bioadhesive 
properties.238,239 The synthetic approaches for sugar˗based polymers can be divided 
into three major categories depending on the role of sugar building blocks involved: 
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(a) polysaccharide derivatisation, where the polymer backbone is mainly composed 
of carbohydrates; (b) carbohydrate˗functionalised polymers, where sugar molecules 
decorate the polymer of interest as pendent groups (i.e. glycopolymers), and (c) 
polymers connected via a sugar linkage, where a saccharide or an oligosaccharide 
is used as a branch site or backbone (Figure 48). Apart from the production of novel 
polymeric systems, carbohydrates are additionally exploited for functionalisation of 
nanoparticles (i.e. glyconanoparticles).240–243 More specifically, glyco˗gold 
nanoparticles are widely applied as nanosensors in studies focused on 
carbohydrate˗protein interactions and in vivo cell imaging, or as drug carriers in the 
development of nano˗ and personalised medicine.241  
 
Figure 48: Schematic illustration and classification of carbohydrate˗modified polymers [Adapted 
from Zhang et al. (2015)].238 
Given the previous discussion on the unsuccessful extension of mixed 
C6˗modified alginate disaccharides (Sections 8.2. and 8.3.) and failed synthesis of a 
non˗self oligosaccharide (Section 8.4.), it was considered that native mannuronate 
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60 and C6˗bioisosteric mannuronates, 78 and 115 could be used in their deprotected 
forms to functionalise polymers for generation of novel biomaterials. The 
azidopropanol linker attached at the anomeric centre of the 60 and 78 offers the 
opportunity for conjugation to polymers (or nanoparticles) containing alkyne groups 
via click chemistry. In addition, reduction of the azide to the amine is beneficial, as it 
could be coupled to carboxylic acids for the production of amide˗linked materials. In 
other words, the linker on these monosaccharide building blocks can be used as a 
handle for their attachment to polymers, producing novel glycopolymers (Figure 48b 
and 49). 
 
Figure 49: Schematic representation of native and C6˗modified mannuronate conjugation by 
coupling terminal amine with the carboxylic acid groups of a polymer. 
The approach taken here was towards a global deprotection of 60, 78 and 115 
using hydrogenolysis which would, unavoidably, lead to the production of 
aminopropanol linkers. The methods evaluated are discussed in further detail below. 
9.1. Synthesis of 3˗aminopropyl (β˗D˗mannopyranoside) uronic acid 171 
Introductory Section 3 comprises of examples of alginate˗based biomaterials 
that mainly result from hydrophobic derivatisation of alginate, or from crosslinking of 
it with other polymers. There are currently no examples in the literature where 
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mannuronic acids are linked to polymers for production of biomaterials exhibiting 
novel physicochemical properties.  For the synthesis of a conjugable mannuronic 
acid 171, native acceptor 60 was used (Scheme 38). Hydrolysis of C6˗methyl ester 
with 0.45 M aq. KOH, followed by hydrogenolysis with 0.15 equiv. Pd/C, 0.15 equiv. 
Pd(OH)2/C  and 1.0 equiv. of 0.1 M HCl in EtOH/THF (1.5/1, v/v, 0.05 M), furnished 
171 in 36% yield (over 2 steps). TLC analysis of the hydrogenolysis step showed 
conversion of the starting material to a baseline product in 32 h. NMR spectra 
collected confirmed complete deprotection, as no Bn groups were present. HRMS 
spectrum found major ion at m/z 250.0928 which corresponds to (M˗H)˗ for 171 
(C9H17NO7, 171 requires (M˗H)˗, 250.0927). 
 
Scheme 38: Synthesis of 171 (i) 0.45 M KOH, THF/H2O (1/1, v/v), RT, 2 h (ii) H2(g), Pd/C (10%), 
Pd(OH)2/C (20%), 0.1 M aq. HCl, EtOH/THF (1.5/1, v/v), RT, 32 h, 36% (over 2 steps) . 
9.2. Synthesis of 3˗aminopropyl (β˗D˗mannopyranoside) hydroxamic acid 
172 
Conjugation of C6˗hydroxamic acid mannuronates to polymers would be 
compelling to achieve, as these weak acids constitute one of the most important 
families of organic bioligands, widely used in biomedicine and biotechnology.244 For 
example, hydroxamate˗containing siderophores are exploited as drug˗conjugate 
complexes for the treatment of iron overload associated with repeated blood 
transfusions, cancer and malaria.192 In addition, bacterial cells evolved high˗affinity 
iron uptake mechanisms comprised of siderophores, and are activated under stress 
conditions caused by restricted access to soluble iron.245 Considering that one of the 
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crucial mechanisms of antibiotic resistance in bacteria is decreased outer membrane 
permeability, siderophore˗drug complexes are used to ‘smuggle’ the antibiotic 
molecule into the bacterial cell.246 This strategy is also known as ‘Trojan horse’ 
strategy, whereby a Fe(III) siderophore is linked to the drug that is subsequently 
released in its free active form when the siderophore˗drug conjugate reaches the 
cytoplasm, killing the microorganism.192,191 The ‘Trojan horse’ approach may also 
employ heavy metals (e.g. Ga3+), whose facilitated transport into the bacterial cell 
can prevent biofilm formation, by bacterial iron metabolism interruption.192 As a 
hydroxamate˗containing monosaccharide, 172 could be attached on the backbone 
of polymers, or surface of nanoparticles, producing systems with alternative chelating 
properties for various applications, such as delivery of metal˗based drugs, metals to 
promote cell apoptosis, or siderophore˗drug conjugates. 
 
Scheme 39: Attempted synthesis of 172 under hydrogenolysis and oxidative debenzylation conditions 
(i) H2(g), Pd/C (10%), Pd(OH)2/C (20%), 5% aq. NaHCO3, EtOH/THF (1.5/1), RT, 21 h (ii) 
NaBrO3/Na2S2O4, EtOAc, RT, 32 h, 40% (iii) H2(g), Pd/C (10%), Pd(OH)2/C (20%), 0.1 M aq. HCl, 
EtOH/THF (1.5/1), RT, 6 h. 
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a The concentration of the reaction during hydrogenolysis was kept 0.05 M and the solvents used 
initially were EtOH/THF (1.5/1, v/v) while 2nd and 3rd attempts (same entries) MeOH/H2O (1/1, v/v) 
were used. 
b The temperature was at RT at all times. 
c TLC solvent system used was H2O/MeCN, 1/2. 
d Theoretical isotope mass (M+H)+ 267.1192, (M˗H)˗ 265.1041 and (M+Cl)˗ 301.0808. 
e The starting material used was the 3˗azidopropyl N˗benzyl (phenyl 
2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 173 obtained from entry 6. 
Global deprotection and reduction of the azido˗group in hydroxamate acceptor 
78 was not as straightforward as the deprotection of native acceptor 60 discussed 
above. Scheme 39 and Table 3 summarise the conditions applied to substrate 78 for 
the synthesis of 172. Reductive cleavage by hydrogenolysis using Pd/C (0.35 equiv. 
in total during 28 h), Pd(OH)2/C (0.35 equiv. in total during 28 h) and 0.1 M HCl (1.0 
equiv.) did not furnish desirable material 172 (Entry 1). NMR and HRMS analysis of 
isolated product was inconclusive. Based on the knowledge obtained from the 
hydrogenolysis of 125 to C6˗hydroxamic α˗phosphate 34 (Section 7.1.), the same 
 Table 3: Deprotection conditions used for the conversion of 78 to 172 
  Hydrogenolysis conditionsa,b 
Entry Pd/C (10 %)         
total equiv. 
Pd(OH)2/C 
(20 %)    
total equiv. 
Acid or base 
used 
Duration Observation by TLC 
analysis NMR and 
HRMS datac 
1 0.35 0.35 0.1 M HCl         
(1.0 equiv.) 
28 h Unidentified product 
2 0.42 0.42 5% aq. NaHCO3         
(2.0 equiv.) 
21 h 171: 84% yield 
3 0.5 0.5 5% aq. NaHCO3          
(1 equiv.) and 




and 3 h 
(HCl) 
Unidentified product 
4 0.5 ˗ 5% aq. NaHCO3          
(1 equiv.) and 








5e 0.1 0.1 0.1 M HCl         
(1.0 equiv.) 
6 h 171: 94% yield 
 Oxidative debenzylation conditions with NaBrO3 and Na2S2O4 
 NaBrO3   
(0.45  M aq.) 
total equiv. 
Na2S2O4 
(0.2 M aq.) 
total equiv. 
EtOAc Duration Observation by TLC 
analysis NMR and 
HRMS data 
6 9 8 0.08 M 32 h 173: 40% yield 
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conditions were applied next using Pd/C (0.42 equiv. in total during 21 h), Pd(OH)2/C 
(0.42 equiv. in total during 21 h), and 5% aq. NaHCO3 (2.0 equiv.). TLC analysis 
showed complete conversion of the starting material 78 to a lower Rf material. NMR 
and HRMS data showed the production of uronic acid 171 (84% yield), indicating 
hydrolysis of the hydroxamate functionality under these set of conditions (Entry 2, 
Scheme 39). 
Following these results, a subsequent approach was the application of an 
oxidative debenzylation protocol, using NaBrO3 and Na2S2O4.247 As opposed to 
reductive debenzylation, these oxidative debenzylation conditions demonstrated 
selective removal of benzyl ethers in the presence of azides. Furthermore, 
NaBrO3/Na2S2O4 were reported to be carried out in high conversion, with ester and 
amide type of protecting groups remaining intact. TLC analysis of a reaction mixture 
with 78, 0.45 M NaBrO3 (4.5 equiv.) and 0.2 M Na2S2O4 (4.0 equiv.) displayed a slow 
conversion after 16 h (Entry 6, Scheme 39). An additional batch of NaBrO3/Na2S2O4 
was added to force the reaction to completion, however, after 32 h a mixture of 
compounds was still present according to TLC analysis. Purification by flash column 
chromatography isolated N˗benzylated 173 as the major compound (40% yield). In 
order to cleave the remaining Bn group, 173 was subjected under hydrogenolysis 
conditions where the catalysts were added in batches (2 x 0.05 equiv. every 3 h) and 
the reaction was monitored by TLC analysis (Entry 5, Scheme 39).The addition of 
0.1 M HCl was considered to avoid the formation of uronic acid 171 (as observed in 
entry 2 where 5% aq. NaHCO3 was added), however, these conditions afforded only 
171 (94% yield) after 6 h. 
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Based on the information gathered from the above observations, Pd(OH)2/C 
was regarded to be responsible for the hydrolysis of the hydroxamate functionality to 
the corresponding carboxylic acid. Therefore, a new bottle of Pearlman’s catalyst 
was used in the next attempt (Entry 3). The reaction was monitored every 3 h and 
during the initial 6 h (where 1.0 equiv. of 5% aq. NaHCO3 was present in the mixture) 
TLC analysis suggested that the reaction was quenched presumably by the formed 
amino˗group which poisoned the catalyst. Upon filtration through Celite®, the 
remaining crude material was re˗dissolved in MeOH/H2O (1/1, v/v, 0.05 M) and was 
subjected under the same hydrogenolysis conditions (0.25 equiv. of each catalyst 
with the exception of adding 1.0 equiv of 0.1 M HCl). TLC analysis after 3 h showed 
the presence of a deprotected material (Rf = 0.19) which was isolated and 
characterised. ESI˗MS data obtained did not display expected theoretical isotope 
pattern for 172 (C9H18N2O7, 172 requires (M˗H)˗ 265.1041). 13C NMR spectrum of this 
material showed carbonyl carbon at 173.5 ppm, and the carbon peak of α˗carbon in 
anomeric linker (OCH2CH2CH2) appeared to be at 45.6 ppm (instead of 37.5 ppm as 
observed in the NMR data of 171 and 174), indicating that a replacement of the 
amino˗group with an oxygen˗containing functionality could be responsible for the 
downfield shift. NMR and HRMS analysis were inconclusive and no plausible 
structure was proposed, as alkylation of the structure to match the obtained data 
could not be explained under these conditions. The same results were obtained by 
repeating the experimental procedure using only Pd/C as a catalyst (Entry 4). 
According to the above results, an alternative reaction occurred under 
hydrogenolysis conditions, which was not observed earlier during deprotection of 
C6˗hydroxamate 1˗phosphate 125. Considering that similar conditions (catalyst 
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equivalents) were used for deprotection of 125 and 78, the anomeric 3˗azidopropanol 
linker may be accountable for the undesirable reaction. 
9.3. Synthesis of 3˗aminopropyl (6˗C˗tetrazol˗5˗yl)˗α/β˗D˗mannopyranoside 
174 
Similar to Sections 9.1. and 9.2., carbohydrate˗functionalisation of polymers 
(or nanoparticles) using tetrazole˗containing monosaccharide 174 could lead to the 
production of novel biomaterials. As explained in Section 5., tetrazolic acids exhibit 
stronger hydrogen bond interactions and at the same time are more lipophilic 
compared to carboxylate anions.182 
 
 
Scheme 40: Synthesis of 174 (ii) H2(g), Pd/C (10%), Pd(OH)2/C (20%), 0.1 M aq. HCl, EtOH/THF 
(1.5/1, v/v), RT, 56 h, 96%. 
Hydrogenolysis of 115 (α/β = 3/1 after flash column purification) with 0.5 equiv. 
of Pd/C and Pd(OH)2/C furnished 174 (96% yield) in the same ratio (α/β = 3/1) 
(Scheme 40). TLC analysis showed conversion of 115 to a lower Rf spot after 24 h, 
and NMR data collected confirmed its successful deprotection. 13C NMR spectrum 
indicated 2 peaks corresponding to the quaternary carbons (Cq tetrazole) of the 
anomeric mixture with a chemical shift of 160.1 ppm, close to that observed for 
C6˗tetrazole 1˗phosphate 35 (160.8 ppm). ESI˗MS spectrum confirmed the mass of 
115, where the major ion was observed at m/z 276.1309 (C9H19N5O5, 115 requires 
(M+H)+ 276.1308). 
α/β= 3/1 (after column chromatography) α/β= 3/1  
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10. Conclusions and Future Directions 
Herein is presented the first synthesis set of C6˗hydroxamate and 
C6˗tetrazole mannopyrannoside analogues for the synthesis of modified alginate 
building blocks. As reported in the sections above, the project faced synthetic 
obstacles due to the design and methodology development performed at its initial 
stages. Undoubtedly, considering the information gathered up to this point, new 
routes could be designed for the construction of designer alginate oligomers. 
10.1. Late stage C6˗modification of alginate oligosaccharides 
10.1.1. Future directions for β˗mannosylation approach 
The synthesis of tetrasaccharide 168 could be attempted again under the 
same gylcosylation conditions (Section 8.6.1.) or different types of disaccharide 
donor 167 could be used by replacing sulfoxide anomeric group with other orthogonal 
groups to thiophenol (e.g. N˗PTFA, TCA), allowing the application of alternative 
glycosylation conditions. Following successful synthesis of β˗linked tetrasaccharide 
168, conversion of it to donors 175 and thioglycoside acceptor 176 (in the same way 
164 was converted) could be achieved to deliver octasaccharide 177 when 
assembled (Figure 50). Finally, when converted to an O˗glycoside, 177 could be 
modified at C6 position by hydrolysis (acidic and basic), oxidation and coupling to 
H2NOH, to give designer alginate octasaccharide 178. Hydrolysis of the remaining 
C6˗methyl ester groups and global deprotection under hydrogenolysis conditions 




Figure 50: Schematic illustration of future work involving the assembly of tetrasaccharides 175 and 
176 towards the synthesis of a modified alginate oligosaccharide. 
10.1.2. Future work with disaccharide 170 as a building block for solid 
phase synthesis 
As discussed in Section 8.6.2., disaccharide 170 could be employed as a 
building block for the solid˗phase synthesis of a modified alginate oligosaccharide, 




Figure 51: Schematic representation of future work for the solid phase assembly of C6˗modified 
alginate oligosaccharide involving building block 170. 
An acceptor˗bound approach is generally considered as more profitable because the 
attachment of the nucleophile allows the use for excess of the donor which would 
then drive the reaction to completion.237 As for the donor˗bound approach, side 
reactions usually occur by decomposition of the reactive species (donor), which 
results in a direct reduction in overall yield.  
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Conversion of thioglycoside 170 to N˗PTFA donor 179 orthogonally protected 
at C4 position, could be first attached on the resin (e.g. Merrifield resin functionalised 
with a butanediol linker), and C4˗OH liberation would furnish the acceptor 
disaccharide that can be then glycosylated with 179 at a specific amount of cycles 
(Figure 51). Synthesis of an oligosaccharide (e.g. 180) and subsequent cleavage of 
it from the resin, could be subjected to a series of reaction steps, leading to 
C6˗modification in a chemoselective fashion. For the production of an alginate 
oligomer bearing C6˗hydroxamic acid functionalities, the steps that could be taken 
are hydrogenolysis of the material, and conversion of the remaining methyl esters to 
hydroxamic acids with aq. H2NOH in MeOH to give 182. 
10.2. C5˗ and C6˗modified 1˗phosphate building blocks 
Sugar 1˗phosphates C6˗hydroxamic acid 34, C6˗tetrazole 35 and C6˗amide 
126 could be employed for the chemical synthesis of respective C6˗modified 
GDP˗D˗ManA building blocks via a pyrophosphorylation strategy, involving their 
reaction with activated monophosphate species (e.g. GMP˗morpholidate) in the 
presence of a catalyst (e.g. DCI, N˗MIC). 
Sugar 1˗phosphates 126 and 131 can be used as substrates for GMP, as the 
absence of a charge at the C6˗position makes them ideal candidates for the 
enzymatic synthesis of their respective sugar˗nucleotide analogues. C6˗amide 
GDP˗D˗ManA could be tested as a GMD inhibitor, or it could be used as ‘fuel’ for 
polymerase Alg8, producing a non˗anionic alginate polysaccharide in physiological 
conditions. Moreover, following successful enzymatic synthesis, 5˗C˗Me GDP˗D˗Man 
could then be C6˗oxidised (chemically or enzymatically with GMD if any inhibitory 
effect is not exhibited) for integrating the production of a 5˗C˗Me GDP˗D˗ManA 
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building block 183. Incorporation of 5˗C˗Me˗D˗ManA in a polymannuronate chain 
could consequently probe epimerase AlgG and lyase AlgL (Figure 52). 
 
Figure 52: 5˗C˗Me˗GDP˗D˗ManA 183 could be used as an Alg8 substrate to incorporate 
5˗C˗Me˗D˗ManA in alginate polysaccharide to provide insight on the AlgG (blue) and AlgL (green) 
biochemical pathway. 
Acidic sugar 1˗phosphates 34 and 35 may not be successfully converted to 
their respective C6˗modified GDP˗D˗ManA analogues using GMP (due to their 
charge in physiological conditions). However, they can be employed as donors for 
the enzymatic synthesis of a designer alginate, using a phosphorylase. As opposed 
to sugar nucleotide˗dependent glycosyltransferases, phosphorylases can enable 
efficient and regioselective synthesis of diverse oligosaccharides with sugar 
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1˗phosphates as donors.248,249 For 34 and 35, an inverting phosphorylase could 
promote oligosaccharide assembly via axial˗to˗equatorial substitution on C1 through 
the base catalytic residue (Figure 53). Utilisation of phosphorylases for 
oligosaccharide synthesis has attracted tremendous interest due to high 
regioisomeric purity obtained (separation of product isoforms is not required), 
therefore, the number of reported phosphorylases has gradually increased.249,250 
Recent studies report characterisation and engineering of phosphorylases that could 
be exploited as tools for this purpose248, and considering that the phosphorolysis of 
a glycoside to produce the corresponding sugar 1˗phosphate is reversible249, 
β˗1,4˗mannooligosaccharide phosphorylase (GH130) could be structurally modified 
for oligosaccharide synthesis, instead of hydrolysis. 
 
Figure 53: Schematic representation of β˗stereoselective glycosylation using inverting 
phosphorylase and α˗1˗phosphates as donors [Adapted from Benkoulouche et al. (2019)].248 
10.3. Conjugable 3˗aminopropyl (β˗D˗mannopyranoside) hydroxamic acid 172 
The synthesis of 172 was unsuccessful when 78 was used as the precursor, 
as unidentified products were produced, or hydrolysis of the hydroxamate group 
furnished 171 instead. An alternative route to pursue this synthesis could either be 
the coupling of H2NOH to the carboxylic acid of 171, or the conversion of C6˗methyl 




Scheme 41: Alternative routes proposed for the synthesis of 172. 
10.4. General conclusion on alginate oligosaccharide synthesis 
The research presented in this thesis has shown preliminary results obtained 
from the assembly of novel C6˗hydroxamate and native mannuronate building blocks 
towards modified alginate oligosaccharides, by following a pre˗glycosylation 
oxidation strategy which was previously demonstrated to give β˗linked 
products.150,211 Although synthesis of mixed disaccharide and trisaccharide systems 
was achieved (i.e. 140,143 and 144), the yields of the glycosylation reactions were 
low for further extension from the non˗reducing end. Moreover, the stereochemistry 
of the 1,4˗linkages constructed using hydroxamate donors 67 and 69 was α instead 
of the desirable β, as confirmed by coupled HSQC and nOe spectra. Consequently, 
an alternative approach was designed, based on Crich’s β˗mannosylation 
methodology and preliminary results are discussed in Section 8.6.1. Synthesis of 
β˗linked disaccharides 166 and 167 for oligosaccharide assembly and late˗stage 
C6˗modification is considered a more promising approach, compared to the 
pre˗glycosylation strategy followed initially. Further research using this methodology 





11.1. General methods and materials 
1H NMR spectra were recorded at 400 MHz on a Bruker AVIII400 spectrometer, using 
deuterochloroform (or other indicated solvent) as reference or internal deuterium 
lock. The chemical shift data for each signal are given as δ in units of parts per million 
(ppm) relative to tetramethylsilane (TMS) where δ (TMS) = 0.00 ppm. The multiplicity 
of each signal is indicated by: s (singlet); br s (broad singlet); d (doublet); t (triplet); 
app. t (apparent triplet); dd (doublet of doublets); ddd (doublet of doublet of doublets); 
dddd (doublet of doublet of doublet of doublets); ddt (doublet of doublet of triplets); 
sp (septet) or m (multiplet). The number of protons (n) for a given resonance is 
indicated by nH. Coupling constants (J) are quoted in Hz and are recorded to the 
nearest 0.1 Hz. 1H NMR signals were assigned with the aid of gDQCOSY. 
13C NMR spectra were recorded at 100 MHz on a Bruker AVIII400 spectrometer 
using proton decoupling and internal deuterium lock. The chemical shift data for each 
signal are given as δ in units of ppm relative to TMS where δ (TMS) = 0.00 ppm. 
Where appropriate, coupling constants (J) are quoted in Hz and are recorded to the 
nearest 0.1 Hz. 13C NMR signals were assigned with the aid of gHSQCAD.  





IR spectra were recorded on a Diamond 1000 FTIR spectrometer. Absorption 
maxima are reported in wavenumbers (cm˗1). Intensities of the maxima are quoted 
as strong (s), medium (m) or weak (w). 
Melting points were determined using a Gallenkamp MF˗370 or a Electrothermal 
9100 melting point apparatuses and are uncorrected. 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 
60F254 analytical plates (aluminium support). Visualisation was by absorption of UV 
radiation (245 nm), or thermal development after dipping in 5 % H2SO4 in MeOH.  
Manual flash column chromatography was carried out on silica gel 60 (0.043–0.063 
mm) under a positive pressure of compressed air. 
Automatic Column Flash chromatography was carried out on silica gel (Reveleris® 
X2 system) under a positive pressure of compressed N2. 
Purification by C18 chromatography was conducted using a Thermoscientific ×30 
SPE column (HyperSep C18, 6 mL) eluting with H2O. 
For glycosylation reactions the materials used were co˗evaporated with anhydrous 
toluene (3 x). Oven˗dried glassware and magnetic stirrer bars were used. 
Reactions requiring low temperatures used the following cooling baths: ˗80 °C (liquid 
nitrogen/CH2Cl2), ˗15 °C (NaCl/ ice/water) and 0 °C (ice/water). 
Where appropriate and if not stated otherwise, all non˗aqueous reactions were 
performed under an inert atmosphere of nitrogen, using a vacuum manifold with 
nitrogen passed through 4 Å molecular sieves and self˗indicating silica gel.  
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Dry Solvents (CH2Cl2, DMF, Et2O, toluene, THF) were purified by passing through 
activated alumina columns and used directly from a Pure Solv˗MD solvent 
purification system and were transferred under nitrogen. Anhydrous MeOH was dried 
with 4 Å molecular sieves.  
Brine refers to a saturated aqueous solution of sodium chloride. Hexane refers to 
n˗hexane and petroleum ether to the fraction boiling between 40˗60 °C. 
Chemicals were purchased from Acros UK, Aldrich UK, Avocado UK, Fisher UK or 
Fluka UK. In vacuo refers to the use of a rotary evaporator attached to a diaphragm 
pump. 
Optical rotations were recorded on automatic polarimeter Rudolph autopol I or 
Bellingham and Stanley ADP430 (concentration in g/100 mL). 
MS and HRMS (ESI) were obtained on Waters (Xevo, G2˗XS TOF) or Waters 
Micromass LCT spectrometers using a methanol mobile phase. High resolution (ESI) 
spectra were obtained on a Xevo, G2˗XS TOF mass spectrometer. HRMS was 
obtained using a lock˗mass to adjust the calibrated mass. 
General procedure for strong anion exchange chromatography: BioRad cartridge 
was pre˗washed with minimum 3 column volumes (15 mL) of degassed H2O. The 
sample was dissolved in minimal amount of degassed H2O. The cartridge was eluted 
with 3 column volumes of degassed H2O, followed by 3 column volumes of 1.0 M 
NH4HCO3. Upon injection of the sample onto column, the sample was collected in 5 
mL fractions. When TLC analysis indicated the frations tha contained the compound, 
they were collected directly into flask, freezed and lyophilised. The residue was 
re˗dissolved in H2O and lyophilisation was repeated to ensure all NH4HCO3 is 
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removed. After using the column wash with 3 column volumes of degassed H2O then 
10% MeOH/degassed H2O to store. 
Exchanging salt form: Et3NH+: Syringe filled with Dowex H+ resin was wash with 
MeOH, acetone, CH2Cl2 and H2O before use. 10% Et3N solution in H2O was passed 
through the resin until pH = ~10/11. The sample was dissolved in minimal amount of 
H2O before applied to the resin. The sample was washed through with H2O directly 












11.1.1.  (6˗C˗hydroxamic acid) α˗D˗mannopyranoside 1˗phosphate 
(bis˗ammonium salt) 34 
A suspension of hydroxamate 125 (56 mg, 67 µmol, 1.0 
equiv.), 10% Pd/C (21 mg, 20 µmol, 0.3 equiv.), 20% 
Pd(OH)2/C (14 mg, 20 µmol, 0.3 equiv.) and 5% aq. NaHCO3 
(227 µL, 0.13 mmol, 2.0 equiv.) in a mixture of EtOH/THF (1.3 
mL, 1.5/1 v/v) was stirred under an atmosphere of hydrogen 
(1 atm, balloon) at room temperature for 5 h. TLC analysis (hexane/EtOAc, 1/2) 
showed complete conversion of starting material to a lower Rf spot. The reaction 
mixture was filtered through Celite®, followed by solvent removal in vacuo. 
Purification via strong anion exchange chromatography was conducted manually 
using a Bio˗ScaleTM Mini UNOsphereTM Q (strong anion exchange) cartridge (See 
General methods) and lyophilisation afforded 34 as a white solid (15 mg, 45 µmol, 
67%). Rf 0.30 (MeCN/H2O, 2/1); [𝛼]𝐷
22 ˗6.13 (c. 0.66, H2O); 1H NMR (400 MHz; D2O) 
5.35 (1 H, dd, J = 8.1, 1.2 Hz, H1), 4.07 (1 H, d, J = 8.5 Hz, H5), 3.95 – 3.78 (3 H, m, 
H2, H3, H4); 13C NMR (101 MHz; D2O) δ 167.5 (C(O)N(H)OH), 96.0 (d, J = 5.1 Hz, 
C1), 71.4 (C5), 70.1 (d, J = 8.9 Hz, C2), 69.4 (C3), 67.6 (C4); 31P NMR δ P (162 MHz, 




11.1.2. (6˗C˗tetrazol˗5˗yl)˗α˗D˗mannopyranoside 1˗phosphate 
(bis˗ammonium salt) 35 
 A suspension of C6˗tetrazole 129 and 130 (190 mg, 0.22 
mmol, 1.0 equiv.), 10% Pd/C (140 mg, 0.13 mmol, 0.6 
equiv.), 20% Pd(OH)2/C (92 mg, 0.13 mmol, 0.6 equiv.) 
and 5% aq. NaHCO3 (739 µL, 0.44 mmol, 2.0 equiv.) in a 
mixture of EtOH/THF (4.4 mL, 1.5/1 v/v) was stirred 
under an atmosphere of hydrogen (1 atm, balloon) at room temperature for 24 h. TLC 
analysis (hexane/EtOAc, 1/2) showed complete conversion of starting material to a 
lower Rf spot. The reaction mixture was filtered through Celite®, followed by solvent 
removal in vacuo. Purification via strong anion exchange chromatography was 
conducted manually using a Bio˗ScaleTM Mini UNOsphereTM Q (strong anion 
exchange) cartridge (See General methods) and lyophilisation afforded 35 as a white 
powder (53 mg, 0.16 mmol, 72%). Rf 0.42 (H2O/MeCN, 1/2); [𝛼]𝐷
22 ˗3.0 (c. 1.0, H2O); 
1H NMR (400 MHz; D2O) δ 5.41 (1 H, dd, J = 7.9, 1.7 Hz, H1), 5.08 (1 H, d, J = 9.7 
Hz, H5), 4.05 (1 H, app. t, J = 9.6 Hz, H4), 4.02 – 3.97 (2 H, m, H2 and H3); 13C NMR 
(101 MHz; D2O) δ 160.8 (Cq tetrazole), 96.1 (C1), 70.5 (C2), 69.7 (C3), 69.4 (C4), 
67.1 (C5); 31P NMR δ P (162 MHz, D2O) ˗2.15 (s); HRMS (ES˗) m/z [Found: (M˗H)˗ 
297.0236 C6H10N4O8P requires (M˗H)˗, 297.0233]. 
11.1.3. 1,2,3,4,6˗Penta˗O˗acetyl˗α/β˗D˗mannopyranoside 36 
To a stirred mixture of Ac2O (27.0 mL, d = 1.08, 285.6 mmol, 
10.3 equiv.) and α/β˗D˗mannose (5.0 g, 27.8 mmol, 1.0 
equiv.), H2SO4 (2 drops) was added at 0 °C, under an 
atmosphere of N2. The solution was stirred for 10 min. at 0°C and then allowed to 
warm to room temperature and stirred for a further 50 min. The mixture was then 
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diluted with ice–water (100 mL), and the organic phase extracted with EtOAc (100 
mL). The extract was washed with H2O (3 × 100 mL), sat. aq. NaHCO3 solution (100 
mL), dried over MgSO4, filtered, and the solvent evaporated to dryness to yield 36 as 
a pale yellow viscous oil (9.9 g, 25.3 mmol, 91%). Rf 0.25 (EtOAc/hexane, 1/3); α/β 
= 4/1; 1H NMR (300 MHz; CDCl3) δ α˗anomer = 6.09 (1 H, d, J = 1.9 Hz, H1), 5.37 – 
5.34 (2 H, m, H3, H4), 5.27 (1 H, dd, J = 2.4, 1.9 Hz, H2), 4.29 (1 H, dd, J = 12.5, 4.7 
Hz, H6a), 4.10 (1 H, dd, J = 12.6 Hz, 2.1, H6b), 4.05 (1 H, m, H5), 2.19 (3 H, s, 
C(O)CH3), 2.18 (3 H, s, C(O)CH3), 2.11 (3 H, s, C(O)CH3), 2.07 (3 H, s, C(O)CH3), 
2.02 (3 H, s, C(O)CH3); β˗anomer = 5.88 (1 H, d, J = 1.1 Hz, H1), 5.49 (1 H, dd, J = 
3.2, 1.1 Hz, H2), 5.34–5.37 (1 H, m, H4), 5.15 (1 H, dd, J = 10.0, 3.2 Hz, H3), 4.32 (1 
H, dd, J = 10.5, 5.0 Hz, H6a), 4.16 (1 H, d, J = 2.3 Hz, H6b), 3.82 (1 H, ddd, J = 9.9, 
5.3, 2.3 Hz, H5), 2.23 (3 H, s, C(O)CH3), 2.11 (3 H, s, C(O)CH3), 2.09 (3 H, s, 
C(O)CH3), 2.05 (3 H, s, C(O)CH3), 2.01 (3 H, s, C(O)CH3); 13C NMR (75 MHz; CDCl3) 
δ α˗anomer = 170.7 (C(O)CH3), 170.0 (C(O)CH3), 169.8 (C(O)CH3), 169.6 
(C(O)CH3), 168.1 (C(O)CH3), 90.5 (C1), 70.5 (C5), 68.7 (C3), 68.3 (C2), 65.4 (C4), 
62.0 (C6), 20.9 (C(O)CH3), 20.8 (C(O)CH3), 20.7 (C(O)CH3), 20.7 (C(O)CH3), 20.6 
(C(O)CH3); β˗anomer = 170.2 (C(O)CH3), 169.8 (C(O)CH3), 169.6 (C(O)CH3), 168.4 
(C(O)CH3), 166.4 (C(O)CH3), 90.4 (C1), 73.2 (C5), 70.6 (C3), 68.1 (C2), 65.3 (C4), 
62.0 (C6), 22.2 (C(O)CH3), 20.7 (C(O)CH3), 20.7 (C(O)CH3), 20.5 (C(O)CH3), 20.5 
(C(O)CH3); 13C˗GATED (101 MHz; CDCl3): 90.5 (1JC1˗H1 = 180 Hz, C1 α˗anomer), 
90.4 (1JC1’˗H1’ = 164 Hz, C1 β˗anomer); HRMS (ES+) m/z [Found: (M+NH4)+ 408.1496 
C16H26NO11 requires (M+NH4)+, 408.1500]. These data were consistent with 
literature values.202,251  
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11.1.4. Phenyl 2,3,4,6˗tetra˗O˗acetyl˗1˗thio˗α˗D˗mannopyranoside 37 
To a stirred solution of 36 (22.2 g, 56.9 mmol, 1.0 equiv.) in 
anhydrous CH2Cl2 (55 mL) under N2 at room temperature, 
were added successively, thiophenol (8.7 mL, d = 1.078, 85.3 
mmol, 1.5 equiv.) and BF3.Et2O (33.7 mL, d = 1.15, 273.1 mmol, 4.8 equiv.). The 
yellow˗orange solution formed was stirred at room temperature for 2 days, during 
which it turned deep purple in colour and TLC showed higher Rf spot. The mixture 
was then washed successively with sat. aq. NaHCO3 (4 x 80 mL), 5% aq. NaOH 
solution (5 x 70 mL) and brine (3 x 50 mL), dried over MgSO4, filtered and the solvent 
was removed in vacuo. The residue, a pale yellow oil, was crystallised from EtOH (~ 
80 mL) to give 37 as a white powder (18.9 g, 43.0 mmol, 75%). Rf 0.73 
(EtOAc/hexane, 1/2); mp: 86˗88 °C; 1H NMR (300 MHz; CDCl3) δ 7.50–7.30 (5 H, m, 
Ar˗H), 5.49–5.51 (2 H, m, H1, H3), 5.35–5.32 (2 H, m, H2, H4), 4.57–4.53 (1 H, m, H5), 
4.31 (1 H, dd, J = 12.2, 5.7 Hz, H6a), 4.10 (1 H, dd, J = 12.2, 1.5 Hz, H6b), 2.16 (3 H, 
s, C(O)CH3), 2.08 (3 H, s, C(O)CH3), 2.06 (3 H, s, C(O)CH3), 2.03 (3 H, s, C(O)CH3); 
13C NMR (101 MHz; CDCl3) δ 170.5 (C(O)CH3), 169.9 (C(O)CH3), 169.8 (C(O)CH3), 
169.7 (C(O)CH3), 132.7 (Cq Bn), 132.1 (2C), 129.2 (2C), 128.1, 85.7 (C1), 70.9 (C3), 
69.6 (C5), 69.4 (C2), 66.4 (C4), 62.5 (C6), 20.9 (C(O)CH3), 20.7 (C(O)CH3), 20.7 
(C(O)CH3), 20.6 (C(O)CH3); HRMS (ES+) m/z [Found: (M+NH4)+ 458.1475 
C20H28NO9S requires (M+NH4)+, 458.1479]. These data were consistent with 
literature values.203 
11.1.5. Phenyl 1˗thio˗α˗D˗mannopyranoside 38 
To a stirred solution of 37 (7.1 g, 16.1 mmol, 1.0 equiv.) in 
anhydrous MeOH (50 mL), Na(s) (1.8 mg, 80 µmol, 0.005 
equiv.) dissolved in anhydrous MeOH (1 mL) was added 
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dropwise at room temperature. The mixture was stirred for 2 h, then neutralised with 
ion exchange Amberlite 120 (H+) resin (approximately 1.0 g, 5 min), filtered, and 
concentrated under reduced pressure. The residue was dried over P2O5 overnight to 
give 38 as a white foam (4.1 g, 15.2 mmol, 94%), which was used in the next step 
without further purification. Rf 0.05 (EtOAc/hexane, 1/2); 1H NMR (300 MHz; 
D6˗DMSO) δ 7.53 – 7.26 (5 H, m, Ar˗H), 5.33 (1 H, d, J = 1.1 Hz, H1), 5.17 (1 H, br 
s, C2˗OH), 4.93 (1 H, d, J = 4.4 Hz, C4˗OH), 4.87 (1 H, d, J 3.5 Hz, C3˗OH), 4.55 (1 
H, t, J = 5.7 Hz, C6˗OH), 3.88 (1 H, br s, H2), 3.77 (1 H, app. t, J = 6.4 Hz, H5), 3.66 
(1 H, dd, J = 11.8, 3.5 Hz, H6a), 3.55 – 3.41 (3 H, m, H3, H4, H6b); 13C NMR (101 MHz; 
D6˗DMSO) δ 135.4 (Cq), 131.5 (2C), 129.5 (2C), 127.5, 89.4 (C1), 75.9 (C5), 72.4 
(C2), 72.0 (C3), 67.5 (C4), 61.4 (C6); HRMS (ES+) m/z [Found: (M+NH4)+ 290.1061 
C12H20NO5S requires (M+NH4)+, 290.1062]. These data were consistent with 
literature values.203 
11.1.6. Phenyl 4,6˗O˗benzylidene˗1˗thio˗α˗D˗mannopyranoside 39 
To a solution of 38 (4.6 g, 16.8 mmol, 1.0 equiv.) in anhydrous 
DMF (60 mL), were added successively, with stirring at 0 °C, 
benzaldehyde dimethyl acetal (2.52 mL, d = 1.014, 16.8 mmol, 
1.0 equiv.) and HBF4.Et2O (2.31 mL, d = 1.18, 16.8 mmol, 1.0 equiv.). The mixture 
was stirred at room temperature overnight and then neutralised with Et3N (9 mL). 
The residue, a yellow˗orange solid was crystallised from absolute EtOH (~ 20 mL) to 
give 39 (4.1 g, 11.4 mmol, 67%) as a white powder. Rf 0.22 (EtOAc/hexane, 1/2); 
m.p. 201˗203 °C; 1H NMR (300 MHz; D6˗DMSO) δ 7.51–7.32 (10H, m, Ar˗H), 5.64 
(1H, s, CHPh), 5.59 (1 H, d, J = 4.1 Hz, C2˗OH), 5.46 (1 H, s, H1), 5.26 (1H, dd, J = 
6.1 Hz, C3˗OH), 4.13–4.03 (2 H, m, H5, H6a), 4.03 – 3.97 (1 H, m, H2), 3.94 (1 H, app. 
t, J = 8.9 Hz, H4), 3.77 (1 H, app. t, J = 11.0 Hz, H6b), 3.75 – 3.70 (1 H, m, H3); 13C 
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NMR (101 MHz; D6˗DMSO) δ 138.3 (Cq), 134.2 (Cq), 131.8 (2C), 129.7 (2C), 129.3, 
128.5 (2C), 127.9, 126.9 (2C), 101.7 (CHPh), 89.8 (C1), 79.0 (C4), 72.9 (C2), 68.6 
(C3), 68.1 (C6), 65.8 (C5); HRMS m/z (ES+) [Found: (M+H)+ 361.1107 C19H21O5S1 
requires (M+H)+, 361.1104]. These data are consistent with literature values.203 
11.1.7. Phenyl 
2,3˗di˗O˗benzyl˗4,6˗O˗benzylidene˗1˗thio˗α˗D˗mannopyranoside 40 
A solution of 39 (2.8 g, 7.76 mmol, 1.0 
equiv.) in DMF (55 mL) was added to a 
suspension of NaH (60% in mineral oil, 
835 mg, 20.9 mmol, 2.7 equiv.) in DMF (5 mL) at 0 °C and the mixture was stirred 
for 30 min. BnBr (2.48 mL, d= 1.438, 20.9 mmol, 2.7 equiv.) was then added to the 
reaction, which was warmed to room temperature and left stirring overnight. The 
reaction was quenched with MeOH (5 mL) and solvent removed in vacuo. The 
resulting oil was reconstituted between CH2Cl2 (50 mL) and H2O (50 mL), and the 
aqueous layer was extracted with CH2Cl2 (3 x 70 mL). The combined organic layers 
were washed with brine (3 x 50 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure furnishing a yellow oil. Purification by Reveleris® automated 
silica gel flash column chromatography (liquid injection onto column), eluting with 
EtOAc/hexane (0/100, 5/95 and 90/10) afforded a colourless oil. Crystallisation from 
MeOH yielded 40 (3.1 g, 5.7 mmol, 74%) as white crystals. Rf 0.35 (EtOAc/hexane, 
1/2); 1H NMR (400 MHz; CDCl3) δ 7.55 – 7.49 (2 H, m, Ar˗H), 7.41–7.27 (18 H, m, 
Ar˗H), 5.65 (1 H, s, CHPh), 5.51 (1 H, d, J = 0.6 Hz, H1), 4.82 (1 H, d, J = 12.2 Hz, 
CH2Ph˗attached to C3), 4.73 (2 H, s, CH2Ph˗attached to C2), 4.65 (1 H, d, J = 12.2 
Hz, CH2Ph˗attached to C3), 4.36–4.19 (3 H, m, H4, H5, H6a), 4.05 (1 H, dd, J = 2.9, 
1.2 Hz, H2), 3.96 (1 H, dd, J = 9.4, 3.1 Hz, H3), 3.89 (1 H, app. t, J = 9.7 Hz, H6b); 13C 
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NMR (75 MHz; CDCl3) δ 138.4 (Cq), 137.7 (Cq), 137.6 (Cq), 133.8 (Cq), 131.6, 129.2, 
128.9, 128.5, 128.4, 128.25, 128.2, 127.9, 127.7, 126.1, 101.5 (CHPh), 87.1 (C1), 
79.1 (C4), 78.0 (C2), 76.2 (C3), 73.1 (CH2Ph˗attached to C3), 73.0 (CH2Ph˗attached 
to C2), 68.5 (C6), 65.5 (C5); HRMS (ES+) m/z [Found: (M+NH4)+ 558.2304 
C33H36NO5S requires (M+NH4)+, 558.2309]. These data were consistent with 
literature values.204 
43 was isolated as white crystals (15 mg, 33 µmol, 4%). Rf 0.25 (EtOAc/hexane, 1/2); 
1H NMR (400 MHz; CDCl3) δ 7.55 – 7.26 (15 H, m, Ar˗H), 5.58 (2 H, s, H1, CHPh), 
4.75 (1 H, d, J = 11.6 Hz, CH2Ph˗attached to C2), 4.64 (1 H, d, J = 11.6 Hz, 
CH2Ph˗attached to C2), 4.31 (1 H, app. td, J = 9.7, 4.9 Hz, H5), 4.22 (1 H, dd, J = 
10.2, 4.9 Hz, H6a), 4.12 – 4.14 (2 H, m, H2, H3), 3.99 (1 H, app. t, J = 9.5 Hz, H4), 
3.84 (1 H, app. t, J = 10.2 Hz, H6b), 2.47 (1 H, d, J = 7.8 Hz, C3˗OH); 13C NMR (101 
MHz; CDCl3) δ 137.3 (Cq), 133.7 (Cq), 131.8 (Cq), 129.2, 129.2, 128.7, 128.3, 128.2, 
128.1, 127.8, 126.3, 102.2 (CHPh), 86.3 (C1), 80.1 (C3), 79.6 (C4), 73.2 
(CH2Ph˗attached to C2), 69.1 (C2), 68.5 (C6), 64.7 (C5). These data were consistent 
with literature values.206 
11.1.8. Phenyl 2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside 41 
A mixture of 40 (2.8 g, 5.18 mmol, 1.0 equiv.) and 
p˗TsOH.H2O (197 mg, 1.03 mmol, 0.2 equiv.) in MeOH (21 
mL) was heated at reflux (85 °C) for 2 h. The solution was then 
cooled to room temperature and quenched with Et3N (2 mL, pH ~ 7). The solvent 
was evaporated under reduced pressure and the crude product was dissolved in 
CH2Cl2 (80 mL). The organic layer was washed with H2O (2 x 50 mL), saturated 
aqueous NaHCO3 (2 x 50 mL) and brine (1 x 50 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure furnishing a colourless oil. The residue was 
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purified by Reveleris® automated silica gel flash column chromatography (liquid 
injection onto column), eluting with EtOAc/hexane (0/100, 30/70, 50/50 and 100/0) 
to afford 41 (1.7 g, 3.76 mmol, 72%) as a white solid. Rf 0.09 (EtOAc/hexane, 1/2); 
1H NMR (300 MHz; CDCl3) δ 7.43 – 7.20 (15 H, m, Ar˗H), 5.51 (1 H, d, J = 1.2 Hz, 
H1), 4.60 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C2), 4.50 (2 H, s, CH2Ph˗attached 
to C3), 4.49 (1 H, d, J = 12.1 Hz, CH2Ph˗attached to C2), 4.18–4.10 (1 H, m, H4), 
4.09 – 4.02 (1 H, m, H5), 3.92 (1 H, dd, J = 2.9, 1.5 Hz, H2), 3.80 (2 H, m, H6a,b), 3.67 
(1 H, dd, J = 9.2, 3.0 Hz, H3), 3.59 (1 H, d, J = 3.2 Hz, C4˗OH), 2.86 (1 H, t, J = 5.7 
Hz, C6˗OH); 13C NMR (75 MHz; CDCl3) δ 138.0 (Cq), 137.8 (Cq), 134.2 (Cq), 131.9, 
129.2, 128.6, 128.5, 128.2, 128.1, 128.0, 127.9, 127.7, 86.1 (C1), 79.6 (C3), 75.9 
(C2), 73.8 (C5), 72.3 (CH2Ph˗attached to C2), 72.1 (CH2Ph˗attached to C3), 67.0 
(C4), 62.3 (C6); HRMS (ES+) m/z [Found: (M+NH4)+ 470.1993 C26H32NO5S requires 
(M+NH4)+, 470.1996]. These data were consistent with literature values.205 
11.1.9. Phenyl 2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannuronic acid 42 
To a vigorously stirred solution of 41 (500 mg, 1.10 mmol, 1.0 
equiv.) in CH2Cl2 (1.3 mL) and H2O (3.5 mL) was added 
TEMPO (34 mg, 0.22 mmol, 0.2 equiv.) and BAIB (886 mg, 
2.75 mmol, 2.5 equiv.). Stirring was continued for 3h, and the 
reaction mixture was quenched by the addition of 10% aq. Na2S2O3 solution (12 mL) 
and diluted with CH2Cl2 (20 mL). The organic layer was separated and the aqueous 
phase was acidified with 1.0 M aq. HCl to pH = 4, extracted with CH2Cl2 (3 x 20 mL) 
and the combined organic layers dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude oil was purified by Reveleris® automated silica gel flash 
column chromatography (liquid injection onto column), eluting with MeOH/CH2Cl2 
(0/100, 5/95, 10/90 + 2% (v/v) AcOH) to afford the uronic acid 42 (308 mg, 0.66 mmol, 
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60%) as a white foam. Rf 0.18 (EtOAc/petroleum ether, 1/1 + 2% (v/v) AcOH); 1H 
NMR (300 MHz; CDCl3) δ 7.44 – 7.24 (15 H, m, Ar˗H), 5.59 (1 H, d, J = 1.7 Hz, H1), 
4.65 (1 H, d, J = 11.9 Hz, CH2Ph˗attached to C2), 4.64 (1 H, d, J = 11.8 Hz, 
CH2Ph˗attached to C3), 4.57 (1 H, d, J = 8.5 Hz, H5), 4.56 (1 H, d, J = 11.7 Hz, 
CH2Ph˗attached to C2), 4.54 (1 H, d, J = 12.1 Hz, CH2Ph˗attached to C3), 4.33 (1 H, 
app. t, J = 9.1 Hz, H4), 3.92 (1 H, d, J = 3.5 Hz, H2), ) 3.71 (1 H, dd, J = 9.0, 2.8 Hz, 
H3); 13C NMR (75 MHz; CDCl3) δ 172.9 (C(O)OH), 137.6 (Cq), 137.4 (Cq), 133.2 (Cq), 
131.7, 131.3, 129.3, 128.6, 128.5, 128.1, 128.0, 128.0, 127.9, 85.9 (C1), 78.1 (C3), 
75.6 (C2), 72.6 (C5), 72.4 (CH2Ph˗attached to C2 or C3), 71.7 (CH2Ph˗attached to 
C2 or C3), 68.3 (C4); HRMS (ES+) m/z [Found: (M+NH4)+ 484.1784 C26H26O6SNH4 
requires (M+NH4)+, 484.1788]. These data were consistent with literature values.211 
11.1.10. Phenyl 2,3˗di˗O˗benzyl˗6˗O˗acetyl˗1˗thio˗α˗D˗mannopyranoside 
44 
To a stirred solution of 40 (2.0 g, 3.70 mmol, 1.0 equiv.) in aq. 
AcOH (15 mL, 60%, v/v) was heated to reflux (120 °C) for 6h. 
The solution was then cooled to room temperature and 
quenched with sat. aq. NaHCO3 solution (20 mL). The aqueous layer was extracted 
with CH2Cl2 (3 x 15 mL), and the combined organic layers were washed with brine 
(25 mL), dried over MgSO4, filtered and concentrated under reduced pressure. 
Purification using silica gel flash column chromatography, eluting with 
EtOAc/petroleum ether (20/80, 50/50, 90/10) afforded 41 (519 mg, 1.15 mmol, 31%) 
and 44 (238 mg, 0.48 mmol, 13%) as a colourless oils. Rf 0.46 (EtOAc/petroleum 
ether, 1/2); 1H NMR (400 MHz; CDCl3) δ 7.47 – 7.24 (15 H, m, Ar˗H), 5.61 (1 H, d, J 
= 1.1 Hz, H1), 4.69 (1 H, d, J = 12.2 Hz, CH2Ph), 4.57 (1 H, d, J = 11.8 Hz, CH2Ph), 
4.53 (1 H, d, J = 12.3 Hz, CH2Ph), 4.50 (1 H, d, J = 11.7 Hz, CH2Ph), 4.43 (1 H, dd, 
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J = 12.0, 5.7 Hz, H6a), 4.34 (1 H, dd, J = 12.0, 2.1 Hz, H6b), 4.27 (1 H, ddd, J = 9.5, 
5.7, 1.9 H5), 4.01 (1 H, app. t, J = 9.6 Hz, H4), 4.01 (1 H, dd, J = 2.9, 1.3 Hz, H2), 3.68 
(1 H, dd, J = 9.5, 3.1 Hz, H3), 2.64 (1 H, br. s, ), 2.04 (3 H, s, C(O)CH3); 13C NMR 
(101 MHz; CDCl3) δ 171.2 (C(O)CH3), 137.6 (Cq), 134.0 (Cq), 131.6 (Cq), 129.0, 
128.6, 128.4, 128.0, 127.9, 127.9, 127.8, 127.6, 85.6 (C1), 79.3 (C3), 75.4 (C2), 71.9 
(CH2Ph), 71.8 (CH2Ph), 71.5 (C5), 66.7 (C4), 63.6 (C6), 20.8 (C(O)CH3); HRMS 
(ES+) m/z [Found: (M+NH4)+ 512.2095 C28H34NO6S requires (M+NH4)+, 512.2101]; 
These data were consistent with literature values.252 
11.1.11. Methyl (phenyl 2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) 
uronate 54 
To a stirred solution of 42 (2.6 g, 5.57 mmol, 1.0 equiv.) in DMF 
(8 mL) was added MeI (867 µL, d = 2.28, 13.9 mmol, 2.5 
equiv.) and K2CO3 (770 mg, 5.57 mmol, 1.0 equiv.). The 
reaction mixture was stirred overnight and quenched by the addition of MeOH (1 
mL).The solvents were removed in vacuo and the crude was taken up in EtOAc (100 
mL) and washed with H2O (100 mL). The aqueous layer was extracted with EtOAc 
(50 mL), and the combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Purification by Reveleris® automated silica gel 
flash column chromatography (liquid injection onto column), eluting with 
EtOAc/hexane (0/100, 5/95, 20/80, 70/30, 100/0) afforded 54 as a colourless oil (2.1 
g, 4.29 mmol, 77%). Rf 0.38 (EtOAc /hexane, 1/2); 1H NMR (300 MHz; CDCl3) δ 7.49–
7.24 (15  H, m, Ar˗H), 5.62 (1 H, d, J = 2.4 Hz, H1), 4.69 (1 H, d, J = 12.1 Hz, CH2Ph), 
4.65 (1 H, d, J = 8.8 Hz, H5), 4.64 (1 H, d, J = 12.3 Hz, CH2Ph), 4.59 (1 H, d, J = 11.6 
Hz, CH2Ph), 4.56 (1 H, d, J = 12.1 Hz, CH2Ph), 4.38 (1 H, app. td, J = 8.9, 2.3 Hz, 
H4), 3.95 (1 H, app. t, J = 2.7 Hz, H2), 3.76 (3 H, s, C(O)OCH3), 3.71 (1 H, dd, J = 
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8.9, 2.9 Hz, H3), 3.09 (1 H, d, J = 2.4 Hz, C4˗OH); 13C NMR (75 MHz; CDCl3) δ 170.4 
(C(O)OCH3), 137.9 (Cq), 137.7 (Cq), 133.7 (Cq), 131.5, 129.2, 128.5, 128.45, 128.04, 
127.9, 127.9, 127.7, 86.1 (C1), 78.1 (C3), 75.6 (C2), 72.7 (C5), 72.5 (CH2Ph), 72.3 
(CH2Ph), 68.5 (C4), 52.7 (C(O)OCH3); HRMS m/z (ES+) [Found: (M+H)+ 481.1684 
C27H29O6S requires (M+H)+, 481.1685]. These data were consistent with literature 
values.211 
11.1.12. Methyl (phenyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) uronate 55 
Uronate 54 (200 mg, 0.42 mmol, 1.0 equiv.) was dissolved in 
pyridine/ Ac2O (3/1) solution (4 mL) and stirred for 3 h, 
followed by the addition of MeOH (1 mL). The solvents were 
then removed under reduced pressure and the crude taken up in CH2Cl2 (50 mL). 
The organic layer was washed with 1.0 M aq. HCl (2 x 40 mL) and sat. aq. NaHCO3 
solution (50 mL). The organic layer was dried over MgSO4, filtered and concentrated 
under reduced pressure furnishing a colourless oil. The crude was then purified by 
Reveleris® automated silica gel flash column chromatography (liquid injection onto 
column), eluting with EtOAc/hexane (0/100, 30/70, 50/50 and 100/0) to afford 55 as 
a white solid (158 mg, 0.30 mmol, 72%). Rf 0.09 (EtOAc/hexane, 1/2); 1H NMR (300 
MHz; CDCl3) δ 7.64 – 7.23 (15 H, m, Ar˗H), 5.80 (1 H, d, J = 7.1 Hz, H1), 5.56 (1 H, 
dd, J = 5.9, 4.6 Hz, H4), 4.62 (1 H, d, J = 11.9 Hz, CH2Ph), 4.59 (1 H, d, J = 12.1 Hz, 
CH2Ph),  4.56 (1 H, d, J = 4.2 Hz, H5), 4.50 (1 H, d, J = 11.9 Hz, CH2Ph), 4.55 (1H, 
d, J = 12.3 Hz, CH2Ph),  3.80 (1 H, dd, J = 6.0, 2.9 Hz, H3), 3.74 (1 H, bd, J = 4.8 Hz, 
H2), 3.59 (3H, s, CO2CH3), 2.02 (3 H, s, C(O)CH3); 13C NMR (75 MHz; CDCl3) δ 169.8 
(C=O of C(O)CH3 or CO2CH3), 168.5 (C=O of C(O)CH3 or CO2CH3), 137.5 (Cq), 
137.4 (Cq), 133.7 (Cq), 131.0, 128.9, 128.4, 128.2, 128.0, 127.9, 127.2, 82.9 (C1), 
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73.9 (C2, C3), 72.8 (C5), 72.4 (2 x CH2Ph), 69.5 (C4), 52.4 (CO2CH3), 20.9 
(C(O)CH3); 13C˗GATED (126 MHz; CDCl3): 82.9 (1JC1˗H1 =164 Hz, C1); HRMS (ES+) 
m/z  [Found: (M+H)+ 523.1780 C29H31O7S requires (M+H)+, 523.1785]. These data 
were consistent with literature values.211 
11.1.13. Methyl (phenyl 
4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) uronate 56 
To a mixture of 54 (500 mg, 1.04 mmol, 1.0 equiv.) and Lev2O 
(250 µL, d = 1.35, 1.56 mmol, 1.5 equiv.) in CH2Cl2 (5 mL) was 
added pyridine (252 µL, d = 0.978, 3.12 mmol, 3.0 equiv.). The 
reaction mixture was left stirring at room temperature for 18 h. Upon completion of 
the reaction, the mixture was diluted with CH2Cl2 (50 mL), and the organic layer was 
washed successively with 1.0 M aq. HCl (2 x 30 mL) and sat. aq. NaHCO3 solution 
(2 x 30 mL). The organic layer was dried over MgSO4, filtered and concentrated 
under reduced pressure furnishing a colourless oil. The crude was purified using 
silica gel flash column chromatography, eluting with EtOAc/hexane (30/70, 40/60, 
50/50, 90/10) to afford 56 as a colourless oil (530 mg, 0.92 mmol, 88%). Rf 
(EtOAc/hexane, 1/2); 1H NMR (400 MHz; CDCl3) δ 7.55 – 7.24 (15 H, m, Ar˗H), 5.78 
(1 H, d, J = 7.2 Hz, H1), 5.57 (1 H, dd, J = 5.9, 4.6 Hz, H4), 4.64 (1 H, d, J = 11.8 Hz, 
CH2Ph), 4.59 (1 H, d, J = 12.2 Hz, CH2Ph), 4.56 (1 H, d, J = 11.9 Hz, CH2Ph), 4.55 
(1 H, d, J = 3.8 Hz, H5), 4.53 (1 H, d, J = 11.7 Hz, CH2Ph), 3.86 (1 H, dd, J = 5.9, 2.8 
Hz, H3), 3.75 (1 H, d, J = 6.1 Hz, H2), 3.58 (3 H, s, CO2CH3), 2.74 – 2.69 (2 H, m, 
CH2 Lev), 2.57 – 2.51 (2 H, m, CH2 Lev), 2.18 (3 H, s, CH3 Lev); 13C NMR (101 MHz; 
CDCl3) δ 206.1 (C=O Lev ketone), 171.6 (C=O Lev or CO2CH3), 168.5 (C=O Lev or 
CO2CH3), 137.7 (Cq), 137.5 (Cq), 133.8 (Cq), 131.1, 128.9, 128.4, 128.1, 127.9, 
127.8, 127.8, 127.2, 82.9 (C1), 74.3 (C2), 73.9 (C3), 72.8 (C5), 72.6 (CH2Ph), 72.4 
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(CH2Ph), 69.8 (C4), 52.3 (CO2CH3), 37.8 (CH2 Lev), 29.8 (CH3 Lev), 28.0 (CH2 Lev); 
13C˗GATED (101 MHz; CDCl3): 82.9 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: 
(M+NH4)+ 596.2338 C32H38NO8S requires (M+NH4)+, 596.2313]; These data were 
consistent with literature values.211 
11.1.14. Methyl (phenyl 4˗O˗tert˗butyl 
dimethylsilyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) uronate 57 
To a mixture of 54 (100 mg, 0.21 mmol, 1.0 equiv.), 
imidazole (mg, 0.62 mmol, 3.0 equiv.) and DMAP (42mg, 
0.62 mmol, 0.5 equiv.) in DMF (2 mL) was added 
TBDMSOTf (144 µL, d = 1.151, 0.62 mmol, 3.0 equiv.). The reaction mixture was left 
stirring overnight at room temperature and was quenched with H2O (1 mL). The 
mixture was concentrated under reduced pressure, and the remaining crude was 
reconstituted in CH2Cl2 (25 mL) and H2O (20 mL). The organic layer was washed, 
separated, dried over MgSO4, filtered and concentrated under reduced pressure to 
furnish a colourless oil. Purification by silica gel flash column chromatography, eluting 
with EtOAc/hexane (0/100, 5/95, 10/90) afforded 31, as a colourless oil (120 mg, 
0.20 mmol, 96%). Rf 0.77 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +22.3 (c. 4.65, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 7.62 – 7.20 (15 H, m, Ar˗H), 5.68 (1 H, d, J = 7.4 Hz, H1), 4.58 
(1 H, d, J = 11.8 Hz, CH2Ph), 4.55 (1 H, d, J = 11.5 Hz, CH2Ph), 4.50 (1 H, d, J = 
11.9 Hz, CH2Ph), 4.42 (1 H, d, J = 12.0 Hz, CH2Ph), 4.40 – 4.35 (2 H, m, H4, H5), 
3.81 (1 H, dd, J = 7.5, 2.6 Hz, H2), 3.60 (3 H, s, CO2CH3), 3.54 (1 H, dd, J = 5.6, 2.7 
Hz, H3), 0.80 (9 H, s, C(CH3)3), 0.00 (3 H, s, Si(CH3)2), ˗0.08 (3 H, s, Si(CH3)2); 13C 
NMR (101 MHz; CDCl3) δ 169.7 (CO2CH3), 138.0 (Cq), 137.9 (Cq), 134.0 (Cq), 131.3, 
128.8, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 127.0, 82.9 (C1), 77.3 (C3), 76.4 
(C4), 73.7 (C2), 72.5 (CH2Ph), 72.5 (CH2Ph), 69.7 (C5), 52.0 (CO2CH3), 25.7 
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(C(CH3)3), 18.0 (C(CH3)3), ˗4.7 (Si(CH3)2), ˗5.2 (Si(CH3)2); 13C˗GATED (101 MHz; 
CDCl3): 82.9 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+NH4)+ 612.2832 
C33H46NO6SSi requires (M+NH4)+, 612.2810]. 
11.1.15. 3˗bromopropyl (methyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) uronate 58 
A solution of 55 (100 mg, 0.19 mmol, 1.0 equiv.), Ph2SO 
(50 mg, 0.25 mmol, 1.3 equiv.) and TTBP (125 mg, 0.48 
mmol, 2.5 equiv.) in CH2Cl2 (5 mL) was stirred over 
activated MS4Å for 40 min. The mixture was cooled to ˗60 °C and Tf2O (41 µL, d = 
1.720, 0.25 mmol, 1.3 equiv.) was then added. The mixture was allowed to warm to 
˗40 oC over 10 min. followed by cooling to ˗90 °C, upon 3˗bromopropanol (26 µL, d = 
1.537, 0.29 mmol, 1.5 equiv.) in CH2Cl2 (0.7 mL) was added. The reaction mixture 
was allowed to warm to room temperature, and stirring was continued for 1 h. After 
the addition of Et3N to pH = 7, the organic layer was washed with H2O (10 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. Purification using 
silica gel flash column chromatography, eluting with EtOAc/hexane (20/80, 50/50, 
90/10) afforded 58 as white crystals (72 mg, 0.13 mmol, 67%). Rf 0.37 
(EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗121 (c. 0.95, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.47–
7.21 (10 H, m, Ar˗H), 5.52 (1 H, app. t, J = 9.4 Hz, H4), 4.92 (1 H, d, J = 12.6 Hz, 
CH2Ph˗attached to C2), 4.81 (1 H, d, J = 12.6 Hz, CH2Ph˗attached to C2), 4.51 (1 H, 
d, J =12.3 Hz, CH2Ph˗attached to C3), 4.45 (1 H, d, J = 0.8 Hz, H1), 4.38 (1 H, d, J = 
12.3 Hz, CH2Ph˗attached to C3), 4.06 (1 H, dt, J = 9.9, 5.3 Hz, OCH2CH2CH2Br), 
3.89 (1 H, d, J = 2.4 Hz, H2), 3.86 (1 H, d, J = 9.3 Hz, H5), 3.72 (3 H, s, CO2CH3), 
3.61 (1 H, ddd, J = 9.7, 8.2, 4.7 Hz, OCH2CH2CH2Br), 3.56–3.42 (3 H, m, H3, 
OCH2CH2CH2Br) 2.22 (1 H, tdt, J 8.1, 5.6, 4.1 Hz, OCH2CH2CH2Br), 2.09 (1 H, dddd, 
156 
 
J = 14.6, 7.3, 5.1, 2.1 Hz, OCH2CH2CH2Br), 2.02 (3 H, s, C(O)CH3); 13C NMR (101 
MHz; CDCl3) δ 169.6 (C(O)OCH3), 168.0 (C(O)CH3), 138.3 (Cq), 137.8 (Cq), 131.1, 
129.3, 128.4, 128.1, 127.8, 127.6, 127.4, 124.8, 101.6 (C1), 78.2 (C3), 73. 9 
(CH2Ph˗attached to C2), 73.7 (C5), 73.2 (C2), 71.6 (CH2Ph˗attached to C3), 69.0 
(C4), 67.8 (OCH2CH2CH2Br), 52.6 (CO2CH3), 32.7 (OCH2CH2CH2Br), 30.4 
(OCH2CH2CH2Br), 20.8 (C(O)CH3); 13C˗GATED (126 MHz; CDCl3): 101.6 (1JC1˗H1 = 
156 Hz, C1); HRMS (ES+) m/z [Found: (M+NH4)+ 568.1539 C26H35BrNO8 requires 
(M+NH4)+, 568.1541]; IR νmax/cm˗1 1745 (s, C=O), 1045 (s, C˗Oester), 1145 (s, 
C˗Oether), 695 (s, C˗Br). 
11.1.16. 3˗azidopropyl (methyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) uronate 59 
Compound 58 (30 mg, 54 µmol, 1.0 equiv.) and NaN3 
(21 mg, 0.33 mmol, 6.0 equiv.) were dissolved in 
acetone (3 mL) and the reaction mixture was stirred for 
2 days at 50 °C. Upon completion, the reaction mixture was cooled to room 
temperature and petroleum ether (40 mL) was added. The organic layer was washed 
with H2O (30 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to afford 59 as a white solid (27 mg, 52 µmol, 97%). Rf 0.60 (EtOAc/toluene, 
3/7); 1H NMR (400 MHz; CDCl3) δ 7.54 – 7.11 (10 H, m, Ar˗H), 5.52 (1 H, app. t, J = 
9.3 Hz, H4), 4.92 (1H, d, J = 12.5 Hz, CH2Ph˗attached to C2), 4.81 (1 H, d, J = 12.6 
Hz, CH2Ph˗attached to C2), 4.51 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.43 
(1 H, s, H1), 4.37 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.09–4.00 (1 H, m, 
OCH2CH2CH2N3), 3.89 (1 H, d, J = 2.6 Hz, H2), 3.85 (1 H, d, J = 9.3 Hz, H5), 3.72 (3 
H, s, CO2CH3), 3.56– 3.47 (2 H, m, H3, OCH2CH2CH2N3), 3.39 (2 H, t, J = 6.6 Hz, 
OCH2CH2CH2N3), 2.02 (3 H, s, C(O)CH3), 1.90 – 1.81 (2 H, m, OCH2CH2CH2N3); 13C 
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NMR (101 MHz; CDCl3) δ 169.6 (CO2CH3),168.0 (C(O)CH3), 138.3 (Cq), 137.8 (Cq), 
128.4, 128.3, 128.1, 127.7, 127.6, 127.5, 101.5 (C1), 78.2 (C3), 73.9 
(CH2Ph˗attached to C2), 73.7 (C5), 73.2 (C2), 71.6 (CH2Ph˗attached to C3), 69.0 
(C4), 67.0 (1C, OCH2CH2CH2N3), 52.6 (CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 
(OCH2CH2CH2N3), 20.8 (C(O)CH3). These data were consistent with literature 
values.211 
11.1.17. 3˗azidopropyl (methyl 2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) 
uronate 60 
To a stirred solution of 59 (100 mg, 0.19 mmol, 1.0 equiv.) 
in anhydrous MeOH (3 mL), Na (45 µg, 1.9 µmol, 0.01 
equiv.) dissolved in anhydrous MeOH (0.5 mL) was 
added dropwise at room temperature. The mixture was stirred for 24 h, then 
neutralised with ion exchange Amberlite 120 (H+) resin (approximately 50 mg, 5 min), 
filtered, and concentrated under reduced pressure. Flash column chromatography, 
eluting with EtOAc/hexane (20/80, 50/50, 90/10) afforded 60 as a colourless oil (78 
mg, 0.16 mmol, 87%). Rf 0.42 (EtOAc/toluene, 3/7); 1H NMR (400 MHz; CDCl3) δ 
7.48 – 7.23 (10 H, m, Ar˗H), 4.94 (1 H, d, J =12.4 Hz, CH2Ph), 4.78 (1 H, d, J = 12.5 
Hz, CH2Ph), 4.57 (1 H, d, J = 12.0 Hz, CH2Ph), 4.51 (1 H, d, J = 12.0 Hz, CH2Ph), 
4.43 (1 H, d, J = 0.6 Hz, H1), 4.30 (1 H, app. t, J = 9.5 Hz, H4), 4.04 (1 H, dt, J = 9.7, 
5.6 Hz, OCH2CH2CH2N3), 3.88 (1 H, d, J = 2.8 Hz, H2), 3.81 (3 H, s, CO2CH3), 3.76 
(1 H, d, J = 9.6 Hz, H5), 3.57 (1 H, ddd, J = 9.7, 7.8, 5.1 Hz, OCH2CH2CH2N3), 3.40 
(2 H, t, J = 6.7 Hz, OCH2CH2CH2N3), 3.36 (1 H, dd, J = 9.5, 3.0 Hz, H3), 2.97 (1 H, 
br. s, C4˗OH), 2.00 – 1.82 (2 H, m, OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 
169.8 (CO2CH3), 138.4 (Cq), 137.9 (Cq), 128.5, 128.3, 128.2, 127.8, 127.7, 127.6, 
102.1 (C1), 80.4 (C3), 75.1 (C5), 74.3 (CH2Ph), 73.7 (C2), 71.9 (CH2Ph), 68.3 (C4), 
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66.9 (OCH2CH2CH2N3), 52.6 (CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 
(OCH2CH2CH2N3); 13C˗GATED (126 MHz; CDCl3): 102.1 (1JC1˗H1 = 156 Hz, C1); 
HRMS (ES+) m/z [Found: (M+NH4)+ 489.2354 C24H33N4O7N requires (M+NH4)+, 
489.2344]. These data are consistent with literature values.211 
11.1.18. O˗benzyl (phenyl 2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) 
hydroxamate 61 
To a mixture of 42 (700 mg, 1.50 mmol, 1.0 equiv.) and 
O˗benzylhydroxylamine hydrochloride (263 mg, 1.65 mmol, 1.1 
equiv.) in CH2Cl2 (5 mL) was added successively PyBOP (858 
mg, 1.65 mmol, 1.1 equiv.) and DIPEA (653 µL, d = 0.742, 3.75 
mmol, 2.5 equiv.). The reaction mixture was stirred at room temperature for 3 h. Upon 
completion of the reaction, the solvent was removed under reduced pressure and the 
crude material was purified using silica gel flash column chromatography, eluting with 
EtOAc/hexane (30/70, 40/60, 50/50, 90/10) to afford 61 as a colourless oil (772 mg, 
1.35 mmol, 90%). Rf 0.30 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +120 (c. 1.0, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 8.84 (1 H, br. s, C(O)NHOBn), 7.39 – 7.21 (20H, m, Ar˗H), 5.38 
(1 H, d, J = 1.4 Hz, H1), 4.87 (1 H, d, J = 11.1 Hz, CH2Ph˗attached to C3), 4.84 (1 H, 
d, J = 10.7 Hz, C(O)NHOCH2Ph), 4.83 (1 H, d, J =11.2 Hz, CH2Ph˗attached to C3), 
4.66 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C2), 4.64 (1 H, d, J = 12.0 Hz, 
C(O)NHOCH2Ph), 4.58 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C2), 4.54 (1 H, d, J 
= 9.7 Hz, H5), 4.30 (1 H, app. t, J = 9.5 Hz, H4), 3.90 (1 H, dd, J = 2.8, 1.8 Hz, H2), 
3.72 (1 H, dd, J = 9.2, 3.0 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 168.4 (C(O)NHOBn), 
138.5 (Cq), 137.9 (Cq), 134. 9 (Cq), 133.1 (Cq), 132.2, 129.5, 129.4, 128.9, 128.7, 
128.5, 128.5, 128.5, 128.2, 128.1, 128.0, 127.95, 127.9, 127.8, 86.7 (C1), 78.4 
(C(O)NHOCH2Ph), 77.9 (C3), 76.7 (C2), 73.2 (CH2Ph˗attached to C3), 73.0 
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(CH2Ph˗attached to C2), 71.2 (C5), 69.8 (C4); HRMS (ES+) m/z  [Found: (M+H)+ 
572.2111 C33H34NO6S requires (M+H)+, 572.2107]; IR νmax/cm˗1 3313 (m, N˗H), 1659 
(s, C=O), 1071 (s, C˗Oether). 
11.1.19. O˗benzyl (phenyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 62 and 
O˗benzyl N˗acetyl (phenyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 63 
To a stirred solution of 61 (2.2 g, 
3.85 mmol, 1.0 equiv.) in CH2Cl2 (30 
mL) was added Ac2O (800 µL, d = 
1.08, 8.47 mmol, 2.2 equiv.) and 
pyridine (1.6 mL, d = 0.978, 19.2 
mmol, 5.0 equiv.). The reaction mixture was stirred for 16 h. CH2Cl2 (15 mL) was 
added and the organic layer was washed successively with 1.0 M aq. HCl (2 x 15 
mL), sat. aq. NaHCO3 solution (2 x 15 mL) and brine (15 mL). The organic layer was 
then dried over MgSO4 filtered and concentrated under reduced pressure to furnish 
a yellow oil. Purification using silica gel flash column chromatography, eluting with 
EtOAc/hexane (0/100, 30/70, 40/60, 90/10) afforded 62 as a white solid (1.6 g, 2.62 
mmol, 68%). Rf 0.60 (EtOAc/Toluene, 3/7); m.p. 143˗145 °C; [𝛼]𝐷
22 +31.4 (c. 0.95, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 8.54 (1 H, br. s, C(O)NHOBn), 7.44 – 7.15 (20 
H, m, Ar˗H), 5.59 (1 H, app. t, J = 8.7 Hz, H4), 5.37 (1 H, d, J = 2.8 Hz, H1), 4.86 (1 
H, d, J = 11.4 Hz, C(O)NHOCH2Ph), 4.76 (1 H, d, J = 11.4 Hz, C(O)NHOCH2Ph), 
4.66 (1 H, d, J 12.0 Hz, CH2Ph˗attached to C2 or C3), 4.64 (1 H, d, J =12.0 Hz, 
CH2Ph), 4.63 (1 H, d, J =11.6 Hz, CH2Ph), 4.57 (1 H, d, J = 8.6 Hz, H5), 4.56 (1 H, d, 
J = 12.0 Hz, CH2Ph), 3.89 (1 H, app. t, J = 2.8 Hz, H2), 3.80 (1 H, dd, J = 8.7, 2.8 Hz, 
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H3), 2.11 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 169.9 (C(O)CH3), 165.0 
(C(O)NHOBn), 137.6 (Cq), 137.6 (Cq), 135.1 (Cq), 132.6 (Cq), 132.3, 129.7, 129.3, 
128.7, 128.5, 128.5, 128.5, 128.2, 128.0, 127.9, 85.8 (C1), 78.2 (C(O)NHOCH2Ph), 
75.9 (C2), 75.7 (C3), 72.8 (CH2Ph), 72.6 (CH2Ph), 71.7 (C5), 69.2 (C4), 21.0 
(C(O)CH3); HRMS (ES+) m/z [Found: (M+H)+ 614.2205 C35H36NO7S requires 
(M+H)+, 614.2207]; IR νmax/cm˗1 3257 (m, N˗H), 1749 (s, C=Oester), 1676 (s, 
C=Oamide), 1454, 1494 (C=Caromatic),  1110 (s, C˗Oester), 1069 (s, C˗Oether). 
63 was isolated as a colourless oil (505 mg, 0.77 mmol, 20%). Rf 0.78 
(EtOAc/Toluene, 3/7); [𝛼]𝐷
22 +45.7 (c. 4.25, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.45 
– 7.20 (20 H, m, Ar˗H), 5.63 (1 H, app. t, J = 9.6 Hz, H4), 5.53 (1 H, d, J = 1.9 Hz, 
H1), 5.05 (2 H, s, C(O)NAcOCH2Ph) 4.82 (1 H, d, J = 9.7 Hz, H5), 4.67 (1 H, d, J = 
12.4 Hz, CH2Ph˗attached to C2), 4.62 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to C2), 
4.54 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.44 (1 H, d, J = 12.2 Hz, 
CH2Ph˗attached to C3), 3.95 (1 H, app. t, J = 1.7 Hz, H2), 3.72 (1 H, dd, J = 9.3, 1.8 
Hz, H3), 2.12 (3 H, s, NC(O)CH3), 1.83 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) 
δ 169.3 (C(O)CH3), 165.0 (NC(O)CH3), 145.6 (C(O)NAcOBn), 137.8 (Cq), 137.2 (Cq), 
133.5 (Cq), 131.9 (Cq), 128.5, 128.4, 128.4, 127.9, 127.9, 127.9, 127.8, 127.8, 127.8, 
127.7, 86.2 (C1), 76.8 (2C, C3, C(O)NAcOCH2Ph), 75.7 (C2), 72.3 (CH2Ph˗attached 
to C2), 71.9 (CH2Ph˗attached to C3), 70.2 (C5), 67.4 (C4), 20.8 (C(O)CH3), 20.1 
(NC(O)CH3); 13C˗GATED (101 MHz; CDCl3): 86.2 (1JC1˗H1 = 172 Hz, C1); HRMS 
(ES+) m/z  [Found: (M+NH4)+ 673.2567 C37H41N2O8S requires (M+NH4)+, 673.2578]; 




11.1.20. O˗benzyl (4˗O˗acetyl˗2,3˗di˗O˗benzyl˗ bicyclo [3.2.1˗O]) 
hydroxamate 64  
A solution of 62 (100 mg, 0.16 mmol, 1.0 equiv.), Ph2SO (53 mg, 
0.26 mmol, 1.6 equiv.) and TTBP (108 mg, 0.41 mmol, 2.5 equiv.) 
in CH2Cl2 (5 mL) was stirred over activated MS4Å for 30 min. The 
mixture was cooled to ˗60 °C and Tf2O (67 µL, d = 1.720, 0.41 
mmol, 2.5 equiv.) was then added. The mixture was allowed to warm to ˗40 °C over 
10 min. followed by re˗cooling to ˗90 °C, when 3˗bromopropanol (22 µL, d = 1.537, 
0.24 mmol, 1.5 equiv.) in CH2Cl2 (0.5 mL) was added. The reaction mixture was 
warmed to room temperature and stirring was continued for further 1 h. The reaction 
was quenched by the addition of Et3N until pH = 7 and the crude mixture was filtered 
through Celite® and concentrated under reduced pressure. The residue was purified 
by Reveleris® automated silica gel flash column chromatography (liquid injection onto 
column), eluting with EtOAc/hexane (0/100, 30/70, 50/50, 90/10) to afford compound 
64 as a colourless oil (50 mg, 0.1 mmol, 62%). Rf 0.28 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 
+21.0 (c. 1.10, CHCl3); 1H NMR (300 MHz; CDCl3) δ 7.71 – 7.21 (15 H, m, Ar˗H), 
5.80 (1 H, app. t, J = 1.2 Hz, H1), 5.06 (1 H, app. br. t, J = 1.9 Hz, H4), 4.94 (2 H, s, 
C(O)NOCH2Ph), 4.74 (1 H, app. t, J = 2.0 Hz, H5), 4.71 (1 H, d, J = 12.2 Hz, 
CH2Ph˗attached to C3), 4.56 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.54 (1 H, 
d, J = 12.2, Hz, CH2Ph˗attached to C2), 4.39 (1 H, d, J = 12.2, Hz, CH2Ph˗attached 
to C2), 3.85 (1 H, ddd, J = 4.8, 3.1, 1.6 Hz, H3), 3.65 (1 H, dd, J = 5.0, 1.6 Hz, H2), 
2.09 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 169.6 (C(O)CH3), 150.4 
(C(O)NOBn), 145.7, 137.8 (Cq), 137.5 (Cq), 137.3 (Cq), 131.1, 129.3, 128.5, 128.3, 
128.2, 128.2, 128.0, 127.8, 127.7, 127.7, 124.8, 104.6 (C1), 76.4 
(C(O)N(C1)OCH2Ph), 73.7 (C3), 73.0 (C5), 72.4 (CH2Ph˗attached to C3), 72.2 (C2), 
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71.1 (CH2Ph˗attached to C2), 69.1 (C4), 20.9 (C(O)CH3); HRMS (ES+) m/z  [Found: 
(M+H)+ 504.2009 C29H30NO7 requires (M+H)+, 504.2017]; IR νmax/cm˗1 1740 (s, 
C=Oester), 1701 (m, C=Oamide), 1223 (s, C˗Oester) 1065 (m, C˗Oether). 
11.1.21. O˗benzyl, N˗benzyl (phenyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 67 
N˗benzylation: To a stirred solution of 62 (900 mg, 1.47 mmol, 
1.0 equiv.) and K2CO3 (244 mg, 1.76 mmol, 1.2 equiv.)  in DMF 
(11 mL) was added BnBr (192 µL, d = 1.438, 1.62 mmol, 1.1 
equiv.) at room temperature. The reaction mixture stirred for 
15 h, diluted with EtOAc (40 mL), washed with H2O (40 mL) and brine (40 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. Purification of the 
crude product by Reveleris® automated silica gel flash column chromatography 
(liquid injection onto column), eluting with EtOAc/hexane (0/100, 5/95, 20/80 and 
90/10) afforded 67 as a colourless oil (435 mg, 0.62 mmol, 42%). 
C4˗OH Acetylation: To a stirred solution of 68 (1.0 g, 1.51 mmol, 1.0 equiv.) in CH2Cl2 
(15 mL) was added Ac2O (214 µL, d= 1.08, 2.27 mmol, 1.5 equiv.) and pyridine (367 
µL, d= 0.978, 4.53 mmol, 3.0 equiv.). After 16 h the reaction mixture was diluted with 
CH2Cl2 (30 mL) and washed with 1.0 M aq. HCl (30 mL), sat. aq. NaHCO3 solution 
(30 mL) and brine (30 mL). The organic layer was then dried over MgSO4, filtered 
and concentrated under reduced pressure. Purification using silica gel flash column 
chromatography, eluting with EtOAc/petroleum ether (10/90, 20/80, 30/70) afforded 
67 as a colourless oil (922 mg, 1.31 mmol, 87%). 
Rf 0.80 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +46.7 (c. 1.17, CHCl3); 1H NMR (400 MHz; CDCl3) 
δ 7.40 – 7.20 (25 H, m, Ar˗H), 5.73 (1 H, app. t, J = 9.6 Hz, H4), 5.55 (1 H, d, J = 2.0 
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Hz, H1), 5.42 (1 H, d, J = 11.9 Hz, C(O)N(CH2Ph)OBn), 5.35 (1 H, d, J = 12.0 Hz, 
C(O)N(CH2Ph)OBn), 5.00 (1 H, d, J = 12.5 Hz, C(O)N(Bn)OCH2Ph), 4.97 (1 H, d, J 
= 12.5 Hz, C(O)N(Bn)OCH2Ph), 4.65 (2 H, s, CH2Ph˗attached to C2), 4.63 (1 H, d, J 
= 9.8 Hz, H5), 4.57 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.49 (1 H, d, J = 
12.2 Hz, CH2Ph˗attached to C3), 3.98 (1 H, app. t, J = 2.5 Hz, H2), 3.74 (1 H, dd, J = 
9.4, 2.9 Hz, H3), 1.80 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 169.3 
(C(O)CH3), 150.7 (C(O)N(Bn)OBn), 137.9 (Cq), 137.9 (Cq), 137.8 (Cq), 137.2 (Cq), 
133.7 (Cq), 131.7, 129.1, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 127.7, 
127.7, 127.7, 127.6, 127.6, 86.2 (C1), 76.8 (C3), 76.4 (C(O)N(Bn)OCH2Ph), 76.0 
(C2), 73.2 (C(O)N(CH2Ph)OBn), 72.4 (CH2Ph˗attached to C2), 72.0 
(CH2Ph˗attached to C3), 71.3 (C5), 68.3 (C4), 20.7 (C(O)CH3); 13C˗GATED (101 
MHz; CDCl3): 86.2 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 704.2681 
C42H42NO7S requires (M+H)+, 704.2676]; IR νmax/cm˗1 1751 (m, C=Oester), 1639 (m, 
C=Oamide), 1496, 1454 (C=Caromatic), 1223 (s, C˗Oester), 1024 (s, C˗Oether).  
11.1.22. O˗benzyl, N˗benzyl 
(phenyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 68 
To a stirred solution of 61 (180 mg, 0.31 mmol, 1.0 equiv.) and 
K2CO3 (65.3 mg, 0.47 mmol, 1.5 equiv.)  in DMF (3.5 mL) was 
added BnBr (41.2 µL, d = 1.438, 0.35 mmol, 1.1 equiv.) at room 
temperature. The reaction mixture stirred for 16 h, diluted with 
EtOAc (60 mL), washed with H2O (50 mL) and brine (50 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. Purification of the crude product 
by Reveleris® automated silica gel flash column chromatography (liquid injection onto 
column), eluting with EtOAc/hexane (0/100, 5/95, 20/80 and 90/10) afforded 68 as a 




(c. 0.22, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.40 – 7.14 (25 H, m, Ar˗H), 5.59 (1 
H, d, J = 1.3 Hz, H1), 5.22 (1 H, d, J = 12.2 Hz, C(O)N(CH2Ph)OBn), 5.16 (1 H, d, J 
= 12.2 Hz, C(O)N(CH2Ph)OBn), 5.06 (1 H, d, J = 12.3 Hz, C(O)N(Bn)OCH2Ph), 5.00 
(1 H, d, J = 12.3 Hz, C(O)N(Bn)OCH2Ph), 4.71 (1 H, d, J = 11.9 Hz, CH2Ph), 4.69 (1 
H, d, J = 12.2 Hz, CH2Ph), 4.64 (1 H, d, J = 10.7 Hz, CH2Ph), 4.62 (2 H, d, J = 8.8 
Hz, H5), 4.59 (1 H, d, J = 11.6 Hz, CH2Ph), 4.43 (1 H, app. td, J = 9.6, 2.9 Hz, H4), 
3.96 (1 H, dd, J = 2.9, 1.6 Hz, H2), 3.66 (1 H, dd, J = 9.8, 3.0 Hz,  H3), 2.57 (1 H, d, J 
= 2.9 Hz, C4˗OH); 13C NMR (101 MHz; CDCl3) δ 151.8 (C(O)N(Bn)OBn), 138.2 (Cq), 
137.9 (Cq), 137.7 (Cq), 136.7 (Cq), 134.0 (Cq), 130.8, 129.2, 128.5, 128.4, 128.4, 
128.2, 128.0, 127.94, 127.9, 127.8, 127.7, 127.4, 86.3 (C1), 78.2 (C3), 77.2 (C2), 
76.5 (C(O)N(Bn)OCH2Ph), 72.8 (CH2Ph), 72.6 (CH2Ph), 72.3 (C(O)N(CH2Ph)OBn), 
71.8 (C5), 67.8 (C4); 13C˗GATED (101 MHz; CDCl3): 86.3 (1JC1˗H1 = 168 Hz, C1); 
HRMS (ES+) m/z [Found: (M+H)+ 662.2589 C40H40NO6S requires (M+H)+, 662.2571]; 
IR νmax/cm˗1 1640 (m, C=Oamide), 1454 (m, C=Caromatic), 1223 (s, C˗Oester), 1024 (s, 
C˗Oether). 
11.1.23. O˗benzyl, N˗benzyl (phenyl 
4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 69 
To a mixture of 68 (90 mg, 0.13 mmol, 1.0 equiv.) and Lev2O 
(43 µL, d = 1.35, 0.27 mmol, 2.0 equiv.) in CH2Cl2 (1 mL) was 
added pyridine (44 µL, 0.54 mmol, 4.0 equiv.). The reaction 
mixture was left stirring at room temperature for 18 h. Upon 
completion of the reaction, the mixture was diluted with CH2Cl2 (15 mL), and the 
organic layer was washed successively with 1.0 M aq. HCl (2 x 10 mL) and sat. aq. 
NaHCO3 solution (2 x 10 mL). The organic layer was dried over MgSO4, filtered and 
concentrated under reduced pressure furnishing a colourless oil. The crude was 
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purified using silica gel flash column chromatography, eluting with Et2O/petroleum 
ether (30/70, 40/60, 50/50, 90/10) to afford 43 as a colourless oil (76 mg, 0.12 mmol, 
91%). Rf 0.58 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +51.5 (c. 1.0, CHCl3); 1H NMR (400 MHz; 
CDCl3) δ 7.38 – 7.22 (25 H, m, Ar˗H), 5.74 (1 H, app. t, J = 9.6 Hz, H4), 5.54 (1 H, d, 
J = 2.0 Hz, H1), 5.39 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 5.32 (1 H, d, J = 12.0 
Hz, C(O)N(CH2Ph)OBn), 4.99 (2 H, s, C(O)N(Bn)OCH2Ph), 4.67 (1 H, d, J = 12.5 Hz, 
CH2Ph˗attached to C2), 4.64 (1 H, d, J = 12.9 Hz, CH2Ph˗attached to C2), 4.64 (1 H, 
d, J = 9.8 Hz, H5), 4.58 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.53 (1 H, d, J 
= 12.2 Hz, CH2Ph˗attached to C3), 3.98 – 3.94 (1 H, m, H2), 3.75 (1 H, dd, J = 9.4, 
2.9 Hz, H3), 2.66 – 2.38 (3 H, m, CH2, CH2 Lev), 2.31 – 2.19 (1 H, m, CH2 Lev), 2.12 
(3 H, s, CH3 Lev); 13C NMR (101 MHz; CDCl3) δ 206.2 (C=O Lev ketone), 171.1 (C=O 
Lev), 150.6 (C(O)N(Bn)OBn), 137.9 (Cq), 137.9 (Cq), 137.8 (Cq), 137.1 (Cq), 131.6 
(Cq), 129.1, 128.4, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.6, 
127.5, 86.1 (C1), 77.2 (C3), 76.4 (C(O)N(Bn)OCH2Ph), 76.1 (C2), 73.1 
(C(O)N(CH2Ph)OBn), 72.4 (CH2Ph˗attached to C2), 72.1 (CH2Ph˗attached to C3), 
71.1 (C5), 68.6 (C4), 38.0 (CH2 Lev), 29.8 (CH3 Lev), 28.0 (CH2 Lev); 13C˗GATED 
(101 MHz; CDCl3): 86.1 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 
760.2955 C45H46NO8S requires (M+H)+, 760.2939]. 
11.1.24. N,O˗dibenzyl hydroxylamine 71 
A solution of tert˗butyl˗N˗(benzyloxy)carbamate 70 (1.0 g, 4.48 
mmol, 1.0 equiv.) in DMF (30 mL) was added to a suspension of 
NaH (60% in mineral oil, 270 mg, 6.72 mmol, 1.5 equiv.) in DMF 
(10 mL) at 0 °C and the mixture was stirred for 30 min. BnBr (800 µL, d= 1.438, 6.72 
mmol, 1.5 equiv.) was then added to the reaction, which was warmed to room 
temperature and left stirring for 3 h. The reaction was quenched with MeOH (3 mL) 
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and the solvents were removed in vacuo. The resulting oil was reconstituted between 
CH2Cl2 (50 mL) and H2O (40 mL), and the aqueous layer was extracted with CH2Cl2 
(2 x 50 mL). The combined organic layers were washed with brine (2 x 40 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure furnishing a yellow 
oil which was directly used for the next step. The crude yellow oil was stirring for 24 
h in 3% (v/v) TFA in CH2Cl2 (20 mL). The solvent was then removed under reduced 
pressure and purification by Reveleris® automated silica gel flash column 
chromatography (liquid injection onto column), eluting with EtOAc/hexane (0/100, 
5/95, 20/80) afforded 71 as a colourless oil (592 mg, 2.78 mmol, 62% in 2 steps). Rf 
(EtOAc/hexane, 1/2); 1H NMR (400 MHz; CDCl3) δ 7.38 – 7.28 (10 H, m, Ar˗H), 5.73 
(1 H, s, N(H)Bn), 4.66 (2 H, s, OCH2Ph), 4.05 (2 H, s, N(H)CH2Ph); 13C NMR (101 
MHz; CDCl3) δ 137.9 (Cq Bn), 137.6 (Cq Bn), 129.0 (2 C), 128.5 (2 C), 128.4 (2 C), 
128.4 (2C), 127.8, 127.4, 76.3 (OCH2Ph), 56.6 (N(H)CH2Ph); HRMS (ES+) m/z 
[Found: (M+H)+ 214.1226 C14H16NO requires (M+H)+, 214.1243]; These data were 
consistent with literature values.215 
11.1.25. O˗benzyl, N˗benzyl (phenyl 
4,5˗ene˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) hydroxamate 72 
To a stirred solution of 42 (100 mg, 0.21 mmol, 1.0 equiv.), 
PyBOP (278 mg, 0.53 mmol, 2.5 equiv.) and DIPEA (75 µL, d = 
0.742, 0.43 mmol, 2.0 equiv.) in CH2Cl2 (2 mL) at 0 °C, 71 (49 
mg, 0.23 mmol, 1.1 equiv.) in CH2Cl2 (0.1 mL) was added. The 
reaction mixture was left stirring for 40 min. at 0 °C and the solvent was removed 
under reduced pressure. The remaining crude was purified using silica gel flash 
column chromatography, eluting with EtOAc/hexane (30/70, 40/60, 50/50, 90/10) to 
afford 72 as a colourless oil (51 mg, 79 µmol, 38%, 61% based on recovered starting 
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material˗40 mg). Rf 0.59 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +42.8 (c. 0.85, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 7.47 – 7.21 (25 H, m, Ar˗H), 5.77 (1 H, dd, J = 3.3, 0.8 Hz, H1), 
5.62 (1 H, d, J = 5.4 Hz, H4), 4.74 (1 H, d, J = 9.6 Hz, C(O)N(Bn)OCH2Ph), 4.71 (1 
H, d, J = 9.7 Hz, C(O)N(Bn)OCH2Ph), 4.69 (1 H, d, J = 12.3 Hz, C(O)N(CH2Ph)OBn), 
4.66 (2 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn, CH2Ph˗attached to C2), 4.64 (1 H, d, 
J = 10.8 Hz, CH2Ph˗attached to C3), 4.61 (1 H, d, J = 10.9 Hz, CH2Ph˗attached to 
C3), 4.58 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C2), 4.27 (1 H, app. t, J = 3.7 Hz, 
H2), 3.88 (1 H, ddd, J = 5.2, 4.1, 1.0 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 163.7 
(C(O)N(Bn)OBn), 146.0 (C5), 137.93 (Cq), 137.6 (Cq), 136.0 (Cq), 134.8 (Cq), 132.7 
(Cq), 132.6, 129.4 129.1, 128.6, 128.5, 128.5, 128.4, 128.4, 128.4, 128.1, 128.0, 
127.9, 127.8, 127.7, 105.3 (C1), 85.0 (C4), 77.2 (C(O)N(Bn)OCH2Ph), 72.7 (C3), 
72.3 (CH2Ph˗attached to C3), 71.1 (CH2Ph˗attached to C2), 68.3 (C2), 52.9 
(C(O)N(CH2Ph)OBn); HRMS (ES+) m/z [Found: (M+H)+ 644.2485 C40H38NO5S 
requires (M+H)+, 644.2465]; IR νmax/cm˗1 1652 (w, C=Oamide), 1454 (m, C=Caromatic), 
1071 (s, C˗Oether), 909 (m, C=Calkene). 
11.1.26. 3˗bromopropyl (O˗benzyl, N˗benzyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 73 
A solution of 67 (100 mg, 0.14 mmol, 1.0 equiv.), Ph2SO 
(37 mg, 0.18 mmol, 1.3 equiv.) and TTBP (88 mg, 0.35 
mmol, 2.5 equiv.) in CH2Cl2 (3 mL) was stirred over 
activated MS4Å for 40 min. The mixture was cooled to ˗60 
°C and Tf2O (30 µL, d = 1.720, 0.18 mmol, 1.3 equiv.) was then added. The mixture 
was stirred for 5 min. followed by cooling to ˗80 °C, upon 3˗bromopropanol (19 µL, d 
= 1.537, 0.21 mmol, 1.5 equiv.) was added. The reaction mixture was allowed to 
warm up to ˗20 °C, and stirring was continued for 1 h. At that temperature Et3N was 
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added until pH = 7, the organic layer was washed with H2O (10 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. Purification using silica 
gel flash column chromatography, eluting with Et2O/petroleum ether (10/90, 20/80, 
30/170) afforded 73 as a colourless oil (91 mg, 0.12 mmol, 89%). Rf 0.58 
(EtOAc/hexane, 1/2); [𝛼]𝐷
22 +12.8 (c. 0.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.42 
– 7.23 (25 H, m, Ar˗H), 5.63 (1 H, app. t, J = 9.9 Hz, H4), 5.50 (1 H, d, J = 12.0 Hz, 
C(O)N(CH2Ph)OBn), 5.45 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 4.99 (1 H, d, J 
= 12.6 Hz, C(O)N(Bn)OCH2Ph), 4.94 (1 H, d, J = 12.6 Hz, C(O)N(Bn)OCH2Ph), 4.89 
(1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 4.81 (1 H, d, J = 12.3 Hz, 
CH2Ph˗attached to C2), 4.52 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.39 (1 H, 
s, H1) 4.38 (1 H, d, J = 11.3 Hz, CH2Ph˗attached to C3), 3.95 – 3.88 (1 H, m, 
OCH2CH2CH2Br), 3.89 (1 H, d, J = 2.6 Hz, H2), 3.81 (1 H, d, J = 10.0 Hz, H5), 3.61 – 
3.52 (1 H, m, OCH2CH2CH2Br), 3.43 (1 H, dd, J = 9.7, 3.1 Hz, H3), 3.46 – 3.39 (2 H, 
m, OCH2CH2CH2Br), 2.09 (2 H, dddd, J = 26.8, 21.7, 11.0, 5.6 Hz, OCH2CH2CH2Br), 
1.77 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 169.3 (C(O)CH3), 150.9 
(C(O)N(Bn)OBn), 138.5 (Cq), 137.9 (Cq), 137.9 (Cq), 137.3 (Cq), 128.4, 128.3, 128.2, 
128.1, 128.1, 128.0, 127.7, 127.7, 127.7, 127.6, 127.4, 127.4, 101.8 (C1), 78.9 (C3), 
76.3 (C(O)N(Bn)OCH2Ph), 74.1 (2 C, C5 and CH2Ph˗attached to C2), 73.9 (C2), 73.1 
(C(O)N(CH2Ph)OBn), 71.4 (CH2Ph˗attached to C3), 68.1 (C4), 67.4 
(OCH2CH2CH2Br), 32.8 (OCH2CH2CH2Br), 30.2 (OCH2CH2CH2Br), 20.7 (C(O)CH3); 
13C˗GATED (101 MHz; CDCl3): 101.8 (1JC1˗H1 = 152 Hz, C1); HRMS (ES+) m/z 
[Found: (M+H)+ 732.2188 C39H43BrNO8 requires (M+H)+, 732.2167]; IR νmax/cm˗1 
1745 (m, C=Oester), 1637 (w, C=Oamide), 1051 (m, C˗Oester). 
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11.1.27. 3˗bromopropyl (O˗benzyl, N˗benzyl 4˗O˗ 
levulinoyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 74 
A solution of 69 (100 mg, 0.13 mmol, 1.0 equiv.), Ph2SO 
(34 mg, 0.19 mmol, 1.3 equiv.) and TTBP (81 mg, 0.33 
mmol, 2.5 equiv.) in CH2Cl2 (2.5 mL) was stirred over 
activated MS4Å for 40 min. The mixture was cooled to 
˗60 °C and Tf2O (28 µL, d = 1.720, 0.17 mmol, 1.3 equiv.) was then added. The 
mixture was stirred for 5 min. followed by cooling to ˗90 °C, upon 3˗bromopropanol 
(18 µL, d = 1.537, 0.20 mmol, 1.5 equiv.) was added. The reaction mixture was 
allowed to warm up to ˗20 °C, and stirring was continued for 1 h. At that temperature 
Et3N was added until pH = 7, the organic layer was washed with H2O (10 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. Purification using 
silica gel flash column chromatography, eluting with Et2O/petroleum ether (10/90, 
20/80, 30/170) afforded 49 as a colourless oil (80 mg, 0.10 mmol, 78%). Rf 0.46 
(EtOAc/hexane, 1/2); [𝛼]𝐷
22 +39.5 (c. 0.84, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.40 
– 7.24 (20 H, m, Ar˗H), 5.65 (1 H, app. t, J = 9.9 Hz, H4), 5.48 (1 H, d, J = 12.0 Hz, 
C(O)N(CH2Ph)OBn), 5.42 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 4.98 (1 H, d, J 
= 12.5 Hz, C(O)N(Bn)OCH2Ph), 4.95 (1 H, d, J = 12.4 Hz, C(O)N(Bn)OCH2Ph), 4.88 
(1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 4.81 (1 H, d, J = 12.3 Hz, 
CH2Ph˗attached to C2), 4.52 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.43 (1 H, 
d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.39 (1 H, s, H1), 3.94 – 3.88 (1 H, m, 
OCH2CH2CH2Br), 3.88 (1 H, d, J = 2.6 Hz, H2), 3.83 (1 H, d, J = 10.0 Hz, H5), 3.56 
(1 H, ddd, J = 9.8, 7.7, 4.8 Hz, OCH2CH2CH2Br), 3.44 (1 H, dd, J = 9.8, 2.9 Hz, H3), 
3.46 – 3.38 (2 H, m, OCH2CH2CH2Br), 2.64 – 2.37 (3 H, m, CH2, CH2 Lev), 2.27 – 
2.15 (1 H, m, CH2 Lev), 2.11 (3 H, s, CH3 Lev), 2.10 – 1.97 (2 H, m, OCH2CH2CH2Br); 
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13C NMR (101 MHz; CDCl3) δ 206.3 (C=O Lev ketone), 171.2 (C=O Lev), 150.7 
(C(O)N(Bn)OBn), 138.5 (Cq), 137.9 (2 C, Cq), 137.3 (Cq), 128.4, 128.3, 128.2, 128.1, 
128.1, 128.1, 127.7, 127.7, 127.6, 127.6, 127.4, 101.7 (C1), 78.8 (C3), 76.3 
(C(O)N(Bn)OCH2Ph), 74.0, 73.9, 73.8 (3C, C2, C5, CH2Ph˗attached to C2), 73.1 
(C(O)N(CH2Ph)OBn), 71.5 (CH2Ph˗attached to C3), 68.3 (C4), 67.4 
(OCH2CH2CH2Br), 37.9 (CH2 Lev), 32.7 (OCH2CH2CH2Br), 30.3 (OCH2CH2CH2Br), 
29.8 (CH3 Lev), 27.8 (CH2 Lev); 13C˗GATED (101 MHz; CDCl3): 101.7 (1JC1˗H1 = 156 
Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 788.2465 C42H47BrNO9 requires (M+H)+, 
788.2429]. 
11.1.28. 3˗bromopropyl (4˗O˗acetyl˗2,3˗di˗O˗benzyl˗α˗D˗mannopyranoside) 
hydroxamate 75 
To stirred solution of 67 (130 mg, 0.18 mmol, 1.0 equiv.) and 
3˗bromopropanol (25 µL, d = 1.537, 0.28 mmol, 1.5 equiv.) 
in CH2Cl2 (3.5 mL) over activated MS4Å for 1 h before NBS 
(49 mg 0.28 mmol, 1.5 equiv.) was added. The reaction 
mixture was cooled down to ˗10 °C and TMSOTf (17 µL, d = 1.225, 90 µmol, 0.5 
equiv.) was added dropwise. The reaction mixture was stirred for 45 min. at 0 °C and 
45 min. at room temperature. The reaction mixture was quenched by the addition of 
Et3N to pH = 7 followed by concentration under reduced pressure. Purification using 
silica gel flash column chromatography, eluting with Et2O/hexane (5/95, 10/90, 
15/85) afforded 39 as a colourless oil (11 mg, 20 µmol, 11 %). Rf 0.40 
(EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗25.2 (c. 0.09, CHCl3); 1H NMR (400 MHz; CDCl3) 7.71 
(1 H, s, N(H)OH), 7.42 – 7.19 (15 H, m, Ar˗H), 5.57 (1 H, t, J = 9.6 Hz, H4), 4.87 (1 
H, d, J = 2.0 Hz, H1), 4.83 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C2), 4.64 (1 H, d, 
J = 12.2 Hz, CH2Ph˗attached to C2), 4.61 (2 H, s, CH2Ph˗attached to C3), 4.24 (1 H, 
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d, J = 9.8 Hz, H5), 3.87 (1 H, dd, J = 9.4, 2.9 Hz, H3), 3.83 – 3.77 (1 H, m, 
OCH2CH2CH2Br), 3.78 – 3.74 (1 H, m, H2), 3.56 – 3.51 (1 H, m, OCH2CH2CH2Br), 
3.42 (2 H, t, J = 6.3 Hz, OCH2CH2CH2Br), 2.13 – 2.03 (2 H, m, OCH2CH2CH2Br), 
2.06 (3 H, s, C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 170.3 (C(O)N(H)OH), 169.7 
(C(O)CH3), 138.1, 137.9 (Cq), 137.9 (Cq), 129.0, 128.5, 128.4, 128.0, 127.9, 127.8, 
127.6, 126.8, 125.4, 99.2 (C1), 76.5 (C3), 74.7 (C2), 73.4 (CH2Ph˗attached to C2), 
72.7 (CH2Ph˗attached to C3), 71.6 (C5), 68.7 (C4), 66.0 (OCH2CH2CH2Br), 32.1 
(OCH2CH2CH2Br), 29.7 (OCH2CH2CH2Br), 20.9 (C(O)CH3); 13C˗GATED (126 MHz; 
CDCl3) 99.2 (1JC1˗H1 =172 Hz, C1). 
11.1.29. 3˗azidopropyl (O˗benzyl, N˗benzyl 
4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 76 
Compound 73 (20 mg, 27 µmol, 1.0 equiv.) and NaN3 (11 
mg, 0.18 mmol, 6.5 equiv.) were dissolved in acetone (1.5 
mL) and the reaction mixture was stirred for 48 h at 55 °C. 
Upon completion, the reaction mixture was cooled to room 
temperature and EtOAc (10 mL) was added. The organic layer was washed with H2O 
(10 mL), dried over MgSO4, filtered and concentrated under reduced pressure to 
afford the crude product. Purification using silica gel flash column chromatography, 
eluting with EtOAc/hexane (10/90, 20/80, 40/60) afforded 76 as a colourless oil (14 
mg, 20 µmol, 76%). Rf 0.60 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗50.8 (c. 0.93, CHCl3); 1H 
NMR (400 MHz; CDCl3) 7.43 – 7.19 (20 H, m, Ar˗H), 5.63 (1 H, app. t, J = 9.9 Hz, 
H4), 5.50 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 5.45 (1 H, d, J = 12.0 Hz, 
C(O)N(CH2Ph)OBn), 4.99 (1 H, d, J = 12.6 Hz, C(O)N(Bn)OCH2Ph), 4.94 (1 H, d, J 
= 12.6 Hz, C(O)N(Bn)OCH2Ph), 4.89 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 
4.81 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 4.52 (1 H, d, J = 12.3 Hz, 
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CH2Ph˗attached to C3), 4.38 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.37 (1 H, 
s, H1), 3.94 – 3.85 (1 H, m, OCH2CH2CH2N3), 3.89 (1 H, d, J = 2.8 Hz, H2), 3.81 (1 
H, d, J = 10.0 Hz, H5), 3.48 (1 H, ddd, J = 9.8, 7.6, 5.1 Hz, OCH2CH2CH2N3), 3.43 (1 
H, dd, J = 9.7, 2.8 Hz, H3), 3.38 – 3.25 (2 H, m, OCH2CH2CH2N3), 1.85 (2 H, ddd, J 
= 18.1, 11.5, 4.8 Hz, OCH2CH2CH2N3), 1.77 (3 H, s, C(O)CH3); 13C NMR (101 MHz; 
CDCl3) δ 169.3 (C(O)CH3), 150.8 (C(O)N(Bn)OBn), 138.5 (Cq), 137.9 (Cq), 137.8 
(Cq), 137.3 (Cq), 128.4, 128.30, 128.2, 128.1, 128.0, 127.7, 127.7, 127.7, 127.6, 
127.5, 127.39, 124.8, 101.7 (C1), 78.8 (C3), 76.3 (C(O)N(Bn)OCH2Ph), 74.1 (2 C, 
C5, CH2Ph˗attached to C2), 74.0 (C2), 73.1 (C(O)N(CH2Ph)OBn), 71.4 
(CH2Ph˗attached to C3), 68.1 (C4), 66.6 (OCH2CH2CH2N3), 48.3 (OCH2CH2CH2N3), 
29.1 (OCH2CH2CH2N3), 20.7 (C(O)CH3); 13C˗GATED (101 MHz; CDCl3): 101.7 
(1JC1˗H1 = 152 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 695.3097 C39H43N4O8 
requires (M+H)+, 695.3075]; IR νmax/cm˗1 2095 (m, N=N=N), 1746 (m, C=Oester), 1637 
(w, C=Oamide), 1050 (s, C˗Oester). 
11.1.30. 3˗azidopropyl (O˗benzyl, N˗benzyl 4˗O˗ 
levulinoyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 77 
Compound 74 (90 mg, 1.14 mmol, 1.0 equiv.) and NaN3 
(37 mg, 5.70 mmol, 5.0 equiv.) and TBAI (2.1 g, 5.70 
mmol, 5.0 equiv.) were dissolved in DMF (12 mL) and the 
reaction mixture was stirred for 24 h at 65 °C. Upon 
completion, the reaction mixture was cooled to room temperature and EtOAc (25 mL) 
was added. The organic layer was washed with H2O (20 mL), brine (20 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure to afford the crude 
product. Purification using silica gel flash column chromatography, eluting with 
EtOAc/hexane (20/80, 40/60, 50/50) afforded 77 as a colourless oil (62 mg, 0.83 
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mmol, 73%). Rf 0.38 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗41.5 (c. 2.0, CHCl3); 1H NMR (400 
MHz; CDCl3) 7.41 – 7.23 (20 H, m, Ar˗H), 5.65 (1 H, app. t, J = 9.9 Hz, H4), 5.48 (1 
H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 5.42 (1 H, d, J = 12.0 Hz, 
C(O)N(CH2Ph)OBn), 4.98 (1 H, d, J = 12.4 Hz, C(O)N(Bn)OCH2Ph), 4.95 (1 H, d, J 
= 12.5 Hz, C(O)N(Bn)OCH2Ph), 4.88 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 
4.81 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 4.52 (1 H, d, J = 12.3 Hz, 
CH2Ph˗attached to C3), 4.43 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.37 (1 H, 
s, H1), 3.90 – 3.84 (1H, m, OCH2CH2CH2N3) 3.88 (1 H, d, J = 3.0 Hz, H2), 3.82 (1 H, 
d, J = 10.0 Hz, H5), 3.48 (1 H, ddd, J = 6.6, 6.0, 3.6 Hz, OCH2CH2CH2N3), 3.44 (1 H, 
dd, J = 9.8, 2.8 Hz, H3), 3.30 (2 H, ddd, J 13.9, 9.9, 4.0 Hz, OCH2CH2CH2N3), 2.63 – 
2.37 (3 H, m, CH2, CH2 Lev), 2.24 (1 H, ddd, J = 10.8, 8.8, 4.0 Hz, CH2 Lev), 2.10 (3 
H, s, CH3 Lev), 1.81 (2 H, ddt, J = 24.6, 12.3, 6.3 Hz, OCH2CH2CH2N3); 13C NMR 
(101 MHz; CDCl3) δ 206.2 (C=O Lev ketone), 171.2 (C=O Lev), 150.7 
(C(O)N(Bn)OBn), 138.5 (Cq), 137.8 (2 C, Cq), 137.3 (Cq), 128.4, 128.3, 128.1, 128.1, 
128.1, 128.0, 127.7, 127.7, 127.6, 127.6, 127.4, 101.7 (C1), 78.7 (C3), 76.3 
(C(O)N(Bn)OCH2Ph), 74.0, 73.9, 73.9 (3C, C2, C5, CH2Ph˗attached to C2), 73.1 
(C(O)N(CH2Ph)OBn), 71.5 (CH2Ph˗attached to C2), 68.3 (C4), 66.6 
(OCH2CH2CH2N3), 48.3 (OCH2CH2CH2N3), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 29.1 
(OCH2CH2CH2N3), 27.8 (CH2 Lev); 13C˗GATED (101 MHz; CDCl3): 101.7 (1JC1˗H1 = 




11.1.31. 3˗azidopropyl (O˗benzyl, N˗benzyl 
2,3˗di˗O˗benzyl˗1˗β˗D˗mannopyranoside) hydroxamate 78 
To a stirred solution of 76 (280 mg, 0.40 mmol, 1.0 equiv.) 
in anhydrous MeOH (3.5 mL), Na (93 µg, 4.0 µmol, 0.01 
equiv.) dissolved in anhydrous MeOH (0.5 mL) was added 
dropwise at room temperature. The mixture was stirred for 
24 h, then neutralised with ion exchange Amberlite 120 (H+) resin (approximately 50  
mg, 5 min), filtered, and concentrated under reduced pressure. Flash column 
chromatography, eluting with EtOAc/hexane (20/80, 50/50, 90/10) afforded 78 as a 
colourless oil (198 mg, 0.3 mmol, 76%). 
C6˗hydroxamate 77 (1.9 g, 3.0 mmol, 1.0 equiv.) was dissolved in a mixture of 
pyridine/AcOH (30 mL, 4/1 v/v), after which H2N˗NH2.AcOH (1.4 g, 14.9 mmol, 5.0 
equiv.) was added. The mixture was stirred for 1 h at room temperature and was 
diluted with EtOAc (100 mL). The organic layer was washed with 1.0 M aq. HCl (2 x 
80 mL), sat. aq. NaHCO3 solution (2 x 80 mL) and brine (80 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to furnish a yellow oil. Purification by silica gel flash column 
chromatography, eluting with EtOAc/hexane (20/80, 50/50, 90/10) afforded 78 as a 
colourless oil (1.8 g, 2.76 mmol, 92%). Rf 0.56 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗31.5 (c. 
0.65, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.50 – 7.25 (20 H, m, Ar˗H), 5.41 (1 H, d, 
J = 12.1 Hz, C(O)N(CH2Ph)OBn), 5.32 (1 H, d, J = 12.2 Hz, C(O)N(CH2Ph)OBn), 
5.05 (1 H, d, J = 12.1 Hz, C(O)N(Bn)OCH2Ph), 4.99 (1 H, d, J = 12.2 Hz, 
C(O)N(Bn)OCH2Ph), 4.93 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to C2), 4.78 (1 H, d, 
J = 12.4 Hz, CH2Ph˗attached to C2), 4.58 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to 
C3), 4.54 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C3), 4.37 (1 H, s, H1), 4.32 (1 H, 
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dd, J = 9.5, 2.8 Hz, H4), 3.97 – 3.88 (1 H, m, OCH2CH2CH2N3), 3.86 (1 H, d, J = 2.9 
Hz, H2), 3.71 (1 H, dd, J = 9.4, 2.1, H5), 3.52 – 3.42 (1 H, m, OCH2CH2CH2N3), 3.36 
– 3.30 (3 H, m, H3, OCH2CH2CH2N3), 2.53 (1 H, d, J = 2.9 Hz, C4˗OH), 1.93 – 1.76 
(2 H, m, OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 151.4 (C(O)N(Bn)OBn), 
138.6 (Cq), 138.1 (Cq), 137.5 (Cq), 136.9 (Cq), 128.5, 128.4, 128.3, 128.3, 128.2, 
128.1, 128.1, 128.0, 127.7, 127.5, 127.4, 102.1 (C1), 80.1 (C3), 76.6 
(C(O)N(Bn)OCH2Ph), 74.8 (C5), 74.5 (C2), 74.3 (CH2Ph˗attached to C2), 72.8 
(C(O)N(CH2Ph)OBn), 72.2 (CH2Ph˗attached to C3), 67.5 (C4), 66.6 
(OCH2CH2CH2N3), 48.3 (OCH2CH2CH2N3), 29.2 (OCH2CH2CH2N3); 13C˗GATED 
(101 MHz; CDCl3): 102.1 (1JC1˗H1 = 152 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 
653.2971 C37H41N4O7 requires (M+H)+, 653.2970]. 
11.1.32. 3˗propionitrile (phenyl 
2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) amide 79 3˗propionitrile (phenyl 
4,5˗ene˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) amide 83 
To a stirred solution of 42 (100 mg, 0.21 
mmol, 1.0 equiv.), PyBOP (280 mg, 0.53 
mmol, 2.5 equiv.) and DIPEA (75 µL, d = 
0.742, 0.43 mmol, 2.0 equiv.) in CH2Cl2 
(2 mL), was added 3˗aminopropionitrile 
(24 µL, d = 0.952, 0.32 mmol, 1.5 equiv.) in CH2Cl2 (0.1 mL) at 0 °C. The mixture 
was left stirring for 40 min. and was diluted with CH2Cl2 (10 mL). The organic layer 
was washed 1.0 M aq. HCl (2 x 10 mL), sat. aq. NaHCO3 solution (2 x 10 mL) and 
brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification using silica gel flash column chromatography, eluting with EtOAc/toluene 
(0/100, 5/95, 10/90, 20/80) afforded 79 as a white solid (51 mg, 0.1 mmol, 47%). Rf 
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0.29 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 +56.4 (c. 7.5, CHCl3); mp: 102˗105 °C; 1H NMR (400 
MHz; CDCl3) δ 7.40 – 7.29 (15 H, m, Ar˗H), 6.87 (1 H, t, J = 6.1 Hz, 
C(O)N(H)CH2CH2C≡N), 5.45 (1 H, d, J = 1.5 Hz, H1), 4.88 (1 H, d, J = 12.0 Hz, 
CH2Ph), 4.72 (1 H, d, J = 12.0 Hz, CH2Ph), 4.68 (1 H, d, J = 12.0 Hz, CH2Ph), 4.64 
(1 H, d, J = 12.0 Hz, CH2Ph), 4.53 (1 H, d, J = 9.8 Hz, H5), 4.38 (1 H, s, C4˗OH), 4.26 
(1 H, app. t, J = 9.5 Hz, H4), 3.94 (1 H, dd, J = 2.8, 1.8 Hz, H2), 3.77 (1 H, dd, J = 9.3, 
3.0 Hz, H3), 3.64 (1 H, td, J = 12.6, 6.2 Hz, C(O)N(H)CH2CH2C≡N), 3.39 (1 H, ddt, J 
= 13.8, 7.8, 5.9 Hz, C(O)N(H)CH2CH2CN), 2.66 (1 H, dd, J = 11.7, 5.0 Hz, 
C(O)N(H)CH2CH2CN), 2.61 – 2.51 (1 H, m, C(O)N(H)CH2CH2C≡N); 13C NMR (101 
MHz; CDCl3) δ 172.1 (C(O)N(H)CH2CH2C≡N), 138.4 (Cq), 137.8 (Cq), 132.8 (Cq), 
132.4, 129.4, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 117.4 
(C(O)N(H)CH2CH2C≡N), 86.8 (C1), 78.5 (C3), 77.2 (C2), 73.3 (CH2Ph), 73.1 
(CH2Ph), 70.9 (C5), 69.8 (C4), 35.1 (C(O)N(H)CH2CH2C≡N), 18.3 
(C(O)N(H)CH2CH2C≡N); HRMS (ES+) m/z [Found: (M+NH4)+ 536.2217 C29H34N3O5S 
requires (M+NH4)+, 536.2219]; IR νmax/cm˗1 3401 (w, N˗Hamide), 2249 (w, C≡N), 1655, 
1530 (s, C=Oamide), 1496, 1454 (m, C=Caromatic), 1102 (C˗N). 
83 was isolated as a colourless oil (46 mg, 90 µmol, 44%). Rf 0.32 (EtOAc/toluene, 
3/7); [𝛼]𝐷
22 +72.0 (c. 7.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.49 – 7.28 (15 H, m, 
Ar˗H), 6.73 (1 H, t, J = 6.2 Hz, C(O)N(H)CH2CH2C≡N), 6.23 (1 H, dd, J = 3.5, 0.9 Hz, 
H4), 5.59 (1 H, d, J = 5.3 Hz, H1), 4.70 (1 H, d, J = 12.1 Hz, CH2Ph), 4.69 (1 H, d, J 
= 12.0 Hz, CH2Ph), 4.64 (1 H, d, J = 12.1 Hz, CH2Ph), 4.60 (1 H, d, J = 11.9 CH2Ph), 
4.29 (1 H, app. t, J = 3.8 Hz, H3), 3.85 (1 H, ddd, J = 5.1, 4.1, 0.9 Hz, H2), 3.62 – 3.43 
(2 H, m, C(O)N(H)CH2CH2C≡N), 2.69 – 2.52 (2 H, m, C(O)N(H)CH2CH2C≡N); 13C 
NMR (101 MHz; CDCl3) δ 161.5 (C(O)N(H)CH2CH2C≡N), 143.6 (C5), 137.8 (Cq), 
137.5 (Cq), 133.4 (Cq), 131.9, 129.4, 128.6, 128.5, 128.5, 128.1, 128.0, 127.9, 127.8, 
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117.9 (C(O)N(H)CH2CH2C≡N), 106.1 (C4), 85.1 (C1), 72.81 (C2), 72.5 (CH2Ph), 71.2 
(CH2Ph), 68.3 (C3), 35. 6 (C(O)N(H)CH2CH2C≡N), 18.2 (C(O)N(H)CH2CH2C≡N); 
HRMS (ES+) m/z [Found: (M+NH4)+ 518.2115 C29H32N3O4S requires (M+NH4)+, 
518.2114]; IR νmax/cm˗1 3354 (w, N˗Hamide), 2248 (w, C≡N), 1655, 1517 (s, C=Oamide), 
1454 (m, C=Caromatic), 1057 (C˗N). 
11.1.33. 3˗propionitrile (phenyl 4˗O˗tert˗butyl dimethylsilyl 
2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) amide 80 
To a mixture of 79 (50 mg, 0.1 mmol, 1.0 equiv.), imidazole 
(20 mg, 0.29 mmol, 3.0 equiv.) and DMAP (5.9 mg, 50 
µmol, 0.5 equiv.)  in DMF (1 mL) was added TBDMSOTf 
(66 µL, d = 1.151, 0.29 mmol, 3.0 equiv.) dropwise. The 
reaction mixture was left stirring overnight at room 
temperature and was quenched with H2O (0.1 mL). The mixture was concentrated 
under reduced pressure, and the remaining crude was reconstituted in CH2Cl2 (10 
mL) and H2O (5 mL). The organic layer was washed, separated, dried over Na2SO4, 
filtered and concentrated under reduced pressure to furnish a colourless oil. 
Purification by silica gel flash column chromatography, eluting with EtOAc/hexane 
(0/100, 10/90, 20/80) afforded 80 as a white solid (50 mg, 79 µmol, 80%). Rf 0.46 
(EtOAc/hexane, 1/2); [𝛼]𝐷
26 +14.0 (c. 1.0, CHCl3); mp: 119˗122 °C; 1H NMR (400 
MHz; CDCl3) δ 7.67 – 7.23 (15 H, m, Ar˗H), 6.29 (1 H, t, J = 6.1 Hz, 
C(O)N(H)CH2CH2C≡N), 5.35 (1 H, d, J = 7.4 Hz, H1), 4.57 (1 H, d, J = 12.1 Hz, 
CH2Ph), 4.56 (1 H, d, J = 11.8 Hz, CH2Ph), 4.50 (1 H, app. t, J = 3.4 Hz, H4), 4.49 (1 
H, d, J = 11.8 Hz, CH2Ph), 4.47 (1 H, d, J = 12.0 Hz, CH2Ph), 4.19 (1 H, d, J = 3.9 
Hz, H5), 3.81 (1 H, dd, J = 7.3, 2.6 Hz, H2), 3.56 (1 H, dd, J = 5.2, 2.6 Hz, H3), 3.28 
(1 H, dq, J = 13.1, 6.6 Hz, C(O)N(H)CH2CH2C≡N), 3.19 (1 H, td, J = 13.2, 6.5 Hz, 
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C(O)N(H)CH2CH2C≡N), 2.31 (1 H, dt, J = 16.6, 6.6 Hz, C(O)N(H)CH2CH2C≡N), 2.25 
– 2.12 (1 H, m, C(O)N(H)CH2CH2C≡N), 0.80 (9 H, s, C(CH3)3), 0.00 (3 H, s, Si(CH3)2), 
˗0.08 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 169.3 (C(O)N(H)CH2CH2C≡N), 
137.9 (Cq), 137.8 (Cq), 133.5 (Cq), 133.0, 129.2, 128.4, 128.3, 128.2, 128.1, 128.0, 
127.9, 127.8, 117.6 (C(O)N(H)CH2CH2C≡N), 84.1 (C1), 77.5 (C5), 74.2 (C2), 72.4 
(CH2Ph), 72.4 (CH2Ph), 68.7 (C4), 35.3 (C(O)N(H)CH2CH2C≡N), 25.8 (C(CH3)3), 
18.0 (C(CH3)3), ˗4.8 (Si(CH3)2), ˗5.0 (Si(CH3)2); HRMS (ES+) m/z [Found: (M+NH4)+ 
650.3082 C35H48N3O5SSi requires (M+NH4)+, 650.3078]; IR νmax/cm˗1 3217 (w, 
N˗Hamide), 2255 (w, C≡N), 1678, 1659 (s, C=Oamide), 1496, 1455 (m, C=Caromatic), 1243 
(s, Si˗C), 1096 (s, C˗N), 1068 (s, Si˗O). 
11.1.34. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗C˗(1H˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 82 
Nitrile 89 (60 mg, 0.11 mmol, 1.0 equiv.) was dissolved 
in toluene (10 mL) and TMSN3 (84 µL, d = 0.872, 0.64 
mmol, 6.0 equiv.) and Bu2SnO (11 mg, 43 µmol, 0.4 
equiv.) were added. The mixture was heated to 120 °C 
and stirred for 16 h. Upon completion, the mixture was cooled down to room 
temperature, diluted with EtOAc (50 mL) and washed with 0.1 M aq. HCl solution (50 
mL). The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. Purification of this crude material by silica gel flash column 
chromatography, eluting with MeOH/CH2Cl2 (0/100, 1/99, 2/98) afforded 82 as a 
brown oil (34 mg, 56 µmol, 51%). Rf 0.71 (MeOH/CH2Cl2, 1/2); [𝛼]𝐷
22 +88.7 (c. 1.75, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.47 – 7.26 (15 H, m, Ar˗H), 5.64 (1 H, d, J = 
8.9 Hz, H5), 5.54 (1 H, d, J = 1.8 Hz, H1), 4.74 (1 H, d, J = 11.7 Hz, CH2Ph), 4.73 (1 
H, d, J = 11.8Hz, CH2Ph), 4.69 (1 H, d, J = 11.7 Hz, CH2Ph), 4.65 (1 H, d, J = 11.8 
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Hz, CH2Ph), 4.41 (1 H, app. t, J = 8.8 Hz, H4), 4.09 (1 H, app. t, J = 2.6 Hz, H2), 3.84 
(1 H, dd, J = 8.6, 2.8 Hz, H3), 0.78 (9 H, s, C(CH3)3), 0.00 (3 H, s, Si(CH3)2), ˗0.41 (3 
H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 155.8 (Cq tetrazole), 137.6 (Cq), 137.1 
(Cq), 132.8 (Cq), 132.2, 129.2, 128.6, 128.5, 128.3, 128.1, 128.0, 86.8 (C1), 79.7 
(C3), 76.5 (C2), 73.3 (CH2Ph), 72.7 (CH2Ph), 71.0 (C4), 68.5 (C5), 25.6 (C(CH3)3), 
17.9 (C(CH3)3), ˗4.3 (Si(CH3)2), ˗5.9 (Si(CH3)2); HRMS (ES+) m/z [Found: (M+H)+ 
605.2628 C32H41N4O4SSi requires (M+H)+,605.2618]. 
11.1.35. Phenyl 2,3˗di˗O˗benzyl˗6˗O˗benzoyl˗1˗thio˗α˗D˗mannopyranoside 
84 
To a stirred solution of 41 (1.0 g, 2.21 mmol, 1.0 equiv.), 
pyridine (357 µL, d = 0.978, 4.42 mmol, 2.0 equiv.), DMAP 
(81 mg, 0.7 mmol, 0.3 equiv.) in CH2Cl2 (10 mL) was added 
BzCl dropwise (269 µL, d = 1.211, 2.32 mmol, 1.05 equiv.) at 0 °C. The reaction was 
left stirring overnight at room temperature, and diluted with CH2Cl2 (15 mL). The 
mixture was washed with 1.0 M aq. HCl (10 mL), sat. aq. NaHCO3 (10 mL) and brine 
(10 mL). The organic layer was dried over MgSO4, filtered and concentrated under 
reduced pressure to afford the crude product. Purification by Reveleris® automated 
silica gel flash column chromatography (liquid injection onto column), eluting with 
EtOAc/hexane (0/100, 5/95 and 10/90) afforded 84 as a colourless oil (1.1 g, 2.0 
mmol, 90%). Rf 0.37 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +48.2 (c. 7.5, CHCl3);  1H NMR (400 
MHz; CDCl3) δ 8.03 – 7.19 (20 H, m, Ar˗H), 5.65 (1 H, d, J = 1.3 Hz, H1), 4.69 (1 H, 
d, J = 12.1 Hz, CH2Ph˗attached to C2), 4.65 – 4.59 (2 H, m, H6a,b), 4.61 (1 H, d, J = 
12.7 Hz, CH2Ph˗attached to C2), 4.55 (1 H, d, J = 10.5 Hz, CH2Ph˗attached to C3), 
4.52 (1 H, d, J = 10.1 Hz, CH2Ph˗attached to C3), 4.43 (1 H, dt, J = 9.6, 3.9 Hz, H5), 
4.15 (1 H, dd, J = 9.6 Hz, H4), 4.04 (1 H, dd, J = 3.0, 1.6 Hz, H2), 3.73 (1 H, dd, J = 
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9.5, 3.0 Hz, H3), 2.64 (1 H, br. s, C4˗OH); 13C NMR (101 MHz; CDCl3) δ 166.7 
(C(O)Ph), 137.8 (Cq), 137.7 (Cq), 134.1 (Cq), 133.0 (Cq), 131.5, 130.1, 129.8, 129.1, 
128.6, 128.4, 128.3, 128.1, 128.0, 127.8, 127.5, 85.7 (C1), 79.6 (C3), 75.7 (C2), 72.1 
(CH2Ph), 71.9 (CH2Ph), 71.7 (C5), 66.9 (C4), 64.1 (C6); HRMS (ES+) m/z [Found: 
(M+NH4)+ 574.2257 C33H32O6SNH4 requires (M+NH4)+, 574.2258]; IR νmax/cm˗1 3477 
(br. s, C4˗OH), 1718 (s, C=Oester), 1273 (s, C˗Oester), 1070 (s, C˗Oether), 1025 (s, 
C˗OH). 
11.1.36. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗O˗benzoyl˗1˗thio˗α˗D˗mannopyranoside 85 
To a mixture of 84 (900 mg, 1.62 mmol, 1.0 equiv.), 
imidazole (330 mg, 4.85 mmol, 3.0 equiv.) and DMAP 
(99 mg, 0.81 mmol, 0.5 equiv.) in DMF (10 mL) was 
added TBDMSOTf (1.1 mL, d = 1.151, 4.85 mmol, 3.0 equiv.) dropwise. The reaction 
mixture was left stirring overnight at room temperature and was quenched with H2O 
(2 mL). The mixture was concentrated under reduced pressure, and the remaining 
crude was reconstituted in CH2Cl2 (50 mL) and H2O (30 mL). The organic layer was 
washed, separated, dried over MgSO4, filtered and concentrated under reduced 
pressure to furnish a colourless oil. Purification by silica gel flash column 
chromatography, eluting with EtOAc/hexane (0/100, 5/95, 10/90) afforded 85, as a 
colourless oil (846 mg, 1.27 mmol, 78%). Rf 0.75 (EtOAc/hexane, 1/2); [𝛼]𝐷
26 +57.8 
(c. 1.37, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.96 – 7.10 (20 H, m, Ar˗H), 5.54 (1 
H, d, J = 1.7, H1), 4.61 (1 H, dd, J = 11.6, 1.8 Hz, H6b), 4.57 (1 H, d, J = 12.0 Hz, 
CH2Ph), 4.57 (1 H, s, J = 11.9 Hz, CH2Ph), 4.52 (1 H, d, J = 11.8 Hz, CH2Ph), 4.50 
(1 H, d, J = 12.0 Hz, CH2Ph), 4.39 (1 H, dd, J = 11.6, 5.8 Hz, H6a), 4.35 – 4.29 (1 H, 
m, H5), 4.19 (1 H, t, J = 9.1 Hz, H4), 3.91 (1 H, dd, J = 2.7, 2.0 Hz, H2), 3.61 (1 H, dd, 
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J = 8.9, 2.9 Hz, H3), 0.82 (9 H, s, C(CH3)3), 0.00 (6 H, d, J = 1.5 Hz, Si(CH3)2); 13C 
NMR (101 MHz; CDCl3) δ 166.4 (C(O)Ph), 138.1 (Cq), 138.1 (Cq), 132.8 (Cq), 131.3 
(Cq), 130.1, 129.7, 129.0, 128.3, 128.3, 127.9, 127.6, 127.6, 127.5, 127.3, 85.7 (C1), 
80.3 (C3), 76.2 (C2), 72.6 (C5), 72.1 (CH2Ph), 71.8 (CH2Ph), 68.2 (C4), 64.2 (C6), 
26.0 (C(CH3)3), 18.2 (C(CH3)3), ˗3.8 (Si(CH3)2), ˗5.0 (Si(CH3)2); HRMS (ES+) m/z 
[Found: (M+NH4)+ 688.3127 C39H50NO6SSi requires (M+NH4)+, 688.3123]; IR 
νmax/cm˗1 1713 (s, C=Oester), 1276 (m, C˗Oester), 1253 (m, Si˗C), 1096 (s, Si˗O), 1024 
(m, C˗Oether). 
11.1.37. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗1˗thio˗α˗D˗mannopyranoside 86 
To a stirred solution of 85 (800 mg, 1.19 mmol, 1.0 
equiv.) in anhydrous MeOH and THF (7 mL, 1/1 v/v), Na 
(14 mg, 0.60 mmol, 0.5 equiv.) dissolved in anhydrous 
MeOH (2 mL) was added dropwise at room temperature. The mixture was stirred 
overnight, then neutralised with ion exchange Amberlite 120 (H+) resin 
(approximately 0.7 g, 10 min), filtered, and concentrated under reduced pressure. 
Purification by silica gel flash column chromatography, eluting with Et2O/hexane 
(0/100, 5/95, 10/90) afforded 86 as a colourless oil (596 mg, 1.07 mmol, 90%). Rf 
0.69 (EtOAc/hexane, 1/2); [𝛼]𝐷
26 +81.3 (c. 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 
7.35 – 7.13 (15 H, m, Ar˗H), 5.37 (1 H, d, J = 1.8 Hz, H1), 4.51 (2 H, d, J = 12.5 Hz, 
CH2Ph), 4.49 (1 H, d, J = 11.8 Hz, CH2Ph), 4.44 (1 H, d, J = 11.9 Hz, CH2Ph), 4.02 
– 3.96 (1 H, m, H4), 3.96 – 3.91 (1 H, m, H5), 3.82 (1 H, dd, J = 2.8, 2.0 Hz, H2), 3.72 
(1 H, ddd, J 11.5, 6.6, 2.4 Hz, H6b), 3.64 (1 H, ddd, J = 11.6, 6.5, 5.2 Hz, H6a), 3.53 
(1 H, dd, J = 8.4, 2.9 Hz, H3), 1.70 (1 H, t, J = 6.6 Hz, C6˗OH), 0.78 (9 H, s, C(CH3)3), 
0.00 (3 H, s, Si(CH3)2), ˗0.05 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 138.1 
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(Cq), 138.0 (Cq), 134.0 (Cq), 132.0, 129.1, 128.4, 128.3, 127.9, 127.7, 127.7, 127.6, 
86.2 (C1), 80.4 (C3), 76.4 (C2), 74.8 (C5), 72.5 (CH2Ph), 72.0 (CH2Ph), 67.9 (C4), 
62.2 (C6), 26.0 (C(CH3)3), 18.2 (C(CH3)3), ˗3.8 (Si(CH3)2), ˗4.9 (Si(CH3)2); HRMS 
(ES+) m/z [Found: (M+NH4)+ 584.2875 C32H46NO5SSi requires (M+NH4)+, 584.2850]; 
IR νmax/cm˗1 1454 (w, C=Caromatic), 1248 (m, C˗Si), 1084 (s, Si˗O). 
11.1.38. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗aldehyde˗1˗thio˗α˗D˗mannopyranoside 87 
To a stirred solution of 86 (60 mg, 0.11 mmol, 1.0 
equiv.) in DMSO (1 mL) was added Et3N (44 µL, d = 
0.726, 0.32 mmol, 3.0 equiv.) and sulfur trioxide 
pyridine complex (51 mg, 0.32 mmol, 3.0 equiv.) at room temperature. The reaction 
mixture was left stirring for 1 h before it was diluted with EtOAc (30 mL) and H2O (20 
mL). The whole was extracted with EtOAc (3 x 15 mL) and the extracts were washed 
with H2O (6 x 20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. Crude aldehyde 87 was obtained 
as a colourless oil (60 mg, 0.11 mmol, 98%) and was carried on the next step without 
further purification. Rf 0.684 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 ˗14.4 (c. 0.33, CHCl3);  1H 
NMR (400 MHz; CDCl3) δ 9.77 (1 H, s, CHO), 7.56 – 7.25 (15 H, m, Ar˗H), 5.56 (1 
H, d, J = 6.4 Hz, H1), 4.57 (1 H, d, J = 11.9 Hz, CH2Ph), 4.52 (2 H, s, CH2Ph), 4.43 
(1 H, d, J = 11.9 Hz, CH2Ph), 4.26 – 4.20 (2 H, m, H4, H5), 3.83 (1 H, dd, J = 6.2, 2.3 
Hz, H2), 3.60 (1 H, dd, J = 5.8, 2.5 Hz, H3), 0.82 (9 H, s, C(CH3)3), 0.00 (3 H, s, 
Si(CH3)2), ˗0.07 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 198.0 (CHO), 137.8 
(Cq), 137.6 (Cq), 133.5 (Cq), 132.4, 131.8, 129.0, 128.5, 128.4, 128.0, 127.9, 127.8, 
127.5, 83.8 (C1), 81.15 (C5), 77.2 (C3), 73.8 (C2), 72.5 (CH2Ph), 72.3 (CH2Ph), 68.9 
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(C4), 25.7 (C(CH3)3), 18.0 (C(CH3)3), ˗4.6 (Si(CH3)2), ˗5.0 (Si(CH3)2); HRMS (ES+) 
m/z [Found: (M+NH4)+ 582.2723 C32H44NO5SSi requires (M+NH4)+, 582.2704]. 
11.1.39. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗oxime˗1˗thio˗α˗D˗mannopyranoside 88 
Crude aldehyde 87 (4.5 g, 7.97 mmol, 1.0 equiv.) was 
dissolved in THF (790 mL) and a solution of H2NOH.HCl 
(554 mg, 7.97 mmol, 1.0 equiv.) dissolved in H2O (15 
mL) was added dropwise. The mixture was cooled to 0 
°C and a solution of Na2CO3 (1.0 g, 9.56 mmol, 1.2 equiv.) dissolved in H2O (9.5 mL) 
was added dropwise. The solution was slowly warmed to room temperature and 
stirred for 24 h. The mixture was diluted with H2O (30 mL) and then extracted with 
EtOAc (4 x 300 mL). The organic layers were combined, dried over Na2SO4, filtered 
and concentrated under reduced pressure. The obtained crude oil was purified using 
silica gel flash column chromatography, eluting with Et2O/petroleum ether (0/100, 
5/95, 10/90, 20/80) to furnish 88 as a colourless oil. Cis and trans (1/6.7) were 
isolated separately (major isomer: 2.82 g, 4.86 mmol, 61%, minor isomer: 416 mg, 
0.72 mmol, 9%) and both were used in the next step; Major isomer Rf 0.78; minor 
isomer Rf 0.68; (EtOAc/petroleum ether, 1/2); major: [𝛼]𝐷
22 +57.7 (c. 0.46, CHCl3); 
minor: [𝛼]𝐷
22 +41.3 (c. 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) Major isomer δ 7.46 – 
7.17 (16 H, m, Ar˗H, HC=N), 5.40 (1 H, d, J = 1.8 Hz, H1), 4.58 (1 H, d, J = 10.5 Hz, 
CH2Ph), 4.57 (1 H, m, H5), 4.55 (1 H, d, J = 10.1 Hz, CH2Ph), 4.54 (1 H, d, J = 12.4 
Hz, CH2Ph), 4.50 (1 H, d, J = 11.9 Hz, CH2Ph), 4.06 (1 H, app. t, J = 9.0 Hz, H4), 
3.89 – 3.86 (1 H, m, H2), 3.59 (1 H, dd, J = 8.9, 2.9 Hz, H3), 0.81 (9 H, s, C(CH3)3), 
0.00 (3 H, s, Si(CH3)2), ˗0.01 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 149.3 
(HC=N), 138.1 (Cq), 137.9 (Cq), 134.0 (Cq), 131.9, 129.1, 128.4, 128.4, 127.9, 
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127.85, 127.8, 127.7, 127.6, 86.3 (C1), 79.8 (C3), 76.3 (C2), 72.5 (C5), 72.5 (CH2Ph), 
72.2 (CH2Ph), 69.8 (C4), 25.8 (C(CH3)3), 18.1 (C(CH3)3), ˗4.0 (Si(CH3)2), ˗4.6 
(Si(CH3)2); HRMS (ES+) m/z [Found: (M+NH4)+ 597.2815 C32H45N2O5SSi requires 
(M+NH4)+, 597.2813]. 
11.1.40. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗nitrile˗1˗thio˗α˗D˗mannopyranoside 89 Phenyl 
2,3˗di˗O˗benzyl˗6˗nitrile˗1˗thio˗α˗D˗mannopyranoside 90 
Oxime 88 (120 mg, 0.21 mmol, 
1.0 equiv.) was dissolved in dry 
acetonitrile (21 mL) and POCl3 
(19 µL, d = 1.645, 0.21 mmol, 
1.0 equiv.) was added at room temperature. The solution was stirred for 5 min. at 
room temperature, heated up to 65 °C and then stirred for 3 h. The reaction was 
quenched with sat. aq. NaHCO3 solution (20 mL) and extracted with EtOAc (3 x 60 
mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified using silica 
gel flash column chromatography, eluting with Et2O/petroleum ether (0/100, 5/95, 
10/90, 20/80) to furnish 89 as a yellow oil (26 mg, 46 µmol, 22%). Rf 0.90 
(EtOAc/hexane, 1/2); [𝛼]𝐷
22 +39.4 (c. 0.53, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.44 
– 7.21 (15 H, m, Ar˗H), 5.45 (1 H, d, J = 3.0 Hz, H1), 4.76 (1 H, d, J = 8.3 Hz, H5), 
4.60 (1 H, d, J = 11.9 Hz, CH2Ph), 4.58 (1 H, d, J = 12.1 Hz, CH2Ph), 4.55 (1 H, d, J 
= 12.1 Hz, CH2Ph), 4.53 (1 H, d, J = 12.0 Hz, CH2Ph), 4.21 (1 H, app. t, J = 8.2 Hz, 
H4), 3.84 (1 H,  app. t, J = 2.9 Hz, H2), 3.49 (1 H, dd, J = 8.2, 2.9 Hz, H3), 0.89 (9 H, 
s, C(CH3)3), 0.18 (3 H, s, Si(CH3)2), 0.05 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; 
CDCl3) δ 137.5 (Cq), 137.1 (Cq), 132.9 (Cq), 131.5, 129.4, 129.3, 129.1, 128.5, 128.5, 
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128.4, 128.2, 128.1, 128.0, 127.9, 127.9, 127.6, 127.2, 124.4, 117.0 (C≡N), 85.9 
(C1), 78.8 (C3), 75.3 (C2), 72.6 (CH2Ph), 72.5 (CH2Ph), 69.4 (C4), 64.7 (C5), 25.8 
(C(CH3)3), 18.0 (C(CH3)3), ˗4.1 (Si(CH3)2), ˗4.8 (Si(CH3)2); HRMS (ES+) m/z [Found: 
(M+NH4)+ 579.2732 C32H43N2O4SSi requires (M+NH4)+, 579.2707]. 
90 was isolated as a yellow oil (24 mg, 54 µmol, 26%). Rf 0.82 (EtOAc/hexane, 1/2); 
[𝛼]𝐷
22 +15.4 (c. 0.95, CHCl3);  1H NMR (400 MHz; CDCl3) δ 7.41 – 7.28 (15 H, m, 
Ar˗H), 5.51 (1 H, d, J = 1.7 Hz, H1), 4.87 (1 H, d, J = 9.8 Hz, H5), 4.66 (1 H, d, J = 
12.0 Hz, CH2Ph), 4.60 (1 H, d, J = 12.0 Hz, CH2Ph), 4.57 (1 H, d, J = 12.2 Hz, CH2Ph), 
4.55 (1 H, d, J = 11.8 Hz, CH2Ph), 4.32 (1 H, app. t, J = 9.6 Hz, H4), 3.96 (1 H, dd, J 
= 2.7, 2.0 Hz, H2), 3.57 (1 H, dd, J = 9.3, 2.9 Hz, H3), 2.92 (1 H, br. s, C4˗OH); 13C 
NMR (101 MHz; CDCl3) δ 137.3 (Cq), 137.2 (Cq), 132.7 (Cq), 131.5, 129.4, 128.7, 
128.6, 128.3, 128.3, 128.1, 128.0, 128.0, 116.6 (C≡N), 86.6 (C1), 78.4 (C3), 75.4 
(C2), 72.5 (CH2Ph), 72.4 (CH2Ph), 68.3 (C4), 63.1 (C3); HRMS (ES+) m/z [Found: 
(M+NH4)+ 465.1857 C26H29N2O4S requires (M+NH4)+, 465.1843]. 
11.1.41. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗C˗(1˗para˗methoxybenzyl 




To a stirred solution of 58 (130 
mg, 0.21 mmol, 1.0 equiv.) in 
DMF (2 mL) was added 
successively, KI (53 mg, 0.32 
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mmol, 1.5 equiv.), K2CO3 (44 mg, 0.32 mmol, 1.5 equiv.) and PMBCl (58 µL, d = 
1.155, 0.43 mmol, 2.0 equiv.). The reaction was left stirring for 4 h and was diluted 
with CH2Cl2 (10 mL). The organic layer was washed with 10% aq. Na2S2O3 solution 
(10 mL) and brine (10 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The crude product was purified using silica gel flash column 
chromatography, eluting with acetone/toluene (1/250, 1/150, 1/100) to furnish 
isomers 79 and 80 (80 mg, 0.11 mmol, 53%) as colourless oils. 
79 was isolated as a yellow oil (42 mg, 58 µmol, 28%). Rf 0.42 (acetone/toluene, 
1/50); [𝛼]𝐷
22 +25.4 (c. 0.53, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.56 – 7.39 (16 H, 
m, Ar˗H), 7.36 (2 H, d, J = 8.7 Hz, Ar˗H PMB), 6.82 (2 H, d, J = 8.8 Hz, Ar˗H PMB), 
5.76 (1 H, d, J = 1.8 Hz, H1), 5.68 (1 H, d, J = 9.4 Hz, H5), 5.66 (1 H, d, J = 15.0 Hz, 
CH2Ph˗PMB), 5.63 (1 H, d, J = 15.0 Hz, CH2Ph˗PMB), 4.83 (1 H, d, J = 11.6 Hz, 
CH2Ph˗attached to C2), 4.81 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C3), 4.78 (1 H, 
d, J = 11.1 Hz, CH2Ph˗attached to C2), 4.75 (1 H, d, J = 11.7 Hz, CH2Ph˗attached to 
C3), 4.59 (1 H, app. t, J = 9.4 Hz, H4), 4.22 – 4.19 (1 H, m, H2), 3.87 (3 H, s, OCH3), 
3.86 – 3.84 (1 H, m, H3), 0.79 (9 H, s, C(CH3)3), 0.00 (3 H, s, Si(CH3)2), ˗0.53 (3 H, 
s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 159.7 (Cq PMB), 152.0 (Cq tetrazole), 
137.8 (Cq), 137.5 (Cq), 133.5 (Cq), 131.1 (Cq), 129.9, 129.2, 128.5, 128.4, 128.0, 
127.9, 127.8, 127.7, 125.7, 114.1, 86.5 (C1), 80.1 (C3), 76.4 (C2), 72.9 
(CH2Ph˗attached to C2), 72.1 (CH2Ph˗attached to C3), 70.0 (C4), 67.7 (C5), 55.2 
(CH2Ph PMB), 50.8 (OCH3), 25.6 (C(CH3)3), 17.8 (C(CH3)3), ˗4.5 (Si(CH3)2), ˗6.1 
(Si(CH3)2); 13C˗GATED (101 MHz; CDCl3): 86.5 (1JC1˗H1 =172 Hz, C1); HRMS (ES+) 
m/z [Found: (M+H)+ 725.3177 C40H49N4O5SSi requires (M+H)+, 725.3187]. 
80 was isolated as a yellow oil (38 mg, 52 µmol, 25%). Rf  0.48 (acetone/toluene, 
1/50); [𝛼]𝐷
22 +40.6 (c. 0.86, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.43 – 7.21 (18 H, 
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m, Ar˗H), 6.87 (2 H, d, J = 8.7 Hz, Ar˗H PMB), 5.67 (1 H, d, J = 14.1 Hz, CH2Ph˗PMB), 
5.62 (1 H, d, J = 14.0 Hz, CH2Ph˗PMB), 5.56 (1 H, d, J = 1.9 Hz, H1), 5.40 (1 H, d, J 
= 9.2 Hz, H5), 4.67 (1 H, d, J = 12.3 Hz, CH2Ph˗attached to C2), 4.60 (1 H, app. t, J 
= 9.1 Hz, H4), 4.57 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to C2), 4.56 (1 H, d, J = 
12.9 Hz, CH2Ph˗attached to C3), 4.52 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C3), 
4.01 – 3.99 (1 H, m, H2), 3.79 (3 H, s, OCH3), 3.70 (1 H, dd, J = 8.9, 2.9 Hz, H3), 0.50 
(9H, s, C(CH3)3), ˗0.11 (3 H, s, Si(CH3)2), ˗0.55 (3 H, s, Si(CH3)2); 13C NMR (101 
MHz; CDCl3) δ 164.4 (Cq tetrazole), 160.1 (Cq PMB), 138.0 (Cq), 133.9 (Cq), 131.8 
(Cq), 130.6 (Cq), 129.0, 128.3, 128.3, 127.8, 127.7, 127.6, 127.5, 125.0, 114.3, 86.5 
(C1), 80.2 (C3), 75.7 (C2), 72.1 (CH2Ph˗attached to C2), 71.6 (CH2Ph˗attached to 
C3), 70.4 (C4), 69.1 (C5), 56.5 (CH2Ph PMB), 55.3 (OCH3), 25.5 (C(CH3)3), 17.7 
(C(CH3)3), ˗4.1 (Si(CH3)2), ˗5.9 (Si(CH3)2); 13C˗GATED (101 MHz; CDCl3): 86.5 
(1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 725.3192 C40H50N4O5SSi 
requires (M+H)+, 725.3187]. 
11.1.42. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗C˗(1H˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 
triethylammonium salt 105 
To a stirred solution of 82 (75 mg, 0.12 mmol, 1.0 equiv.) 
in CH2Cl2 (1 mL) was added Et3N (17 µL, d = 0.726, 0.12 
mmol, 1.0 equiv.). The reaction was left stirring for 1 h and 
then was dried in vacuo, giving 105 as a yellow oil (80 mg, 
0.11 mmol, 94%). [𝛼]𝐷
22 ˗42.4 (c. 0.46, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.51 – 
7.26 (15 H, m, Ar˗H), 5.62 (1 H, d, J = 9.3 Hz, H5), 5.56 (1 H, d, J = 1.5 Hz, H1), 4.77 
(1 H, d, J = 11.9 Hz, CH2Ph), 4.74 (1 H, d, J = 11.8 Hz, CH2Ph), 4.71 (1 H, d, J = 
12.0 Hz, CH2Ph), 4.67 (1 H, d, J = 11.3 Hz, CH2Ph), 4.53 (1 H, app. t, J = 9.1 Hz, 
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H4), 4.13 (1 H, app. t, J = 2.2 Hz), 3.86 (1 H, dd, J = 8.9, 2.9 Hz, H3), 3.05 (6 H, q, J 
= 7.3 Hz, N(CH2CH3)3), 1.23 (9 H, t, J = 7.3 Hz, N(CH2CH3)3), 0.75 (9 H, s, C(CH3)3), 
0.00 (3 H, s, Si(CH3)2), ˗0.43 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 159.6 
(Cq tetrazole), 138.2 (Cq), 138.1 (Cq), 134.3 (Cq), 131.9, 128.9, 128.4, 128.3, 128.1, 
127.9, 127.8, 127.6, 127.4, 86.9 (C1), 81.0 (C3), 77.2 (C2), 73.1 (CH2Ph), 72.3 
(CH2Ph), 71.7 (C4), 69.8 (C5), 45.2 (N(CH2CH3)3), 25.7 (C(CH3)3), 17.9 (C(CH3)3), 
8.5 (N(CH2CH3)3), ˗4.4 (Si(CH3)2), ˗5.9 (Si(CH3)2). 
11.1.43. Phenyl 2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl dimethylsilyl˗6˗C˗(1˗benzyl 
˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 106 Phenyl 
2,3˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗C˗(2˗benzyl˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 107 
To a stirred solution of 105 (80 
mg, 0.11 mmol, 1.0 equiv.) in 
DMF (1.1 mL) was added BnBr 
(20 µL, d = 1.438, 0.17 mmol, 1.5 
equiv.). The reaction was left stirring for 3 h and was diluted with CH2Cl2 (10 mL). 
The organic layer was washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified using silica 
gel flash column chromatography, eluting with acetone/toluene (1/250, 1/150, 1/100) 
to furnish the inseparable isomers 106 and 107 as colourless oil in 1/1.2 ratio (24 
mg, 34 µmol, 31%). Rf 0.80 (EtOAc/petroleum ether, 1/50); 1H NMR (400 MHz; 
CDCl3) δ 7.41 – 7.18 (40 H, m, Ar˗H), 5.73 (1 H, d, J = 14.3 Hz, CH2Ph benzyl 
tetrazole, N2˗isomer), 5.68 (1 H, d, J = 14.2 Hz, CH2Ph benzyl tetrazole, N2˗isomer), 
5.57 (1 H, d, J = 2.7 Hz, H1 N1˗isomer), 5.56 (1 H, d, J = 2.4 Hz, H1 N2˗isomer), 5.54 
(2 H, d, J = 1.9 Hz, CH2Ph benzyl tetrazole, N1˗isomer), 5.50 (1 H, d, J = 9.5 Hz, H5 
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N1˗isomer), 5.40 (1 H, d, J = 9.2 Hz, H5 N2˗isomer), 4.67 (1 H, d, J = 12.2 Hz, CH2Ph), 
4.65 (1 H, d, J = 11.6 Hz, CH2Ph), 4.63 (1 H, d, J = 12.2 Hz, CH2Ph), 4.61 (1 H, d, J 
= 11.9 Hz, CH2Ph), 4.60 (1 H, m, H4 N2˗isomer) 4.59 (1 H, d, J = 11.7 Hz, CH2Ph), 
4.57 (1 H, d, J  = 12.3 Hz, CH2Ph), 4.54 (2 H, s, CH2Ph), 4.43 (1 H, app. t, J = 9.1 
Hz, H4 N1˗isomer), 4.04 (1 H, app. t, J  = 2.8 Hz, H2 N1˗isomer), 4.00 (1 H, app. t, J  
= 2.6 Hz, H2 N2˗isomer), 3.70 (1 H, dd, J  = 8.9, 2.9 Hz, H3 N1 and N2˗isomers), 0.63 
(9 H, s, C(CH3)3), 0.51 (9 H, s, C(CH3)3), ˗0.11 (3 H, s, Si(CH3)2), ˗0.17 (3 H, s, 
Si(CH3)2), ˗0.54 (3 H, s, Si(CH3)2), ˗0.68 (3 H, s, Si(CH3)2); 13C NMR (101 MHz; 
CDCl3) 164.5 (Cq tetrazole, N2˗isomer), 152.3 (Cq tetrazole, N1˗isomer), 138.0 (Cq), 
137.9 (Cq), 137.8 (Cq), 137.5 (Cq), 134.5 (Cq), 133.9 (Cq), 133.6 (Cq), 133.5 (Cq), 
132.8, 131.8, 131.0, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 
128.3, 128.3, 128.0, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5, 86.5 (C1, N1 or 
N2˗isomer), 86.4 (C1, N1 or N2˗isomer), 80.2 (C3, N1 or N2˗isomer), 80.1 (C3, N1 or 
N2˗isomer), 76.3 (C2, N1˗isomer), 75.7 (C2, N2˗isomer), 72.9 (CH2Ph), 72.1 (2C, 
CH2Ph), 71.6 (CH2Ph), 70.4 (C4, N2˗isomer), 69.9 (C4, N1˗isomer), 69.1 (C5, 
N2˗isomer), 67.8 (C5, N1˗isomer), 56.9 (CH2Ph tetrazole, N2˗isomer), 51.2 (CH2Ph 
tetrazole, N1˗isomer), 25.6 (C(CH3)3), 25.5 (C(CH3)3), 17.8 (C(CH3)3), 17.7 (C(CH3)3), 
˗4.2 (Si(CH3)2), ˗4.5 (Si(CH3)2), ˗5.9 (Si(CH3)2), ˗6.0 (Si(CH3)2); 13C˗GATED (101 
MHz; CDCl3): 86.5 and 86.4 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 
695.3084 C39H47N4O4SSi requires (M+H)+, 695.3082]. 
11.1.44. Phenyl 
2,3,4˗tri˗O˗benzyl˗6˗aldehyde˗1˗thio˗α˗D˗mannopyranoside 109 
To a stirred solution of 108 (420 mg, 0.77 mmol, 1.0 equiv.) 
in dimethyl sulfoxide (7.7 mL) was added Et3N (323 µL, d = 
0.726, 2.32 mmol, 3.0 equiv.) and sulfur trioxide pyridine 
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complex (369 mg, 2.32 mmol, 3.0 equiv.) at room temperature. The reaction mixture 
was left stirring for 1 h before it was diluted with EtOAc (25 mL) and H2O (20 mL). 
The whole was extracted with EtOAc (3 x 20 mL) and the extracts were washed with 
H2O (5 x 30 mL) and brine (2 x 30 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. Crude aldehyde 109 was obtained 
as a yellow oil (400 mg, 0.74 mmol, 96%) and was carried on the next step without 
further purification. Rf 0.83 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +40.5 (c. 1.0, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 9.73 (1 H, s, CHO), 7.49 – 7.27 (20 H, m, Ar˗H), 5.59 (1 H, t, J 
= 6.3 Hz, H1), 4.69 (1 H, d, J = 12.9 Hz, CH2Ph), 4.63 (1 H, d, J = 12.8 Hz, CH2Ph), 
4.59 (2 H, d, J = 12.0 Hz, CH2Ph), 4.55 (1 H, d, J = 11.9 Hz, CH2Ph), 4.54 (1 H, d, J 
= 12.5 Hz, CH2Ph), 4.49 (1 H, d, J = 7.7 Hz, H5), 4.08 (1 H, app. t, J = 7.7 Hz, H4), 
3.94 – 3.91 (1 H, m, H2), 3.87 (1 H, dd, J = 7.6, 2.8 Hz, H3); 13C NMR (101 MHz; 
CDCl3) δ 197.6 (CHO), 137.6 (Cq), 137.6 (Cq), 137.6 (Cq), 133.5 (Cq), 131.6, 129.1, 
128.5, 128.4, 128.0, 128.0, 128.0, 127.9, 127.9, 127.9, 127.6, 84.9 (C1), 77.4 (C3), 
77.2 (C5), 75.0 (C2), 74.7 (C4), 74.3 (CH2Ph), 72.3 (CH2Ph), 72.2 (CH2Ph). These 
data were consistent with literature values.253 
11.1.45. Phenyl 2,3,4˗tri˗O˗benzyl˗6˗oxime˗1˗thio˗α˗D˗mannopyranoside 
110 
Crude aldehyde 109 (4.72 g, 8.73 mmol, 1.0 equiv.) was 
dissolved in THF (873 mL) and a solution of H2NOH.HCl (606 
mg, 8.73 mmol, 1.0 equiv.) dissolved in H2O (17.5 mL) was 
added dropwise. The mixture was cooled to 0 °C and a solution of Na2CO3 (1.1 g, 
10.5 mmol, 1.2 equiv.) dissolved in H2O (10.5 mL) was added dropwise. The solution 
was slowly warmed to room temperature and stirred for 24 h. The mixture was diluted 
with H2O (200 mL) and then extracted with EtOAc (4 x 400 mL). The organic layers 
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were combined, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The obtained crude oil was purified using silica gel flash column 
chromatography, eluting with Et2O/petroleum ether (0/100, 5/95, 10/90, 20/80) to 
furnish 110 as a colourless oil. Cis and trans (1/7) isomers were isolated separately 
(major isomer: 3.8 g, 6.54 mmol, 78%, minor isomer: 550 mg, 0.99 mmol, 11%) and 
both were used for the next step. Major isomer Rf 0.70; minor isomer Rf 0.62 
(EtOAc/petroleum ether, 1/2); major: [𝛼]𝐷
22 +87.7 (c. 3.1, CHCl3); 1H NMR (400 MHz; 
CDCl3) major isomer δ 7.46 (1 H, d, J = 6.5 Hz, HC=N), 7.47 – 7.25 (20 H, m, Ar˗H), 
5.49 (1 H, d, J = 1.5 Hz, H1), 4.86 (1 H, d, J = 10.9 Hz, CH2Ph), 4.73 (1 H, dd, J = 
10.5, 5.6 Hz, H5), 4.68 (1 H, d, J = 12.4 Hz, CH2Ph), 4.66 (1 H, d, J = 11.7 Hz, CH2Ph), 
4.65 (1 H, d, J = 10.7 Hz, CH2Ph), 4.64 (1 H, d, J = 12.3 Hz, CH2Ph), 4.61 (1 H, d, J 
= 11.7 Hz, CH2Ph), 4.01 (1 H, app. t, J = 9.4 Hz, H4), 4.01– 3.98 (1 H, m, H2), 3.87 
(1 H, dd, J = 9.2, 2.9 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 148.7 (HC=N), 138.1 
(Cq), 137.7 (Cq), 133.9 (Cq), 131.7 (Cq), 129.1, 128.4, 128.4, 128.3, 128.5, 128.0, 
127.8, 127.8, 127.8, 127.6, 86.1 ( C1), 79.5 (C3), 76.4 (1 C, C2 or C4), 76.3 (1 C, C2 
or C4), 75.1 (CH2Ph), 72.4 (CH2Ph), 72.3 (CH2Ph), 70.6 (C5); HRMS (ES+) m/z 
[Found: (M+Na)+ 578.1993 C33H33NO5SNa requires (M+Na)+, 578.1977]. 
11.1.46. Phenyl 2,3,4˗tri˗O˗benzyl˗6˗nitrile˗1˗thio˗α˗D˗mannopyranoside 
111 
Oxime 110 (4.35 g, 7.83 mmol, 1.0 equiv.) was dissolved in dry 
MeCN (783 mL) and POCl3 (729 µL, d = 1.645, 7.83 mmol, 1.0 
equiv.) was added at room temperature. The solution was 
stirred for 5 min. at room temperature, heated up to 65 °C and then stirred for 3 h. 
The reaction was quenched with sat. aq. NaHCO3 solution (20 mL) and extracted 
with EtOAc (3 x 300 mL). The organic layers were combined, dried over Na2SO4, 
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filtered and concentrated under reduced pressure. The crude product was purified 
using silica gel flash column chromatography, eluting with EtOAc/petroleum ether 
(0/100, 5/95, 10/90, 20/80) to furnish 111 as a yellow oil (2.5 g, 4.65 mmol, 59%). Rf 
0.76 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +71.0 (c. 0.93, CHCl3); 1H NMR (400 MHz; CDCl3) 
δ 7.38 – 7.28 (20 H, m, Ar˗H), 5.48 (1 H, d, J = 2.2 Hz, H1), 4.88 (1 H, d, J = 12.9 Hz, 
CH2Ph), 4.88 (1H, d, J = 9.7 Hz, H5), 4.68 (1 H, d, J = 12.1 Hz, CH2Ph), 4.66 (2 H, d, 
J = 11.6 Hz, CH2Ph), 4.63 (1 H, d, J = 11.9 Hz, CH2Ph), 4.60 (1 H, d, J = 11.7 Hz, 
CH2Ph), 4.19 (1 H, app.t, J = 9.2 Hz, H4), 3.93 (1 H, app. t, J = 2.6 Hz, H2), 3.71 (1 
H, dd, J = 8.9, 2.9 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 137.5 (Cq), 137.3 (Cq), 
137.2 (Cq), 132.7 (Cq), 131.5 (Cq), 129.3, 128.5, 128.5, 128.5, 128.4, 128.2, 128.1, 
128.0, 128.0, 127.9, 117.1 (C≡N), 86.2 (C1), 78.4 (C3), 76.1 (C4), 75.8 (C2 or 
CH2Ph), 75.7 (C2 or CH2Ph), 72.7 (CH2Ph), 72.6 (CH2Ph), 62.2 (C5); HRMS (ES+) 
m/z [Found: (M+H)+ 538.2068 C33H33NO4S requires (M+H)+, 358.2052]. 
11.1.47. Phenyl 
2,3,4˗tri˗O˗benzyl˗6˗C˗(1H˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 112 
Nitrile 111 (2.5 g, 4.65 mmol, 1.0 equiv.) was dissolved in 
toluene (465 mL) and TMSN3 (3.7 mL, d = 0.872, 27.9 mmol, 
6.0 equiv.) and Bu2SnO (463 mg, 1.86 mmol, 0.4 equiv.) 
were added. The mixture was heated to 120 °C and stirred 
for 16 h. Upon completion, the mixture was cooled down to room temperature, diluted 
with EtOAc (400 mL) and washed with 0.1 M aq. HCl (250 mL). The organic layer 
was dried over Na2SO4, filtered and concentrated under reduced pressure to afford 
the crude product. Purification of the crude material by silica gel flash column 
chromatography, eluting with MeOH/CH2Cl2 (0/100, 2/98, 5/95) afforded 112 as a 
brown oil (1.5 g, 2.58 mmol, 55%). Rf 0.65 (MeOH/CH2Cl2, 1/9); [𝛼]𝐷
22 +95.0 (c. 1.96, 
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CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.37 – 7.08 (20 H, m, Ar˗H), 5.61 (1 H, d, J = 
9.7 Hz, H5), 5.54 (1 H, d, J = 1.7 Hz, H1), 4.71 (2 H, d, J = 11.9 Hz, CH2Ph), 4.70 (1 
H, d, J  = 10.5 Hz, CH2Ph), 4.65 (2 H, d, J = 11.8 Hz, CH2Ph), 4.38 (1 H, d, J = 10.7 
Hz, CH2Ph), 4.19 (1 H, app. t, J = 9.4 Hz, H4), 4.08 (1 H, dd, J = 2.7, 2.1 Hz, H2), 
3.99 (1 H, dd, J = 9.2, 2.9 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 155.0 (Cq tetrazole), 
137.6 (Cq), 137.1 (Cq), 137.0 (Cq), 132.8 (Cq), 132.0, 129.3, 128.7, 128.6, 128.6, 
128.4, 128.4, 128.4, 128.1, 128.1, 128.0, 127.9, 86.8 (C1), 79.4 (C3), 76.6 (C2 and 
C4), 75.0 (CH2Ph), 73.3 (CH2Ph), 72.8 (CH2Ph), 66.5 (C5); HRMS (ES+) m/z [Found: 
(M+H)+ 581.2251 C33H34N4O4S requires (M+H)+, 581.2223]. 
11.1.48. Phenyl 2,3,4˗tri˗O˗benzyl˗6˗C˗(1˗para˗methoxybenzyl 
˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannopyranoside 113 Phenyl 
2,3,4˗tri˗O˗benzyl˗6˗C˗(2˗para˗methoxybenzyl˗tetrazol˗5˗yl)˗1˗thio˗α˗D˗mannop
yranoside 114 
To a stirred solution of 112 (920 mg, 1.37 
mmol, 1.0 equiv.) in DMF (10 mL) was 
added successively, KI (341 mg, 2.06 
mmol, 1.5 equiv.), K2CO3 (227 mg, 1.65 
mmol, 1.2 equiv.) and PMBCl (279 µL, d = 1.155, 2.06 mmol, 1.5 equiv.). The reaction 
was left stirring for 16 h and was diluted with CH2Cl2 (30 mL). The organic layer was 
washed with 10% aq. Na2S2O3 solution (30 mL) and brine (30 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified 
using silica gel flash column chromatography, eluting with EtOAc/petroleum ether 
(5/95, 10/90, 15/85) to furnish isomers 113 and 114 (732 mg, 1.04 mmol, 76%) as 
colourless oils.  
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113 was isolated as a yellow oil (374 mg, 0.53 mmol, 39%). Rf 0.72 (EtOAc/petroleum 
ether, 1/2); [𝛼]𝐷
22 +48.5 (c. 2.75, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.39 – 6.95 (21 
H, m, Ar˗H), 7.00 (2 H, d, J = 8.8 Hz, Ar˗H PMB), 6.65 (2 H, d, J = 8.8 Hz, Ar˗H PMB), 
5.61 (1 H, d, J = 1.6 Hz, H1), 5.45 (1 H, d, J = 9.9 Hz, H5), 5.28 (1 H, d, J = 15.0 Hz, 
CH2Ph˗PMB), 5.19 (1 H, d, J = 15.0 Hz, CH2Ph˗PMB), 4.72 (2 H, d, J = 12.5 Hz, 
CH2Ph), 4.70 (1 H, d, J = 11.7 Hz, CH2Ph), 4.67 (1 H, d, J = 11.0 Hz, CH2Ph), 4.65 
(1 H, d, J = 12.3 Hz, CH2Ph), 4.45 (1 H, app. t, J = 9.6 Hz, H4), 4.33 (1 H, d, J = 10.6 
Hz, CH2Ph), 4.08 (1 H, dd, J = 2.7, 2.0 Hz, H2), 3.93 (1 H, dd, J = 9.2, 2.8 Hz, H3), 
3.70 (3 H, s, OCH3); 13C NMR (101 MHz; CDCl3) δ 159.6 (Cq PMB), 152.2 (Cq 
tetrazole), 137.8 (Cq), 137.5 (Cq), 137.5 (Cq), 133.3 (Cq), 130.7 (Cq), 129.3, 129.3, 
128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 125.6, 114.1, 86.3 
(C1), 79.7 (C3), 76.4 (C2), 76.0 (C4), 75.1 (CH2Ph), 72.8 (CH2Ph), 72.5 (CH2Ph), 
65.6 (C5), 55.2 (OCH3), 50.5 (CH2Ph PMB); 13C˗GATED (101 MHz; CDCl3): 86.3 
(1JC1˗H1 =172 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 701.2829 C41H42N4O4S 
requires (M+H)+, 701.2798]. 
114 was isolated as a yellow oil (355 mg, 0.51 mmol, 37%). Rf 0.73 (EtOAc/petroleum 
ether, 1/2); 1H NMR (400 MHz; CDCl3) δ 7.38 – 7.13 (21 H, m, Ar˗H), 6.84 (2 H, d, J 
= 8.0 Hz, Ar˗H PMB), 6.76 (2 H, d, J = 8.7 Hz, Ar˗H PMB), 5.57 (1 H, d, J = 1.3 Hz, 
H1), 5.52 (1 H, d, J = 9.9 Hz, H5), 5.27 (1 H, d, J = 15.0 Hz, CH2Ph˗PMB), 5.18 (1 H, 
d, J = 15.0 Hz, CH2Ph˗PMB), 4.63 (1 H, d, J = 11.5 Hz, CH2Ph), 4.63 (1 H, d, J = 
11.6 Hz, CH2Ph), 4.59 (1 H, d, J = 11.9 Hz, CH2Ph), 4.58 (1 H, app. t, J = 9.9 Hz, 
H4), 4.56 (1 H, d, J = 11.5 Hz, CH2Ph), 4.08 – 4.06 (1 H, m, H2), 3.94 (1 H, dd, J = 
9.3, 1.2 Hz, H3), 4.33 (1 H, d, J = 10.7 Hz, CH2Ph), 4.23 (1 H, d, J = 10.8 Hz, CH2Ph), 
3.67 (1 H, s, OCH3); 13C NMR (101 MHz; CDCl3) δ 164.3 (Cq tetrazole), 160.0 (Cq 
PMB), 138.1 (Cq), 138.1 (Cq), 137.8 (Cq), 133.8 (Cq), 132.0 (Cq), 129.4, 129.3, 128.6, 
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128.5, 128.3, 128.1, 128.1, 127.9, 127.8, 127.7, 125.3, 114.3, 86.6 (C1), 79.8 (C3), 
76.3 (C2), 76.0 (C4), 75.1 (CH2Ph), 72.4 (CH2Ph), 72.2 (CH2Ph), 67.1 (C5), 56.5 
(CH2Ph PMB), 55.3 (OCH3); 13C˗GATED (101 MHz; CDCl3): 86.6 (1JC1˗H1 =168 Hz, 
C1); HRMS (ES+) m/z [Found: (M+H)+ 701.2829 C41H42N4O4S requires (M+H)+, 
701.2798]. 
11.1.49. 3˗(benzyloxycarbonylamino) propyl 
(2,3,4˗tri˗O˗benzyl˗6˗C˗(2˗para˗methoxybenzyl˗tetrazol˗5˗yl)˗α/β˗D˗mannopyran
oside 115 
A solution of 113 and 114 (290 mg, 0.41 mmol, 
1.0 equiv.) and 
3˗(benzyloxycarbonylamino)˗1˗propanol (259 
mg, 1.24 mmol, 3.0 equiv.) in in CH2Cl2 (4.1 mL) 
was stirred over activated MS4Å for 1 h before NIS (139 mg, 0.62 mmol, 1.5 equiv.) 
was added. The mixture was cooled to ˗40 °C before AgOTf (53 mg, 0.21 mmol, 0.5 
equiv.) was added. The reaction was warmed up to 0 °C and stirred for 3 h. Upon 
completion, Et3N was added until pH = 7, and subsequently diluted with CH2Cl2 (20 
mL). The organic layer was washed with 10% aq. Na2S2O3 solution (20 mL), brine 
(20 mL), dried over MgSO4, filtered and concentrated under reduced pressure. Flash 
column chromatography, eluting with EtOAc/petroleum (30/70, 40/60 and 50/50) 
afforded 115 (N2 isomer) as a colourless oil in an anomeric mixture of α/β = 1/1 ratio 
(110 mg, 0.14 mmol, 34%). Rf  0.66 (EtOAc/toluene, 3/7); 1H NMR (400 MHz; CDCl3) 
7.40 – 7.22 (23 H, m, Ar˗H), 7.19 – 7.09 (6 H, m, Ar˗H PMB), 6.83 – 6.73 (4 H, m, 
Ar˗H PMB), 5.65 (1 H, d, J = 14.4 Hz, CH2Ph PMB), 5.60 (1 H, d, J = 14.6 Hz, CH2Ph 
PMB), 5.60 (1 H, d, J = 14.6 Hz, CH2Ph PMB), 5.55 (1 H, d, J = 14.4 Hz, CH2Ph 
PMB), 5.09 (1 H, d, J = 12.0 Hz, CH2Ph), 5.03 (1 H, d, J = 12.4 Hz, CH2Ph), 4.96 (1 
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H, d, J = 12.6 Hz, CH2Ph), 4.92 (1 H, d, J = 9.9 Hz, H5 α˗anomer), 4.85 (1 H, d, J = 
2.2 Hz, H1 α˗anomer), 4.83 (1 H, d, J = 12.6 Hz, CH2Ph), 4.78 (1 H, d, J = 12.5 Hz, 
CH2Ph), 4.73 (1 H, d, J = 11.2 Hz, CH2Ph), 4.69 (2 H, d, J = 10.7 Hz, CH2Ph), 4.63 
(2 H, d, J = 11.8 Hz, CH2Ph), 4.62 (1 H, d, J = 9.6 Hz, H5  β˗anomer), 4.59 (1 H, d, J 
= 11.7 Hz, CH2Ph), 4.55 (1 H, d, J = 3.0 Hz, H1 β˗anomer), 4.53 (1 H, d, J = 12.8 Hz, 
CH2Ph), 4.49 (2 H, app. t, J = 9.7 Hz, H4  α and β˗anomer), 4.47 (1 H, d, J = 12.8 Hz, 
CH2Ph), 4.28 (1 H, d, J = 10.7 Hz, CH2Ph), 4.24 (1 H, d, J = 10.7 Hz, CH2Ph), 3.96 
(1 H, d, J = 2.7 Hz, H2 β˗anomer), 3.95 (1 H, dd, J = 9.4, 2.9 Hz, H3 α˗anomer), 3.93 
– 3.88 (1 H, m, OCH2CH2CH2NHCbz α˗anomer), 3.90 – 3.79 (2 H, m, H2 α˗anomer, 
OCH2CH2CH2NHCbz β˗anomer), 3.72 (3 H, s, OCH3 α˗anomer), 3.70 (3 H, s, OCH3 
β˗anomer), 3.59 (1 H, dd, J = 9.4, 2.7 Hz, H3 β˗anomer), 3.56 – 3.50 (1 H, m, 
OCH2CH2CH2NHCbz α˗anomer), 3.47 – 3.40 (1 H, m, OCH2CH2CH2NHCbz 
β˗anomer), 3.28 (4 H, m, OCH2CH2CH2NHCbz α and β˗anomer), 1.78 (4 H, dt, J = 
12.9, 6.9 Hz, OCH2CH2CH2NHCbz α and β˗anomer); 13C NMR (101 MHz; CDCl3) δ 
164.5 (Cq tetrazole α˗anomer), 164.0 (Cq tetrazole β˗anomer), 160.0 (Cq PMB), 156.4 
(C=O CBz), 138.6 (Cq), 138.4 (2 C, Cq), 138.2 (2 C, Cq), 138.1 (Cq), 138.1 (Cq), 136.6 
(Cq), 130.0 (Cq), 130.0 (Cq), 129.1, 128.5, 128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 
127.7, 127.7, 127.7, 127.6, 127.6, 127.4, 114.3, 102.2 (C1 β˗anomer), 98.9 (C1 
α˗anomer), 81.8 (C3 β˗anomer), 79.9 (C3 α˗anomer), 77.2 (2 C, C4, α and 
β˗anomer), 75.0 (C2 α˗anomer), 74.8 (CH2Ph), 74.2 (CH2Ph), 74.2 (C2 β˗anomer), 
74.1 (CH2Ph), 72.9 (CH2Ph), 72.5 (2 C, CH2Ph), 71.7 (CH2Ph), 69.8 (C5 β˗anomer), 
67.6 (OCH2CH2CH2NHCbz α˗anomer), 66.6 (CH2Ph), 66.4 (C5 α˗anomer), 65.8 
(OCH2CH2CH2NHCbz β˗anomer), 56.4 (2 C, CH2Ph PMB), 55.2 (2 C, OCH3), 38.4 
(OCH2CH2CH2NHCbz α˗anomer), 38.2 (OCH2CH2CH2NHCbz β˗anomer), 29.7 
(OCH2CH2CH2NHCbz β˗anomer), 29.5 (OCH2CH2CH2NHCbz α˗anomer); 
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13C˗GATED (101 MHz; CDCl3): 102.2 (1JC1˗H1 =156 Hz, C1 β˗anomer); HRMS (ES+) 
m/z [Found: (M+H)+ 800.3693 C46H51N5O8 requires (M+H)+, 800.3659]. 
11.1.50. Methyl (phenyl 
4,5˗ene˗2,3˗di˗O˗benzyl˗1˗thio˗α˗D˗mannopyranoside) uronate 118 
To a stirred solution of 55 (150 mg, 0.29 mmol, 1.0 equiv.) in 
THF (1.5 mL) being cooled to ˗70 °C, whereby a 1 M solution 
of LDA (34 µL, 0.35 mmol, 1.2 equiv.) in THF/hexane was 
added dropwise. The reaction mixture was kept between ˗80 
°C and ˗70 °C for 15 min. before MeI (268 µL, d = 2.28, 0.43 mmol, 1.5 equiv.) was 
added dropwise, and warmed to room temperature over 40 min. The reaction was 
quenched with sat. aq. NH4Cl solution (10 mL) and diluted with CH2Cl2 15 (mL). The 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers 
were washed with brine (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure furnishing a yellow oil. Purification by silica gel flash column 
chromatography, eluting with EtOAc/hexane (0/100, 20/80, 40/60, 90/10) afforded 
118, as a colourless oil (82 mg, 0.18 mmol, 61%). Rf 0.65 (EtOAc/hexane, 1/2); [𝛼]𝐷
26 
+68.0 (c. 1.0, CHCl3); 1H NMR (300 MHz; CDCl3) δ 7.54–7.25 (15 H, m, Ar˗H), 6.25 
(1 H, dd, J = 2.7, 1.3 Hz, H4), 5.71 (1 H, d, J = 3.8 Hz, H1), 4.72 (1 H, d, J = 12.2 Hz, 
CH2Ph˗attached to C2), 4.63 (1 H, d, J  = 12.3 Hz, CH2Ph˗attached to C2), 4.61 (1 
H, d, J  = 12.0 Hz, CH2Ph˗attached to C3), 4.56 (1 H, d, J  = 12.0 Hz, CH2Ph˗attached 
to C3), 4.34 (1 H, dd, J  = 4.1, 2.9 Hz, H3), 3.94 (1 H, td, J = 4.0, 1.3 Hz, H2), 3.79 (3 
H, s, CO2CH3); 13C NMR (75 MHz; CDCl3) δ 162.3 (CO2CH3), 141.6 (C5), 137.7 (Cq), 
137.4 (Cq), 132.8 (Cq), 132.5, 129.2, 128.5, 128.2, 128.2, 128.0, 127.9, 127.7, 110.4 
(C4), 85.0 (C1), 72.0 (CH2Ph˗attached to C2), 71.3 (CH2Ph˗attached to C3) , 71.1 
(C2), 68.8 (C3), 52.5 (CO2CH3); HRMS (ES+) m/z  [Found: (M+NH4)+ 480.1847 
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C27H30NO5S requires (M+NH4)+, 480.1839]; IR νmax/cm˗1 1731 (m, C=Oester), 1652 (w, 
C=C), 1086 (s, C˗Oether). 
11.1.51. 2,3,4,6˗penta˗O˗acetyl˗5˗C˗methyl˗α/β˗D˗mannopyranoside 120, 
121, 1,2,3,6˗tetra˗O˗acetyl˗5˗C˗methyl˗α/β˗D˗mannofuranoside 122, 123 
To a stirred mixture of Ac2O (847 µL, d = 
1.08, 9.0 mmol, 10.3 equiv.) and 5˗C˗methyl˗ 
α/β˗D˗mannopyranose (170 mg, 0.87 mmol, 
1.0 equiv.), H2SO4 (47 µL, d = 1.83, 0.87 
µmol, 0.001 equiv.) was added at 0 °C, under 
an atmosphere of N2. The solution was 
stirred for 10 min. at 0°C and then allowed to 
warm to room temperature and stirred for a further 45 min. The mixture was then 
diluted with ice–water (10 mL), and the organic phase extracted with EtOAc (2 x 10 
mL). The extract was washed with H2O (10 mL), sat. aq. NaHCO3 solution (15 mL), 
dried over MgSO4, filtered, and the solvent evaporated to dryness to pyranoses 120 
(40%), 121 (43%) and furanoses 122 (5%), 123 (12%) as a pale yellow viscous oil 
(218 mg, 0.54 mmol, 62%); Rf 0.25 (EtOAc/petroleum ether, 1/1); 1H NMR (400 MHz; 
CDCl3) δ α˗pyranoside: 6.11 (1 H, d, J = 2.3 Hz, H1), 5.58 (1 H, d, J = 10.5 Hz, H4), 
5.29 – 5.26 (2 H, m, H2, H3 α or β), 4.11 (1 H, d, J = 12.0 Hz, H6a), 3.96 (1 H, d, J = 
12.0 Hz, H6b), 2.02 (3 H, s, C(O)CH3), 2.06 (3 H, s, C(O)CH3), 2.12 (3 H, s, C(O)CH3), 
2.14 (3 H, s, C(O)CH3), 2.17 (3 H, s, C(O)CH3), 1.39 (3 H, s, C5˗CH3). β˗pyranoside: 
6.06 (1 H, d, J = 1.4 Hz, H1), 5.48 (1 H, d, J = 10.4 Hz, H4), 5.49 – 5.46 (2 H, m, H2, 
H3 α or β), 4.00 (1 H, d, J = 11.9 Hz, H6a), 4.00 (1 H, d, J = 12.0 Hz, H6b), 2.01 (3 H, 
s, C(O)CH3), 2.05 (3 H, s, C(O)CH3), 2.10 (3 H, s, C(O)CH3), 2.12 (3 H, s, C(O)CH3), 
2.21 (3 H, s, C(O)CH3), 1.40 (3 H, s, C5˗CH3); 13C NMR (101 MHz; CDCl3) δ 170.6 
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(C(O)CH3), 170.5 (C(O)CH3), 170.2 (C(O)CH3), 170.0 (C(O)CH3), 169.9 (C(O)CH3), 
169.7 (C(O)CH3), 169.5 (C(O)CH3), 169.4 (C(O)CH3), 168.6 (C(O)CH3), 168.4 
(C(O)CH3), 99.6 (C1 α˗furanoside), 98.3 (β˗furanoside) 91.0 (C1 α˗pyranoside), 86.8 
(C1 β˗pyranoside), 78.2 (C5 α˗pyranoside), 76.1 (C5 β˗pyranoside), 68.9 (C2 
α˗pyranoside), 68.4 (C3 β˗pyranoside), 68.3 (C2 β˗pyranoside), 67.3 (C6 
α˗pyranoside), 67.2 (C6 β˗pyranoside), 66.6 (C3 α˗pyranoside), 66.5 (C4 
α˗pyranoside), 66.2 (C4 β˗pyranoside), 21.2 (C(O)CH3), 20.8 (C(O)CH3), 20.8 
(C(O)CH3), 20.8 (C(O)CH3), 20.7 (C(O)CH3), 20.7 (C(O)CH3), 20.7 (C(O)CH3), 20.7 
(C(O)CH3), 20.6 (C(O)CH3), 20.6 (C(O)CH3), 19.3 (C5˗CH3 α˗pyranoside), 15.0 
(C5˗CH3 β˗pyranoside); 13C˗GATED (101 MHz; CDCl3): 99.6 (1JC1˗H1 = 180 Hz, 143), 
98.3 (1JC1˗H1 = 184 Hz, 144), 91.1 (1JC1˗H1 = 176 Hz, 141), 86.8 (1JC1’˗H1’ = 164 Hz, 
142); Pyranosides HRMS (ES+) m/z [Found: (M+Na)+ 427.1226 C17H24O11Na 
requires (M+Na)+, 427.1216]; These data were consistent with literature values.225 
11.1.52. Di˗O˗benzyl (O˗benzyl, N˗benzyl 
(4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗di˗O˗benzyl)˗1˗phosphate˗α˗D˗mannopyranosid
e) hydroxamate 124 
Hydroxamate thioglycoside 69 (420 mg, 0.55 mmol, 1.0 
equiv.) was stirred with activated MS4Å for 1 h in CH2Cl2 
(4.5 mL). Dibenzyl phosphate (230 mg, 0.83 mmol, 1.5 
equiv.) was added, and the solution was stirred for further 
30 min. before being cooled down to ˗30 °C. NIS (187 mg, 0.83 mmol, 1.5 equiv.) 
and AgOTf (42 mg, 0.16 mmol, 0.3 equiv.) were added successively and the reaction 
mixture was stirred for further 2.5 h, allowing the temperature to reach ˗10 °C. When 
TLC analysis indicated complete conversion of 69 to a lower Rf value material, the 
reaction was quenched by the addition of Et3N (770 µL, d = 0.726, 5.5 mmol, 10.0 
200 
 
equiv.)  and diluted with CH2Cl2 (20 mL). The organic layer was washed with 10% 
aq. Na2S2O3 solution (15 mL), brine (15 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. Flash column chromatography, eluting with 
EtOAc/petroleum ether (20/80, 30/70 and 40/60) afforded 124 as a colourless oil (280 
mg, 0.30 mmol, 55%). Rf  0.66 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 ˗36.5 (c. 0.73, CHCl3); 1H 
NMR (400 MHz; CDCl3) δ 7.34 – 7.22 (30 H, m, Ar˗H), 5.70 (1 H, dd, J = 6.1, 1.9 Hz, 
H1), 5.69 (1 H, app. t, J = 9.9 Hz, H4), 5.40 (1 H, d, J = 11.9 Hz, C(O)N(CH2Ph)OBn), 
5.36 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 4.99 (1 H, d, J = 11.7 Hz, 
OP(O)OCH2Ph), 4.97 (1 H, d, J = 11.4 Hz, OP(O)OCH2Ph), 4.95 (1 H, d, J = 11.5 
Hz, OP(O)OCH2Ph), 4.93 (1 H, d, J = 11.7 Hz, OP(O)OCH2Ph), 4.92 (1 H, d, J = 12.9 
Hz, C(O)N(Bn)OCH2Ph), 4.89 (1 H, d, J = 12.7 Hz, C(O)N(Bn)OCH2Ph), 4.69 (1 H, 
d, J = 12.1 Hz, CH2Ph˗attached to C2), 4.57 (1 H, d, J = 12.1 Hz, CH2Ph˗attached to 
C2), 4.48 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.45 (1 H, d, J = 12.1 Hz, 
CH2Ph˗attached to C3), 4.28 (1 H, d, J = 9.7 Hz, H5), 3.75 (1 H, dd, J = 9.7, 2.9 Hz, 
H3), 3.67 (1 H, app. t, J = 2.5 Hz, H2), 2.64 – 2.35 (3 H, m, CH2 Lev), 2.29 – 2.14 (1 
H, m, CH2 Lev), 2.11 (3 H, s, CH3 Lev); 13C NMR (101 MHz; CDCl3) δ 206.2 (C=O 
Lev ketone), 171.1 (C=O Lev), 150.3 (C(O)N(Bn)OBn), 137.9 (Cq), 137.7 (Cq), 137.6 
(Cq), 137.0 (Cq), 135.5 (1 C, d, J = 6.8 Hz, Cq), 135.4 (1 C, d, J = 6.8 Hz, Cq) 128.7, 
128.6, 128.6, 128.6, 128.4, 128.2, 128.2, 128.2, 128.1, 128.1, 127.8, 127.7, 127.7, 
127.6, 127.6, 96.0 (1 C, d, J = 6.0 Hz, C1), 76.3 (C(O)N(Bn)OCH2Ph), 75.5 (C3), 
74.2 (d, J = 9.2 Hz, C2), 73.5 (C(O)N(CH2Ph)OBn), 73.1 (CH2Ph˗attached to C2), 
72.3 (CH2Ph˗attached to C3), 72.2 (C5), 69.7 (d, J = 5.3 Hz, OP(O)OCH2Ph), 69.5 
(d, J = 5.4 Hz, OP(O)OCH2Ph), 67.9 (C4), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 27.8 (CH2 
Lev); 13C˗GATED (101 MHz; CDCl3): 96.0 (1JC1˗H1 = 180 Hz, C1); 31P NMR δ P (162 
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MHz, CDCl3) ˗2.82 (s); HRMS (ES+) m/z [Found: (M+Na)+ 950.3311 C53H54NO12PNa 
requires (M+Na)+, 950.3276]. 
11.1.53. Di˗O˗benzyl (O˗benzyl, N˗benzyl 
2,3˗di˗O˗benzyl)˗1˗phosphate˗α˗D˗mannopyranoside) hydroxamate 125 
C6˗hydroxamate 124 (270 mg, 0.29 mmol, 1.0 equiv.) was 
dissolved in a mixture of pyridine/AcOH (3 mL, 4/1 v/v), after 
which H2N˗NH2.AcOH (53 mg, 0.58 mmol, 2.0 equiv.) was 
added. The mixture was stirred for 1 h and then was diluted 
with EtOAc (25 mL), washed with 1 M HCl (20 mL), sat. aq. NaHCO3 solution (20 
mL) and brine (20 mL). The organic layer was then dried over MgSO4 filtered and 
concentrated under reduced pressure to furnish a yellow oil. Purification using silica 
gel flash column chromatography, eluting with EtOAc/toluene (0/100, 30/70, 40/60, 
90/10) afforded 125 as a colourless oil (173 mg, 0.21 mmol, 72%). Rf 0.62 
(EtOAc/Toluene, 3/7); [𝛼]𝐷
22 +3.34 (c. 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.33 
– 7.21 (30 H, m, Ar˗H), 5.72 (1 H, dd, J = 6.7, 1.6 Hz, H1), 5.31 (1 H, d, J = 12.1 Hz, 
C(O)N(CH2Ph)OBn), 5.27 (1 H, d, J = 12.1 Hz, C(O)N(CH2Ph)OBn), 5.01 (1 H, d, J 
= 12.1 Hz, C(O)N(Bn)OCH2Ph), 4.97 (1 H, d, J = 11.0 Hz, OP(O)OCH2Ph), 4.94 (1 
H, d, J = 11.6 Hz, OP(O)OCH2Ph), 4.93 (1 H, d, J = 12.3 Hz, C(O)N(Bn)OCH2Ph), 
4.91 (1 H, d, J = 12.0 Hz, OP(O)OCH2Ph), 4.89 (1 H, d, J = 11.7 Hz, OP(O)OCH2Ph), 
4.63 (1 H, d, J = 12.1 Hz, CH2Ph), 4.60 (1 H, d, J = 12.1 Hz, CH2Ph), 4.58 (1 H, d, J 
= 11.9 Hz, CH2Ph), 4.49 (1 H, d, J = 11.9 Hz, CH2Ph), 4.36 (1 H, app. t, J = 9.6 Hz, 
H4), 4.24 (1 H, d, J = 9.6 Hz, H5), 3.64 (1 H, dd, J = 4.7, 2.8 Hz, H2), 3.62 (1 H, dd, J 
= 9.5, 3.1 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 151.3 (C(O)N(Bn)OBn), 138.1 (Cq), 
137.6 (Cq), 137.4 (Cq), 136.7 (Cq), 135.5 (d, J = 3.2 Hz, Cq), 135.4 (d, J = 3.1 Hz, Cq), 
128.7, 128.6, 128.6, 128.6, 128.4, 128.4, 128.4, 128.4, 128.1, 128.1, 128.0, 127.9, 
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127.9, 127.8, 127.7, 127.7, 127.6, 96.2 (d, J = 6.0 Hz, C1), 77.2 (C3), 76.5 
(C(O)N(Bn)OCH2Ph), 74.5 (d, J = 8.8 Hz, C2), 73.1 (CH2Ph), 73.0 (C5), 72.9 
(CH2Ph), 72.7 (CH2Ph), 69.7 (d, J = 5.5 Hz, OP(O)OCH2Ph), 69.5 (d, J = 5.5 Hz, 
OP(O)OCH2Ph), 67.0 (C4); 31P NMR δ P (162 MHz, CDCl3) ˗2.81 (s); HRMS (ES+) 
m/z [Found: (M+H)+ 830.3121 C48H50NO10P requires (M+H)+, 830.3089]. 
11.1.54. (6˗C˗amide) α˗D˗mannopyranoside 1˗phosphate (disodium salt) 
126 
 A suspension of hydroxamate 125 (56 mg, 67 µmol, 1.0 
equiv.), 10% Pd/C (86 mg, 81 µmol, 1.2 equiv.), 20% 
Pd(OH)2/C (57 mg, 81 µmol, 1.2 equiv.) and 5% aq. 
NaHCO3 (227 µL, 0.14 mmol, 2.0 equiv.)  in a mixture of 
EtOH/THF (1.4 mL, 1.5/1 v/v) was stirred under an 
atmosphere of hydrogen (1 atm, balloon) at room temperature for 32 h. TLC analysis 
(hexane/EtOAc, 1/2) showed complete conversion of starting material to a lower Rf 
spot. The reaction mixture was filtered through Celite®, followed by solvent removal 
in vacuo to afford 126 as a white solid (19 mg, 60 µmol, 89%). Rf (0.14); [𝛼]𝐷
23 ˗8.72 
(c. 0.46, H2O); 1H NMR (400 MHz; D2O) δ 5.31 (1 H, dd, J = 8.4, 1.5 Hz, H1), 4.20 (1 
H, d, J = 9.9 Hz, H5), 3.93 – 3.87 (2 H, m, H2 and H3), 3.74 (1 H, app. t, J = 9.5 Hz, 
H4); 13C NMR (101 MHz; D2O) δ 174.7 (C(O)NH2), 95.1 (d, J = 4.8 Hz, C1), 71.7 (C5), 
70.6 (d, J = 7.4 Hz, C2), 69.7 (C3), 68.4 (C4); 31P NMR δ P (162 MHz, D2O) 1.89 (s); 
HRMS (ES˗) m/z [Found: (M˗H)˗ 272.0178 C6H10NO9P requires (M˗H)˗, 272.0177]. 
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11.1.55. Di˗O˗benzyl (2,3,˗di˗O˗benzyl˗4˗O˗tert˗butyl 
dimethylsilyl˗6˗C˗(1˗para˗methoxybenzyl 
˗tetrazol˗5˗yl)˗1˗phosphate˗α˗D˗mannopyranoside 127 
C6˗tetrazole thioglycoside 103 (50 mg, 69 µmol, 1.0 
equiv.) was stirred with activated MS4Å for 1h in CH2Cl2 
(0.7 mL). Dibenzyl phosphate (29 mg, 0.10 mmol, 1.5 
equiv.) was added, and the solution was stirred for 
further 30 min. before being cooled down to ˗40 °C. NIS (23 mg, 0.10 mmol, 1.5 
equiv.) and AgOTf (11 mg, 40 µmol, 0.6 equiv.) were added successively and the 
reaction mixture was stirred for further 3.5 h, allowing the temperature to reach 0 °C. 
When TLC analysis indicated complete conversion of 103 to a lower Rf value, the 
reaction was quenched by the addition of Et3N (96 µL, d = 0.726, 0.7 mmol, 10.0 
equiv.)  and diluted with CH2Cl2 (10 mL). The organic layer was washed with 10% 
aq. Na2S2O3 solution (10 mL), brine (5 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. Flash column chromatography, eluting with 
EtOAc/toluene (5/95, 10/90 and 30/70) afforded 127 as colourless oil (10 mg, 10 
µmol, 16%). Rf 0.54 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 ˗61.6 (c. 0.4, CHCl3); 1H NMR (400 
MHz; CDCl3) δ 7.33 – 7.27 (21 H, m, Ar˗H), 7.22 (2 H, d, J = 8.8 Hz, Ar˗H PMB), 6.67 
(1 H, d, J = 8.8 Hz, Ar˗H PMB), 5.72 (1 H, dd, J = 6.4, 2.1 Hz, H1), 5.48 (1 H, d, J = 
14.8 Hz, CH2Ph PMB), 5.39 (1 H, d, J = 14.8 Hz, CH2Ph PMB), 5.17 (1 H, d, J = 9.7 
Hz, H5), 4.99 (1 H, d, J = 9.2 Hz, OP(O)OCH2Ph), 4.98 (1 H, d, J = 9.3 Hz, 
OP(O)OCH2Ph), 4.62 (1 H, d, J = 11.4 Hz, CH2Ph), 4.56 (1 H, d, J = 11.5 Hz, CH2Ph), 
4.53 (1 H, d, J = 11.9 Hz, CH2Ph), 4.46 (1 H, d, J = 11.7 Hz, CH2Ph), 4.34 (1 H, app. 
t, J = 9.4 Hz, H4), 3.72 (3 H, s, OCH3), 3.73 – 3.70 (1 H, m, H2), 3.64 (1 H, dd, J = 
9.0, 2.7 Hz, H3), 0.59 (9H, s, C(CH3)3), ˗0.22 (3 H, s, Si(CH3)2), ˗0.79 (3 H, s, 
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Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 159.8 (Cq PMB), 151.3 (Cq tetrazole), 137.7 
(Cq), 137.4 (Cq), 135.3 (d, J = 6.1 Hz, Cq OP(O)OBn), 135.2 (d, J = 6.1 Hz, Cq 
OP(O)OBn), 130.1(Cq), 128.9, 128.7, 128.7, 128.5, 128.4, 128.2, 128.1, 128.1, 
128.0, 127.8, 127.7, 125.7, 114.2 (Ar˗C), 95.9 (d, J = 5.7 Hz, C1), 78.7 (C3), 74.5 
(C2), 73.8 (CH2Ph), 72.2 (CH2Ph), 70.0 (d, J = 5.7 Hz, OP(O)OCH2Ph), 69.9 (d, J = 
5.5 Hz, OP(O)OCH2Ph), 69.1 (C4), 68.8 (C5), 50.7 (CH2Ph PMB), 25.6 (C(CH3)3), 
17.8 (C(CH3)3), ˗4.6 (Si(CH3)2), ˗6.1 (Si(CH3)2); 31P NMR δ P (162 MHz, CDCl3) ˗2.93 
(s); HRMS (ES+) m/z [Found: (M+H)+ 893.3719 C48H58N4O9SPSi requires (M+H)+, 
893.3711]. 
11.1.56. Di˗O˗benzyl (2,3,4˗tri˗O˗benzyl˗6˗C˗(1˗para˗methoxybenzyl 
˗tetrazol˗5˗yl)˗1˗phosphate)˗α˗D˗mannopyranoside 129 Di˗O˗benzyl 
2,3,4˗tri˗O˗benzyl˗6˗C˗(2˗para˗methoxybenzyl˗tetrazol˗5˗yl)˗1˗phosphate)˗α˗D˗
mannopyranoside 130 
C6˗tetrazole thioglycoside 113 and 114 
(730 mg, 1.04 mmol, 1.0 equiv.) was 
stirred with activated MS4Å for 1h in 
CH2Cl2 (10 mL). Dibenzyl phosphate 
(580 mg, 2.08 mmol, 2.0 equiv.) was added, and the solution was stirred for further 
30 min. before being cooled down to ˗30 °C. NIS (350 mg, 1.56 mmol, 1.5 equiv.) 
and AgOTf (133 mg, 0.52 mmol, 0.5 equiv.) were added successively and the 
reaction mixture was stirred for further 3.5 h, allowing the temperature to reach 0 °C. 
When TLC analysis indicated complete conversion of 113 and 114 to a lower Rf 
value, the reaction was quenched by the addition of Et3N (1.4 mL, d = 0.726, 10.4 
mmol, 10.0 equiv.) and diluted with CH2Cl2 (50 mL). The organic layer was washed 
with 10% aq. Na2S2O3 solution (30 mL), brine (30 mL), dried over MgSO4, filtered 
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and concentrated under reduced pressure. Flash column chromatography, eluting 
with EtOAc/toluene (5/95, 10/90 and 30/70) afforded 129 and 130 as colourless oils 
in a 50/50 ratio (650 mg, 0.75 mmol, 72%). Rf 0.66 (EtOAc/toluene, 3/7); 1H NMR 
(400 MHz; CDCl3) δ 7.38 – 7.27 (35 H, m, Ar˗H), 7.14 (2 H, d, J = 7.2 Hz, Ar˗H PMB), 
7.07 (2 H, d, J = 8.7 Hz, Ar˗H PMB), 6.93 (2 H, d, J = 6.7 Hz, Ar˗H), 6.82 (2 H, d, J = 
6.5 Hz, Ar˗H), 6.75 (2 H, d, J = 8.8 Hz, Ar˗H PMB), 6.65 (2 H, d, J = 8.8 Hz, Ar˗H 
PMB), 5.76 (1 H, dd, J = 6.3, 1.8 Hz, H1 N2˗isomer), 5.69 (1 H, dd, J = 6.3, 2.1 Hz, 
H1 N1˗isomer), 5.65 (1 H, d, J = 14.0 Hz, CH2Ph PMB), 5.61 (1 H, d, J = 14.2 Hz, 
CH2Ph PMB), 5.33 (1 H, d, J = 15.0 Hz, CH2Ph PMB), 5.16 (1 H, d, J = 13.4 Hz, 
CH2Ph PMB), 5.15 (1 H, d, J = 10.0 Hz, H5 N1˗isomer or N2˗isomer), 5.12 (1 H, d, J 
= 9.7 Hz, H5 N1˗isomer or N2˗isomer), 5.04 (2 H, d, J = 8.6 Hz, OP(O)OCH2Ph), 4.96 
(2 H, d, J = 8.3 Hz, OP(O)OCH2Ph), 4.95 (2 H, d, J = 8.3 Hz, OP(O)OCH2Ph), 4.94 
(2 H, d, J = 8.3 Hz, OP(O)OCH2Ph), 4.72 (1 H, d, J = 11.9 Hz, CH2Ph), 4.71 (1 H, d, 
J = 11.0 Hz, CH2Ph), 4.69 (1 H, d, J = 11.2 Hz, CH2Ph), 4.64 (1 H, d, J = 11.8 Hz, 
CH2Ph), 4.64 (1 H, d, J = 10.1 Hz, CH2Ph), 4.60 (1 H, d, J = 11.8 Hz, CH2Ph), 4.57 
(1 H, d, J = 10.6 Hz, CH2Ph), 4.54 (2 H, d, J = 11.7 Hz, CH2Ph), 4.53 (1 H, app. t, J 
= 9.6 Hz, H4 N2˗isomer), 4.49 (1 H, d, J = 11.6 Hz, CH2Ph), 4.39 (1 H, app. t, J = 9.8 
Hz, H4 N1˗isomer), 4.29 (1 H, d, J = 10.6 Hz, CH2Ph), 4.21 (1 H, d, J = 10.7 Hz, 
CH2Ph), 3.89 (1 H, dd, J = 9.6, 3.2 Hz, H3 N2˗isomer), 3.86 (1 H, dd, J = 9.6, 3.0 Hz, 
H3 N1˗isomer), 3.78 (1 H, dd, J = 4.8, 2.2 Hz, H2 N2˗isomer), 3.74 – 3.72 (1 H, m, H2 
N1˗isomer), 3.71 (3 H, s, OCH3), 3.70 (3 H, s, OCH3); 13C NMR (101 MHz; CDCl3) δ 
163.8 (Cq tetrazole N2˗isomer), 160.0 (Cq PMB), 159.7 (Cq PMB), 151.5 (Cq tetrazole 
N1˗isomer), 138.1 (Cq), 138.0 (Cq), 137.9 (Cq), 137.7 (Cq), 137.4 (Cq), 137.4 (Cq), 
135.6 (d, J = 6.7 Hz, Cq OP(O)OBn), 135.5 (d, J = 6.7 Hz, Cq OP(O)OBn), 135.2 (d, 
J = 6.2 Hz, Cq OP(O)OBn), 135.1 (d, J = 6.4 Hz, Cq OP(O)OBn), 130.0 (Cq), 129.6 
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(Cq), 128.9, 128.7, 128.7, 128.6, 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 
128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 
127.6, 127.6, 127.4, 125.8, 125.2, 114.3, 114.2, 96.2 (d, J = 6.1 Hz, C1 N2˗isomer), 
96.1 (d, J = 6.1 Hz, C1 N1˗isomer), 78.6 (C3 N1˗isomer or N2˗isomer), 78.4 (C3 
N1˗isomer or N2˗isomer), 76.4 (C4 N2˗isomer), 75.1 (2 C, CH2Ph), 76.0 (C4 
N1˗isomer), 74.5 (d, J = 9.6 Hz, C2 N1˗isomer), 74.3 (d, J = 9.3 Hz, C2 N2˗isomer), 
73.5 (CH2Ph), 72.9 (CH2Ph), 72.6 (CH2Ph), 72.5 (CH2Ph), 70.1 (d, J = 5.6 Hz, 
OP(O)OCH2Ph, 70.0 (d, J = 5.7 Hz, OP(O)OCH2Ph), 69.7 (d, J = 5.4 Hz, 
OP(O)OCH2Ph), 69.6 (d, J = 5.5 Hz, OP(O)OCH2Ph), 67.9 (C5 N2˗isomer), 66.5 (C5 
N1˗isomer), 56.5 (CH2Ph PMB), 55.2 (2 C, OCH3), 50.4 (CH2Ph PMB); 31P NMR δ P 
(162 MHz, CDCl3) ˗2.88 (s), ˗2.79 (s); HRMS (ES+) m/z [Found: (M+H)+ 869.3370 
C49H51N4O9P requires (M+H)+, 869.3315]. 
11.1.57. 5˗C˗methyl˗α/β˗D˗mannopyranose 1˗phosphate 131, 132, 
5˗C˗methyl˗α/β˗D˗mannofuranose 1˗phosphate 133 
H3PO4 (240 mg, 2.45 mmol, 10 equiv.) 
was added to a mixture of 120, 121, 123 
(100 mg, 0.25 mmol, 1.0 equiv.) in a 
Schlenk tube under inert atmosphere. 
The reaction mixture was heated under 
vacuum for 2 hours at 60 °C. The black 
solution was cooled and diluted in 
anhydrous THF (4 mL). TLC (2/1 
EtOAc/petroleum ether) showed complete conversion of the starting material (Rf 
0.60) to a new baseline product (Rf 0.00). The mixture was stirred for 5 min. before 
being added to an excess of 1 M LiOH aq. (20 mL) at 0 °C. An off˗white precipitate 
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formed and the solution was stirred for 72 h at room temperature. Upon completion, 
the reaction mixture was filtered under vacuum through a Whatman GF/A glass 
microfibre filter paper and ion exchange Amberlite 120 (H+) resin was added to the 
filtrate until pH = 7. The solution was filtered again and the filtrate was concentrated 
in vacuo. The residue was treated with MeOH (3 mL) and a cloudy precipitate formed 
which was centrifuged at 4000 rpm for 10 min. The supernatant was removed and 
the crude product was dried under vacuum prior to purification via strong anion 
exchange chromatography was conducted manually using a Bio˗ScaleTM Mini 
UNOsphereTM Q (strong anion exchange) cartridge (See General methods) and 
lyophilisation afforded 131 (56%), 132 (23%), and 133 (21%) as a white powder (15 
mg, 48 µmol, 19%). Rf 0.36 (MeCN/H2O, 2/1); 1H NMR (400 MHz; D2O) δ α˗anomer 
5.27 (1H, dd, J = 9.1, 2.2 Hz, H1), 4.09 (1H, dd, J = 10.2, 3.3 Hz, H3), 3.93–3.91 (1H, 
m, H2), 3.78 (1H, d, J = 10.2 Hz, H4), 3.39 (2H, q, J = 11.9 Hz, H6a,b); β˗anomer δ 
5.19 (1H, dd, J = 8.6, 1.1 Hz, H1), 3.96 (1H, d, J = 2.8 Hz, H2), 3.84 (1H, dd, J = 10.2, 
3.4 Hz, H3), 3.64 (1H, d, J = 10.2 Hz, H4), 3.54–3.45 (2H, m, H6a,b); 13C NMR (101 
MHz, D2O) δ α˗anomer 95.8 (C1, d, J = 3.9 Hz), 79.8 (C5), 71.8 (C2), 68.0 (C4), 
67.2 (C6), 66.7 (C3), 18.0 (C5˗CH3); 13C˗GATED (101 MHz; D2O): 95.8 (1JC1˗H1 = 
172 Hz, 145), 89.3 (1JC1˗H1 = 168 Hz, 146); 31P NMR δ P (162 MHz, D2O) α˗anomer 
1.85 (s). β˗anomer 2.27 (s); HRMS (ES˗) m/z [Found: (M˗H)˗ 273.0385 C7H13O9P 
requires (M˗H)˗, 273.0381]. 
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11.1.58. 3˗azidopropyl (methyl 2,3˗di˗O˗benzyl˗4˗O˗(methyl 
(4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl) 
uronate)˗β˗D˗mannopyranoside) uronate 134 
A solution of 55 (160 mg, 0.31 mmol, 1.0 
equiv.) and 60 (216 mg, 0.46 mmol, 1.5 
equiv.) in in CH2Cl2 (5 mL) was stirred 
over activated MS4Å for 30 min. before NIS (90 mg 0.40 mmol, 1.3 equiv.) was 
added. The mixture was cooled to ˗60 °C before TMSOTf (5.6 µL, d = 1.225, 31 µmol, 
0.1 equiv.) was added. The reaction was left stirring for 30 min. at room temperature, 
and upon completion, Et3N was added until pH = 7. The reaction mixture was filtered 
through Celite® and concentrated under reduced pressure. Purification by Reveleris® 
automated silica gel flash column chromatography (liquid injection onto column), 
eluting with EtOAc/toluene (0/100, 5/95 and 10/90) afforded 134 as a colourless oil 
(150 mg, 0.17 mmol, 56%). Rf 0.42 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 ˗35.3 (c. 3.65, CHCl3); 
1H NMR (500 MHz; CDCl3) δ 7.50 – 7.21 (20 H, m, Ar˗H), 5.44 (1 H, app. t, J = 9.8 
Hz, H4’), 4.88 (1H, d, J = 12.3 Hz, CH2Ph), 4.84 (1 H, d, J = 12.2 Hz, CH2Ph), 4.79 
(1 H, d, J = 12.3 Hz, CH2Ph), 4.78 (2 H, d, J = 12.1 Hz, CH2Ph), 4.76 (1 H, d, J = 
12.2 Hz, CH2Ph), 4.72 (1 H, d, J =11.9 Hz, CH2Ph), 4.60 (1 H, d, J = 12.2 Hz, CH2Ph), 
4.54 (1 H, d, J = 12.3 Hz, CH2Ph), 4.52 (1 H, d, J = 0.9 Hz, H1’), 4.46 (1 H, s, H1), 
4.43 (1 H, app. t, J = 8.8 Hz, H4), 4.03 (1 H, dt, J = 9.7, 5.7 Hz, OCH2CH2CH2N3), 
3.93 (1 H, d, J = 8.8 Hz, H5), 3.89 – 3.88 (2 H, m, H2’, H2), 3.71 (1 H, d, J = 9.8 Hz, 
H5’), 3.67 (3 H, s, CO2CH3), 3.66 (1 H, dd, J = 8.8, 3.0 Hz, H3), 3.58 (3 H, s, CO2CH3), 
3.55 (1 H, m, OCH2CH2CH2N3), 3.49 (1 H, dd, J = 9.8, 2.8 Hz, H3’), 3.37 (2 H, t, J = 
6.8 Hz, OCH2CH2CH2N3), 2.02 (3 H, s, C(O)CH3), 1.95 – 1.84 (2 H, m, 
OCH2CH2CH2N3); 13C NMR (126 MHz; CDCl3) δ 169.8 (C(O)CH3), 168.7 (CO2CH3), 
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167.8 (CO2CH3), 138.7 (Cq), 138.6 (Cq), 138.4 (Cq), 137.8 (Cq), 128.4, 128.3, 128.2, 
128.1, 128.1, 127.9, 127.7, 127.5, 127.5, 127.4, 127.3, 127.2, 102.4 (C1’), 101.9 
(C1), 79.4 (C3), 78.5 (C3’), 77.6 (C4), 75.0 (C2’ or C2), 74.5 (C5), 74.4 (CH2Ph), 74.0 
(C2’ or C2, CH2Ph), 73.4 (C5’), 72.2 (CH2Ph), 71.7 (CH2Ph), 68.7 (C4’), 66.9 
(OCH2CH2CH2N3), 52.4 (CO2CH3), 52.4 (CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 
(OCH2CH2CH2N3), 20.8 (C(O)CH3); 13C˗GATED (126 MHz; CDCl3): 102.4  (1JC1’˗H1’ 
= 155 Hz, C1’), 101.9 (1JC1˗H1 = 156 Hz, C1); HRMS (ES+) m/z [Found: (M+NH4)+ 
901.3877 C47H57N4O14 requires (M+NH4)+, 901.3871]. 
11.1.59. 3˗azidopropyl (methyl 2,3˗di˗O˗benzyl˗4˗O˗(methyl 
(2,3˗di˗O˗benzyl˗α˗D˗mannopyranosyl) uronate)˗β˗D˗mannopyranoside) 
uronate 135 
To a stirred solution of 134 (50 mg, 56 
µmol, 1.0 equiv.) in anhydrous MeOH (1 
mL), Na (65 µg, 2.8 µmol, 0.05 equiv.) 
dissolved in anhydrous MeOH (30 µL) was 
added at room temperature. The mixture 
was stirred for 2 h, then neutralised with ion exchange Amberlite 120 (H+) resin 
(approximately 0.1 g, 5 min), filtered, and concentrated under reduced pressure. 
Flash column chromatography, eluting with EtOAc/hexane (20/80, 50/50, 70/30, 
90/10) afforded 85 as a colourless oil (15 mg, 18 µmol, 32%, 46% based on 
recovered starting material, 16 mg). Rf 0.42 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 ̠ 17.8 (c. 0.74, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.65 – 6.80 (20 H, m, Ar˗H), 5.42 (1 H, s, H1’), 
4.94 (1 H, d, J = 12.5 Hz, CH2Ph), 4.73 (1 H, d, J = 12.5 Hz, CH2Ph), 4.63 (1 H, d, J 
= 11.9 Hz, CH2Ph), 4.55 (1 H, d, J = 11.9 Hz, CH2Ph), 4.45 (1 H, app. t, J = 9.3 Hz, 
H4), 4.43 (1 H, s, H1), 4.40 (1 H, d, J = 11.6 Hz, CH2Ph), 4.32 (1 H, d, J = 12.2 Hz, 
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CH2Ph), 4.23 (1 H, d, J = 12.3 Hz, CH2Ph), 4.22 (1 H, d, J = 9.3 Hz, H4’), 4.19 (1 H, 
d, J = 11.9 Hz, CH2Ph), 4.07 – 3.98 (1 H, m, OCH2CH2CH2N3), 4.01 (1 H, d, J = 9.7 
Hz, H5’), 3.91 (1 H, d, J = 2.6 Hz, H2), 3.84 (1 H, d, J = 9.4 Hz, H5), 3.80 (3 H, s, 
CO2CH3), 3.76 (3 H, s, CO2CH3), 3.67 – 3.62  (2 H, m, H2’, H3’), 3.57 – 3.49 (1 H, m, 
OCH2CH2CH2N3), 3.43 – 3.36 (2 H, m, OCH2CH2CH2N3), 3.40 (1 H, dd, J = 9.3, 2.7 
Hz, H3), 2.95 (1 H, br. s, C4˗OH), 2.01 – 1.78 (2 H, m, OCH2CH2CH2N3); 13C NMR 
(101 MHz; CDCl3) δ 170.9 (CO2CH3), 168.3 (CO2CH3), 138.5 (Cq), 138.3 (Cq), 138.3 
(Cq), 137.4 (Cq), 128.5, 128.4, 128.2, 128.1, 128.0, 127.6, 127.6, 127.5, 127.4, 127.4, 
102.0 (C1), 99.8 (C1’), 81.5 (C3), 78.2 (C2’), 75.8 (C5), 75.0 (C3’), 74.7 (C4), 74.1 
(CH2Ph), 72.9 (C2), 72.4 (2 C, CH2Ph), 72.4 (C5’), 71.0 (CH2Ph), 68.4 (C4’), 67.0 
(OCH2CH2CH2N3), 52.6 (CO2CH3), 52.5 (CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 
(OCH2CH2CH2N3); 13C˗GATED (101 MHz; CDCl3): 102.0 (1JC1˗H1 = 156 Hz, C1), 99.8 
(1JC1’˗H1’ = 176 Hz, C1’); HRMS (ES+) m/z [Found: (M+Na)+ 864.3343 C45H51N3O13Na 
requires (M+Na)+, 864.3320]. 
11.1.60. 3˗azidopropyl (methyl 2,3˗di˗O˗benzyl˗4˗O˗(methyl 
(2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl) uronate)˗β˗D˗mannopyranoside) 
uronate 136 
To a stirred solution of 137 (70 mg, 73 
µmol, 1.0 equiv.) in anhydrous MeOH 
(0.7 mL) at 0 °C, was added AcCl (1.6 
µL, d = 1.104, 20 µmol, 0.3 equiv.) and the reaction was left stirring at room 
temperature for 24 h. The mixture was then neutralised and diluted with sat. aq. 
NaHCO3 (20 mL). The aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure to furnish a colourless oil. Purification by silica gel flash column 
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chromatography, eluting with Et2O/toluene (10/90, 20/80, 25/75) afforded 136 as a 
colourless oil (20 mg, 24 µmol, 32%). Rf 0.30 (EtOAc/hexane, 1/2); 1H NMR (400 
MHz; CDCl3) δ 7.38 – 7.22 (20 H, m), 4.84 (1 H, d, J = 12.3 Hz, CH2Ph), 4.79 (1 H, 
d, J = 12.1 Hz, CH2Ph), 4.76 (1 H, d, J = 12.1 Hz, CH2Ph), 4.75 (1 H, d, J = 12.3 Hz, 
CH2Ph), 4.72 (1 H, s, H1’), 4.67 (1 H, d, J = 12.2 Hz, CH2Ph), 4.60 (1 H, d, J = 12.3 
Hz, CH2Ph), 4.57 (1 H, d, J = 12.0 Hz, CH2Ph), 4.55 (1 H, d, J = 12.3 Hz, CH2Ph), 
4.48 (1 H, d, J = 0.7 Hz, H1), 4.45 (1 H, app. t, J = 8.6 Hz, H4), 4.19 (1 H, app. t, J = 
9.6 Hz, H4’), 4.07 – 3.99 (1 H, m, OCH2CH2CH2N3), 3.90 (1 H, d, J = 8.7 Hz, H5), 3.85 
(1 H, d, J = 2.3 Hz, H2), 3.83 (1 H, d, J = 2.5 Hz, H2’), 3.70 (1 H, dd, J = 9.0, 4.4 Hz, 
H3), 3.64 (3 H, s, CO2CH3), 3.62 (3 H, s, CO2CH3), 3.59 (1 H, d, J = 9.6 Hz, H5’), 3.57 
– 3.51(1 H, m, OCH2CH2CH2N3), 3.36 (2 H, t, J = 6.7 Hz, OCH2CH2CH2N3), 3.32 (1 
H, dd, J = 9.5, 2.8 Hz, H3’), 2.93 (1 H, br. s, C4˗OH), 1.94 – 1.81 (2 H, m, 
OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 169.9 (CO2CH3), 168.6 (CO2CH3), 
138.8 (Cq), 138.7 (Cq), 138.4 (Cq), 138.0 (Cq), 128.5, 128.3, 128.2, 128.1, 128.1, 
127.8, 127.8, 127.7, 127.5, 127.4, 127.4, 127.1, 102.5 (C1’), 101.8 (C1), 80.4 (C3’), 
79.4 (C5’), 77.2 (C4), 75.2 (C2’), 74.8 (C3), 74.6 (CH2Ph), 74.5 (C5), 73.9 (C2, 
CH2Ph), 72.1 (CH2Ph), 71.9 (CH2Ph), 68.2 (C4’), 66.9 (OCH2CH2CH2N3), 52.5 
(CO2CH3), 52.4 (CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 (OCH2CH2CH2N3); 
13C˗GATED (101 MHz; CDCl3): 102.5 (1JC1˗H1 = 156 Hz, C1’), 101.8 (1JC1’˗H1’ = 156 
Hz, C1); HRMS (ES+) m/z [Found: (M+NH4)+ 859.3781 C45H55N4O13 requires 
(M+NH4)+, 859.3766]; These data were consistent with literature values.211 
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11.1.61. 3˗azidopropyl (methyl 2,3˗di˗O˗benzyl˗4˗O˗(methyl (4˗O˗tert˗butyl 
dimethylsilyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl) 
uronate)˗β˗D˗mannopyranoside) uronate 137 
A solution of 57 (110 mg, 0.18 mmol, 
1.0 equiv.) and 60 (96 mg, 0.20 mmol, 
1.1 equiv.) in in CH2Cl2 (3.5 mL) was 
stirred over activated MS4Å for 30 min. before NIS (54 mg, 0.24 mmol, 1.3 equiv.) 
was added. The mixture was cooled to ˗10 °C before TMSOTf (6.7 µL, d = 1.225, 40 
µmol, 0.2 equiv.) was added. The reaction was left stirring for 30 min. at room 
temperature, and upon completion, Et3N was added until pH = 7. The reaction 
mixture was filtered through Celite® and concentrated under reduced pressure. 
Purification by silica gel flash column chromatography, eluting with EtOAc/toluene 
(0/100, 5/95, 10/90) afforded 137, as a colourless oil (105 mg, 0.11 mmol, 61%). Rf 
0.76 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 +8.0 (c. 0.21, CHCl3); 1H NMR (400 MHz; CDCl3) δ 
7.41 – 7.15 (20 H, m, Ar˗H), 4.82 (1 H, d, J = 12.3 Hz, CH2Ph), 4.80 (1 H, d, J = 12.5 
Hz, CH2Ph), 4.74 (1 H, d, J = 12.7 Hz, CH2Ph), 4.71 (1 H, s, H1’), 4.70 (1 H, d, J = 
12.9 Hz, CH2Ph), 4.67 (1 H, d, J = 12.3 Hz, CH2Ph), 4.56 (1 H, d, J = 11.8 Hz, CH2Ph), 
4.55 (1 H, d, J = 12.2 Hz, CH2Ph), 4.47 (1 H, d, J = 11.4 Hz, CH2Ph), 4.45 (1 H, s, 
H1), 4.41 (1 H, app. t, J = 8.6 Hz, H4), 4.30 (1 H, app. t, J = 9.2 Hz, H4’), 4.08 – 3.99 
(1 H, m, OCH2CH2CH2N3), 3.86 (1 H, d, J = 8.6 Hz, H5), 3.83 (1 H, d, J = 2.5 Hz, H2’), 
3.80 (1 H, d, J = 2.2 Hz, H2), 3.74 (1 H, d, J = 9.2 Hz, H5’), 3.62 (6 H, s, CO2CH3), 
3.62 – 3.56 (1 H, m, H3), 3.52 (1 H, ddd, J = 9.6, 7.6, 5.2 Hz, OCH2CH2CH2N3), 3.35 
(2 H, t, J = 6.7 Hz, OCH2CH2CH2N3), 3.28 (1 H, dd, J = 9.2, 2.7 Hz, H3’), 1.92 – 1.82 
(2 H, m, OCH2CH2CH2N3), 0.81 (9 H, s, C(CH3)3), 0.00 (6 H, s, Si(CH3)2); 13C NMR 
(101 MHz; CDCl3) δ 168.7 (CO2CH3), 168.7 (CO2CH3), 139.2 (Cq), 138.8 (Cq), 138.5 
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(Cq), 137.9 (Cq), 128.4, 128.2, 128.1, 128.1, 128.0, 127.6, 127.5, 127.5, 127.5, 127.4, 
127.3, 127.2, 102.6 (C1’), 101.7 (C1), 81.8 (C3’), 79.1 (C3), 77.5 (C5’), 77.2 (C4), 
75.0 (C2’), 74.6 (C5), 74.5 (CH2Ph), 74.4 (C2), 73.9 (CH2Ph), 72.6 (CH2Ph), 71.4 
(CH2Ph), 68.9 (C4’), 66.8 (OCH2CH2CH2N3), 52.3 (CO2CH3), 52.0 (CO2CH3), 48.3 
(OCH2CH2CH2N3), 29.1 (OCH2CH2CH2N3), 25.8 (C(CH3)3), 18.0 (C(CH3)3), ˗3.9 
(Si(CH3)2), ˗5.3 (Si(CH3)2); HRMS (ES+) m/z [Found: (M+NH4)+ 973.4639 
C51H69N4O13Si requires (M+NH4)+, 973.4630]. 
11.1.62. 3˗azidopropyl (methyl 
2,3˗di˗O˗benzyl˗4˗O˗(O˗benzyl˗(4˗O˗acetyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranosy
l) hydroxamate)˗β˗D˗mannopyranoside) uronate 138 
A solution of 63 (110 mg, 0.17 mmol, 1.0 
equiv.) and 60 (87 mg, 0.18 mmol, 1.1 
equiv.) and in CH2Cl2 (5 mL) was stirred 
over activated MS4Å for 1 h before NIS (60 mg 0.27 mmol, 1.6 equiv.) was added. 
The mixture was cooled to ˗60 °C before TMSOTf (3.5 µL, d = 1.225, 20 µmol, 0.1 
equiv.) was added. The reaction was left stirring for 1 h at room temperature, and 
upon completion, Et3N was added until pH = 7. The reaction mixture was filtered 
through Celite® and concentrated under reduced pressure. Purification by 
SephadexTM LH˗20, eluting with CH2Cl2 and purification by Reveleris® automated 
silica gel flash column chromatography (liquid injection onto column), eluting with 
EtOAc/toluene (0/100, 5/95 and 10/90) afforded 88 as a colourless oil (90 mg, 92 
µmol, 54%). Rf 0.42 (EtOAc/toluene, 3/7); [𝛼]𝐷
22 ˗45.2 (c. 0.7, CHCl3); 1H NMR (400 
MHz; CDCl3) δ 8.37 (1 H, br. s, C(O)NHOBn), 7.38 – 7.07 (25 H, m, Ar˗H), 5.60 (1 
H, app. t, J = 9.8 Hz, H4’), 4.83 (1 H, d, J = 12.3 Hz, CH2Ph), 4.80 (2 H, d, J = 12.2 
Hz, CH2Ph), 4.71 (1 H, s, H1’), 4.71 (1 H, d, J = 12.5 Hz, CH2Ph), 4.54 (1 H, d, J = 
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12.2 Hz, CH2Ph), 4.48 (1 H, d, J = 12.4 Hz, CH2Ph), 4.47 (1 H, d, J = 12.6 Hz, CH2Ph), 
4.44 (1 H, app. t, J = 9.8 Hz, H4), 4.43 (2 H, d, J = 12.7 Hz, CH2Ph), 4.40 (1 H, d, J = 
12.7 Hz, CH2Ph), 4.38 (1 H, s, H1), 4.01 (1 H, ddd, J = 11.2, 9.4, 5.4 Hz, 
OCH2CH2CH2N3), 3.92 (1 H, d, J = 9.9 Hz, H5’), 3.85 (1 H, d, J = 2.8 Hz, H2’), 3.82 (1 
H, d, J = 2.8 Hz, H2), 3.79 (1 H, d, J = 9.6 Hz, H5), 3.72 (3 H, s, CO2CH3), 3.52 (1 H, 
dd, J = 9.7, 2.8 Hz, H3’), 3.57 – 3.44 (1 H, m, OCH2CH2CH2N3), 3.39 (1 H, dd, J = 
6.9, 2.7 Hz, H3), 3.42 – 3.35 (2 H, m, OCH2CH2CH2N3), 2.07 (3 H, s, C(O)CH3), 1.97 
– 1.80 (2 H, m, OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 170.0 (C(O)CH3), 
169.7 (C(O)NHOBn), 168.6 (CO2CH3), 138.3 (Cq), 138.3 (Cq), 138.0 (Cq), 137.8 (Cq), 
137.2 (Cq), 128.9, 128.5, 128.5, 128.4, 128.2, 128.2, 128.2, 127.9, 127.8, 127.7, 
127.6, 127.5, 126.3, 124.6, 102.1 (C1), 100.6 (C1’), 79.2 (C3), 79.0 (C3’), 75.2 (C4), 
74.7 (C5), 74.7 (2 C, C2’ and CH2Ph), 73.9 (CH2Ph), 73.5 (CH2Ph), 73.4 (C2),  73.1 
(C5’), 72.4 (CH2Ph), 72.2 (CH2Ph), 68.1 (C4’), 67.0 (OCH2CH2CH2N3), 52.5 
(CO2CH3), 48.3 (OCH2CH2CH2N3), 29.1 (OCH2CH2CH2N3), 21.0 (C(O)CH3); 
13C˗GATED (101 MHz; CDCl3): 102.4 (1JC1˗H1 = 154 Hz, C1), 101.9 (1JC1’˗H1’ = 165 
Hz, C1’); IR νmax/cm˗1 3260 (w, N˗H), 2096 (w, N=N=N), 1745 (s, C=Oester), 1708 (m, 
C=Oamide), 1229 (m, C˗Oester), 1089 (s, C˗Oether), 1054 (s, C˗Oester). 
11.1.63. 3˗azidopropyl (methyl 
2,3˗di˗O˗benzyl˗4˗O˗(O˗benzyl˗N˗benzyl˗(4˗O˗acetyl˗2,3˗di˗O˗benzyl˗α˗D˗mann
opyranosyl) hydroxamate)˗β˗D˗mannopyranoside) uronate 139 
A solution of 67 (180 mg, 0.26 mmol, 1.1 
equiv.) and 60 (113 mg, 0.23 mmol, 1.0 
equiv.) and in CH2Cl2 (5 mL) was stirred over 
activated MS4Å for 1 h before NIS (88 mg 
0.39 mmol, 1.5 equiv.) was added. The 
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mixture was cooled to 0 °C before TMSOTf (4.2 µL, d = 1.225, 20 µmol, 0.1 equiv.) 
was added. The reaction was left stirring for 30 min. at 0 °C, and upon completion, 
Et3N was added until pH = 7. The reaction mixture was filtered through Celite® and 
concentrated under reduced pressure. Flash column chromatography, eluting with 
EtOAc/toluene (0/100, 5/95 and 10/90) afforded 139 as a colourless oil (32 mg, 28 
µmol, 12%, α/β = 9/1). Rf  0.53 (EtOAc/toluene, 3/7); 1H NMR (400 MHz; CDCl3) δ 
7.44 – 7.09 (30 H, m, Ar˗H), 5.63 (1 H, app. t, J = 9.9 Hz, H4’), 5.44 (2 H, s, 
C(O)N(CH2Ph)OBn), 5.39 (1 H, d, J = 1.8 Hz, H1’), 4.95 (2 H, s, C(O)N(Bn)OCH2Ph), 
4.92 (1 H, d, J = 12.6 Hz, CH2Ph˗attached to C2), 4.73 (1 H, d, J = 12.5 Hz, 
CH2Ph˗attached to C2), 4.53 (1 H, d, J = 12.7 Hz, CH2Ph˗attached to C3’), 4.50 (1 
H, d, J = 12.5 Hz, CH2Ph˗attached to C3’) 4.42 (1 H, s, H1), 4.40 (1 H, d, J =10.3 Hz, 
H4), 4.38 (1 H, d, J = 11.2 Hz, CH2Ph˗attached to C3), 4.34 (1 H, d, J = 12.1 Hz, 
CH2Ph˗attached to C2’), 4.23 (1 H, d, J = 12.0 Hz, CH2Ph˗attached to C2’), 4.18 (1 
H, d, J = 11.5 Hz, CH2Ph˗attached to C3), 4.06 – 3.99 (1 H, m, OCH2CH2CH2N3), 
3.95 (1 H, d, J = 10.0 Hz, H5’), 3.90 (1 H, d, J = 2.6 Hz, H2), 3.81 (1 H, d, J = 9.4 Hz, 
H5), 3.78 (1 H, dd, J = 9.9, 2.7 Hz, H3’), 3.65 (1 H, app. t, J = 2.3 Hz, H2’), 3.59 (3 H, 
s, CO2CH3), 3.53 (1 H, ddd, J = 9.5, 8.0, 5.1 Hz, OCH2CH2CH2N3), 3.38 (2 H, ddd, J 
= 11.2, 8.6, 2.2 Hz, OCH2CH2CH2N3), 3.36 (1 H, dd, J = 9.2, 2.3 Hz, H3) 1.97 – 1.82 
(2 H, m, OCH2CH2CH2N3), 1.79 (3 H, s C(O)CH3); 13C NMR (101 MHz; CDCl3) δ 
169.6 (C(O)CH3), 168.1 (CO2CH3), 151.2 (C(O)N(Bn)OBn), 138.4 (Cq), 138.3 (2 C, 
Cq), 138.2 (Cq), 137.4 (Cq), 137.3 (Cq), 128.5, 128.3, 128.3, 128.3, 128.2, 128.2, 
128.1, 128.1, 128.0, 127.9, 127.9, 127.6, 127.6, 127.5, 127.5, 127.4, 127.4, 127.2, 
127.2, 102.0 (C1), 99.4 (C1’), 81.5 (C3), 76.1 (C3’), 76.1 (C(O)N(Bn)OCH2Ph), 75.8 
(C5), 75.4 (C2’), 74.5 (C4), 74.0 (CH2Ph˗attached to C2), 73.4 (C(O)N(CH2Ph)OBn), 
72.8 (C2), 72.3 (CH2Ph˗attached to C2’), 72.1 (CH2Ph˗attached to C3’), 71.7 (C5’), 
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71.0 (CH2Ph˗attached to C3), 68.5 (C4’), 67.0 (OCH2CH2CH2N3), 52.9 (CO2CH3), 
48.3 (OCH2CH2CH2N3), 29.1 (OCH2CH2CH2N3), 20.7 (C(O)CH3); 13C˗GATED (101 
MHz; CDCl3): 102.0 (1JC1˗H1 = 156 Hz, C1), 99.4 (1JC1’˗H1’ = 176 Hz, C1’); HRMS (ES+) 
m/z [Found: (M+H)+ 1065.4525 C60H65N4O14 requires (M+H)+,1065.4497]; IR 
νmax/cm˗1 2095 (m, N=N=N), 1746 (m, C=Oester), 1638 (w, C=Oamide), 1229 (m, 
C˗Oester), 1084 (s, C˗Oether), 1024 (C˗Oester). 
11.1.64. 3˗azidopropyl (methyl 
2,3˗di˗O˗benzyl˗4˗O˗(O˗benzyl˗N˗benzyl˗(4˗O˗acetyl˗2,3˗di˗O˗benzyl˗α˗D˗mann
opyranosyl) hydroxamate)˗β˗D˗mannopyranoside) uronate 140 
To a stirred solution of 139 (10 mg, 9 µmol, 1.0 
equiv.) in anhydrous MeOH (0.15 mL), Na (10 
µg, 0.4 µmol, 0.05 equiv.) dissolved in 
anhydrous MeOH (10 µL) was added at room 
temperature. The mixture was stirred for 16 h, 
then neutralised with ion exchange Amberlite 120 (H+) resin (approximately 50 mg, 
3 min), filtered, and concentrated under reduced pressure. Flash column 
chromatography, eluting with Et2O/petroleum ether (20/80, 50/50, 90/10) afforded 
140 as a colourless oil (5 mg, 5 µmol, 54%).  
Disaccharide 141 (100 mg, 90 µmol, 1.0 equiv.) was dissolved in a mixture of 
pyridine/AcOH (4/1 v/v, 1.5 mL), after which H2N˗NH2.AcOH (41 mg, 0.44 mmol, 5.0 
equiv.) was added. The mixture was stirred for 1 h at room temperature and was 
diluted with EtOAc (20 mL). The organic layer was washed with 1 M aq. HCl (2 x 15 
mL), sat. aq. NaHCO3 solution (2 x 10 mL) and brine (15 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to 
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furnish a yellow oil. Purification by silica gel flash column chromatography, eluting 
with EtOAc/hexane (20/80, 50/50, 90/10) afforded 140 as a colourless oil (65 mg, 
0.63 mmol, 70%). Rf 0.58 (EtOAc/toluene, 3/7); 1H NMR (400 MHz; CDCl3) δ 7.38 – 
7.17 (30 H, m, Ar˗H), 5.39 (1 H, s, H1’), 5.39 (1 H, d, J = 11.7 Hz, CH2Ph), 5.33 (1 H, 
d, J = 12.0 Hz, CH2Ph), 5.05 (1 H, d, J = 12.2 Hz, CH2Ph), 4.99 (1 H, d, J = 12.2 Hz, 
CH2Ph), 4.90 (1 H, d, J = 12.3 Hz, CH2Ph), 4.71 (1 H, d, J = 12.4 Hz, CH2Ph), 4.62 
(1 H, d, J = 11.7 Hz, CH2Ph), 4.54 (1 H, d, J = 11.8 Hz, CH2Ph), 4.43 (1 H, s, H1), 
4.42 (1 H, d, J = 13.7 Hz, CH2Ph), 4.42 (1 H, app. t, J = 8.9 Hz, H4) 4.30 (2 H, s, 
CH2Ph), 4.23 (1 H, app. t, J = 9.6 Hz, H4’), 4.23 (1 H, d, J = 11.5 Hz, CH2Ph), 4.06 – 
4.00 (1 H, m, OCH2CH2CH2N3), 3.98 (1 H, d, J = 9.6 Hz, H5’), 3.90 (1 H, d, J = 1.9 
Hz, H2) 3.82 (1 H, d, J = 9.1 Hz, H5), 3.67 (1 H, d, J = 2.3 Hz, H2’), 3.66 (1 H, dd, J = 
9.6, 2.3 Hz, H3’),  3.58 (3 H, s, CO2CH3), 3.53 (1 H, dd, J = 13.7, 8.6 Hz, 
OCH2CH2CH2N3), 3.43 – 3.35 (3 H, m, H3, OCH2CH2CH2N3), 2.27 (1 H, d, J = 2.2 
Hz, C4˗OH), 1.90 (2 H, ddd, J = 28.6, 14.0, 7.4 Hz, OCH2CH2CH2N3); 13C NMR (101 
MHz; CDCl3) δ 168.2 (CO2CH3), 152.4 (C(O)N(Bn)OBn), 138.5 (Cq), 138.4 (Cq), 
138.3 (Cq), 137.7 (Cq), 137.4 (Cq), 137.1 (Cq), 128.5, 128.4, 128.3, 128.2, 128.2, 
128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 127.4, 127.3, 101.9 
(C1), 99.4 (C1’), 81.5 (C3), 78.1 (C3’), 76.4 (CH2Ph), 75.6 (C5), 75.3 (C2’), 74.0 
(CH2Ph and C4), 73.3 (CH2Ph), 72.9 (C5’), 72.8 (C2), 72.3 (CH2Ph), 72.3 (CH2Ph), 
70.9 (CH2Ph), 67.3 (C4’), 66.9 (OCH2CH2CH2N3), 52.9 (CO2CH3), 48.3 
(OCH2CH2CH2N3), 29.1 (OCH2CH2CH2N3); 13C˗GATED (101 MHz; CDCl3): 101.9 
(1JC1˗H1 = 156 Hz, C1), 99.4 (1JC1’˗H1’ = 176 Hz, C1’); HRMS (ES+) m/z [Found: (M+H)+ 
1023.4412 C58H63N4O13 requires (M+H)+,1023.4386]. 
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11.1.65. 3˗azidopropyl (methyl 
2,3˗di˗O˗benzyl˗4˗O˗(O˗benzyl˗N˗benzyl˗(4˗O˗ 
levulinoyl˗2,3˗di˗O˗benzyl˗α˗D˗mannopyranosyl) 
hydroxamate)˗β˗D˗mannopyranoside) uronate 141 
A solution of 69 (200 mg, 0.26 mmol, 1.0 
equiv.) and 60 (136 mg, 0.29 mmol, 1.1 
equiv.) and in CH2Cl2 (5 mL) was stirred 
over activated MS4Å for 1 h before NIS (89 
mg 0.39 mmol, 1.5 equiv.) was added. The 
mixture was cooled to ˗40 °C before TMSOTf (4.8 µL, d = 1.225, 20 µmol, 0.1 equiv.) 
was added. The reaction was left stirring for 1 h at ˗40 °C, 2 h at ˗25 °C, 3 h at ˗20 
°C and 30 min. at ˗10 °C, and quenched with Et3N until pH = 7. The reaction mixture 
was filtered through Celite® and concentrated under reduced pressure. Flash column 
chromatography, eluting with Et2O/toluene (0/100, 10/90, 20/80) afforded 141 as a 
colourless oil (80 mg, 80 µmol, 30%, α/β = 9/1). Rf 0.30 (EtOAc/toluene, 3/7); 1H 
NMR (400 MHz; CDCl3) δ 7.39 – 7.10 (30 H, m, Ar˗H), 5.64 (1 H, app. t, J = 9.9 Hz, 
H4’), 5.43 (1 H, d, J = 12.6 Hz, CH2Ph), 5.40 (1 H, d, J = 12.1 Hz, CH2Ph), 5.38 (1 H, 
d, J = 2.0 Hz, H1’), 4.97 (1 H, d, J = 12.6 Hz, CH2Ph), 4.94 (1 H, d, J = 12.7 Hz, 
CH2Ph), 4.92 (1 H, d, J = 12.5 Hz, CH2Ph), 4.73 (1 H, d, J = 12.5 Hz, CH2Ph), 4.56 
(1 H, d, J = 12.2 Hz, CH2Ph), 4.52 (1 H, d, J = 12.1 Hz, CH2Ph), 4.52 (1 H, d, J = 
12.1 Hz, CH2Ph), 4.42 (1 H, s, H1), 4.37 (1 H, d, J = 11.3 Hz, CH2Ph), 4.36 (1 H, app. 
t, J = 10.5 Hz, H4’), 4.34 (1 H, d, J = 11.9 Hz, CH2Ph), 4.22 (1 H, d, J = 12.0 Hz, 
CH2Ph), 4.18 (1 H, d, J = 11.6 Hz, CH2Ph), 4.03 (1 H, dt, J = 9.7, 5.6 Hz, 
OCH2CH2CH2N3), 3.96 (1 H, d, J = 10.0 Hz, H5’), 3.90 (1 H, d, J = 2.7 Hz, H2), 3.81 
(1 H, d, J = 9.4 Hz, H5), 3.79 (1 H, dd, J = 10.4, 2.1 Hz, H3’), 3.64 (1 H, app. t, J = 2.1 
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Hz, H2’), 3.58 (3 H, s, CO2CH3), 3.53 (1 H, ddd, J = 9.5, 8.0, 5.1 Hz, OCH2CH2CH2N3), 
3.42 – 3.36 (2 H, m, OCH2CH2CH2N3), 3.36 (1 H, dd, J = 9.3, 2.7 Hz, H3), 2.65 – 2.38 
(3 H, m, CH2 Lev), 2.31 – 2.20 (1 H, m, CH2 Lev), 1.99 – 1.81 (3 H, m, CH3 Lev), 
1.99 – 1.81 (2 H, m, OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 206.4 (C=O 
Lev ketone), 171.5 (C=O Lev), 168.1 (C=O CO2CH3), 151.1 (C(O)N(Bn)OBn), 138.4 
(Cq), 138.2 (Cq), 138.2 (Cq), 138.1 (Cq), 137.3 (Cq), 137.3 (Cq), 128.5, 128.3, 128.2, 
128.2, 128.1, 128.1, 1280, 127.9, 127.6, 127.5, 127.5, 127.4, 127.2, 127.2, 101.9 
(C1), 99.4 (C1’), 81.5 (C3), 76.1, 76.0 (2 C, C3’ CH2Ph), 75.8 (C5), 75.4 (C2’), 74.5 
(C4), 74.0 (CH2Ph), 73.4 (CH2Ph), 72.7 (C2), 72.3 (CH2Ph), 72.2 (CH2Ph), 71.5 (C5’), 
70.9 (CH2Ph), 68.7 (C4’), 67.0 (OCH2CH2CH2N3), 52.9 (CO2CH3), 48.3 
(OCH2CH2CH2N3), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 29.0 (OCH2CH2CH2N3), 27.9 
(CH2 Lev); 13C˗GATED (101 MHz; CDCl3): 101.9 (1JC1˗H1 = 156 Hz, C1), 99.4 (1JC1’˗H1’ 
= 176 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 1121.4770 C63H68N4O15 requires 
(M+H)+, 1121.4754]. 
11.1.66. 3˗azidopropyl (O˗benzyl˗N˗benzyl˗2,3˗di˗O˗benzyl˗4˗O˗(methyl 
2,3˗di˗O˗benzyl (4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl) 
uronate)˗β˗D˗mannopyranoside) hydroxamate 142 
A solution of donor 56 (120 mg, 0.21 mmol, 1.0 equiv.) and acceptor 78 (108 mg, 
0.17 mmol, 0.8 equiv.) and in CH2Cl2 (4 
mL) was stirred over activated MS4Å for 
30 min. before NIS (61 mg 0.27 mmol, 1.3 
equiv.) was added. The mixture was cooled to ˗40 °C before TMSOTf (7.5 µL, d = 
1.225, 40 µmol, 0.2 equiv.) was added. The reaction was allowed to warm at 0 °C 
within 45 min, and upon completion, Et3N was added until pH = 7. The reaction 
mixture was filtered through Celite® and concentrated under reduced pressure. Flash 
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column chromatography, eluting with Et2O/toluene (0/100, 5/95 and 10/90) afforded 
142 as a colourless oil (129 mg, 0.11 mmol, 55%). Rf  0.38 (EtOAc/toluene, 3/7); 
[𝛼]𝐷
22 ˗29.6  (c. 0.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.44 – 7.16 (30 H, m), 5.46 
(1 H, d, J = 12.2 Hz, CH2Ph), 5.35 (1 H, app. t, J = 9.8 Hz, H4’), 5.31 (1 H, d, J = 12.2 
Hz, CH2Ph), 4.92 (1 H, d, J = 11.8 Hz, CH2Ph), 4.88 (1 H, d, J = 10.0 Hz, CH2Ph), 
4.85 (1 H, s, J = 13.9 Hz, CH2Ph), 4.85 (2 H, s, CH2Ph), 4.83 (4 H, d, J = 14.2 Hz, 
CH2Ph), 4.67 (1 H, d, J = 12.3 Hz, CH2Ph), 4.57 (1 H, d, J = 12.4 Hz, CH2Ph), 4.44 
(1 H, s, H1’), 4.39 (1 H, s, H1), 4.36 (1 H, d, J = 11.5 Hz, CH2Ph), 4.35 (1 H, d, J = 9.4 
Hz, H4), 4.23 (1 H, d, J = 12.4 Hz, CH2Ph), 3.95 – 3.88 (1 H, m, OCH2CH2CH2N3), 
3.85 (1 H, d, J = 9.7 Hz, H5), 3.82 (1 H, d, J = 2.9 Hz, H2), 3.76 (1 H, d, J = 2.6 Hz, 
H2’), 3.53 (3 H, s, CO2CH3), 3.50 (1 H, d, J = 9.0 Hz, H5’), 3.46 (1 H, dd, J = 9.2, 2.9 
Hz, H3), 3.48 – 3.39 (1 H, m, OCH2CH2CH2N3), 3.31 (2 H, dd, J = 9.9, 3.9 Hz, 
OCH2CH2CH2N3), 3.21 (1 H, dd, J = 9.8, 2.8 Hz, H3’), 2.69 – 2.64 (2 H, m, CH2 Lev), 
2.55 – 2.46 (2 H, m, CH2 Lev), 2.14 (3 H, s, CH3 Lev), 1.88 – 1.76 (2 H, m, 
OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 206.2 (C=O Lev ketone), 171.5 
(C=O Lev), 167.9 (C=O CO2CH3), 151.8 (C(O)N(Bn)OBn), 139.0 (2 C, Cq), 138.8 
(Cq), 138.7 (Cq), 138.0 (Cq), 137.1 (Cq), 128.5, 128.4, 128.3, 128.2, 128.2, 128.1, 
128.1, 128.1, 128.0, 127.6, 127.6, 127.4, 127.4, 127.3, 127.2, 102.3 (C1’), 101.8 
(C1), 79.9 (C3), 78.4 (C3’), 77.3 (C4), 76.6 (CH2Ph), 75.1 (C2), 74.9 (C2’), 74.6 (C5, 
CH2Ph), 74.3 (CH2Ph), 73.3 (C5’), 73.3 (CH2Ph), 72.8 (CH2Ph), 71.2 (CH2Ph), 68.9 
(C4’), 66.6 (OCH2CH2CH2N3), 52.3 (CO2CH3), 48.3 (OCH2CH2CH2N3), 37.9 (CH2 
Lev), 29.8 (CH3 Lev), 29.2 (OCH2CH2CH2N3), 27.9 (CH2 Lev); 13C˗GATED (101 MHz; 
CDCl3): 102.3 (1JC1’˗H1’ = 156 Hz, C1’), 101.8 (1JC1˗H1 = 156 Hz, C1); HRMS (ES+) m/z 
[Found: (M+H)+ 1121.4755 C63H69N4O15 requires (M+H)+, 1121.4754]. 
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11.1.67. 3˗azidopropyl (O˗benzyl˗N˗benzyl˗2,3˗di˗O˗benzyl˗4˗O˗(methyl 
2,3˗di˗O˗benzyl (2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl) 
uronate)˗β˗D˗mannopyranoside) hydroxamate 143 
Disaccharide 142 (40 mg, 35 µmol, 1.0 
equiv.) was dissolved in a mixture of 
pyridine/AcOH (0.5 mL, 4/1 v/v), after which 
H2N˗NH2.AcOH (16 mg, 0.18 mmol, 5.0 equiv.) was added. The mixture was stirred 
for 30 min. and then was diluted with EtOAc (5 mL), washed with 1 M aq. HCl (5 mL), 
sat. aq. NaHCO3 solution (5 mL) and brine (5 mL). The organic layer was then dried 
over MgSO4 filtered and concentrated under reduced pressure to furnish a yellow oil. 
Purification using silica gel flash column chromatography, eluting with Et2O/toluene 
(0/100, 30/70, 40/60, 90/10) afforded 143 as a colourless oil (29 mg, 28 µmol, 81%). 
Rf 0.60 (EtOAc/Toluene, 3/7); [𝛼]𝐷
22 ̠ 44.5 (c. 0.25, CHCl3); 1H NMR (400 MHz; CDCl3) 
δ 7.43 – 7.20 (30 H, m, Ar˗H), 5.46 (1 H, d, J = 12.2 Hz, CH2Ph), 5.33 (1 H, d, J = 
12.2 Hz, CH2Ph), 4.93 (1 H, d, J = 11.8 Hz, CH2Ph), 4.89 (1 H, d, J = 12.2 Hz, CH2Ph), 
4.88 (1 H, d, J = 10.6 Hz, CH2Ph), 4.86 (1 H, d, J = 11.0 Hz, CH2Ph), 4.85 (1 H, d, J 
= 12.5 Hz, CH2Ph), 4.81 (1 H, d, J = 12.1 Hz, CH2Ph), 4.63 (1 H, d, J = 12.2 Hz, 
CH2Ph), 4.56 (1 H, d, J = 12.2 Hz, CH2Ph), 4.52 (1 H, s, H1’), 4.43 (1 H, d, J = 12.6 
Hz, CH2Ph), 4.42 (1 H, t, J = 9.2 Hz, H4), 4.41 (1 H, s, H1), 4.36 (1 H, d, J = 12.0 Hz, 
CH2Ph), 4.12 (1 H, td, J = 9.6, 1.2 Hz, H4’), 3.96 – 3.90 (1 H, m, OCH2CH2CH2N3), 
3.88 (1 H, d, J = 9.7 Hz, H5), 3.84 (1 H, d, J = 2.9 Hz, H2), 3.76 (1 H, d, J = 2.2 Hz, 
H2’), 3.59 (3 H, s, CO2CH3), 3.58 – 3.54 (1 H, m, OCH2CH2CH2N3), 3.50 (1 H, dd, J 
= 9.3, 2.7 Hz, H3), 3.46 (1 H, d, J = 9.6 Hz, H5’), 3.32 (2 H, td, J = 6.7, 1.5 Hz, 
OCH2CH2CH2N3), 3.12 (1 H, dd, J = 9.5, 2.8 Hz, H3’), 2.85 (1 H, d, J = 1.7 Hz, C4˗OH), 
1.90 – 1.77 (2 H, m, OCH2CH2CH2N3); 13C NMR (101 MHz; CDCl3) δ 170.0 (C=O 
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CO2CH3), 151.8 (C(O)N(Bn)OBn), 139.1 (Cq), 139.0 (Cq), 138.8 (Cq), 138.0 (Cq), 
137.1 (Cq), 137.0 (Cq), 128.5, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.0, 
127.7, 127.6, 127.5, 127.4, 127.3, 127.3, 102.6 (C1’), 101.7 (C1), 80.3 (C3’), 80.2 
(C3), 77.2 (C4), 76.6 (CH2Ph), 75.3 (C2), 75.2 (C2’), 74.9 (C5), 74.8 (CH2Ph), 74.7 
(C5’), 74.3 (CH2Ph), 73.3 (CH2Ph), 72.6 (CH2Ph), 71.3 (CH2Ph), 68.0 (C4’), 66.6 
(OCH2CH2CH2N3), 52.3 (CO2CH3), 48.3 (OCH2CH2CH2N3), 32.8, 30.3, 29.2 
(OCH2CH2CH2N3); 13C˗GATED (101 MHz; CDCl3): 102.6 (1JC1’˗H1’ = 156 Hz, C1’), 
101.7 (1JC1˗H1 = 156 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 1023.4412 
C58H63N4O13 requires (M+H)+, 1023.4386]. 
11.1.68. 3˗azidopropyl (O˗benzyl˗N˗benzyl˗(2,3˗di˗O˗benzyl˗4˗O˗(methyl 
2,3˗di˗O˗benzyl˗4˗O˗(O˗benzyl˗N˗benzyl˗(4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗α˗D˗ma
nnopyranosyl) hydroxamate)˗β˗D˗mannopyranosyl) 
uronate)˗β˗D˗mannopyranoside) hydroxamate 144 
A solution of 69 (140 mg, 
0.18 mmol, 1.0 equiv.), 
Ph2SO (48 mg, 0.24 mmol, 
1.3 equiv.) and TTBP (110 
mg, 0.46 mmol, 2.5 equiv.) 
in CH2Cl2 (3.5 mL) was stirred over activated MS4Å for 1 h. The mixture was cooled 
to ˗60 °C and Tf2O (39 µL, d = 1.720, 0.24 mmol, 1.3 equiv.) was then added. The 
mixture was allowed to warm to ˗40 oC over 10 min. followed by cooling to ˗90 °C, 
upon 143 (132 mg, 0.13 mmol, 0.7 equiv.) in CH2Cl2 (0.5 mL) was added. The 
reaction mixture was allowed to warm to room temperature, and stirring was 
continued for 1 h. After the addition of Et3N to pH = 7, the organic layer was washed 
with H2O (5 mL), dried over MgSO4, filtered and concentrated under reduced 
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pressure. Purification using silica gel flash column chromatography, eluting with 
EtOAc/petroleum ether (20/80, 50/50, 90/10) afforded 144 as colourless oil (43 mg, 
26 µmol, 14%, α/β = 3.5/1). Rf 0.27 (EtOAc/toluene, 3/7); 1H NMR (400 MHz; CDCl3) 
δ 7.38 – 7.10 (50 H, m, Ar˗H), 5.61 (1 H, app. t, J = 9.8 Hz, H4’’), 5.42 (1 H, d, J = 
12.2 Hz, CH2Ph), 5.33 (1 H, d, J = 12.2 Hz, CH2Ph), 5.28 (1 H, d, J = 12.8 Hz, CH2Ph), 
5.25 (1 H, d, J = 12.5 Hz, CH2Ph), 4.94 (1 H, d, J = 12.9 Hz, CH2Ph), 4.91 (1 H, d, J 
= 12.8 Hz, CH2Ph), 4.87 (1 H, d, J = 12.3 Hz, CH2Ph), 4.86 (1 H, d, J = 12.2 Hz, 
CH2Ph), 4.84 (1 H, d, J = 11.9 Hz, CH2Ph), 4.82 (1 H, d, J = 12.0 Hz, CH2Ph), 4.80 
(1 H, d, J = 12.1 Hz, CH2Ph), 4.79 (1 H, d, J = 12.6 Hz, CH2Ph), 4.75 (1 H, d, J = 
12.2 Hz, CH2Ph), 4.66 (1 H, d, J = 12.0 Hz, CH2Ph), 4.63 (1 H, d, J = 12.5 Hz, CH2Ph), 
4.51 (1 H, d, J = 12.2 Hz, CH2Ph), 4.49 (1 H, d, J = 12.4 Hz, CH2Ph), 4.46 (1 H, s, 
H1’’), 4.44 (1 H, d, J = 11.9 Hz, CH2Ph), 4.43 (1 H, s, H1’), 4.41 (1 H, d, J = 12.6 Hz, 
CH2Ph), 4.36 (1 H, app. t, J = 9.4 Hz, H4), 4.35 (1 H, s, H1), 4.33 (1 H, d, J = 12.5 Hz, 
CH2Ph), 3.87 (1 H, ddd, J = 11.4, 10.2, 6.5 Hz, OCH2CH2CH2N3), 3.80 (1 H, d, J = 
2.8 Hz, H2), 3.79 (1 H, d, J = 3.4 Hz, H2’’), 3.78 (1 H, d, J = 9.7 Hz, H5), 3.75 (1 H, d, 
J = 9.9 Hz, H5’’), 3.67 (1 H, d, J = 2.7 Hz, H2), 3.53 (1 H, d, J = 9.5 Hz, H5’), 3.50 – 
3.44 (1 H, m, OCH2CH2CH2N3), 3.44 – 3.39 (1 H, m, H3), 3.40 (3 H, s, CO2CH3), 3.33 
(1 H, dd, J = 9.3, 3.1 Hz, H3’’), 3.31 (2 H, ddd, J = 8.9, 7.7, 2.5 Hz, OCH2CH2CH2N3), 
3.15 (1 H, dd, J = 9.2, 3.1 Hz, H3’), 2.53 – 2.32 (3 H, m, CH2 Lev), 2.18 – 2.10 (1 H, 
m, CH2 Lev), 2.08 (3 H, s, CH3 Lev), 1.82 (2 H, dt, J = 20.1, 6.8 Hz, OCH2CH2CH2N3); 
13C NMR (101 MHz; CDCl3) δ 206.3 (C=O Lev ketone), 171.1 (C=O Lev), 168.9 (C=O 
CO2CH3), 151.6 (C(O)N(Bn)OBn), 150.5 (C(O)N(Bn)OBn), 139.1 (Cq), 139.0 (Cq), 
138.8 (Cq), 138.8 (Cq), 138.7 (Cq), 138.0 (Cq), 137.9 (Cq), 137.3 (Cq), 137.1 (Cq), 
137.0 (Cq), 128.4, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.1, 128.1, 
128.0, 128.0, 127.9, 127.7, 127.6, 127.6, 127.6, 127.4, 127.4, 127.3, 127.2, 127.2, 
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127.1, 102.4 (C1’), 102.3 (C1’’), 101.7 (C1), 80.0 (C3), 79.1 (C3’), 78.6 (C3’’), 77.7 
(C4’), 77.2 (C4), 76.8 (CH2Ph), 76.5 (2C, C2’ and CH2Ph), 76.1 (CH2Ph), 75.4 (C2’’), 
75.1 (2C, C2 and C5), 74.9 (CH2Ph), 74.8 (CH2Ph), 74.6 (C5’), 74.3 (CH2Ph), 74.2 
(CH2Ph), 73.6 (C5’’), 73.3 (CH2Ph), 73.2 (CH2Ph), 72.8 (CH2Ph), 72.6 (CH2Ph), 72.5 
(CH2Ph), 71.4 (CH2Ph), 68.2 (C4’’), 66.5 (OCH2CH2CH2N3), 52.0 (CO2CH3), 48.3 
(OCH2CH2CH2N3), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 29.1 (OCH2CH2CH2N3), 27.8 
(CH2 Lev); HRMS (ES+) m/z [Found: (M+NH4)+ 1689.7330 C97H105N6O21 requires 
(M+NH4)+, 1689.7327]. 
11.1.69. O˗benzyl, N˗benzyl 
(4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗hydroxyl˗α/β˗D˗mannopyranoside) 
hydroxamate 147 
A solution of 69 (100 mg, 0.13 mmol, 1.0 equiv.) in 
CH2Cl2/H2O (1.4 mL, 10/1 v/v) was cooled to 0 °C followed 
by the addition of NIS (30 mg 0.13 mmol, 1.0 equiv.), and 
catalytic amount of AgOTf (6.8 mg 26 µmol, 0.2 equiv.). 
The reaction was left stirring at 0 °C for 4 h before it was quenched by the addition 
of 10% aq. Na2S2O3 solution (5 mL) and diluted with CH2Cl2 (15 mL). The organic 
layer was subsequently washed with sat. aq. NaHCO3 solution (10 mL) and brine (10 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified using silica gel flash column chromatography, eluting with 
Et2O/toluene (5/95, 10/90, 20/80) to furnish 147 as a yellow oil (68 mg, 0.10 mmol, 
78%). Rf 0.50 (EtOAc/toluene, 3/7); The NMR data reported refer to the major 
α˗anomer (α/β = 9/1): 1H NMR (400 MHz; CDCl3) δ 7.41 – 7.20 (20 H, m, Ar˗H), 5.70 
(1 H, app. t, J = 9.7 Hz, H4), 5.46 (1 H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 5.42 (1 
H, d, J = 12.0 Hz, C(O)N(CH2Ph)OBn), 5.20 (1 H, dd, J = 3.5, 2.2 Hz, H1), 4.97 (1 H, 
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d, J = 12.7 Hz, C(O)N(Bn)OCH2Ph), 4.93 (2 H, d, J = 13.1 Hz, C(O)N(Bn)OCH2Ph), 
4.76 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C2), 4.64 (1 H, d, J = 12.1 Hz, 
CH2Ph˗attached to C2), 4.59 (1 H, d, J = 12.1 Hz, CH2Ph˗attached to C3), 4.54 (1 H, 
d, J = 12.2 Hz, CH2Ph˗attached to C3), 4.33 (1 H, d, J = 9.9 Hz, H5), 3.90 (1 H, dd, J 
= 9.5, 2.9 Hz, H3), 3.77 – 3.74 (1 H, app. t, J = 2.6 Hz, H2), 3.38 (1 H, d, J = 3.7 Hz, 
C1˗OH), 2.63 – 2.35 (4 H, m, CH2 Lev), 2.30 – 2.21 (1 H, m, CH2 Lev), 2.09 (3 H, s, 
CH3 Lev); 13C NMR (101 MHz; CDCl3) δ 206.4 (C=O Lev ketone), 171.4 (C=O Lev), 
151.5 (C(O)N(Bn)OBn), 138.2 (Cq), 138.2 (Cq), 137.7 (Cq), 137.2 (Cq), 128.3, 128.3, 
128.3, 128.2, 128.1, 127.7, 127.7, 127.6, 127.5, 127.5, 93.0 (C1), 76.2 (2C, C3, 
(C(O)N(Bn)OCH2Ph), 74.8 (C2), 73.3 (C(O)N(CH2Ph)OBn), 72.9 (CH2Ph˗attached 
to C2), 72.2 (CH2Ph˗attached to C3), 70.5 (C5), 68.7 (C4), 37.9 (CH2 Lev), 29.8 (CH3 
Lev), 27.9 (CH2 Lev); 13C˗GATED (101 MHz; CDCl3): α˗anomer: 93.0 (1JC1˗H1 = 176 
Hz, C1), β˗anomer: 93.7 (1JC1˗H1 = 164 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 
668.2860 C39H42NO9 requires (M+H)+, 668.2854]. 
11.1.70. O˗benzyl, N˗benzyl (4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗ 
O˗Phenyl˗N˗trifluoroacetimidate˗α˗D˗mannopyranoside) hydroxamate 148 
Hemiacetal 147 (70 mg, 0.10 mmol, 1.0 equiv.) was 
dissolved in acetone/H2O (1.1 mL, 20/1 v/v) and the 
solution was cooled to 0 °C. N˗PTFA.Cl (25 µL, d = 1.31, 
0.16 mmol, 1.5 equiv.) and K2CO3 (17 mg, 0.12 mmol, 1.2 
equiv.) were added and the resulting suspension was stirred for 20 h at room 
temperature. The reaction mixture was diluted with EtOAc (10 mL) and H2O (10 mL), 
the organic layer was then washed with brine (10 mL), collected dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified 
using silica gel flash column chromatography, eluting with Et2O/toluene (5/95, 10/90, 
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20/80) to furnish 148 as a colourless oil (58 mg, 69 µmol, 66%). Rf 0.68 
(EtOAc/tolene, 3/7); 1H NMR (400 MHz; CDCl3) δ 7.38 – 7.22 (25 H, m, Ar˗H), 7.11 
(1 H, t, J = 7.5 Hz, CH NPh), 6.69 (2 H, d, J = 7.7 Hz, CH NPh), 6.26 (1 H, br. s, H1), 
5.76 (1 H, t, J = 9.7 Hz, H4), 5.44 (1 H, d, J = 11.9 Hz, C(O)N(CH2Ph)OBn), 5.38 (1 
H, d, J = 11.9 Hz, C(O)N(CH2Ph)OBn), 5.02 (1 H, d, J = 12.4 Hz, 
C(O)N(Bn)OCH2Ph), 4.99 (1 H, d, J = 12.5 Hz, C(O)N(Bn)OCH2Ph), 4.72 (1 H, d, J 
= 10.2 Hz, CH2Ph), 4.63 (1 H, d, J = 10.3 Hz, CH2Ph), 4.61 (1 H, d, J = 12.1 Hz, 
CH2Ph), 4.54 (1 H, d, J = 12.1 Hz, CH2Ph), 4.27 (1 H, d, J = 9.9 Hz, H5), 3.82 (1 H, 
dd, J = 9.5, 2.7 Hz, H3), 3.77 (1 H, s, H2), 2.68 – 2.41 (3 H, m, CH2 Lev), 2.30 – 2.20 
(1 H, m, CH2 Lev), 2.13 (3 H, s, CH3 Lev); 13C NMR (101 MHz; CDCl3) δ 206.2 (C=O 
Lev ketone), 171.2 (C=O Lev), 150.2 (C(O)N(Bn)OBn), 143.1 (Cq NPh), 142.3 (q, J 
= 36.0 Hz, C=NPh), 137.7 (Cq), 137.7 (Cq), 137.5 (Cq), 137.0 (Cq), 128.7, 128.4, 
128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.8, 127.7, 127.7, 127.5, 124.5, 119.4 
(CH NPh), 115.8 (q, J = 287.3 Hz, CF3), 94.9 (C1), 75.4, 73.5 (C3), 73.0 (CH2Ph), 
72.8 (2C, C2, C5), 72.6 (CH2Ph), 67.7 (C4), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 27.8 
(CH2 Lev); 13C˗GATED (101 MHz; CDCl3): 94.9 (1JC1˗H1 = 172 Hz, C1); HRMS (ES+) 
m/z [Found: (M+Na)+ 861.2972 C47H45F3N2O9Na requires (M+Na)+, 861.2969]. 
11.1.71. O˗benzyl, N˗benzyl (4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗O˗tert˗butyl 
dimethylsilyl˗α/β˗D˗mannopyranoside) hydroxamate 149 
A stirred solution of imidate hydroxamate donor 148 (60 
mg, 71 µmol, 1.0 equiv.) and hydroxamate acceptor 78 
(37 mg, 57 µmol, 0.8 equiv.) in CH2Cl2 (0.6 mL) was 
cooled down to ˗78 °C before TBDMSOTf (4.9 µL, d = 
1.151, 21 µmol, 0.3 equiv.). The reaction was stirred at ˗78 °C for 24 h before it was 
quenched by the addition of Et3N (997 µL, d = 0.726, 0.71 mmol, 10 equiv.). The 
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reaction mixture was diluted with CH2Cl2 (20 mL), washed with brine (15 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. Flash column 
chromatography, eluting with EtOAc/toluene (5/95, 10/90 and 15/85) afforded 
undesirable by˗product 149 as a colourless oil in an anomeric ratio of α/β = 1/1 (9 
mg, 11 µmol, 16%). Rf  0.84 (Et2O /toluene, 3/7);  1H NMR (400 MHz; CDCl3) 7.41 – 
7.17 (40 H, m, Ar˗H), 5.68 (1 H, app. t, J = 9.9 Hz, H4 α˗anomer), 5.62 (1 H, app. t, J 
= 9.9 Hz, H4 β˗anomer), 5.52 (1 H, d, J = 11.9 Hz, CH2Ph), 5.43 (1 H, d, J = 11.9 Hz, 
CH2Ph), 5.38 (1 H, d, J = 11.9 Hz, CH2Ph), 5.38 (1 H, d, J = 10.5 Hz, CH2Ph), 5.04 
(1 H, d, J = 1.9 Hz, H1 α˗anomer), 4.99 (1 H, d, J =  12.7 Hz, CH2Ph), 4.96 (2 H, d, J 
= 11.3 Hz, CH2Ph), 4.95 (2 H, d, J = 12.7 Hz, CH2Ph), 4.83 (2 H, d, J = 13.2 Hz, 
CH2Ph), 4.72 (1 H, s, H1 β˗anomer), 4.60 (1 H, d, J = 12.9 Hz, CH2Ph), 4.58 (1 H, d, 
J = 12.3 Hz, CH2Ph), 4.57 (1 H, d, J = 12.6 Hz, CH2Ph), 4.51 (1 H, d, J = 12.3 Hz, 
CH2Ph), 4.42 (1 H, d, J = 12.3 Hz, CH2Ph), 4.20 (1 H, d, J = 9.8 Hz, H5 α˗anomer), 
3.86 (1 H, dd, J = 9.8, 2.9 Hz, H3 α˗anomer), 3.85 (1 H, d, J = 10.0 Hz, H5 β˗anomer), 
3.82 (1 H, d, J = 2.7 Hz, H2 β˗anomer), 3.53 (1 H, t, J = 2.2 Hz, H2 α˗anomer), 3.46 
(1 H, dd, J = 9.7, 2.8 Hz, H3 β˗anomer), 2.65 – 2.17 (8 H, m, CH2 Lev), 2.12 (3 H, s, 
CH3 Lev), 2.10 (3 H, s, CH3 Lev), 0.88 (9 H, s, C(CH3)3), 0.80 (9 H, s, C(CH3)3), 0.07 
(3 H, s, Si(CH3)2), 0.06 (3 H, s, Si(CH3)2), ˗0.01 (3 H, s, Si(CH3)2), ˗0.06 (3 H, s, 
Si(CH3)2); 13C NMR (101 MHz; CDCl3) δ 206.4 (C=O Lev ketone), 206.3 (C=O Lev 
ketone), 171.3 (C=O Lev), 171.2 (C=O Lev), 151.1 (C(O)N(Bn)OBn), 151.1 
(C(O)N(Bn)OBn), 138.8 (Cq), 138.8 (Cq), 138.3 (Cq), 138.1 (Cq), 138.0 (Cq), 138.0 
(Cq), 137.3 (Cq), 137.2 (Cq), 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.1, 
128.0, 127.9, 127.8, 127.8 127.7, 127.6, 127.6, 127.6, 127.6, 127.5, 127.5, 127.2, 
96.8 (C1 β˗anomer), 93.4 (C1 α˗anomer), 78.7 (C3 β˗anomer), 76.3 (C3 α˗anomer), 
76.2 (CH2Ph), 76.1 (CH2Ph), 75.9 (C2 α˗anomer), 75.4 (C2 β˗anomer), 74.3 
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(CH2Ph), 73.8 (C5 β˗anomer), 73.3 (CH2Ph), 73.1 (CH2Ph), 72.9 (CH2Ph), 72.3 
(CH2Ph), 71.4 (CH2Ph), 70.6 (C5 α˗anomer), 68.7 (C4 α or β˗anomer), 68.3 (C4 α or 
β˗anomer), 38.0 (CH2 Lev), 37.9 (CH2 Lev), 29.9 (CH3 Lev), 29.8 (CH3 Lev), 28.0 
(CH2 Lev), 27.8 (CH2 Lev), 25.7 (C(CH3)3), 25.6 (C(CH3)3), 17.9 (C(CH3)3), 17.8 
(C(CH3)3), ˗4.0 (Si(CH3)2), ˗4.7 (Si(CH3)2), ˗5.4 (Si(CH3)2), ˗5.9(Si(CH3)2); 
13C˗GATED (101 MHz; CDCl3): α˗anomer: 93.5 (1JC1˗H1 = 168 Hz, C1), β˗anomer: 
96.8 (1JC1˗H1 = 156 Hz, C1). 
11.1.72. O˗benzyl, N˗benzyl 
(4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗1˗O˗acetyl˗α˗D˗mannopyranoside) 
hydroxamate 150 
To a stirred solution of 147 (150 mg, 0.22 mmol, 1.0 equiv.) 
in CH2Cl2 (2.2 mL) was added Ac2O (42 µL, d = 1.08, 0.44 
mmol, 2.0 equiv.) and pyridine (36 µL, d = 0.978, 0.44 
mmol, 2.0 equiv.) at room temperature. The reaction 
mixture was left stirring for 16 h before it was diluted with CH2Cl2 (15 mL). The organic 
layer was washed successively with 1.0 M aq. HCl (2 x 10 mL), sat. aq. NaHCO3 
solution (2 x 10 mL) and brine (15 mL), dried over Na2SO4, filtered and concentrated 
under reduced pressure to furnish a yellow oil. Purification using silica gel flash 
column chromatography, eluting with EtOAc/hexane (0/100, 30/70, 40/60, 90/10) 
afforded colourless oil 150 as a single anomer (α˗anomer) (142 mg, 0.20 mmol, 
89%). Rf 0.83 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 +27.5 (c. 0.46, CHCl3); 1H NMR (400 MHz; 
CDCl3) δ 7.37 – 7.25 (20 H, m, Ar˗H), 6.18 (1 H, d, J = 2.2 Hz, H1), 5.73 (1 H, app. t, 
J = 9.8 Hz, H4), 5.40 (2 H, s, C(O)N(CH2Ph)OBn), 5.00 (1 H, d, J = 12.4 Hz, 
C(O)N(Bn)OCH2Ph), 4.96 (1 H, d, J = 12.4 Hz, C(O)N(Bn)OCH2Ph), 4.75 (1 H, d, J 
= 12.2 Hz, CH2Ph˗attached to C2), 4.69 (1 H, d, J = 12.2 Hz, CH2Ph˗attached to C2), 
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4.57 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to C3), 4.53 (1 H, d, J = 12.7 Hz, 
CH2Ph˗attached to C3), 4.19 (1 H, d, J = 10.0 Hz, H5), 3.80 (1 H, dd, J = 9.6, 3.0 Hz, 
H3), 3.70 (1 H, app. t, J = 2.6 Hz, H2), 2.67 – 2.40 (3 H, m, CH2 Lev), 2.29 – 2.20 (1 
H, m, CH2 Lev), 2.12 (3 H, s, CH3 Lev), 2.05 (3 H, s, C(O)CH3); 13C NMR (101 MHz; 
CDCl3) δ 206.2 (C=O Lev ketone), 171.2 (C=O Lev), 168.6 (C(O)CH3), 150.6 
(C(O)N(Bn)OBn), 137.8 (Cq), 137.7 (Cq), 137.6 (Cq), 137.1 (Cq), 128.4, 128.3, 128.2, 
128.0, 127.8, 127.8, 127.8, 127.7, 127.7, 127.5, 91.6 (C1), 76.3 
(C(O)N(Bn)OCH2Ph), 75.6 (C3), 73.6 (C(O)N(CH2Ph)OBn), 73.5 (C2), 72.8 
(CH2Ph˗attached to C2), 72.7 (C5), 72.2 (CH2Ph˗attached to C3), 68.1 (C4), 37.9 
(CH2 Lev), 29.8 (CH3 Lev), 27.8 (CH2 Lev), 21.0 (C(O)CH3); 13C˗GATED (101 MHz; 
CDCl3): 91.6 (1JC1˗H1 = 176 Hz, C1); HRMS (ES+) m/z [Found: (M+H)+ 710.2975 




Compound 150 (120 mg, 0.17 mmol, 1.0 equiv.) was 
dissolved in CH2Cl2 (0.6 mL) in a round˗bottomed flask, 
which was stoppered with a septum and cooled in an 
ice˗water bath. PBr3 (27 µL, d = 2.88, 0.29 mmol, 1.7 
equiv.) and H2O (18 µL, 1.01 mmol, 6.0 equiv.) were 
added dropwise. After 40 min, the reaction mixture was diluted with CH2Cl2 (20 mL) 
and extracted with H2O (2 x 20 mL), saturated aqueous NaHCO3 (20 mL), and brine 
(2 x 20 mL). The organic layer was dried over Na2SO4 filtered and concentrated 
under reduced pressure to furnish crude colourless oil 152 as a mixture of α and 
β˗anomers (84 mg, 0.13 mmol, 80%, α/β = 5.6/1); Rf 0.83 (EtOAc/toluene, 3/7); data 
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reported for α˗anomer: 1H NMR (400 MHz; CDCl3) δ 9.75 (1 H, br. s, C(O)N(H)OBn), 
7.42 – 7.27 (20 H, m, Ar˗H), 5.96 (1 H, d, J = 6.6 Hz, H1), 5.78 (1 H, dd, J = 5.4, 4.3 
Hz, H4), 4.81 (1 H, d, J = 11.0 Hz, C(O)N(H)OCH2Ph), 4.76 (1 H, d, J = 11.9 Hz, 
CH2Ph˗attached to C3), 4.71 (1 H, d, J = 11.0 Hz, C(O)NHOCH2Ph), 4.64 (1 H, d, J 
= 12.8 Hz, CH2Ph˗attached to C2), 4.61 (1 H, d, J = 12.4 Hz, CH2Ph˗attached to C2), 
4.56 (1 H, d, J = 11.9 Hz, CH2Ph˗attached to C3), 4.36 (1 H, d, J = 4.0 Hz, H5), 3.96 
(1 H, dd, J = 5.6, 2.9 Hz, H3), 3.69 (1 H, dd, J = 6.6, 2.9 Hz, H2), 2.86 –  2.60 (4 H, 
m, CH2 Lev), 2.18 (3 H, s, CH3 Lev), 2.08 (3 H, s, C(O)CH3); 13C NMR (101 MHz; 
CDCl3) δ 206.4 (C=O Lev ketone), 171.6 (C=O Lev), 170.3 (C(O)CH3) 163.9 
(C(O)N(H)OBn), 137.7 (Cq), 137.4 (Cq), 135.1 (Cq), 129.6, 129.3, 129.2, 128.8, 
128.7, 128.7, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 91.0 (C1), 78.3 
(C(O)N(H)OCH2Ph), 74.4 (C5), 73.9 (C3), 73.2 (C2), 72.7 (CH2Ph˗attached to C3), 
72.6 (CH2Ph˗attached to C2), 68.8 (C4), 38.0 (CH2 Lev), 29.8 (CH3 Lev), 28.0 (CH2 
Lev), 20.8 (C(O)CH3); 13C˗GATED (101 MHz; CDCl3): 91.0 (1JC1˗H1 = 180 Hz, C1); 
HRMS (ES+) m/z [Found: (M+H)+ 620.2498 C34H38NO10 requires (M+H)+, 620.2496]. 
11.1.74. O˗methyl (O˗benzyl˗N˗benzyl˗ (2,3,4˗tri˗O˗benzyl 
(4˗O˗levulinoyl˗2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl)˗α˗D˗mannopyranoside)˗h
ydroxamate 154 
A solution of 69 (50 mg, 66 µmol, 1.0 equiv.), 
Ph2SO (32 mg, 0.15 mmol, 2.4 equiv.) and 
TTBP (16 mg, 66 µmol, 1.0 equiv.) in CH2Cl2 
(1.3 mL) was stirred over activated MS4Å for 45 
min. The mixture was cooled to ˗78 °C and Tf2O 
(11 µL, d = 1.720, 69 µmol, 1.05 equiv.) and left stirring for 45 min. until the 
temperature reached ˗60 °C. A solution of the C6˗OH acceptor 153 (30 mg, 66 µmol, 
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1.0 equiv.)  in CH2Cl2 (1.3 mL) was slowly added. The reaction mixture was allowed 
to warm up to ˗20 °C, and stirring was continued for 3 h. At that temperature Et3N 
was added until pH = 7, the organic layer was washed with H2O (10 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. Purification using silica 
gel flash column chromatography, eluting with acetone/toluene (10/90, 20/80, 
30/170) afforded 154 as a colourless oil (20 mg, 18 µmol, 27%). Rf 0.54 
(EtOAc/hexane, 1/2); [𝛼]𝐷
26 ˗44.8 (c. 0.33, CHCl3); 1H NMR (400 MHz; CDCl3) 7.40 – 
7.18 (35 H, m, Ar˗H), 5.62 (1 H, t, J = 9.9 Hz, H4’), 5.47 (1 H, d, J = 11.9 Hz, CH2Ph), 
5.39 (1 H, d, J = 11.9 Hz, CH2Ph), 4.98 (1 H, d, J = 12.6 Hz, CH2Ph), 4.94 (1 H, d, J 
= 12.5 Hz, CH2Ph), 4.91 (1 H, d, J = 12.2 Hz, CH2Ph), 4.87 (1 H, d, J = 11.4 Hz, 
CH2Ph), 4.77 (1 H, d, J = 12.2 Hz, CH2Ph), 4.69 (1 H, d, J = 12.6 Hz, CH2Ph), 4.68 
(1 H, s, H1), 4.66 (1 H, d, J = 12.6 Hz, CH2Ph), 4.61 (1 H, d, J = 11.8 Hz, CH2Ph), 
4.58 (1 H, d, J = 12.0 Hz, CH2Ph), 4.51 (1 H, d, J = 11.4 Hz, CH2Ph), 4.46 (1 H, d, J 
= 12.4 Hz, CH2Ph), 4.37 (1 H, d, J = 12.4 Hz, CH2Ph), 4.26 (1 H, s, H1’), 4.12 (1 H, 
dd, J = 10.6, 1.6 Hz, H6a), 3.88 (1 H, dd, J = 8.7, 3.0 Hz, H3), 3.80 (1 H, d, J = 9.8 Hz, 
H5’) 3.78 (1 H, d, J = 10.0 Hz, H5), 3.77 – 3.71 (3 H, m, H2, H2’ H4) 3.49 (1 H, dd, J = 
10.6, 6.5 Hz, H6b), 3.34 (1 H, dd, J = 9.7, 2.8 Hz, H3’), 3.21 (3 H, s, OCH3), 2.64 – 
2.37 (3 H, m, CH2 Lev), 2.27 – 2.16 (1 H, m, CH2 Lev), 2.10 (3 H, s, CH3 Lev); 13C 
NMR (101 MHz; CDCl3) δ 206.3 (C=O Lev ketone), 171.2 (C=O Lev), 150.8 
(C(O)N(Bn)OBn), 138.5 (Cq), 138.4 (Cq), 138.3 (Cq), 138.2 (Cq), 137.9 (Cq), 137.9 
(Cq), 137.2 (Cq), 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 127.9, 127.8, 
127.7, 127.6, 127.6, 127.6, 127.2, 102.2 (C1’), 98.8 (C1), 80.2 (C3), 78.4 (C3’), 76.2 
(CH2Ph), 74.9 (CH2Ph), 74.7, 74.4, 73.9, 73.7, 73.4 (5 C, C2 or C2’, C4, C5, C5’, 
CH2Ph), 73.0 (CH2Ph), 72.7 (CH2Ph), 72.0 (CH2Ph), 71.3 (2 C, C2 or C2’, CH2Ph), 
68.4 (C4’), 54.6 (OCH3), 37.9 (CH2 Lev), 29.8 (CH3 Lev), 27.8 (CH2 Lev); 13C˗GATED 
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(101 MHz; CDCl3): 102.2 (1JC1’˗H1’ = 156 Hz, C1’), 98.8 (1JC1˗H1 = 168 Hz, C1); HRMS 





To a stirred solution of 40 (3.2 g, 5.92 mmol, 1.0 equiv.) in 
CH2Cl2 (65 mL) at ˗78 °C was added m˗CPBA (1.3 g, 5.92 
mmol, 77%, 1.0 equiv.) after which the mixture was warmed 
to ˗30 °C in 40 min. and stirred for further 3 h before 
quenching with sat. aq. NaHCO3 solution (50 mL) and washing with brine (60 
mL).The organic layer was dried over Na2SO4 filtered and concentrated under 
reduced pressure to furnish a yellow oil. Purification using silica gel flash column 
chromatography, eluting with EtOAc/petroleum ether (0/100, 30/70, 40/60) afforded  
163 as a single diastereoisomer (2.4 g, 4.32 mmol, 73%); Rf 0.63 (EtOAc/petroleum 
ether, 1/2); 1H NMR (400 MHz; CDCl3) δ 7.54 – 7.21 (20 H, m, Ar˗H), 5.63 (1 H, s, 
CHPh), 4.82 (1 H, d, J = 12.1 Hz, CH2Ph˗attached to C3), 4.67 (1 H, d, J = 12.1 Hz, 
CH2Ph˗attached to C3), 4.60 (1 H, d, J = 11.9 Hz, CH2Ph˗attached to C2), 4.56 (1 H, 
d, J = 11.9 Hz, CH2Ph˗attached to C2), 4.50 (1 H, d, J = 1.0 Hz, H1), 4.39 (1 H, dd, J 
= 3.1, 1.3 Hz, H2), 4.33 (1 H, dd, J = 10.0, 8.6 Hz, H4), 4.28 (1 H, dd, J = 9.6, 3.2 Hz, 
H3), 4.22 (1 H, dd, J = 10.3, 4.8 Hz, H6a), 4.15 – 4.06 (1 H, m, H5), 3.76 (1 H, app. t, 
J = 10.1 Hz, H6a); 13C NMR (101 MHz; CDCl3) δ 141.6, 138.3 (Cq), 137.3 (Cq), 137.3 
(Cq), 131.6 (Cq), 129.4, 129.0, 128.4, 128.3, 128.2, 128.2, 127.9, 127.8, 127.6, 126.1, 
124.3, 101.6 (CHPh), 97.6 (C1), 78.0 (C4), 76.3 (C3), 73.5 (CH2Ph˗attached to C3), 
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73.2 (CH2Ph˗attached to C2), 72.9 (C2), 70.1 (C5), 68.2 (C6); These data were 
consistent with literature values.236 
11.1.76. Methyl (phenyl 
2,3˗di˗O˗benzyl˗4˗O˗(2,3˗di˗O˗benzyl˗4,6˗O˗benzylidene˗β˗D˗mannopyranosyl)˗t
hio˗α˗D˗mannopyranoside) uronate 164 
To a stirred solution of sulfoxide donor 163 
(1.4 g, 2.51 mmol, 1.0 equiv.) and TTBP (1.3 
g, 2.03 mmol, 2.0 equiv.) in CH2Cl2 (98 mL) 
cooled at ˗78 °C was added Tf2O (453 µL, d = 1.720, 2.76 mmol, 1.1 equiv.) and 5 
min. later, a solution of thioglycoside acceptor 54 (1.3 g, 2.63 mmol, 1.05 equiv.) in 
CH2Cl2 (12 mL) was added dropwise. The opaque reaction mixture was stirred at ˗78 
°C for 30 min. and the reaction was quenched by the addition of sat. aq. NaHCO3 
solution (15 mL) when TLC analysis indicated consumption of the donor. The organic 
layer was washed with brine (20 mL) dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified using silica gel flash column 
chromatography, eluting with EtOAc/petroleum ether (20/80, 30/70, 50/50) to furnish 
164 as a white foam (1.68 g, 1.88 mmol, 75%). Rf 0.71 (EtOAc/petroleum ether, 1/2); 
[𝛼]𝐷
22 ˗6.2 (c. 1.7, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.65 – 7.26 (30 H, m, Ar˗H), 
5.79 (1 H, d, J = 8.4 Hz, H1), 5.59 (1 H, s, CHPh), 4.80 (1 H, d, J = 12.0 Hz, CH2Ph), 
4.75 (1 H, d, J = 12.0 Hz, CH2Ph), 4.70 (1 H, d, J = 12.5 Hz, CH2Ph), 4.62 (1 H, d, J 
= 0.8 Hz, H1’), 4.60 (1 H, d, J = 12.2 Hz, CH2Ph), 4.56 (1 H, d, J = 12.8 Hz, CH2Ph), 
4.53 (1 H, d, J = 11.6 Hz, CH2Ph), 4.52 (1 H, t, J = 10.3 Hz, H4), 4.51 (1 H, d, J = 9.0 
Hz, H5), 4.50 (1 H, d, J = 12.3 Hz, CH2Ph), 4.42 (1 H, d, J = 11.6 Hz, CH2Ph), 4.19 
(1 H, dd, J = 10.7, 4.5 Hz, H6a’), 4.16 (app. t, J = 9.6 Hz, H4’), 4.04 (1 H, br. dd, J 2.4, 
10.1 Hz, H3), 3.90 (1 H, dd, J = 0.8, 2.8 Hz, H2’), 3.83 (1 H, app. t, J = 10.2 Hz, H6b’), 
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3.77 (1 H, dd, J = 8.4, 2.7, H2), 3.57 (3 H, s, CO2CH3), 3.57 (1 H, dd, J = 9.8, 3.2 Hz, 
H3’), 3.29 (1 H, td, J = 9.8, 4.8 Hz, H5’); 13C NMR (101 MHz; CDCl3) δ 169.4 (CO2CH3), 
138.3 (Cq), 138.2 (Cq), 137.8 (Cq), 137.5 (Cq), 133.9 (Cq), 131.1 (Cq), 128.9, 128.8, 
128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 
127.0, 126.1, 101.5 (CHPh), 101.1 (C1’), 82.4 (C1), 78.4 (C4’), 77.6 (C3’), 76.5 (C2’), 
75.7 (C4), 75.2 (CH2Ph), 74.8 (C2), 74.6 (C3), 73.4 (C5), 72.8 (CH2Ph), 72.4 
(CH2Ph), 72.4 (CH2Ph), 68.4 (C6’), 67.7 (C5’), 52.2 (CO2CH3); 13C˗GATED (101 
MHz; CDCl3): 101.1 (1JC1’˗H1’ = 156 Hz, C1’), 82.4 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) 
m/z [Found: (M+NH4)+ 928.3766 C54H58NO11S requires (M+NH4)+, 928.3731]. 
11.1.77. Methyl (phenyl 
2,3˗di˗O˗benzyl˗4˗O˗(2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl)˗thio˗α˗D˗mannopyr
anoside) uronate 165 
A mixture of 164 (1.6 g, 1.76 mmol, 1.0 equiv.) 
and p˗TsOH.H2O (33 mg, 0.17 mmol, 0.1 equiv.) 
in MeOH (17 mL) was heated at reflux (85 °C) for 
2 h. The solution was then cooled to room temperature and quenched with Et3N (2 
mL). The solvent was evaporated under reduced pressure and the crude product 
was dissolved in CH2Cl2 (50 mL). The organic layer was washed with H2O (2 x 50 
mL), saturated aqueous NaHCO3 (2 x 50 mL) and brine (1 x 50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure furnishing a colourless oil. 
Purification using silica gel flash column chromatography, eluting with MeOH/CH2Cl2 
(5/95) afforded 165 as a colourless oil (1.0 g, 1.21 mmol, 69%). Rf 0.53 
(MeOH/CH2Cl2, 1/9); [𝛼]𝐷
22 ˗32.0 (c. 2.45, CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.63 
– 7.23 (25 H, m, Ar˗H), 5.79 (1 H, d, J = 7.7 Hz, H1), 4.78 (1 H, d, J = 12.1 Hz, CH2Ph), 
4.64 (1 H, d, J = 12.1 Hz, CH2Ph), 4.61 (2 H, d, J = 12.4 Hz, CH2Ph), 4.60 (1 H, d, J 
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= 2.8 Hz, H1’), 4.57 (1 H, d, J = 11.7 Hz, CH2Ph), 4.54 (1 H, d, J = 10.2 Hz, H5), 4.54 
(1 H, app. t, J = 8.1 Hz, H4), 4.50 (1 H, d, J = 11.8 Hz, CH2Ph), 4.46 (1 H, d, J = 11.7 
Hz, CH2Ph), 4.31 (1 H, d, J = 11.8 Hz, CH2Ph), 3.97 (1 H, dd, J = 10.2, 2.6 Hz, H3), 
3.94 (1 H, app. td, J = 9.6, 2.4 Hz, H4’), 3.90 (1 H, d, J = 2.8 Hz, H2’), 3.87 – 3.77 (1 
H, m, H6a’ or b’), 3.79 (1 H, dd, J = 7.9, 2.4 Hz, H2), 3.75 – 3.67 (1 H, m, H6a’ or b’), 3.59 
(3 H, s, CO2CH3), 3.28 (1 H, dd, J = 9.5, 3.1 Hz, H3’), 3.32 – 3.23 (1 H, m, H5’), 2.49 
(1 H, d, J = 2.3 Hz, C4˗OH), 2.15 (1 H, t, J = 6.5 Hz, C6˗OH); 13C NMR (101 MHz; 
CDCl3) δ 169.4 (CO2CH3), 138.3 (Cq), 137.8 (Cq), 137.5 (Cq), 133.9 (Cq), 131.0 (Cq), 
128.8, 128.6, 128.4, 128.33, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.7, 127.0, 
100.5 (C1’), 82.7 (C1), 81.2 (C3’), 76.0 (C5’), 75.4 (C4), 74.9 (2C, C2, C3), 74.5 
(CH2Ph), 73.7 (C2’), 73.1 (C5), 72.9 (CH2Ph), 72.5 (CH2Ph), 71.1 (CH2Ph), 67.3 
(C4’), 62.9 (C6’), 52.2 (CO2CH3); 13C˗GATED (101 MHz; CDCl3): 100.5 (1JC1’˗H1’ = 
156 Hz, C1’), 82.7 (1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+Na)+ 
845.3032 C47H50O11SNa requires (M+Na)+, 845.2972]. 
11.1.78. Methyl (phenyl 
2,3˗di˗O˗benzyl˗4˗O˗(2,3˗di˗O˗benzyl˗6˗benzoyl˗β˗D˗mannopyranosyl)˗thio˗α˗D˗
mannopyranoside) uronate 166 
To a stirred solution of 165 (470 mg g, 0.57 
mmol, 1.0 equiv.), pyridine (46 µL, d = 0.978, 
0.57 mmol, 1.0 equiv.), DMAP (7 mg, 57 µmol, 
0.1 equiv.) in CH2Cl2 (5.7 mL) was added BzCl 
(69 µL, d = 1.211, 0.60 mmol, 1.05 equiv.) dropwise at 0 °C. The reaction was left 
stirring overnight at room temperature, and diluted with CH2Cl2 (10 mL). The mixture 
was washed with 1.0 M aq. HCl (10 mL), sat. aq. NaHCO3 (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4, filtered and concentrated under 
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reduced pressure to afford the crude product. Purification using silica gel flash 
column chromatography, eluting with EtOAc/hexane (30/70 and 40/60) afforded 166 
as a colourless oil (402 mg, 0.43 mmol, 76%). Rf 0.18 (EtOAc/hexane, 1/2); [𝛼]𝐷
22 
˗37.5 (c. 1.45, CHCl3); 1H NMR (400 MHz; CDCl3) δ 8.07 – 7.15 (30 H, m), 5.79 (1 
H, d, J = 9.1 Hz, H1), 4.76 (1 H, d, J = 12.2 Hz, CH2Ph), 4.69 – 4.61 (1 H, m, H6a’ or b’) 
4.67 (1 H, d, J = 11.4 Hz, CH2Ph), 4.66 (1 H, s, H1’), 4.60 (1 H, d, J = 11.7 Hz, CH2Ph), 
4.63 – 4.57 (1 H, m, H4), 4.58 – 4.52 (1 H, m, H6a’ or b’), 4.58 – 4.52 (1 H, m, H5, 
CH2Ph), 4.47 (1 H, d, J = 11.9 Hz, CH2Ph), 4.39 (1 H, d, J = 11.8 Hz, CH2Ph), 4.31 
(1 H, d, J = 12.2 Hz, CH2Ph), 4.28 (1 H, d, J = 12.1 Hz, CH2Ph), 4.13 – 4.08 (1 H, m, 
H3), 4.05 (1 H, t, J = 9.5 Hz, H4’), 3.93 (1 H, d, J  = 2.8 Hz, H2’), 3.66 (1 H, dd, J = 9.2, 
2.5 Hz, H2), 3.56 (1 H, ddd, J = 10.7, 6.1, 2.6 Hz, H5’), 3.45 (3 H, s, CO2CH3), 3.34 (1 
H, dd, J = 9.4, 2.9 Hz, H3’), 2.68 (1 H, br. s, C4˗OH); 13C NMR (101 MHz; CDCl3) δ 
169.4 (CO2CH3), 166.6 (C(O)Ph), 138.5 (Cq), 137.8 (Cq), 137.5 (Cq), 133.8 (Cq), 
133.0 (Cq), 131.0 (Cq), 129.9, 129.7, 128.7, 128.6, 128.3, 128.2, 128.1, 128.0, 127.9, 
127.7, 127.6, 127.5, 127.4, 126.8, 100.6 (C1’), 81.6 (C1), 81.0 (C3’), 75.1 (C4), 74.6 
(C5’), 74.2 (3C, C2, C3, CH2Ph), 73.7 (C5), 73.6 (C2’), 72.9 (CH2Ph), 71.8 (CH2Ph), 
71.2 (CH2Ph), 66.4 (C4’), 63.8 (C6’), 52.0 (CO2CH3); 13C˗GATED (101 MHz; CDCl3): 
100.6 (1JC1’˗H1’ = 156 Hz, C1’), 81.6 (1JC1˗H1 = 164 Hz, C1); HRMS (ES+) m/z [Found: 
(M+Na)+ 949.3234 C54H54O12SNa requires (M+Na)+, 849.3228]. 
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11.1.79. Methyl (phenyl 
2,3˗di˗O˗benzyl˗4˗O˗(2,3˗di˗O˗benzyl˗4,6˗O˗benzylidene˗β˗D˗mannopyranosyl)˗t
hio˗α˗D˗mannopyranoside (R/S) S˗Oxide) uronate 167 
To a stirred solurion of disaccharide 164 (120 
mg, 0.13 mmol, 1.0 equiv.) in CH2Cl2 (3.3 mL) at 
˗78 °C was added m˗CPBA (32 mg, 0.14 mmol, 
77%, 1.1 equiv.) followed by warming to ˗40 °C 
over 2 h, whereupon TLC analysis (EtOAc/petroleum ether, 1/2) indicated no starting 
material remained. The reaction was quenched by the addition of saturated aqueous 
NaHCO3 solution (25 mL) and the organic layer was separated and washed with 
brine (2 x 25 mL). The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure furnishing crude 125 as a yellow oil. Purification using silica 
gel flash column chromatography, eluting with EtOAc/hexane (0/100, 20/80, 40/60, 
90/10) afforded 124 (79 mg, 86 µmol, 66%) as a mixture of two diastereoisomers 
(75/25). Analytical data only for major; Rf 0.18 (EtOAc/hexane, 1/2); 1H NMR (400 
MHz; CDCl3) δ 7.78 – 7.26 (30 H, m, Ar˗H), 5.62 (1 H, s, CHPh), 5.05 (1 H, d, J = 
10.1 Hz, H1), 4.98 (1 H, d, J = 12.0 Hz, CH2Ph), 4.90 (1 H, d, J = 12.0 Hz, CH2Ph), 
4.67 (1 H, d, J = 12.5 Hz, CH2Ph), 4.65 (1 H, d, J = 10.1 Hz, CH2Ph), 4.60 (1 H, d, J 
= 12.5 Hz, CH2Ph), 4.60 (1 H, d, J = 10.4 Hz, CH2Ph), 4.58 (1 H, s, H1’), 4.57 (1 H, 
d, J = 11.9 Hz, CH2Ph), 4.50 (1 H, m, H4), 4.48 (1 H, d, J = 11.2 Hz, CH2Ph), 4.39 (1 
H, dd, J = 10.1, 2.6 Hz, H2), 4.35 (1 H, d, J = 1.4 Hz, H5), 4.25 – 4.15 (3 H, m, H3, 
H4’, H6a’), 3.99 (1 H, d, J = 3.0 Hz, H2’), 3.91 – 3.81 (1 H, m, H6b’), 3.56 (1 H, dd, J = 
9.9, 3.1 Hz, H3’), 3.41 (3 H, s, CO2CH3), 3.30 (1 H, ddd, J = 13.8, 9.4, 4.5 Hz, H5’); 
13C NMR (101 MHz; CDCl3) δ 168.7 (CO2CH3), 140.10 (Cq), 138.4 (Cq), 138.1 (Cq), 
137.4 (Cq), 137.4 (Cq), 130.4 (Cq), 129.3, 128.9, 128.7, 128.5, 128.4, 128.4, 128.3, 
238 
 
128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 127.6, 127.5, 126.1, 126.0, 125.2, 101.5 
(CHPh), 100.7 (C1’), 87.3 (C1), 78.3 (C3), 77.2 (C3’), 75.8 (C2’), 75.3 (CH2Ph), 74.6 
(C4), 74.4 (C5), 73.9 (C4’), 72.7 (CH2Ph), 72.6 (CH2Ph), 72.2 (CH2Ph), 71.3 (C2), 
68.3 (C6’), 52.0 (CO2CH3); 13C˗GATED (101 MHz; CDCl3): 100.7 (1JC1’˗H1’ = 156 Hz, 
C1’); HRMS (ES+) m/z [Found: (M+Na)+ 949.3283 C54H54O12SNa requires (M+Na)+, 
949.3228]. 
11.1.80. Methyl (phenyl 
2,3˗di˗O˗benzyl˗4˗O˗(2,3˗di˗O˗benzyl˗β˗D˗mannuronic 
acid)˗thio˗α˗D˗mannopyranoside) uronate 169 
To a vigorously stirred solution of 165 (480 mg, 
0.58 mmol, 1.0 equiv.) in CH2Cl2 (2.6 mL) and 
H2O (1.3 mL) was added TEMPO (18 mg, 0.12 
mmol, 0.2 equiv.) and BAIB (468 mg, 1.46 mmol, 2.5 equiv.). Stirring was continued 
for 1 h, and the reaction mixture was quenched by the addition of 10% aq. Na2S2O3 
solution (10 mL) and diluted with CH2Cl2 (15 mL). The organic layer was separated 
and the aqueous phase was acidified with 1.0 M aq. HCl to pH = 4, extracted with 
CH2Cl2 (3 x 10 mL) and the combined organic layers dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification using silica gel flash column 
chromatography, eluting with MeOH/CH2Cl2 (0/100, 5/95, 10/90 + 2% (v/v) AcOH) to 
afford the disaccharide 169 (342 mg, 0.41 mmol, 70%) as a white foam. Rf 0.56 
(EtOAc/petroleum ether, 2/1 + 2% (v/v) AcOH); [𝛼]𝐷
22 ˗10.9 (c. 0.86, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 7.52 – 7.20 (25 H, m, Ar˗H), 5.60 (1 H, br. s, H1), 4.79 (1 H, d, J 
= 12.2 Hz, CH2Ph), 4.76 (H, d, J = 11.8 Hz, CH2Ph), 4.72 (1 H, d, J = 12.5 Hz, 
CH2Ph), 4.66 (1 H, s, H1’), 4.64 (1 H, d, J = 11.6 Hz, CH2Ph), 4.62 (1H, d, J = 12.0 
Hz, CH2Ph), 4.57 (1 H, d, J = 11.9 Hz, CH2Ph), 4.54 (1 H, d, J = 11.7 Hz, CH2Ph), 
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4.54 (1 H, d, J = 8.0 Hz, H5), 4.49 (1 H, d, J = 11.9 Hz, CH2Ph), 4.44 (1 H, t, J = 7.7 
Hz, H4), 4.22 (1 H, t, J = 9.5 Hz, H4’), 3.87 (1 H, br. s, H2), 3.82 (1 H, d, J = 2.5 Hz, 
H2’), 3.74 (1 H, d, J = 9.7 Hz, H5’), 3.65 (3 H, s, CO2CH3), 3.41 (1 H, dd, J = 9.3, 2.9 
Hz, H3’), 3.38 (1 H, dd, J = 7.6, 1.6 Hz, H3); 13C NMR (101 MHz; CDCl3) δ 171.0 
(C(O)OH), 169.3 (CO2CH3), 138.2 (Cq), 138.0 (Cq), 137.4 (Cq), 137.0 (Cq), 131.6 (Cq), 
129.1, 129.0, 128.5, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 127.8, 127.7, 125.3, 
100.5 (C1’), 85.4 (C1), 80.2 (C3’), 78.1 (C3), 75.7 (2 C, C2, C4), 74.9 (2 C, C2’, 
CH2Ph), 73.2 (2 C, C5’, CH2Ph), 72.6 (C5 or CH2Ph), 72.4 (2 C, C5 or CH2Ph, 
CH2Ph), 68.4 (C4’), 52.5 (CO2CH3); HRMS (ES+) m/z [Found: (M+NH4)+ 854.3213 
C47H52NO12S requires (M+NH4)+, 854.3210]. 
11.1.81. Methyl (phenyl 2,3˗di˗O˗benzyl˗4˗O˗(benzyl 
2,3˗di˗O˗benzyl˗β˗D˗mannopyranosyl˗benzyluronate)˗thio˗α˗D˗mannopyranosi
de) uronate 170 
To a stirred solution of 169 (320 mg, 0.38 mmol, 
1.0 equiv.) in DMF (3.8 mL) was added BnBr (91 
µL, d= 1.438, 0.76 mmol, 2.0 equiv.) and K2CO3 
(79 mg, 0.57 mmol, 1.5 equiv.). The reaction mixture was stirred overnight and the 
solvents were removed in vacuo. The crude was taken up in EtOAc (50 mL) and 
washed with H2O (40 mL). The aqueous layer was extracted with EtOAc (50 mL), 
and the combined organic layers were dried over MgSO4, filtered and concentrated 
under reduced pressure. Purification using silica gel flash column chromatography, 
eluting with with EtOAc/hexane (20/80, 30/70, 40/60) afforded 170 (330 mg, 0.36 
mmol, 93%) as a colourless oil. Rf 0.31 (EtOAc/hexane, 2/1); [𝛼]𝐷
22 ˗13.9 (c. 3.2, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.64 – 7.14 (30 H, m, Ar˗H), 5.77 (1 H, d, J = 
8.7 Hz, H1), 5.23 (1 H, d, J = 12.2 Hz, CH2Ph), 5.15 (1 H, d, J = 12.2 Hz, CH2Ph), 
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4.75 (1 H, d, J = 12.2 Hz, CH2Ph), 4.63 (1 H, d, J = 11.3 Hz, CH2Ph), 4.56 (1 H, d, J 
= 12.0 Hz, CH2Ph), 4.55 – 4.49 (1 H, m, H4), 4.50 (1 H, d, J = 9.8 Hz, H5), 4.50 (1 H, 
d, J = 11.9 Hz, CH2Ph), 4.43 (2 H, d, J = 12.9 Hz, CH2Ph), 4.40 (2 H, d, J = 11.6 Hz, 
CH2Ph), 4.31 (1 H, td, J = 9.5, 2.5 Hz, H4’), 4.15 (1 H, br. s, H3), 3.86 (1 H, d, J = 2.5 
Hz, H2’), 3.80 (1 H, d, J =  9.6 Hz, H5’), 3.72 (1 H, dd, J = 8.8, 2.4 Hz, H2), 3.48 (1 H, 
s, CO2CH3), 3.35 (1 H, dd, J = 9.5, 2.8 Hz, H3’),  2.98 (1 H, d, J = 2.5 Hz, C4˗OH); 
13C NMR (101 MHz; CDCl3) δ 169.4 (CO2CH3), 168.9 (CO2Bn), 138.4 (Cq), 137.9 
(Cq), 137.8 (Cq), 137.8 (Cq), 135.0 (Cq), 133.9 (Cq), 128.7, 128.6, 128.6, 128.5, 128.4, 
128.3, 128.3, 128.2, 128.2, 127.9, 127.9, 127.8, 127.7, 127.6, 126.9, 101.4 (C1’), 
82.2 (C1), 80.0 (C3’), 76.1 (C5), 75.2 (C5’), 74.8 (C3), 74.5 (CH2Ph), 74.3 (C2), 74.0 
(C2), 73.8 (C4), 73.1 (CH2Ph), 72.0 (CH2Ph), 71.8 (CH2Ph), 68.1(C4’), 67.4 (CH2Ph), 
52.1 (CO2CH3); 13C˗GATED (101 MHz; CDCl3): 101.4 (1JC1’˗H1’ = 156 Hz, C1’), 82.2 
(1JC1˗H1 = 168 Hz, C1); HRMS (ES+) m/z [Found: (M+NH4)+ 944.3685 C54H58NO12S 
requires (M+NH4)+, 944.3680]. 
11.1.82. 3˗aminopropyl (α˗D˗mannopyranoside) uronic acid 171 
Mannuronate 60 (100 mg, 0.21 mmol, 1.0 
equiv.) was dissolved in a mixture of 
THF/H2O (5 mL 1/1 v/v) and treated with 
0.45 M KOH (0.6 mL) for 2 h (pH = 9˗10). The reaction mixture was neutralised with 
with ion exchange Amberlite 120 (H+) resin (approximately 50 mg, 10 min), until pH 
= 3, filtered through Celite® and concentrated under reduced pressure. The residual 
oil (45 mg, 98 µmol, 1.0 equiv.) was then dissolved in EtOH/THF (2.0 mL, 1.5/1 v/v), 
after which Pd/C (10%) (16 mg, 15 µmol, 0.15 equiv.), Pd(OH)2/C (20%) (1 mg, 15 
µmol, 0.15 equiv.) and 0.1 M aq. HCl (147 µL, 15 µmol, 1.0 equiv.) were added. The 
mixture was stirred for 32 h under an atmosphere of hydrogen (1 atm, balloon) at 
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room temperature. TLC analysis (hexane/EtOAc, 1/2) showed complete conversion 
of starting material to a lower Rf spot. The reaction mixture was filtered through 
Celite®, followed by solvent removal in vacuo to give 171 as a white powder (22 mg, 
76 µmol, 36% over 2 steps). Rf 0.37 (H2O/MeCN, 1/2); [𝛼]𝐷
22 ˗51.3 (c. 0.93, H2O);  1H 
NMR (400 MHz; D2O) δ 4.63 (1 H, d, J = 0.7 Hz, H1), 3.96 – 3.88 (1 H, m, 
OCH2CH2CH2NH3.Cl), 3.91 (1 H, d, J = 2.5 Hz, H2), 3.83 – 3.73 (1 H, m, 
OCH2CH2CH2NH3.Cl), 3.70 – 3.63 (1 H, m, H4), 3.59 (1 H, d, J = 9.0 Hz, H5), 3.58 (1 
H, dd, J = 10.8, 2.1 Hz, H3), 3.16 – 3.02 (2 H, m, OCH2CH2CH2NH3.Cl), 1.96 – 1.88 
(2 H, m, OCH2CH2CH2NH3.Cl); 13C NMR (101 MHz; D2O) δ 176.3 (COOH), 99.8 
(C1), 76.1 (C5), 72.7 (C3), 70.3 (C2), 68.7 (C4), 67.3 (OCH2CH2CH2NH3.Cl), 37.5 
(OCH2CH2CH2NH3.Cl), 26.7 (OCH2CH2CH2NH3.Cl); 13C˗GATED (101 MHz; D2O): 
99.8 (1JC1˗H1 = 160 Hz, C1); HRMS (ES+) m/z [Found: (M˗H)˗ 250.0928 C9H17NO7 
requires (M˗H)˗, 250.0927]. 
11.1.83. 3˗azidopropyl N˗benzyl (phenyl 
2,3˗di˗O˗benzyl˗β˗D˗mannopyranoside) hydroxamate 173 
To a solution of 78 (85 mg, 0.13 mmol, 1.0 equiv.) in EtOAc 
(1.6 mL) was added 0.45 M NaBrO3 aq. solution (176 mg, 
1.17 mmol, 9.0 equiv.). 0.2 M Na2S2O4 aq. solution (181 mg, 
1.04 mmol, 8.0 equiv.) was added over 15 min. and the 
mixture was vigorously stirred for 32 h at room temperature. When TLC analysis 
indicated conversion of 78 to a lower Rf value, the reaction was quenched by the 
addition of 10% aq. Na2S2O3 solution (5 mL) and extracted with EtOAc (2 x 10 
mL).The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. Flash column chromatography, eluting with 
EtOAc/petroleum ether (50/50, 70/30 and 90/10) afforded 140 as a colourless oil (20 
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mg, 52 µmol, 40%). Rf 0.66 (EtOAc/petroleum ether, 1/2); [𝛼]𝐷
22 ˗67.2 (c. 0.31, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 7.39 – 7.33 (5 H, m, Ar˗H), 5.26 (1 H, d, J = 
12.3 Hz, C(O)N(CH2Ph)OBn), 5.23 (1 H, d, J = 12.3 Hz, C(O)N(CH2Ph)OH), 4.52 (1 
H, d, J = 0.8 Hz, H1), 4.08 – 4.01 (2 H, m, H2, H4), 3.99 (1 H, dt, J = 10.0, 5.9 Hz, 
OCH2CH2CH2N3), 3.81 (1 H, d, J = 9.6 Hz, H5), 3.65 (1 H, ddd, J = 10.0, 7.1, 5.6 Hz, 
OCH2CH2CH2N3), 3.60 (2 H, br. s, H3, ˗OH), 3.46 (1 H, br. s, ˗OH), 3.38 (2 H, td, J 
6.6, 3.1 Hz, OCH2CH2CH2N3), 2.99 (1 H, s, ˗OH), 1.88 (4 H, td, J = 12.6, 6.2 Hz, 
OCH2CH2CH2N3), 1.84 (1 H, s, ˗OH); 13C NMR (101 MHz; CDCl3) δ 169.3 
(C(O)N(Bn)OH), 135.0 (Cq), 128.6, 128.5, 128.3, 100.4 (C1), 74.6 (C5), 73.4 (C3), 
70.1 (C2), 68.9 (C4), 67.5 (C(O)N(CH2Ph)OH), 67.0 (OCH2CH2CH2N3), 48.2 
(OCH2CH2CH2N3), 29.0 (OCH2CH2CH2N3); 13C˗GATED (101 MHz; CDCl3): 100.4 
(1JC1˗H1 = 156 Hz, C1). 
11.1.84. 3˗aminopropyl (6˗C˗tetrazol˗5˗yl)˗α/β˗D˗mannopyranoside 174 
C6˗tetrazole 115 (30 mg, 38 µmol, 1.0 equiv.) was 
dissolved in a mixture of EtOH/THF (0.6 mL, 1.5/1 
v/v), after which Pd/C (10%) (20 mg, 19 µmol, 0.5 
equiv.), Pd(OH)2/C (20%) (13 mg, 19 µmol, 0.5 
equiv.) and 0.1 M aq. HCl (380 µL, 38 µmol, 1.0 equiv.) were added. The mixture 
was stirred for 56 h under an atmosphere of hydrogen (1 atm, balloon) at room 
temperature. TLC analysis (hexane/EtOAc, 1/2) showed complete conversion of 
starting material to a lower Rf spot. The reaction mixture was filtered through Celite®, 
followed by solvent removal in vacuo to give white powder 174 in an anomeric 
mixture of α/β = 3/1  (11 mg, 36 µmol, 96%). Rf 0.27 (H2O/MeCN, 1/2); 1H NMR (400 
MHz; D2O) δ 4.86 (1 H, s, H1 α˗anomer), 4.82 (1 H, d, J = 9.8 Hz, H5), 4.74 (1 H, s, 
H1 β˗anomer), 4.61 (1 H, d, J = 9.9 Hz, H5 β˗anomer), 4.15 (1 H, app. t, J = 9.9 Hz, 
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H4 α˗anomer), 4.08 (app. t, J = 9.9 Hz, H4 β˗anomer), 4.03 (1 H, d, J = 3.2 Hz, H2 
β˗anomer), 4.01 – 3.98 (1 H, m, H2 α˗anomer), 3.87 (1 H, dd, J = 9.8, 3.4 Hz, H3 
α˗anomer), 3.84 – 3.76 (2 H, m, OCH2CH2CH2NH3.Cl α and β˗anomer), 3.73 (1 H, 
dd, J = 9.8, 3.2 Hz, H3 β˗anomer), 3.56 (2 H, ddd, J = 17.3, 9.7, 4.5 Hz, 
OCH2CH2CH2NH3.Cl α and β˗anomer), 3.17 – 3.07 (2 H, m, OCH2CH2CH2NH3.Cl 
α˗anomer), 3.02 (2 H, td, J = 12.6, 7.2 Hz, OCH2CH2CH2NH3.Cl β˗anomer), 1.99 (2 
H, dq, J = 13.6, 6.7 Hz, OCH2CH2CH2NH3.Cl α˗anomer), 1.91 – 1.82 (2 H, m, 
OCH2CH2CH2NH3.Cl β˗anomer); 13C NMR (101 MHz; D2O) δ 160.1 (2 C, Cq 
tetrazole), 100.6 (C1 β˗anomer), 100.5 (C1 α˗anomer), 72.7 (C3 β˗anomer), 70.5 (C3 
α˗anomer), 70.5 (C2 β˗anomer), 70.2 (C5 β˗anomer), 70.0 (C2 α˗anomer), 69.6 (C4 
β˗anomer), 69.5 (C4 α˗anomer), 67.6 (OCH2CH2CH2NH3.Cl β˗anomer), 66.6 (C5 
α˗anomer), 65.3 (OCH2CH2CH2NH3.Cl α˗anomer), 37.6 (OCH2CH2CH2NH3.Cl 
β˗anomer), 37.4 (OCH2CH2CH2NH3.Cl α˗anomer), 26.7 (OCH2CH2CH2NH3.Cl 
α˗anomer), 26.6 (OCH2CH2CH2NH3.Cl β˗anomer); 13C˗GATED (101 MHz; D2O): 
100.5 (1JC1˗H1 = 172 Hz, C1 α˗anomer); HRMS (ES+) m/z [Found: (M+H)+ 276.1309 
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